{"docstore/data": {"77dd7ffe-e710-4159-aa23-a0118fc94b7d": {"__data__": {"id_": "77dd7ffe-e710-4159-aa23-a0118fc94b7d", "embedding": null, "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr. ", "original_text": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations . ", "original_text": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call . "}, "hash": "1d11e3e49eb2259ad33e0969c3fc47bd4182fe2d00d675e265388651830c66b9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0": {"__data__": {"id_": "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0", "embedding": null, "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations . ", "original_text": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77dd7ffe-e710-4159-aa23-a0118fc94b7d", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr. ", "original_text": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5a16913bfb226d60cac9cca7d90582f4b8a661dc8904493cd8109410ba6a8ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded . "}, "hash": "a573fc06363246348d6d82412169160576d1372a7538073dcc651ef2f8399a95", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call . ", "start_char_idx": 48, "end_char_idx": 237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a": {"__data__": {"id_": "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a", "embedding": null, "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations . ", "original_text": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a9bbd8a454ba433f9c73f50814c15f87d714c04fa0e6185896a538f2f6da777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "052c7f6f-962e-40a9-8360-f38a1efdd2b5", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.  ", "original_text": "At this time, I would like to turn the \nconference over to Mr. "}, "hash": "522819018a4d3f7c559c4ea49af188780672b7b06285198d0ff1a2540343841f", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded . ", "start_char_idx": 237, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "052c7f6f-962e-40a9-8360-f38a1efdd2b5": {"__data__": {"id_": "052c7f6f-962e-40a9-8360-f38a1efdd2b5", "embedding": null, "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.  ", "original_text": "At this time, I would like to turn the \nconference over to Mr. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n", "original_text": "Today's conference is being recorded . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91b1025363b179c974fb5944bfb92bfa9e2ce4a8d2662e2e3c04a42643b8a6a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d5c2a2f-21af-4292-b98a-0c296fdd9082", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome . ", "original_text": "Kevin Moran, Vice President of Investor Relations . "}, "hash": "d7ed33b6e313d0ec50bb37e27395125ca703b03d4005fcc2dc97c3bce5315921", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the \nconference over to Mr. ", "start_char_idx": 276, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d5c2a2f-21af-4292-b98a-0c296fdd9082": {"__data__": {"id_": "2d5c2a2f-21af-4292-b98a-0c296fdd9082", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome . ", "original_text": "Kevin Moran, Vice President of Investor Relations . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "052c7f6f-962e-40a9-8360-f38a1efdd2b5", "node_type": "1", "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.  ", "original_text": "At this time, I would like to turn the \nconference over to Mr. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "848d4d9bb30d2f2fdf189842c6c3384cb75bbb560a7ed34c01d3506e16026220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1", "node_type": "1", "metadata": {"window": "Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "original_text": "Please go ahead, sir.  \n \n"}, "hash": "517250e60109e3320b92f9e9526eb31e44632c841d4c50663054a2d2dabfa447", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran, Vice President of Investor Relations . ", "start_char_idx": 339, "end_char_idx": 391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1": {"__data__": {"id_": "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1", "embedding": null, "metadata": {"window": "Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d5c2a2f-21af-4292-b98a-0c296fdd9082", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome . ", "original_text": "Kevin Moran, Vice President of Investor Relations . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67b266a931b56ce9992650f7f33df7735a2c02fc201a06bb1f18c573245ae712", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "original_text": "Kevin Moran :  Good morning.  "}, "hash": "f8b27cf649af36776920cbd5517b2a02f6be170f050951e3b22aad2d30bc1a9e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n \n", "start_char_idx": 391, "end_char_idx": 417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1": {"__data__": {"id_": "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1", "embedding": null, "metadata": {"window": "At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "original_text": "Kevin Moran :  Good morning.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1", "node_type": "1", "metadata": {"window": "Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c3de2842142296c96a035fb640e9f1da6e4578fc4e8644f586fd3fcac78acdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927", "node_type": "1", "metadata": {"window": "Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "original_text": "And welcome . "}, "hash": "4d3fa156d6dd489e066ec8923125dfb1daa38c32ea72d2ec01977ba7a79e284b", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Good morning.  ", "start_char_idx": 417, "end_char_idx": 447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927": {"__data__": {"id_": "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927", "embedding": null, "metadata": {"window": "Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "original_text": "And welcome . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the \nconference over to Mr.  Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "original_text": "Kevin Moran :  Good morning.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31722959506963f1772bb890f9f516a1e701c02742ea7d811c6ccee8e5c9b785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "158387f2-a8d1-49bf-a766-07dce22b9e0b", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.  ", "original_text": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . "}, "hash": "3d0b08a5315a07413a498f6f18932533a9d2abfe77f485ebc6e7ba515e72b925", "class_name": "RelatedNodeInfo"}}, "text": "And welcome . ", "start_char_idx": 447, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "158387f2-a8d1-49bf-a766-07dce22b9e0b": {"__data__": {"id_": "158387f2-a8d1-49bf-a766-07dce22b9e0b", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.  ", "original_text": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927", "node_type": "1", "metadata": {"window": "Kevin Moran, Vice President of Investor Relations .  Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "original_text": "And welcome . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63bcd29d06dece2fbd0e1db1f9fc44bc6e78c5cc75930bae2f46d9b8e0b43e50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e83ad495-d5bf-46b4-9229-5021f0307c9c", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n"}, "hash": "25acc89f97742577e31f61766b8263ad5fc598c4efe3257618a7e67a88968238", "class_name": "RelatedNodeInfo"}}, "text": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "start_char_idx": 461, "end_char_idx": 598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e83ad495-d5bf-46b4-9229-5021f0307c9c": {"__data__": {"id_": "e83ad495-d5bf-46b4-9229-5021f0307c9c", "embedding": null, "metadata": {"window": "Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "158387f2-a8d1-49bf-a766-07dce22b9e0b", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.  ", "original_text": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b4a63c37a58f28d6d5b2643c6512d2e0bce81c9a68e0c399b62c3cbe02a0e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f37a5b32-b125-4091-b78a-202a5da5e9fb", "node_type": "1", "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n"}, "hash": "f3db68ebbf97c2d3d6e703d4ebc0aee375030f74dba2144c54e5795b3cad9ac4", "class_name": "RelatedNodeInfo"}}, "text": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "start_char_idx": 598, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f37a5b32-b125-4091-b78a-202a5da5e9fb": {"__data__": {"id_": "f37a5b32-b125-4091-b78a-202a5da5e9fb", "embedding": null, "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e83ad495-d5bf-46b4-9229-5021f0307c9c", "node_type": "1", "metadata": {"window": "Kevin Moran :  Good morning.   And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "original_text": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a0fde13c6df70a19e2e6feca2e9ef61e8863d67c6ba3957c57297b3d2a31d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6157d7b-ae61-43fa-b055-46c36b5856d0", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "original_text": "During the call we will be making forward -looking statements.  "}, "hash": "1dd0460528aa20e1a2ffa43eee6bca2aa50b930e0040a8d61e3801c3911e151f", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "start_char_idx": 722, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6157d7b-ae61-43fa-b055-46c36b5856d0": {"__data__": {"id_": "a6157d7b-ae61-43fa-b055-46c36b5856d0", "embedding": null, "metadata": {"window": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "original_text": "During the call we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f37a5b32-b125-4091-b78a-202a5da5e9fb", "node_type": "1", "metadata": {"window": "And welcome .  Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "original_text": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57e6b22bab0e95186635f6dbebdef9d399a5a8f1dedbfd68cfb4a1f3361dcb7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed3836fb-b350-4ae3-9825-fc14652f9f16", "node_type": "1", "metadata": {"window": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . "}, "hash": "f624c2667fab99b08267c9ca7ba2d8d29d061851d7c9cdf0c5e4f16e6524c813", "class_name": "RelatedNodeInfo"}}, "text": "During the call we will be making forward -looking statements.  ", "start_char_idx": 873, "end_char_idx": 937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed3836fb-b350-4ae3-9825-fc14652f9f16": {"__data__": {"id_": "ed3836fb-b350-4ae3-9825-fc14652f9f16", "embedding": null, "metadata": {"window": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6157d7b-ae61-43fa-b055-46c36b5856d0", "node_type": "1", "metadata": {"window": "Today we will discuss Cardinal Health\u2019s fourth -quarter \nand year end fiscal 2022  results along with our outlook for fiscal year 2023 .  You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "original_text": "During the call we will be making forward -looking statements.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0939dac3803dc1887a0f21c2e05556688d8f97b8512acb2e19b69c2affe52efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f9939ee-c8ad-4287-802b-09465f156045", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. "}, "hash": "b508ebbe2aaa3e0a8ee176088ab47daf2352a4c73640250ff14284be7092e393", "class_name": "RelatedNodeInfo"}}, "text": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "start_char_idx": 937, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f9939ee-c8ad-4287-802b-09465f156045": {"__data__": {"id_": "7f9939ee-c8ad-4287-802b-09465f156045", "embedding": null, "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed3836fb-b350-4ae3-9825-fc14652f9f16", "node_type": "1", "metadata": {"window": "You can find today\u2019s \npress releases and earnings presentation on the IR section of our website at ir.cardinalhealth.com . \n Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ed603323797e3afdb410a201f0cf4788d091de61d921834c2cf0da7f547aa21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bf4abde-cc2e-456a-ad3b-70f73844a35e", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . "}, "hash": "3d7eb21f61cef721c5957d107872a6dc363249c5b39ae298d8dcb4df2b8fb13b", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "start_char_idx": 1111, "end_char_idx": 1281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bf4abde-cc2e-456a-ad3b-70f73844a35e": {"__data__": {"id_": "9bf4abde-cc2e-456a-ad3b-70f73844a35e", "embedding": null, "metadata": {"window": "During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f9939ee-c8ad-4287-802b-09465f156045", "node_type": "1", "metadata": {"window": "Joining me today are Mike Kaufmann, Chief Executive Officer, Jason Hollar, Chief Financial Officer , \nand Trish English, Chief Accounting Officer.  \n \n During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e8602d6639adbc7013aba12a4767b6971d9fc2c5e1927d1f4c34d4051591bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61211d86-3dbe-46e5-99b6-1d2d37064550", "node_type": "1", "metadata": {"window": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "4d5024c7899415e6bad54d0e90461d17dbe44fc95605acc36fa7ba92edf48b61", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "start_char_idx": 1281, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61211d86-3dbe-46e5-99b6-1d2d37064550": {"__data__": {"id_": "61211d86-3dbe-46e5-99b6-1d2d37064550", "embedding": null, "metadata": {"window": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bf4abde-cc2e-456a-ad3b-70f73844a35e", "node_type": "1", "metadata": {"window": "During the call we will be making forward -looking statements.   The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n", "original_text": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1171882efaae2c7b348763117d20ebeb0058a8fececea5583baadc4cb263663e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a260bf9-e266-4737-964a-20747244334f", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "original_text": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  "}, "hash": "0353c34f08ff52f7e3f205ad10ee3b364f3c936865f6affdcfa526592da0cb46", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1421, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a260bf9-e266-4737-964a-20747244334f": {"__data__": {"id_": "0a260bf9-e266-4737-964a-20747244334f", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "original_text": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61211d86-3dbe-46e5-99b6-1d2d37064550", "node_type": "1", "metadata": {"window": "The m atters addressed in the \nstatements are subject to  the risks and uncertainties that could cause actual results to differ materially \nfrom those projected or implied .  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b10961091f5c44d80ec9f5f02dc0521921800c902f28844ad7db55f263303257", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcc0b2be-44bb-4b76-8e68-d8a9874799aa", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "original_text": "With that, I will now tu rn the call over the Mike.  \n \n"}, "hash": "60b4b0ab319d970ef1f837ecd6bef8bd416aa33f6b058155c9e7f7f0b9f25119", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "start_char_idx": 1548, "end_char_idx": 1705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcc0b2be-44bb-4b76-8e68-d8a9874799aa": {"__data__": {"id_": "fcc0b2be-44bb-4b76-8e68-d8a9874799aa", "embedding": null, "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "original_text": "With that, I will now tu rn the call over the Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a260bf9-e266-4737-964a-20747244334f", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of  our presentation for a  full description of these risks and uncertainties.  Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "original_text": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eba3d3d944d53bdf433d764b0b524e1a3fc955d66f4fdd2fa023b59b89227b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f84b242-4d1a-4337-8a28-5c76b713cac5", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n", "original_text": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n"}, "hash": "ca30c42df30c636308e526247f63e802a214e42115f7bdb4c2289ea1443c40fc", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now tu rn the call over the Mike.  \n \n", "start_char_idx": 1705, "end_char_idx": 1761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f84b242-4d1a-4337-8a28-5c76b713cac5": {"__data__": {"id_": "2f84b242-4d1a-4337-8a28-5c76b713cac5", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n", "original_text": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcc0b2be-44bb-4b76-8e68-d8a9874799aa", "node_type": "1", "metadata": {"window": "Please \nnote, that during the discussion today, our comments will be on a non-GAAP basis unless they are \nspecifically called out as GAAP .  GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "original_text": "With that, I will now tu rn the call over the Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddecfc68ad346ce331b7f58ff864682ea76d80b7a251a10d141bccf637502e6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b49122b-2912-4bd8-bda9-53d0f76904b2", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "original_text": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. "}, "hash": "5a4fa4565fe2dd4a88dbcd5b294d45f44adbaf6939b8b8c15bd26efcbe987270", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "start_char_idx": 1761, "end_char_idx": 1825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b49122b-2912-4bd8-bda9-53d0f76904b2": {"__data__": {"id_": "0b49122b-2912-4bd8-bda9-53d0f76904b2", "embedding": null, "metadata": {"window": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "original_text": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f84b242-4d1a-4337-8a28-5c76b713cac5", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for  all re levant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n", "original_text": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22539df09d55088387613a4f4a21f494a57aabf0effee7ae60a70ac614c9c535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "283a64d0-fbc8-4e45-b70d-e8e8746b991f", "node_type": "1", "metadata": {"window": "With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years. ", "original_text": "Effective September 1st, Jason will become Cardinal\u2019s new CEO. "}, "hash": "2e799cade388594970467716d83947c28281e799f4c974576f9c47557d50c359", "class_name": "RelatedNodeInfo"}}, "text": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "start_char_idx": 1825, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "283a64d0-fbc8-4e45-b70d-e8e8746b991f": {"__data__": {"id_": "283a64d0-fbc8-4e45-b70d-e8e8746b991f", "embedding": null, "metadata": {"window": "With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years. ", "original_text": "Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b49122b-2912-4bd8-bda9-53d0f76904b2", "node_type": "1", "metadata": {"window": "During the Q&A portion of today\u2019s call, we kindly ask that you please limit yourself to one question, so \nthat we can try and give everyone an opportunity.   With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "original_text": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "087e87f2abe7623f30e658353066ac6951bd92070a74869317dffccb6d16d6ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f2e3e68-12d7-4ff8-ad8f-8efe92415870", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "original_text": "He has also \nbeen appointed as a board member, effective today.  \n \n"}, "hash": "b77ff460d19c101100a139524bd89cdb26d6e0c2e3cd13bdf662fc0628934f39", "class_name": "RelatedNodeInfo"}}, "text": "Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "start_char_idx": 2038, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f2e3e68-12d7-4ff8-ad8f-8efe92415870": {"__data__": {"id_": "3f2e3e68-12d7-4ff8-ad8f-8efe92415870", "embedding": null, "metadata": {"window": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "original_text": "He has also \nbeen appointed as a board member, effective today.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "283a64d0-fbc8-4e45-b70d-e8e8746b991f", "node_type": "1", "metadata": {"window": "With that, I will now tu rn the call over the Mike.  \n \n Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years. ", "original_text": "Effective September 1st, Jason will become Cardinal\u2019s new CEO. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "548e678ff08ade78a25ca403550983b395fc4a0cd398c4a382e14d4ad07c0070", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f045787f-8e7c-4d01-9e18-d26d5ba880c5", "node_type": "1", "metadata": {"window": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "original_text": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. "}, "hash": "97ead4fa1655089476034efd652430d63172b96e5eaf8619eb34757e7fba8190", "class_name": "RelatedNodeInfo"}}, "text": "He has also \nbeen appointed as a board member, effective today.  \n \n", "start_char_idx": 2101, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f045787f-8e7c-4d01-9e18-d26d5ba880c5": {"__data__": {"id_": "f045787f-8e7c-4d01-9e18-d26d5ba880c5", "embedding": null, "metadata": {"window": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "original_text": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f2e3e68-12d7-4ff8-ad8f-8efe92415870", "node_type": "1", "metadata": {"window": "Mike Kaufmann :  Thanks, Kevin, and good morning, everyone.  \n \n As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "original_text": "He has also \nbeen appointed as a board member, effective today.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "961ec7b0d34631c149861c0582fd8d420e409bcce24f6adaa8d90f29f8227825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5", "node_type": "1", "metadata": {"window": "Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "original_text": "I have been blessed to be a part of the Cardinal Health family for 32 years. "}, "hash": "76b56524cff3702ebc1fbb2baa4fd8e7618f76a92267b877bedf8d76d3f27ed7", "class_name": "RelatedNodeInfo"}}, "text": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "start_char_idx": 2169, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5": {"__data__": {"id_": "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5", "embedding": null, "metadata": {"window": "Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "original_text": "I have been blessed to be a part of the Cardinal Health family for 32 years. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f045787f-8e7c-4d01-9e18-d26d5ba880c5", "node_type": "1", "metadata": {"window": "As I am sure many of you have seen, a short time ago we issued a press release announcing that I \nam stepping down as CEO and as a board member of Cardinal Health, but will continue to serve \nthrough August 31st.  Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "original_text": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "645d2d680bd0d4841d74e7cebe9b99017c8965a078b975b9d3cccf994cb4131d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "368d34fd-56cd-4a0b-894b-512fd781ac3b", "node_type": "1", "metadata": {"window": "He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "original_text": "In that time, \nI\u2019ve seen our company grow and evolve in many ways. "}, "hash": "5b3b69a082ca2a14b2634e177bdc2337bd456507df118da25073e0328ee924f7", "class_name": "RelatedNodeInfo"}}, "text": "I have been blessed to be a part of the Cardinal Health family for 32 years. ", "start_char_idx": 2383, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "368d34fd-56cd-4a0b-894b-512fd781ac3b": {"__data__": {"id_": "368d34fd-56cd-4a0b-894b-512fd781ac3b", "embedding": null, "metadata": {"window": "He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "original_text": "In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5", "node_type": "1", "metadata": {"window": "Effective September 1st, Jason will become Cardinal\u2019s new CEO.  He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "original_text": "I have been blessed to be a part of the Cardinal Health family for 32 years. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdcee9e702c2f521e87a4f3d67dcc19e0f25efa45c1af4a671223198514c9fe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d956a8c5-ac6a-41fb-87e2-8ee587aa2763", "node_type": "1", "metadata": {"window": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n"}, "hash": "4aeb61d1e3f727e842770fd437b77dc325327d3801991edebc314490ed899791", "class_name": "RelatedNodeInfo"}}, "text": "In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "start_char_idx": 2460, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d956a8c5-ac6a-41fb-87e2-8ee587aa2763": {"__data__": {"id_": "d956a8c5-ac6a-41fb-87e2-8ee587aa2763", "embedding": null, "metadata": {"window": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "368d34fd-56cd-4a0b-894b-512fd781ac3b", "node_type": "1", "metadata": {"window": "He has also \nbeen appointed as a board member, effective today.  \n \n They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "original_text": "In that time, \nI\u2019ve seen our company grow and evolve in many ways. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f86acdde991c2d5b00e025491e92f0ce5977cee2c52966282981c40392168451", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ff6a62e-a128-47a1-9e48-7514b4d93fdc", "node_type": "1", "metadata": {"window": "I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . "}, "hash": "9629135f6812f193b18d75652f5192459da2d5a51334358ab25d5e1d23ce3de0", "class_name": "RelatedNodeInfo"}}, "text": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "start_char_idx": 2527, "end_char_idx": 2608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ff6a62e-a128-47a1-9e48-7514b4d93fdc": {"__data__": {"id_": "4ff6a62e-a128-47a1-9e48-7514b4d93fdc", "embedding": null, "metadata": {"window": "I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d956a8c5-ac6a-41fb-87e2-8ee587aa2763", "node_type": "1", "metadata": {"window": "They say timing is everything, and I believe as we start a new fiscal year, the time is right for me to \nstep away as CEO and open the door for a new le ader to take Cardinal Health forward over the \ncoming years.  I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d53dec7f6b61af91e3bb8d912af855a4559e7dd531cbdf6cd05ebd499314a34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a23f46-ca55-47dd-8be9-622ad5778f3c", "node_type": "1", "metadata": {"window": "In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n"}, "hash": "5f81dfe3fdb0622fed855c9abe73e341fa16cf107b14f53e5033036526da6429", "class_name": "RelatedNodeInfo"}}, "text": "Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "start_char_idx": 2608, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a23f46-ca55-47dd-8be9-622ad5778f3c": {"__data__": {"id_": "56a23f46-ca55-47dd-8be9-622ad5778f3c", "embedding": null, "metadata": {"window": "In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ff6a62e-a128-47a1-9e48-7514b4d93fdc", "node_type": "1", "metadata": {"window": "I have been blessed to be a part of the Cardinal Health family for 32 years.  In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives . ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2be9851a486b1608480b9629715ec367780293d40992f23596d27325953862d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "306311a1-dd22-4b43-b868-19542c6ba4bb", "node_type": "1", "metadata": {"window": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "With that, I would like to turn the call over to Jason.  \n "}, "hash": "5acda702f5903041d63d1f45664ce8c9e322a2eace4607ad8c1f87d4e52890e4", "class_name": "RelatedNodeInfo"}}, "text": "He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "start_char_idx": 2739, "end_char_idx": 2892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "306311a1-dd22-4b43-b868-19542c6ba4bb": {"__data__": {"id_": "306311a1-dd22-4b43-b868-19542c6ba4bb", "embedding": null, "metadata": {"window": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "With that, I would like to turn the call over to Jason.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "740bf4fd87bd1b08e1569632af62502a285fa9e558c5b67624fc288132991ce9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a23f46-ca55-47dd-8be9-622ad5778f3c", "node_type": "1", "metadata": {"window": "In that time, \nI\u2019ve seen our company grow and evolve in many ways.  We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f57311387de060b674e657bcbd01fd3534ea372a0a16548df8cb3974f7b7262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce5c954-3a2e-43e6-8639-c89f68f6012b", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "original_text": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years . "}, "hash": "6a09d54e7c222cd695c2519b9d73323fc7c5dbea144be6cd15439bb0757eba4f", "class_name": "RelatedNodeInfo"}}, "text": "With that, I would like to turn the call over to Jason.  \n ", "start_char_idx": 2892, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce5c954-3a2e-43e6-8639-c89f68f6012b": {"__data__": {"id_": "0ce5c954-3a2e-43e6-8639-c89f68f6012b", "embedding": null, "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "original_text": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "306311a1-dd22-4b43-b868-19542c6ba4bb", "node_type": "1", "metadata": {"window": "We are truly essential to care and I\u2019m honored \nto hav e been a part of it .  \n \n Jason has been a tremendous partner over the past 2 -plus years, and has been instrumental in many \nof our strategic initiatives .  He deeply understands our business, priorities, and industry landscape, \nand the Board and I are confide nt that he is the right person for the job.  \n \n With that, I would like to turn the call over to Jason.  \n ", "original_text": "With that, I would like to turn the call over to Jason.  \n ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ba7859be075ef6cc617f0e513c8a1d8efce358240feb0297c7e45e962c612d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d69db0a4-0afe-4673-84fd-b921048d5c9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "original_text": "Let me start by saying how excited I am to be taking on this new \nresponsibility. "}, "hash": "7419fefd6f8ed193664fac943c5ebfc04d5d4eb539c37bc5028c130676e9733e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years . ", "start_char_idx": 0, "end_char_idx": 151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d69db0a4-0afe-4673-84fd-b921048d5c9d": {"__data__": {"id_": "d69db0a4-0afe-4673-84fd-b921048d5c9d", "embedding": null, "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "original_text": "Let me start by saying how excited I am to be taking on this new \nresponsibility. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce5c954-3a2e-43e6-8639-c89f68f6012b", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "original_text": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fa03347422b2eee09bb5509c8c3a7327e3238278dc97cfb980fae286833d798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "133c809e-4a22-4e5b-8323-a39435cb596e", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "original_text": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n"}, "hash": "3936cfaeaf81c6ba66ecd936bb510ea5fd7b46b60fd91fd08debd1d3e56ec13b", "class_name": "RelatedNodeInfo"}}, "text": "Let me start by saying how excited I am to be taking on this new \nresponsibility. ", "start_char_idx": 151, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "133c809e-4a22-4e5b-8323-a39435cb596e": {"__data__": {"id_": "133c809e-4a22-4e5b-8323-a39435cb596e", "embedding": null, "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "original_text": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d69db0a4-0afe-4673-84fd-b921048d5c9d", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "original_text": "Let me start by saying how excited I am to be taking on this new \nresponsibility. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7050a1d9ff11efffb3a4e189864360e9c3a29637fb1fd10d4a641da5fc23d2a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "original_text": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. "}, "hash": "b9ed7bbed3d59afe1128362e61c84c26fd53ffdc28c19a9d4dd4c3ef1bb54442", "class_name": "RelatedNodeInfo"}}, "text": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n", "start_char_idx": 233, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9": {"__data__": {"id_": "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9", "embedding": null, "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "original_text": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "133c809e-4a22-4e5b-8323-a39435cb596e", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "original_text": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f5b7de6a61b2a9a311fbd142ea4d89a3f6d892d7dc7266131d29c8d5ff1a4fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3871e31d-2a32-4ac1-9144-77c8ee8687d2", "node_type": "1", "metadata": {"window": "Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "original_text": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n"}, "hash": "ffd4de8661e7418f0f75ddc680fab31956f136cbebb9ac943b6a8b40d7ef746b", "class_name": "RelatedNodeInfo"}}, "text": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "start_char_idx": 325, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3871e31d-2a32-4ac1-9144-77c8ee8687d2": {"__data__": {"id_": "3871e31d-2a32-4ac1-9144-77c8ee8687d2", "embedding": null, "metadata": {"window": "Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "original_text": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9", "node_type": "1", "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "original_text": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b454d94d34873e7c1ce6918edcf3f48286a68e931a3f8757c465ef08b6667cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56cb784f-e811-455b-9b25-d7b39f80ff11", "node_type": "1", "metadata": {"window": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "original_text": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. "}, "hash": "bf4a2328caae0607624ca0fe78784248e62042a69472074ef3d5da163b2b772f", "class_name": "RelatedNodeInfo"}}, "text": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "start_char_idx": 441, "end_char_idx": 603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56cb784f-e811-455b-9b25-d7b39f80ff11": {"__data__": {"id_": "56cb784f-e811-455b-9b25-d7b39f80ff11", "embedding": null, "metadata": {"window": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "original_text": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3871e31d-2a32-4ac1-9144-77c8ee8687d2", "node_type": "1", "metadata": {"window": "Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "original_text": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9ba1d836662fd39daf1aaf56368e8e9c2debf944376045d5216387c8fdfbcd5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "504c1846-d662-40dc-92df-dcb273bac41f", "node_type": "1", "metadata": {"window": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "original_text": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . "}, "hash": "5257fc3019cfab00aa56a7e0dbf31f5fd3986ba9a59813ca59aba349fea6d05c", "class_name": "RelatedNodeInfo"}}, "text": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "start_char_idx": 603, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "504c1846-d662-40dc-92df-dcb273bac41f": {"__data__": {"id_": "504c1846-d662-40dc-92df-dcb273bac41f", "embedding": null, "metadata": {"window": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "original_text": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56cb784f-e811-455b-9b25-d7b39f80ff11", "node_type": "1", "metadata": {"window": "I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "original_text": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15571c184f893a7b27d8d3d53419eece442ea78ee084189a2081260f1d9b2082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b197624-55f4-4108-b6ca-84d83367b8b5", "node_type": "1", "metadata": {"window": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "original_text": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n"}, "hash": "094a23f4e25899c128e332055561957243a165668becbdf031275469affcc477", "class_name": "RelatedNodeInfo"}}, "text": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "start_char_idx": 702, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b197624-55f4-4108-b6ca-84d83367b8b5": {"__data__": {"id_": "9b197624-55f4-4108-b6ca-84d83367b8b5", "embedding": null, "metadata": {"window": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "original_text": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "504c1846-d662-40dc-92df-dcb273bac41f", "node_type": "1", "metadata": {"window": "I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years.  I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "original_text": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93f380908aa61850fcd67d0ea40d7475046addd1002c4b6c4f607c286986a924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2808e31f-422f-4cf1-9525-2c07393f3df3", "node_type": "1", "metadata": {"window": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "original_text": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . "}, "hash": "94c4425436b7654e7c526a285f6c2e013d164ecf2899ac47a9643a93888173f1", "class_name": "RelatedNodeInfo"}}, "text": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "start_char_idx": 849, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2808e31f-422f-4cf1-9525-2c07393f3df3": {"__data__": {"id_": "2808e31f-422f-4cf1-9525-2c07393f3df3", "embedding": null, "metadata": {"window": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "original_text": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b197624-55f4-4108-b6ca-84d83367b8b5", "node_type": "1", "metadata": {"window": "I hope to preserve the culture that you\u2019ve helped engrain into the fabric of our \norganization and I look forward to what I know will be a smooth transition.  \n \n I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "original_text": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f188e4eed0d5bc48df510bf508d42dbfcd67eca463b0fe8a611495daddc2a04f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5", "node_type": "1", "metadata": {"window": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "original_text": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . "}, "hash": "872064dde72f37524e49ea4dfda1c71dad4f81d7ab5ae01dbc55f09350acfae4", "class_name": "RelatedNodeInfo"}}, "text": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "start_char_idx": 978, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5": {"__data__": {"id_": "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5", "embedding": null, "metadata": {"window": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "original_text": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2808e31f-422f-4cf1-9525-2c07393f3df3", "node_type": "1", "metadata": {"window": "I also want to welcome Trish English, who will be serving as our Interim Chief Financial Of ficer.  Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "original_text": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5beba99703e44032247e3136cb71b40b08ea16ecdba8de8bf82f7d0e86d41e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4473baa4-20de-4865-bb60-a0bf9726ed90", "node_type": "1", "metadata": {"window": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "original_text": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . "}, "hash": "0f390e0f951d263ca008b3149440c22fadb2b885dc3d32680d8f30baae80c441", "class_name": "RelatedNodeInfo"}}, "text": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "start_char_idx": 1125, "end_char_idx": 1389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4473baa4-20de-4865-bb60-a0bf9726ed90": {"__data__": {"id_": "4473baa4-20de-4865-bb60-a0bf9726ed90", "embedding": null, "metadata": {"window": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "original_text": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5", "node_type": "1", "metadata": {"window": "Trish \nmost recently served as our Chief Accounting Officer and has been a valuable member of the \nCardinal Health family for over sixteen years .  I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "original_text": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35c5e0740ee9b340f263a61696fa82f7fd0743dba6229efb3afc994bd32d4e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c50f2c0f-5140-4246-b804-9196ead43812", "node_type": "1", "metadata": {"window": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "original_text": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n"}, "hash": "edfe74da86686b8db1b74a3ef15ecfc5eb7a0671c02def5dba933357e6fae090", "class_name": "RelatedNodeInfo"}}, "text": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "start_char_idx": 1389, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c50f2c0f-5140-4246-b804-9196ead43812": {"__data__": {"id_": "c50f2c0f-5140-4246-b804-9196ead43812", "embedding": null, "metadata": {"window": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "original_text": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4473baa4-20de-4865-bb60-a0bf9726ed90", "node_type": "1", "metadata": {"window": "I look forward to continuing to work with her in this new \ncapacity while we conduct an external search for a permanent CFO.  \n \n Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "original_text": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "155e3a5ac6c0a870a185ee574bf5b1ffbf668809bc2f5b4b60fa3bcc06913059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80ecd765-2ff4-47f8-837a-b481d6f785e6", "node_type": "1", "metadata": {"window": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "original_text": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . "}, "hash": "10180d40ff377cb9af27dc80753323497b4c48ffe94cbfa033b7a57a768561db", "class_name": "RelatedNodeInfo"}}, "text": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "start_char_idx": 1526, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80ecd765-2ff4-47f8-837a-b481d6f785e6": {"__data__": {"id_": "80ecd765-2ff4-47f8-837a-b481d6f785e6", "embedding": null, "metadata": {"window": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "original_text": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c50f2c0f-5140-4246-b804-9196ead43812", "node_type": "1", "metadata": {"window": "Before stepping into the details of our financial performance for the quarter, let me step back and \nsummarize the key points for this past year .  Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "original_text": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fb9f2dd3e4b5f4a52a5ebe93e440573431ca3eb33d93f421208108806be8149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4a642d2-abb5-4f97-b485-f9ffe3da72ea", "node_type": "1", "metadata": {"window": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "original_text": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n"}, "hash": "660b0c2aed5332577a95fea545679d8c5fa63089c470d68f2c114cb2c8091bb5", "class_name": "RelatedNodeInfo"}}, "text": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "start_char_idx": 1787, "end_char_idx": 1927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4a642d2-abb5-4f97-b485-f9ffe3da72ea": {"__data__": {"id_": "e4a642d2-abb5-4f97-b485-f9ffe3da72ea", "embedding": null, "metadata": {"window": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "original_text": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80ecd765-2ff4-47f8-837a-b481d6f785e6", "node_type": "1", "metadata": {"window": "Within our Pharma segment, while we experienced the \neffects of industry -wide inflation and incurred incremental technology investments, we grew the \nbusiness 5%, consistent with both our original guidance for the year as well as our long -term growth \ntargets .  The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "original_text": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce91cc8534a4244a8f79d5dd979b37bb7a8118e27834dd30849d9f4a90666449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54d5f900-9034-49ac-a3eb-c1fc06095440", "node_type": "1", "metadata": {"window": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "original_text": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n"}, "hash": "ac47b0d2aadd18a1e894ecc942594021fd2c49e961a86cf2e5bae274bc2c4c38", "class_name": "RelatedNodeInfo"}}, "text": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "start_char_idx": 1927, "end_char_idx": 2072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54d5f900-9034-49ac-a3eb-c1fc06095440": {"__data__": {"id_": "54d5f900-9034-49ac-a3eb-c1fc06095440", "embedding": null, "metadata": {"window": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "original_text": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4a642d2-abb5-4f97-b485-f9ffe3da72ea", "node_type": "1", "metadata": {"window": "The Medical business was more significantly impacted by these inflationary dynamics,  which \ndrove a significant impact on our results .  However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "original_text": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d5ba93f2d5bb1d1891fa0831ddba3dd36b720290651d57853da15118c5dad70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "748442de-e8e7-4163-bbf2-8ed83c6e013f", "node_type": "1", "metadata": {"window": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "original_text": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n"}, "hash": "0b8280fd1fa6973a5d37c116e01558eee8091fc6e1e0f8532aef7e4ec24a21dd", "class_name": "RelatedNodeInfo"}}, "text": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "start_char_idx": 2072, "end_char_idx": 2304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "748442de-e8e7-4163-bbf2-8ed83c6e013f": {"__data__": {"id_": "748442de-e8e7-4163-bbf2-8ed83c6e013f", "embedding": null, "metadata": {"window": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "original_text": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54d5f900-9034-49ac-a3eb-c1fc06095440", "node_type": "1", "metadata": {"window": "However, we have strong mitigation actions in place, \nincluding pricing, and will present a plan to you today that mitigates all of the inflationary and global \nsupply chain constraint impacts, plus an addit ional 8% of compounded annual growth by fiscal \u201825. \n Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "original_text": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce30f85ebdbcae027bbc99c95af68b9435729a363f121d4d33cf19657b4a98e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cf82343-3133-4347-a74e-ea57d31a4ca5", "node_type": "1", "metadata": {"window": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "original_text": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. "}, "hash": "529169e1dceec0ca2b7027d634f7b95cdf3159977dc2d19ca1cf1c682312b54c", "class_name": "RelatedNodeInfo"}}, "text": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "start_char_idx": 2304, "end_char_idx": 2600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cf82343-3133-4347-a74e-ea57d31a4ca5": {"__data__": {"id_": "9cf82343-3133-4347-a74e-ea57d31a4ca5", "embedding": null, "metadata": {"window": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "original_text": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "748442de-e8e7-4163-bbf2-8ed83c6e013f", "node_type": "1", "metadata": {"window": "Underlying these operating results this past year was a significant focus on cash flow, which results in \nincreased financial flexibility .  We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "original_text": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a6a6a01e05157e33dc5b60c79c2b6679b43113644da2c1da94fc0a5ab6a7c26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "334f6fd8-2457-4bf9-ac23-330db8092f27", "node_type": "1", "metadata": {"window": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n"}, "hash": "61a480558acadcb322a8e4c90a3aee74b9aa605eef06595a30619c96d84d4d31", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "start_char_idx": 2600, "end_char_idx": 2788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "334f6fd8-2457-4bf9-ac23-330db8092f27": {"__data__": {"id_": "334f6fd8-2457-4bf9-ac23-330db8092f27", "embedding": null, "metadata": {"window": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cf82343-3133-4347-a74e-ea57d31a4ca5", "node_type": "1", "metadata": {"window": "We are absolutely focused on shareholder value and intend to dep loy \nthese incremental funds to additional share repurchases for fiscal \u201823. \n \n While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "original_text": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91d8c88475dac710f8a61bc9fe3b1a393f97772262b9664065077effa99c0b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "225ce797-d8d6-49f5-ab4a-4f357314d7bb", "node_type": "1", "metadata": {"window": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n"}, "hash": "773890862674de846e4065a9e8d0466a344dbf935b45d8e171383ce3a26737b6", "class_name": "RelatedNodeInfo"}}, "text": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "start_char_idx": 2788, "end_char_idx": 2903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "225ce797-d8d6-49f5-ab4a-4f357314d7bb": {"__data__": {"id_": "225ce797-d8d6-49f5-ab4a-4f357314d7bb", "embedding": null, "metadata": {"window": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "334f6fd8-2457-4bf9-ac23-330db8092f27", "node_type": "1", "metadata": {"window": "While we remain in a dynamic environment, I am excited to share further details of our plans with you \ntoday and commit to continuing to provide increased clarity to the drivers an d the key metrics \nunderlying our performance.  \n \n So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "803481398950c63c8ed4bb594e06d2db0b26bd62f10a3e4b5cdd024af090e5c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "632230f6-599f-4ba9-bec8-c892a0dfad45", "node_type": "1", "metadata": {"window": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. "}, "hash": "55560f6bc66f26d00c96c2a85d7344afc108d4a139ed1d763a67eeea4d75fc00", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "start_char_idx": 2903, "end_char_idx": 3049, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "632230f6-599f-4ba9-bec8-c892a0dfad45": {"__data__": {"id_": "632230f6-599f-4ba9-bec8-c892a0dfad45", "embedding": null, "metadata": {"window": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "225ce797-d8d6-49f5-ab4a-4f357314d7bb", "node_type": "1", "metadata": {"window": "So, let\u2019s now turn to some of the details driving our results in the fourth quarter, beginning with the \nPharma segment on slide 6\u2026  \n \nFourth -quarter revenue increased 13% to $43 billion, driven by branded pharma ceutical sales growth \nfrom existing and net new PD and Specialty customers.  \n \n Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bacda59fe69010b063538d122c25310d925daf3898b8408b0f8cbb4f7db9a3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c303c7-0ec0-4202-aeb1-696d44f9f23d", "node_type": "1", "metadata": {"window": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "We also incurred higher costs supporting sales \ngrowth.  "}, "hash": "a0307f22abd78dfe2cb271c43860968eac4d578445c730c29e85d930eee9ef67", "class_name": "RelatedNodeInfo"}}, "text": "Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "start_char_idx": 3049, "end_char_idx": 3199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c303c7-0ec0-4202-aeb1-696d44f9f23d": {"__data__": {"id_": "65c303c7-0ec0-4202-aeb1-696d44f9f23d", "embedding": null, "metadata": {"window": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "We also incurred higher costs supporting sales \ngrowth.  ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "350f974d-a5e1-48dd-8d51-1965b8322899", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1c6b84e59eab57610e69a7e1719ed3cc9a269c5a81975a8c35fc08f9b74476f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "632230f6-599f-4ba9-bec8-c892a0dfad45", "node_type": "1", "metadata": {"window": "Segment profit increased 26% to $451 million, driven by generics program performance and a higher \ncontribution from brand sales mix, partially offset by inflationary supply chain  costs.  As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year. ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9061834f77ca362c6a7b89488595043070d0c1ee0140d1099c2d599dac2e9d65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6817acf8-94d1-49f4-8471-a76f9959cb4c", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "original_text": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n"}, "hash": "1ea50b6679fd36a16aab61b551075b780fa4d8487c6778673aa2a529e4bea8a8", "class_name": "RelatedNodeInfo"}}, "text": "We also incurred higher costs supporting sales \ngrowth.  ", "start_char_idx": 3199, "end_char_idx": 3256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6817acf8-94d1-49f4-8471-a76f9959cb4c": {"__data__": {"id_": "6817acf8-94d1-49f4-8471-a76f9959cb4c", "embedding": null, "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "original_text": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c303c7-0ec0-4202-aeb1-696d44f9f23d", "node_type": "1", "metadata": {"window": "As we\u2019ve \npreviously noted, this also reflects a favorable comparison due to prior year inventory adjustments.  \n \n During the quarter, our generics program, including Red Oak, saw strong performance and continued \nto experience consistent market dynami cs.  \n \n Regarding the inflationary supply chain costs, we saw impacts in areas such as transportation and \nlabor, which we expect to continue into next year.  We also incurred higher costs supporting sales \ngrowth.  ", "original_text": "We also incurred higher costs supporting sales \ngrowth.  ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ed899f4eb42a79f6ea864e79c0987c0708155dd9640b5c9719f5bb47381a508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2484d589-145b-4fda-b552-fe014a52d46c", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "original_text": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n"}, "hash": "1900c64ef3e02fbccd365b29cb67b1d8113a458effa40a5d65931e2b0b8d69b3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n", "start_char_idx": 0, "end_char_idx": 159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2484d589-145b-4fda-b552-fe014a52d46c": {"__data__": {"id_": "2484d589-145b-4fda-b552-fe014a52d46c", "embedding": null, "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "original_text": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6817acf8-94d1-49f4-8471-a76f9959cb4c", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "original_text": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1121785da9bc2a422b86dc6be26ac6cb60e874d95133b261ef7c44ecb6bf1922", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a365971b-18e0-4426-9bb4-14f91ac1edb6", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "original_text": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution. "}, "hash": "00ca50671007eee7cf3c0b39d6f7c9f7f779205f0098ce3e152032d284cec1d9", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n", "start_char_idx": 159, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a365971b-18e0-4426-9bb4-14f91ac1edb6": {"__data__": {"id_": "a365971b-18e0-4426-9bb4-14f91ac1edb6", "embedding": null, "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "original_text": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2484d589-145b-4fda-b552-fe014a52d46c", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "original_text": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86f0c5a6092e765715bf67770c375f0f8a481e2580a5ac5f76ef7e57c22ba9ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8416fd13-0eaa-4caa-9de4-3ae6059708f6", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "original_text": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n"}, "hash": "bbefec1206c235579c7c82cb93abade0e25f7baf66f76f981ca985c1a6779239", "class_name": "RelatedNodeInfo"}}, "text": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution. ", "start_char_idx": 346, "end_char_idx": 507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8416fd13-0eaa-4caa-9de4-3ae6059708f6": {"__data__": {"id_": "8416fd13-0eaa-4caa-9de4-3ae6059708f6", "embedding": null, "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "original_text": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a365971b-18e0-4426-9bb4-14f91ac1edb6", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "original_text": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58fe7acc0ed6f1a805c77bc2b80b756bc1ebf17da25a1c80999531f86d517bee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "original_text": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. "}, "hash": "6c8dba37529283a4673156434320e3005c47405e319c19668cd079768fbe750a", "class_name": "RelatedNodeInfo"}}, "text": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "start_char_idx": 507, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c": {"__data__": {"id_": "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c", "embedding": null, "metadata": {"window": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "original_text": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8416fd13-0eaa-4caa-9de4-3ae6059708f6", "node_type": "1", "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "original_text": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5827b55bb3e087781848caba51801fa3a469bf1c0d474b8e67fd452072f9149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f450187e-8c44-4441-ad8d-8ff123737b80", "node_type": "1", "metadata": {"window": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "original_text": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. "}, "hash": "7f245ecf4621cf2f7d9f4e40aaafa9ff7b8af6d2d3ae9732e3a2132f3f970fe6", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "start_char_idx": 766, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f450187e-8c44-4441-ad8d-8ff123737b80": {"__data__": {"id_": "f450187e-8c44-4441-ad8d-8ff123737b80", "embedding": null, "metadata": {"window": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "original_text": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "original_text": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "833a6c3dfdd5d21c0851e0d52fb5b22231639f235c3d3a2ae4af8713f77955c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae", "node_type": "1", "metadata": {"window": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "original_text": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n"}, "hash": "e661745d29d0ae080e7ca9e14bd1b7609020f6d19f28e9f98be9c23afeeb8010", "class_name": "RelatedNodeInfo"}}, "text": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "start_char_idx": 926, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae": {"__data__": {"id_": "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae", "embedding": null, "metadata": {"window": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "original_text": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f450187e-8c44-4441-ad8d-8ff123737b80", "node_type": "1", "metadata": {"window": "Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "original_text": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e59f36605bb9f1243b52fc594b376f27affc636da361001d98d4175e0e34c0bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68", "node_type": "1", "metadata": {"window": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "original_text": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. "}, "hash": "466791ee4b03a989aa850a1cd2552d0a17f14700cd60f4290413429aa1e12d69", "class_name": "RelatedNodeInfo"}}, "text": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "start_char_idx": 1182, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68": {"__data__": {"id_": "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68", "embedding": null, "metadata": {"window": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "original_text": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae", "node_type": "1", "metadata": {"window": "On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "original_text": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5200ff254055cbd71fd74f00714242cf5ed922e26f2ab2cec348598028e795d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aade192-fc7e-4f42-8ddf-92db3eeb184b", "node_type": "1", "metadata": {"window": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "original_text": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. "}, "hash": "fd2c526984f504f19c21e5a53617d0f0b82e6462adb436524ed8dc36a09d7603", "class_name": "RelatedNodeInfo"}}, "text": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "start_char_idx": 1271, "end_char_idx": 1410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aade192-fc7e-4f42-8ddf-92db3eeb184b": {"__data__": {"id_": "3aade192-fc7e-4f42-8ddf-92db3eeb184b", "embedding": null, "metadata": {"window": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "original_text": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68", "node_type": "1", "metadata": {"window": "During the quarter, our Products and Distribution business saw an approximate $100 million impact \nfrom net incremental inflation and supply chain constraints.  This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "original_text": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d19e49b1e67ff5b9b6e1384422948e79fb64397cb34fdae3ebd39aa10c0289d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd431a45-c773-4719-b567-b185903679c3", "node_type": "1", "metadata": {"window": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "original_text": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. "}, "hash": "f144f023a5990de283d7631a0a337358bf4810f7e16ec9a0e4f115852030efdb", "class_name": "RelatedNodeInfo"}}, "text": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "start_char_idx": 1410, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd431a45-c773-4719-b567-b185903679c3": {"__data__": {"id_": "dd431a45-c773-4719-b567-b185903679c3", "embedding": null, "metadata": {"window": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "original_text": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aade192-fc7e-4f42-8ddf-92db3eeb184b", "node_type": "1", "metadata": {"window": "This reflects a gross impact of \napproximately $125 million and approximate $25 million offset from our mitigation actions, which \nincludes our initial wave of price increases o n five Cardinal Health Brand categories that went into \neffect back in March.  I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "original_text": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40daa27833ce3903554a94a930f60575b9c8d8065f4acd6ce1c1861eaee85705", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "815a58ad-e5a0-464f-9b5c-84ff6712d337", "node_type": "1", "metadata": {"window": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "original_text": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. "}, "hash": "250539f01a89b6095470acc24d9fe557309f9986f1caa00f42776505f9ac5843", "class_name": "RelatedNodeInfo"}}, "text": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "start_char_idx": 1543, "end_char_idx": 1632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "815a58ad-e5a0-464f-9b5c-84ff6712d337": {"__data__": {"id_": "815a58ad-e5a0-464f-9b5c-84ff6712d337", "embedding": null, "metadata": {"window": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "original_text": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd431a45-c773-4719-b567-b185903679c3", "node_type": "1", "metadata": {"window": "I\u2019ll elaborate on our plans for further mitigation in fiscal \u201823 and beyond shortly.  \n \n As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "original_text": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fea45e1d95f1faf11ebffd6a1205e423765b258ff8a7e51146aa984d9fc9740", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91a4e21e-30b0-457f-baa7-52a4f1a39624", "node_type": "1", "metadata": {"window": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "original_text": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. "}, "hash": "f23cb502fec67e6fef085ff285689b1e2e2434b3ddc1926bfd51c035366d46b5", "class_name": "RelatedNodeInfo"}}, "text": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "start_char_idx": 1632, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91a4e21e-30b0-457f-baa7-52a4f1a39624": {"__data__": {"id_": "91a4e21e-30b0-457f-baa7-52a4f1a39624", "embedding": null, "metadata": {"window": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "original_text": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "815a58ad-e5a0-464f-9b5c-84ff6712d337", "node_type": "1", "metadata": {"window": "As mentioned, it continues to be a highly dynamic Medical environment, and our Q4 results ca me in \nlower than we had previously expected.  This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "original_text": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb9ea0f1590aa968396b844c87dc1978f56f2544dc29d11403e471443d4a4d57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fdf851b-d343-4121-a7ef-f2b6abffa18f", "node_type": "1", "metadata": {"window": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "original_text": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . "}, "hash": "b798e86272aaae16684f8df0ea86648f225aed603696077b00ee88e802609983", "class_name": "RelatedNodeInfo"}}, "text": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "start_char_idx": 1724, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fdf851b-d343-4121-a7ef-f2b6abffa18f": {"__data__": {"id_": "2fdf851b-d343-4121-a7ef-f2b6abffa18f", "embedding": null, "metadata": {"window": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "original_text": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91a4e21e-30b0-457f-baa7-52a4f1a39624", "node_type": "1", "metadata": {"window": "This primarily reflects overall volume softness in our Products \nand Distribution business, including a lower contribution from PPE.  Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "original_text": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb5c5df83ff60973d1a35d11e47fcf7975e9784f3ea198928e947963925cf092", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "545b5dd4-1ae8-4a76-907f-88c1a6778a35", "node_type": "1", "metadata": {"window": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "original_text": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n"}, "hash": "36ce376dcbf3020adea379151b1afada2f51cd9bdc2b0a0afeffe3f4b473971f", "class_name": "RelatedNodeInfo"}}, "text": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "start_char_idx": 1916, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "545b5dd4-1ae8-4a76-907f-88c1a6778a35": {"__data__": {"id_": "545b5dd4-1ae8-4a76-907f-88c1a6778a35", "embedding": null, "metadata": {"window": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "original_text": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fdf851b-d343-4121-a7ef-f2b6abffa18f", "node_type": "1", "metadata": {"window": "Stepping back, demand for PPE \nhas fluctuated significantly over the past couple  years.  We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "original_text": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products . ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c17eb3079f6864ae22a754b1be258c428cefb9d47f2a50705fdea57bfd239f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6851b8d-aaa9-4830-aa8f-8444a33c289a", "node_type": "1", "metadata": {"window": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "original_text": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. "}, "hash": "8db1346eae207ce94b1f549b184b80e96f37624a471be866cce41e800a186f60", "class_name": "RelatedNodeInfo"}}, "text": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "start_char_idx": 2060, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6851b8d-aaa9-4830-aa8f-8444a33c289a": {"__data__": {"id_": "b6851b8d-aaa9-4830-aa8f-8444a33c289a", "embedding": null, "metadata": {"window": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "original_text": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "545b5dd4-1ae8-4a76-907f-88c1a6778a35", "node_type": "1", "metadata": {"window": "We saw lower volumes as we exited Q3, and \nthe fourth quarter experienced further declines.  We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "original_text": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7811bfdc0125a3d31b953117a900dc0bccf31b5b7b18f3bc936003ee345105fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69966aa9-ae8b-468d-b2e3-6ccd99ed797e", "node_type": "1", "metadata": {"window": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "original_text": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. "}, "hash": "f4c33d61636a12fe68d08b68cc48e93c288e86a410e37bd750347bc0d32224b0", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "start_char_idx": 2198, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69966aa9-ae8b-468d-b2e3-6ccd99ed797e": {"__data__": {"id_": "69966aa9-ae8b-468d-b2e3-6ccd99ed797e", "embedding": null, "metadata": {"window": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "original_text": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6851b8d-aaa9-4830-aa8f-8444a33c289a", "node_type": "1", "metadata": {"window": "We believe this primarily reflects customers\u2019 higher \ninventory levels, and to a lesser extent, some PPE category -specific customer losses driven by \nsupply co nstraints during the pandemic.  We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "original_text": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a38cc747945b66c75347d4b58dec596e85e1b746e975841e89e229547ca82b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d", "node_type": "1", "metadata": {"window": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. "}, "hash": "048ba37f4cda87b2f3561d983568953ff27bd5b8afdb06c9db3644923e2871de", "class_name": "RelatedNodeInfo"}}, "text": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "start_char_idx": 2396, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d": {"__data__": {"id_": "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d", "embedding": null, "metadata": {"window": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69966aa9-ae8b-468d-b2e3-6ccd99ed797e", "node_type": "1", "metadata": {"window": "We continue to have strong conviction in our overall value \nproposition which includes leading brands and clinically -differentiated products .  For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "original_text": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f3671876d9c4dc7bee74bc645ef4bc15d49f9e0b3efa725e924944e93359f5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n"}, "hash": "fe20abf6313aa280bd68edd80fbbe192281c1029068ffa084f5aee4e97ebeb5e", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "start_char_idx": 2554, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4": {"__data__": {"id_": "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4", "embedding": null, "metadata": {"window": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d", "node_type": "1", "metadata": {"window": "For context, PPE \nrepresents approximately 15 % of sales in our overall Cardinal Heal th Brand portfolio, as you\u2019ll see on \nslide 20.  \n \n Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions. ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e23d481230409fd61974f2caf6a98d6cf941f0f4ba1599ce797dc68010f96e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b578fa0-b25b-4fc2-8283-c59860cad4dc", "node_type": "1", "metadata": {"window": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n"}, "hash": "720e79eb1183f84e56fc32d1eac9b7d79d32cb81c4f41adab5991d772d4f9c5b", "class_name": "RelatedNodeInfo"}}, "text": "As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "start_char_idx": 2777, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b578fa0-b25b-4fc2-8283-c59860cad4dc": {"__data__": {"id_": "0b578fa0-b25b-4fc2-8283-c59860cad4dc", "embedding": null, "metadata": {"window": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other increased by $36 million to $64 million, due to a decrease in \nthe value of our deferred compensation plan investments compared to gains in the prior year.  As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f72d8ce5fdb191cf123292002ed36c9370290cf489bfba41ab8b87bc3bf5cbbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f29ad4bb-a505-483a-b0ec-5566106d956c", "node_type": "1", "metadata": {"window": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  "}, "hash": "c143e0ffa91f55cee067f3a7339718bec5800932f9e9717b90dd3078ffe01cb6", "class_name": "RelatedNodeInfo"}}, "text": "Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "start_char_idx": 2865, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f29ad4bb-a505-483a-b0ec-5566106d956c": {"__data__": {"id_": "f29ad4bb-a505-483a-b0ec-5566106d956c", "embedding": null, "metadata": {"window": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a17250224dfc51d993736d65da7abf1164fe26c4c022a753bce71de2be5728d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b578fa0-b25b-4fc2-8283-c59860cad4dc", "node_type": "1", "metadata": {"window": "As a \nremind er, deferred compensation gains or losses reported in Interest and Other are fully offset in \ncorporate SG&A and net neutral to our bottom line.  Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "223373762427d5d7d620d6efef6ff18a01952a72747ddbfe1cf2bda347c0592a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "656c20d0-76a2-4803-ade2-d6b8e2353c04", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "original_text": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n"}, "hash": "9190b9da9730635f78e83873e252a643db310268c884261702d5fb12ba0e5756", "class_name": "RelatedNodeInfo"}}, "text": "The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "start_char_idx": 2997, "end_char_idx": 3125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "656c20d0-76a2-4803-ade2-d6b8e2353c04": {"__data__": {"id_": "656c20d0-76a2-4803-ade2-d6b8e2353c04", "embedding": null, "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "original_text": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f29ad4bb-a505-483a-b0ec-5566106d956c", "node_type": "1", "metadata": {"window": "Additionally, in the fourth quarter a one -time write -\ndown of an equity investment impacted EPS by $0.06 per shar e.  \n \nThe increase in Other expense was partially offset by lower interest due to debt reduction actions.  As \nindicated, we repaid the $280 million of remaining June 2022 notes at maturity.  \n \n Our fourth quarter effective tax rate finished at 25.4 percent, ap proximately 3 percentage points \nhigher than the prior year.  \n \n The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "original_text": "The net result was fourth quarter EPS of $1.05, an increase of 36%, primarily reflecting the growth in \nPharma segment profit.  ", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a4b1e1a762ce451ccf9891fffc7591f45a208e8936e47188d7ada7e6a19ec3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be4d0968-5965-446a-b9b3-fc2afa181077", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "original_text": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n"}, "hash": "a91074d0abe845d6dab86541f663b8f935f1352f3f45043c48673696d57fa381", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n", "start_char_idx": 0, "end_char_idx": 168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be4d0968-5965-446a-b9b3-fc2afa181077": {"__data__": {"id_": "be4d0968-5965-446a-b9b3-fc2afa181077", "embedding": null, "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "original_text": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "656c20d0-76a2-4803-ade2-d6b8e2353c04", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "original_text": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85dacf796920db85cc99332c614a63f9907691e2511f8c7611646e9fc0a6dcf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04ca7c48-b863-4535-9470-35d340fe0eab", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "original_text": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n"}, "hash": "16e431f831845d7b2453f9063558db3646d830ec8231e89d636ca20794c0d599", "class_name": "RelatedNodeInfo"}}, "text": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n", "start_char_idx": 168, "end_char_idx": 246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04ca7c48-b863-4535-9470-35d340fe0eab": {"__data__": {"id_": "04ca7c48-b863-4535-9470-35d340fe0eab", "embedding": null, "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "original_text": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be4d0968-5965-446a-b9b3-fc2afa181077", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "original_text": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac59697543a6b1777027942020a65bb0a7ff78a4bea0bfc7bca52eb97ccfe7d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% . ", "original_text": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n"}, "hash": "679cfe8b3cabc493378df79a9d958e414fa0a6d92acee052c4bb4b3ba2ac1ee3", "class_name": "RelatedNodeInfo"}}, "text": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n", "start_char_idx": 246, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1": {"__data__": {"id_": "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1", "embedding": null, "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% . ", "original_text": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04ca7c48-b863-4535-9470-35d340fe0eab", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "original_text": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2e3bc3cd47545e7225e6a310f54cb734eb4e4891891ab04ed0d4bba570ae3b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73729b7d-58e9-4cf9-89a2-b4d77f54e9df", "node_type": "1", "metadata": {"window": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "original_text": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n"}, "hash": "e64171a3ca5cb2f5e4ceb1fd0962d322a6aea8d6e303a5316b1329c426683fdd", "class_name": "RelatedNodeInfo"}}, "text": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "start_char_idx": 497, "end_char_idx": 753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73729b7d-58e9-4cf9-89a2-b4d77f54e9df": {"__data__": {"id_": "73729b7d-58e9-4cf9-89a2-b4d77f54e9df", "embedding": null, "metadata": {"window": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "original_text": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1", "node_type": "1", "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% . ", "original_text": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6656fa4ccd3bdb915034ca9c7dfa534f2b75fa3de89bf63122f422e5e1f89c3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "906758ae-5ab3-40af-8927-3bf361f1cf28", "node_type": "1", "metadata": {"window": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "original_text": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n"}, "hash": "675dc326e5f8f1b17032fa422c0bc792847b6080ad03ecf19fa6fc04e2876b9f", "class_name": "RelatedNodeInfo"}}, "text": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "start_char_idx": 753, "end_char_idx": 860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "906758ae-5ab3-40af-8927-3bf361f1cf28": {"__data__": {"id_": "906758ae-5ab3-40af-8927-3bf361f1cf28", "embedding": null, "metadata": {"window": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "original_text": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73729b7d-58e9-4cf9-89a2-b4d77f54e9df", "node_type": "1", "metadata": {"window": "Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "original_text": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55061d62262368a11f82fe470b518089467f71bc5f5ac4d7178347084b9ee814", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1ca554b-732e-48ee-9774-5c58268801e4", "node_type": "1", "metadata": {"window": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "original_text": "Our annual effective tax rate finished at 22.1% . "}, "hash": "930c7e2c874a2e6a9e7d0debd9935f05cba0b311fe6fe51ef0c561473cbdf10c", "class_name": "RelatedNodeInfo"}}, "text": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "start_char_idx": 860, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1ca554b-732e-48ee-9774-5c58268801e4": {"__data__": {"id_": "a1ca554b-732e-48ee-9774-5c58268801e4", "embedding": null, "metadata": {"window": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "original_text": "Our annual effective tax rate finished at 22.1% . ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "906758ae-5ab3-40af-8927-3bf361f1cf28", "node_type": "1", "metadata": {"window": "Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "original_text": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb5e6ec3d53a9f70c54537462d7808e306880d7c87d5903ad2ced4f0a1b004b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca86e9ca-b782-4ee2-a0df-42e8e7740993", "node_type": "1", "metadata": {"window": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "original_text": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n"}, "hash": "ef377839a08c6284ff88c372f708bdba5531d154f16770b6d0d50238e6fee578", "class_name": "RelatedNodeInfo"}}, "text": "Our annual effective tax rate finished at 22.1% . ", "start_char_idx": 979, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca86e9ca-b782-4ee2-a0df-42e8e7740993": {"__data__": {"id_": "ca86e9ca-b782-4ee2-a0df-42e8e7740993", "embedding": null, "metadata": {"window": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "original_text": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1ca554b-732e-48ee-9774-5c58268801e4", "node_type": "1", "metadata": {"window": "Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "original_text": "Our annual effective tax rate finished at 22.1% . ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4133de7e4b22b2fb0e25fc58845c2a569c29478fefce02bc09241f39d44669d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b01d0b6-2642-4584-8fac-38a4db273f7d", "node_type": "1", "metadata": {"window": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "original_text": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. "}, "hash": "3931491443eead9bae86062039c49fa77e1c6205cd0058def8c5c6ceeb8a968d", "class_name": "RelatedNodeInfo"}}, "text": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "start_char_idx": 1029, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b01d0b6-2642-4584-8fac-38a4db273f7d": {"__data__": {"id_": "3b01d0b6-2642-4584-8fac-38a4db273f7d", "embedding": null, "metadata": {"window": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "original_text": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca86e9ca-b782-4ee2-a0df-42e8e7740993", "node_type": "1", "metadata": {"window": "Interest and other increased 24% to $165 million, largely due to the items affecting the fourt h quarter. \n Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "original_text": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14e2b0d72b5130bc67a81f360d3945926db7529dbc9b16fc3ab4d23f55fb0ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4918ad5b-c455-4e17-886c-0196723e771e", "node_type": "1", "metadata": {"window": "Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "original_text": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. "}, "hash": "b1a688a485e3eb794faf035d570b1365021dabb0c41de3af032a400918dce50b", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "start_char_idx": 1078, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4918ad5b-c455-4e17-886c-0196723e771e": {"__data__": {"id_": "4918ad5b-c455-4e17-886c-0196723e771e", "embedding": null, "metadata": {"window": "Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "original_text": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b01d0b6-2642-4584-8fac-38a4db273f7d", "node_type": "1", "metadata": {"window": "Of note, this came in higher than our guidance primarily due to the equity investment write -down in \nthe quarter.  \n \n Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "original_text": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29de4ee761ae077203d8a5ee90b44a8c3f6fa59c1cf6aba32295f670d0b908f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae84a2ff-ac7a-447c-aef0-33f93fdaf039", "node_type": "1", "metadata": {"window": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "original_text": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. "}, "hash": "8d819055395b033d2a11cfee832f04cd6895887ef7ba207ebcc87e4ad16e1030", "class_name": "RelatedNodeInfo"}}, "text": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "start_char_idx": 1187, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae84a2ff-ac7a-447c-aef0-33f93fdaf039": {"__data__": {"id_": "ae84a2ff-ac7a-447c-aef0-33f93fdaf039", "embedding": null, "metadata": {"window": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "original_text": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4918ad5b-c455-4e17-886c-0196723e771e", "node_type": "1", "metadata": {"window": "Our annual effective tax rate finished at 22.1% .  The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "original_text": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40fadc3bae4af6178ed3cce0e065c727310340ffe9f50835bbc4ba018375c5d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd8bcbdb-0990-476c-a16d-fba6709a9bb2", "node_type": "1", "metadata": {"window": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "original_text": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n"}, "hash": "3488ec1aed2fb867ce1b460a77beb1ebb06c3fa78e68206afad42a3ae3bc5d40", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "start_char_idx": 1299, "end_char_idx": 1429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd8bcbdb-0990-476c-a16d-fba6709a9bb2": {"__data__": {"id_": "bd8bcbdb-0990-476c-a16d-fba6709a9bb2", "embedding": null, "metadata": {"window": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "original_text": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae84a2ff-ac7a-447c-aef0-33f93fdaf039", "node_type": "1", "metadata": {"window": "The net result was fiscal \u201822 EPS of $5.06 .  \n \n Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "original_text": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8fc60cc9e5db2a1be27214cce8096f07b601beaa9efce7e2a658849c982e041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "695f3d85-2c5f-4a03-beb4-f04b6ecd265b", "node_type": "1", "metadata": {"window": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "original_text": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n"}, "hash": "56ca4997a1af65bda6c9ef1b49243cf97ecacbc10b8ec096601eeb2db19d135e", "class_name": "RelatedNodeInfo"}}, "text": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "start_char_idx": 1429, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "695f3d85-2c5f-4a03-beb4-f04b6ecd265b": {"__data__": {"id_": "695f3d85-2c5f-4a03-beb4-f04b6ecd265b", "embedding": null, "metadata": {"window": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "original_text": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd8bcbdb-0990-476c-a16d-fba6709a9bb2", "node_type": "1", "metadata": {"window": "Now, turning to the balance shee t. In fiscal \u201822, we generated robust operating cash flow of $3.1 \nbillion.  This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "original_text": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e162afbf2b3975655b3fd2524600b1af8b5a409196147c5f0c48c5b4f621ebff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2c1839c-5568-4be4-be29-8763900a9359", "node_type": "1", "metadata": {"window": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "original_text": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . "}, "hash": "32807d4cff34161e0cc5997d2ea9ae00cd52a3f8e9b2b6da8798960eb9c5b4fe", "class_name": "RelatedNodeInfo"}}, "text": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "start_char_idx": 1619, "end_char_idx": 1718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2c1839c-5568-4be4-be29-8763900a9359": {"__data__": {"id_": "f2c1839c-5568-4be4-be29-8763900a9359", "embedding": null, "metadata": {"window": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "original_text": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "695f3d85-2c5f-4a03-beb4-f04b6ecd265b", "node_type": "1", "metadata": {"window": "This includes the previously -defined tax refund of nearly $1 billion and favorable timing of \nworking capital.  Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "original_text": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dcbbf090f3ab9cd12e607e92610895a9674cf2edb293f51ef88718fb29f78bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4115c47-d67d-4f52-81bc-28ce71d7ab57", "node_type": "1", "metadata": {"window": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "original_text": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n"}, "hash": "a94fa99777c56c9219c12355db5874c87e93479e39b0a9ff9511837443fabd5a", "class_name": "RelatedNodeInfo"}}, "text": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "start_char_idx": 1718, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4115c47-d67d-4f52-81bc-28ce71d7ab57": {"__data__": {"id_": "f4115c47-d67d-4f52-81bc-28ce71d7ab57", "embedding": null, "metadata": {"window": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "original_text": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2c1839c-5568-4be4-be29-8763900a9359", "node_type": "1", "metadata": {"window": "Additionally, in fiscal \u201822 we made approximately $500 million in litigat ion payments, \nprimarily related to opioid settlements.  In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "original_text": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends . ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "170bed372c28d0f0b2f155792b93922e3bf780537b8307ad20903a78d130ea62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1a57cd0-1097-4bfb-9817-5aa2345bcd47", "node_type": "1", "metadata": {"window": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "original_text": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n"}, "hash": "870f892fa4035a4eb224b8af382dfdc40f318f56a38cb043a59757e744962e7b", "class_name": "RelatedNodeInfo"}}, "text": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "start_char_idx": 1974, "end_char_idx": 2138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1a57cd0-1097-4bfb-9817-5aa2345bcd47": {"__data__": {"id_": "a1a57cd0-1097-4bfb-9817-5aa2345bcd47", "embedding": null, "metadata": {"window": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "original_text": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4115c47-d67d-4f52-81bc-28ce71d7ab57", "node_type": "1", "metadata": {"window": "In July, we made our second annual payment under the \nnational opioid settlement agreement of approximately $375 million, which will be reflected in Q1 \nfiscal \u201823 operating cash flow .  \n \n We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "original_text": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40939558bf897cd4e29d3423ca58eede5f7ac2a0e2b7aafff658f188f4831a67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "807aef4b-3955-4fb2-b5b5-c51f7c3564ff", "node_type": "1", "metadata": {"window": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. "}, "hash": "3b204dfc14fdc6608a791ec0857d922ce0ca38de3c8370d89f5d26a0c7b9c595", "class_name": "RelatedNodeInfo"}}, "text": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "start_char_idx": 2138, "end_char_idx": 2325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "807aef4b-3955-4fb2-b5b5-c51f7c3564ff": {"__data__": {"id_": "807aef4b-3955-4fb2-b5b5-c51f7c3564ff", "embedding": null, "metadata": {"window": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1a57cd0-1097-4bfb-9817-5aa2345bcd47", "node_type": "1", "metadata": {"window": "We are focused on deploying capital in a balanced, disciplined, and shareholder -friendly manner. \n This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "original_text": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90e89c61e6458278217653fe9884155ff17bdec81b4e448798a49f716204e495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60983600-66d4-48e5-a06e-9cf1c0fb566b", "node_type": "1", "metadata": {"window": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n"}, "hash": "404ec1665bee441e1007ec8b09da0b4adcb647de170c8417110f47306e2f4bc5", "class_name": "RelatedNodeInfo"}}, "text": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "start_char_idx": 2325, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60983600-66d4-48e5-a06e-9cf1c0fb566b": {"__data__": {"id_": "60983600-66d4-48e5-a06e-9cf1c0fb566b", "embedding": null, "metadata": {"window": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "807aef4b-3955-4fb2-b5b5-c51f7c3564ff", "node_type": "1", "metadata": {"window": "This year we invested approximately $385 million of capex back into the business to drive future \ngrowth, paid down approximately $850 million in debt to reduce leverage, and returned $1.6 billion to \nshareholders through share repurchases and dividends .  We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72a029006e3a9e458162774e9c4221782e43dee4d02900712aed68b4614ba6f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a85e280-5561-44e0-a523-b98968f519ec", "node_type": "1", "metadata": {"window": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. "}, "hash": "97b125ae09bcda7121f770608abfb1c9d72d1c01e6d1954ac7dd474bd4d02360", "class_name": "RelatedNodeInfo"}}, "text": "This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "start_char_idx": 2485, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a85e280-5561-44e0-a523-b98968f519ec": {"__data__": {"id_": "2a85e280-5561-44e0-a523-b98968f519ec", "embedding": null, "metadata": {"window": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60983600-66d4-48e5-a06e-9cf1c0fb566b", "node_type": "1", "metadata": {"window": "We ended the year with a cash position of \n$4.7 billion, which does reflect some timing favorability, with no outstanding borrowings on our credit \nfacilities.  \n \n As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d7e49ce59a7cf3abdfab4b7436ae7bde0d47a92d1ea7e1386cf28a095a40043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15d0090d-5a12-4146-bfcd-31e6c9bb7609", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Additionally, "}, "hash": "68f6f3b9c086115a6617cf0d44d316045753b6975e8f3b59f13e88e7cdc046e4", "class_name": "RelatedNodeInfo"}}, "text": "To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "start_char_idx": 2595, "end_char_idx": 2789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15d0090d-5a12-4146-bfcd-31e6c9bb7609": {"__data__": {"id_": "15d0090d-5a12-4146-bfcd-31e6c9bb7609", "embedding": null, "metadata": {"window": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Additionally, ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "65d1702b-a233-4b64-84ec-253e432e1c0e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e189f86b264f775bc9234b8888db97b1912a5c29717db46d7c7b6f409312212", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a85e280-5561-44e0-a523-b98968f519ec", "node_type": "1", "metadata": {"window": "As for the segme nt's full year results, beginning with Pharma on slide 10...  \n \nPharma revenue increased 14% to $165 billion, reflecting consistent drivers with the fourth quarter.  \n \n Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis. ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a01955d64609174dab86afba43cc4ee0107d629704e61aefdd642adb0f5ce31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83b6851f-0537-46fd-9f7e-a4a07216ac7e", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "original_text": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n"}, "hash": "e4f7d413750b0217d9c13ec78a94ea4c2d730ce879832e94480d630869aaf3fc", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, ", "start_char_idx": 1299, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83b6851f-0537-46fd-9f7e-a4a07216ac7e": {"__data__": {"id_": "83b6851f-0537-46fd-9f7e-a4a07216ac7e", "embedding": null, "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "original_text": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15d0090d-5a12-4146-bfcd-31e6c9bb7609", "node_type": "1", "metadata": {"window": "Pharma segment profit increased 5% to $1.8 billion, driven primarily by generics program \nperformance and an improvement in volumes compared to the prior year.  This was partially offset by \ninvestments in technology enhancements and inflationary supply chain costs.  \n \n To be helpful, the tailwind from improved volumes and the headwind from incrementa l IT investments \neffectively offset in fiscal \u201822, each approximately $80 million on a year -over-year basis.  Additionally, ", "original_text": "Additionally, ", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc49f46506bffbf803c29057cb73aab45b140df65a87dec8c18c02f0a98de03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "561ba048-ad71-46e9-bf0f-736b660ca09c", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "original_text": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business. "}, "hash": "d57eff325634ed636ba30f8f60d7bb0175871597552fca95b86e12b04bdb7ae3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n", "start_char_idx": 0, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "561ba048-ad71-46e9-bf0f-736b660ca09c": {"__data__": {"id_": "561ba048-ad71-46e9-bf0f-736b660ca09c", "embedding": null, "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "original_text": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83b6851f-0537-46fd-9f7e-a4a07216ac7e", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "original_text": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dec0a6288d47fcb3bac5f45ed3628d4df9f9ceaf84baa5dccdcbe9333226f28b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63418bdb-1d95-4752-8869-49cf44355fb0", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "original_text": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n"}, "hash": "178687dfc243450993daeee1709ad92e4c49b583e2919e4726d493e0150b2975", "class_name": "RelatedNodeInfo"}}, "text": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business. ", "start_char_idx": 147, "end_char_idx": 301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63418bdb-1d95-4752-8869-49cf44355fb0": {"__data__": {"id_": "63418bdb-1d95-4752-8869-49cf44355fb0", "embedding": null, "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "original_text": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "561ba048-ad71-46e9-bf0f-736b660ca09c", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "original_text": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a1ccbfaaaa5d09192f9af8eb85791497a579a261e77042c0d25bdc0543413ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2435043d-b771-4200-b6b4-0a0d69d0208a", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "original_text": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. "}, "hash": "29286dff29a3af910d3651d84021e61e7562367e8723ef59392209e3bbc88663", "class_name": "RelatedNodeInfo"}}, "text": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n", "start_char_idx": 301, "end_char_idx": 421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2435043d-b771-4200-b6b4-0a0d69d0208a": {"__data__": {"id_": "2435043d-b771-4200-b6b4-0a0d69d0208a", "embedding": null, "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "original_text": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63418bdb-1d95-4752-8869-49cf44355fb0", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "original_text": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45372015851cd3f7d20e05c36606171bd09fed8675f063982e51dee5f7a384db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc04324b-3e92-474a-9565-e4c43cce8c76", "node_type": "1", "metadata": {"window": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "original_text": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n"}, "hash": "00c2f7c045e5fe8d750dd2dadbaf5a0da25f58d29f9f54f840758a00cabfdea9", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "start_char_idx": 421, "end_char_idx": 581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc04324b-3e92-474a-9565-e4c43cce8c76": {"__data__": {"id_": "cc04324b-3e92-474a-9565-e4c43cce8c76", "embedding": null, "metadata": {"window": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "original_text": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2435043d-b771-4200-b6b4-0a0d69d0208a", "node_type": "1", "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "original_text": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62d737e9b388773c5adee9fdd6f661bbc8889d5665a42a8e0a844491dcdae6e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f96d3bff-7815-4bbf-8253-059d88ceeba3", "node_type": "1", "metadata": {"window": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "original_text": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n"}, "hash": "7f7dfb2ffed96ba5cb75aee12f3b1c3a51bc4376a23cddc903c1c7bad0f122fd", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "start_char_idx": 581, "end_char_idx": 755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f96d3bff-7815-4bbf-8253-059d88ceeba3": {"__data__": {"id_": "f96d3bff-7815-4bbf-8253-059d88ceeba3", "embedding": null, "metadata": {"window": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "original_text": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc04324b-3e92-474a-9565-e4c43cce8c76", "node_type": "1", "metadata": {"window": "Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "original_text": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6063810713329a5588aa1ad8e416cfb0b7f8f90882154a5977a370666f580ea5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87042e3b-5edb-4bf9-9e01-c564b3b224f2", "node_type": "1", "metadata": {"window": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "original_text": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n"}, "hash": "f0351afce93c2949bd983d6a824fe33a65b47d26aa72aff2a8c79342739c671e", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "start_char_idx": 755, "end_char_idx": 915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87042e3b-5edb-4bf9-9e01-c564b3b224f2": {"__data__": {"id_": "87042e3b-5edb-4bf9-9e01-c564b3b224f2", "embedding": null, "metadata": {"window": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "original_text": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f96d3bff-7815-4bbf-8253-059d88ceeba3", "node_type": "1", "metadata": {"window": "To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "original_text": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db01a57f31028d3660a66ba0b0e9ec541f342b57a8d208e03cea383435cd9041", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce6f16a8-647d-4e36-a93f-64a732675583", "node_type": "1", "metadata": {"window": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n"}, "hash": "dbfe5d48bb7a339c624066cba1128320bfc7a0a0cab957312d2b0006d4ad68e2", "class_name": "RelatedNodeInfo"}}, "text": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "start_char_idx": 915, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce6f16a8-647d-4e36-a93f-64a732675583": {"__data__": {"id_": "ce6f16a8-647d-4e36-a93f-64a732675583", "embedding": null, "metadata": {"window": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87042e3b-5edb-4bf9-9e01-c564b3b224f2", "node_type": "1", "metadata": {"window": "Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution.  Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "original_text": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5745c38f8aa56254ba007832e417354443fccf537975b1c3d8685901bb0daa88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc6f00cd-9f2e-454b-96b3-a3912de2edcc", "node_type": "1", "metadata": {"window": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "original_text": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n"}, "hash": "dac4a88352ce7777d1f31a3f189a9a9992b2823be7b1c5187f61d8ddedbcc991", "class_name": "RelatedNodeInfo"}}, "text": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "start_char_idx": 1112, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc6f00cd-9f2e-454b-96b3-a3912de2edcc": {"__data__": {"id_": "fc6f00cd-9f2e-454b-96b3-a3912de2edcc", "embedding": null, "metadata": {"window": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "original_text": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce6f16a8-647d-4e36-a93f-64a732675583", "node_type": "1", "metadata": {"window": "Additionally, the favorable comparison to the \nprior year PPE inventory reserve was offset by a lowe r contribution from PPE and the divestiture of \nthe Cordis business.  \n \n Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "original_text": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10c436c8956a931803d2ff4cddb8c48da276c0147613c9f75444e311edc7b825", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "073c1acf-48c0-4eac-8f5b-dca4c5ed0078", "node_type": "1", "metadata": {"window": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "original_text": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n"}, "hash": "0c61361dd79be3bd79d190128e27009d739607dceb58673b09792ddde39fc368", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "start_char_idx": 1191, "end_char_idx": 1392, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "073c1acf-48c0-4eac-8f5b-dca4c5ed0078": {"__data__": {"id_": "073c1acf-48c0-4eac-8f5b-dca4c5ed0078", "embedding": null, "metadata": {"window": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "original_text": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc6f00cd-9f2e-454b-96b3-a3912de2edcc", "node_type": "1", "metadata": {"window": "Now, for our fiscal \u201823 guidance on slide 13...  \n \nWe expect earnings per share in the range of $5.05 to $5.40, which reflects the following \nassumptions.  \n \n First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "original_text": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba83ef7a0e52da468bc53e0effa1aa0f35d86ff74302886435c3976ba8646413", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc073d7d-2989-46dc-b6a3-9fee7f6bee11", "node_type": "1", "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. "}, "hash": "314c0b50093797383f5ae1db9dc347dfe7a21aa479dafa67ef166ff5ee9152f3", "class_name": "RelatedNodeInfo"}}, "text": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "start_char_idx": 1392, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc073d7d-2989-46dc-b6a3-9fee7f6bee11": {"__data__": {"id_": "cc073d7d-2989-46dc-b6a3-9fee7f6bee11", "embedding": null, "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "073c1acf-48c0-4eac-8f5b-dca4c5ed0078", "node_type": "1", "metadata": {"window": "First, for the enterprise , we expect interest and other between $140 to $170 million, which assumes \napproximately $550 million in debt paydown for the March 2023 notes at or before maturity.  \n \n We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "original_text": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30ccf4d4d6afa2b4d563c8e87137debbe02618d611af62a07cef0150bc07309f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acf730fb-4c73-4640-aa1a-eb984bb07f93", "node_type": "1", "metadata": {"window": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n"}, "hash": "df42a530a33a4089c077e3112323ed87287b0e9056d345e22a6dc74f480accba", "class_name": "RelatedNodeInfo"}}, "text": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "start_char_idx": 1617, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acf730fb-4c73-4640-aa1a-eb984bb07f93": {"__data__": {"id_": "acf730fb-4c73-4640-aa1a-eb984bb07f93", "embedding": null, "metadata": {"window": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc073d7d-2989-46dc-b6a3-9fee7f6bee11", "node_type": "1", "metadata": {"window": "We are assuming a non -GAAP effective tax rate in the range of 23% to 25%.  \n \n We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers. ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bf3c86180b05c23b17812b4c000149028af2c15dbfb3445334d67b5d2e4c52b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2782d5b6-9cae-4265-8306-af494048da86", "node_type": "1", "metadata": {"window": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n"}, "hash": "2cc40ce515a8e02bad8e170ccbb7fe253974faf662f53f6012326ea8b315ae96", "class_name": "RelatedNodeInfo"}}, "text": "We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "start_char_idx": 1799, "end_char_idx": 2039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2782d5b6-9cae-4265-8306-af494048da86": {"__data__": {"id_": "2782d5b6-9cae-4265-8306-af494048da86", "embedding": null, "metadata": {"window": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acf730fb-4c73-4640-aa1a-eb984bb07f93", "node_type": "1", "metadata": {"window": "We anticipate diluted weighted average shares outstanding between 262 and 266 million, reflecting \nour plan to complete between $1.5 to $2 billion in share repurchases over the course of the year.  \n \n And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1469fb80cf44e36c8f05abcfbbef9b6e695e0402fc5b618c1f2750838230dd7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a692b3-f848-419f-8dc3-a6fddecec6cc", "node_type": "1", "metadata": {"window": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n "}, "hash": "f46e21ae9f5f7ebc77c7f12b7b1d847efa027cee4ed76637772ba8cc15466dbd", "class_name": "RelatedNodeInfo"}}, "text": "A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "start_char_idx": 2039, "end_char_idx": 2226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a692b3-f848-419f-8dc3-a6fddecec6cc": {"__data__": {"id_": "35a692b3-f848-419f-8dc3-a6fddecec6cc", "embedding": null, "metadata": {"window": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c346995d-f3e6-4eee-b999-c708c41be3d0", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541f0f188298ec225778de00ac2fe7b4cc3a30c43b39d2db05245b67d6d8f6e7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2782d5b6-9cae-4265-8306-af494048da86", "node_type": "1", "metadata": {"window": "And, supporting our capital allocation priorities, we expect adjusted free cash flow in the range of $1.5 \nto $2 billion, which excludes litigation payments and any other significant and unusual or non -\nrecurring items.  \n \n As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37ac5b0cda6a389e42f63a3f2167b83f52924685213897c78ddf5d6b72770176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04286e88-d729-4d6c-a020-d14f126576aa", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "original_text": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.  "}, "hash": "8f1f5e390ca7471f7d309784172e3ce7efcf97450d5d0661a35909d2db1bbad1", "class_name": "RelatedNodeInfo"}}, "text": "The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "start_char_idx": 2226, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04286e88-d729-4d6c-a020-d14f126576aa": {"__data__": {"id_": "04286e88-d729-4d6c-a020-d14f126576aa", "embedding": null, "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "original_text": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.  ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a692b3-f848-419f-8dc3-a6fddecec6cc", "node_type": "1", "metadata": {"window": "As for the segments, beginning with Pharma on slide 14\u2026  \n \nWe expect revenue growth in the range of  10 to 14% driven by growth in existing and net new PD \nand Specialty customers.  We expect segment profit growth in the range of 2 to 5%, based on the \nfollowing key assumptions:  \n \nWe expect continued stability in overall pharmaceutical volumes, along with co nsistent market \ndynamics within our generics program.  \n \n A continuation of the inflationary supply chain costs we\u2019ve seen the last two quarters should result in \nan approximate $50 million headwind, primarily in the first half of the year.  \n \n The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "original_text": "The completion of  ERP technology enhancements should be an approximate $30 million tailwind.  \n ", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "606a7720bb5848eb976919606ab610f60ebb73b026b870b79714c85ea28f9c22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd51e05a-7bb8-4944-85f3-24b0afd787e2", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "original_text": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n"}, "hash": "7760ba9611cf9d8c9ced44c65e810576d61e2a823d7794d63a0a8445fb1ed0cc", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.  ", "start_char_idx": 0, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd51e05a-7bb8-4944-85f3-24b0afd787e2": {"__data__": {"id_": "fd51e05a-7bb8-4944-85f3-24b0afd787e2", "embedding": null, "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "original_text": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04286e88-d729-4d6c-a020-d14f126576aa", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "original_text": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.  ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f2183d2d4b55cb08b018904239d128ccf5762de04709cad14aca3dfef218890", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d7e281a-6666-4787-bae8-cb5f39523c23", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "original_text": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half. "}, "hash": "900f4413fd0e4190365741e73cd61d207ba88d53734aa97be8f59af904103f46", "class_name": "RelatedNodeInfo"}}, "text": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n", "start_char_idx": 216, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d7e281a-6666-4787-bae8-cb5f39523c23": {"__data__": {"id_": "8d7e281a-6666-4787-bae8-cb5f39523c23", "embedding": null, "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "original_text": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd51e05a-7bb8-4944-85f3-24b0afd787e2", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "original_text": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9acf2c27ac3823ba7ca134f7dd6237cf265c05de2dd3bbc4a4a1a68ec3c676ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dfe5b51-69e0-4743-a563-b3b85452cb0a", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "original_text": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. "}, "hash": "5aa541928a678a595aa4d18c8b65ffd18655c6dd6da11c0241c0e2f5d965f582", "class_name": "RelatedNodeInfo"}}, "text": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half. ", "start_char_idx": 324, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dfe5b51-69e0-4743-a563-b3b85452cb0a": {"__data__": {"id_": "3dfe5b51-69e0-4743-a563-b3b85452cb0a", "embedding": null, "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "original_text": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d7e281a-6666-4787-bae8-cb5f39523c23", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "original_text": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30648b0d34da87a060f95efdd3101a942dc493c1f6dbc5150dfdc606322fa064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88ace672-1aee-44d1-ae83-7c9efeb502f0", "node_type": "1", "metadata": {"window": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "original_text": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n"}, "hash": "766794ab46d206f18169fe0803243a9379ca8e4193b1b3db376b4095f202cd40", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "start_char_idx": 626, "end_char_idx": 732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88ace672-1aee-44d1-ae83-7c9efeb502f0": {"__data__": {"id_": "88ace672-1aee-44d1-ae83-7c9efeb502f0", "embedding": null, "metadata": {"window": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "original_text": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dfe5b51-69e0-4743-a563-b3b85452cb0a", "node_type": "1", "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "original_text": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ae3310de2cf471660a18e00ff7e55c01068602a50f02f3640b6c2afe6e59ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c23439c-e2f5-4578-8488-60c51251f51c", "node_type": "1", "metadata": {"window": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "original_text": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. "}, "hash": "afe518455d74193638eb5afcb3d6c28d5ece743334b1c0218d07e5234d3ec395", "class_name": "RelatedNodeInfo"}}, "text": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "start_char_idx": 732, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c23439c-e2f5-4578-8488-60c51251f51c": {"__data__": {"id_": "7c23439c-e2f5-4578-8488-60c51251f51c", "embedding": null, "metadata": {"window": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "original_text": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88ace672-1aee-44d1-ae83-7c9efeb502f0", "node_type": "1", "metadata": {"window": "And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "original_text": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26204fe7a7e57d414a83baa7381472eddbbde78989c511802d3420e201c7a885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e955c05-9a36-4134-8875-98d608b498f9", "node_type": "1", "metadata": {"window": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "original_text": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. "}, "hash": "4a659ba8591b406fdd44faa2a451f226d407b23dc5706ec15c477b345f92cc1b", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "start_char_idx": 891, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e955c05-9a36-4134-8875-98d608b498f9": {"__data__": {"id_": "5e955c05-9a36-4134-8875-98d608b498f9", "embedding": null, "metadata": {"window": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "original_text": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c23439c-e2f5-4578-8488-60c51251f51c", "node_type": "1", "metadata": {"window": "Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "original_text": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "588fcbd16e42c966f47103dc944fa7d54e4272babc1da4a7e93ba3d00ea12c8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67", "node_type": "1", "metadata": {"window": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "original_text": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n"}, "hash": "e77323659069b9d39c4f95078a7d395f0d14d9bb9f4210b216d9324b99199a25", "class_name": "RelatedNodeInfo"}}, "text": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "start_char_idx": 1036, "end_char_idx": 1349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67": {"__data__": {"id_": "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67", "embedding": null, "metadata": {"window": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "original_text": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e955c05-9a36-4134-8875-98d608b498f9", "node_type": "1", "metadata": {"window": "Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million.  While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "original_text": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a98c83d6cf5291384a820ac2815f1726e71e7b29c7542f066e72985bdc1be10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db52f79-56f3-4b77-854b-7e2fffef850b", "node_type": "1", "metadata": {"window": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "original_text": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. "}, "hash": "af10844049f7f5ffb22ba9596066245f68875b329482a37dba18a8cbdf579a02", "class_name": "RelatedNodeInfo"}}, "text": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "start_char_idx": 1349, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db52f79-56f3-4b77-854b-7e2fffef850b": {"__data__": {"id_": "7db52f79-56f3-4b77-854b-7e2fffef850b", "embedding": null, "metadata": {"window": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "original_text": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67", "node_type": "1", "metadata": {"window": "While we do not typically provide quarterly guidance, we thought additional color may be \nhelpful given the puts and takes over the last several quarters.  \n \n Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "original_text": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e62b89ec1328474b8f0f40ac97d2e1da26e9cdc38c580edb81dee3141431cffc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98a5b75a-493f-4873-84a4-15fbdebdddc2", "node_type": "1", "metadata": {"window": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "original_text": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. "}, "hash": "8b2f4fe4c40611177e09fa799fee9de1a7c91b432b472bdc6c484b9b6dbb51b8", "class_name": "RelatedNodeInfo"}}, "text": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "start_char_idx": 1579, "end_char_idx": 1782, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98a5b75a-493f-4873-84a4-15fbdebdddc2": {"__data__": {"id_": "98a5b75a-493f-4873-84a4-15fbdebdddc2", "embedding": null, "metadata": {"window": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "original_text": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db52f79-56f3-4b77-854b-7e2fffef850b", "node_type": "1", "metadata": {"window": "Now turning to Medical on slide 15...  \n \nWe expect revenue to decline in  the range of 3 to 6% due to lower PPE sales and lab testing \nvolumes.  We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "original_text": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c56fcd99f5bd54e4ea8dc952a497fc82f045f0db020367fe5997cfbf239b7453", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5aec7777-8729-47a4-916f-adb71b169c97", "node_type": "1", "metadata": {"window": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "original_text": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. "}, "hash": "d0c21afe4bcce4f6a045628953905e2a4f6e4b0f4967e46dfe11b8a5f0e5f783", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "start_char_idx": 1782, "end_char_idx": 2012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5aec7777-8729-47a4-916f-adb71b169c97": {"__data__": {"id_": "5aec7777-8729-47a4-916f-adb71b169c97", "embedding": null, "metadata": {"window": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "original_text": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98a5b75a-493f-4873-84a4-15fbdebdddc2", "node_type": "1", "metadata": {"window": "We expect segment profit ranging from a decline of 10% to growth of 10%, reflecting the \nfollowing assumptions:  \n \nWe expect a similar net impact of approximately $300 million from inflation, global supply chain \nconstraints, and mitigation actions in fiscal \u201823, or a minimal impact on a year -over-year basis.  This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "original_text": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0979b42f10d9b35f89eb173f32ac9ec5266c1823fb6edb66e91501f2ae988bf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bc50d30-2681-4f2f-95fc-ad4d90c15d54", "node_type": "1", "metadata": {"window": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "original_text": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. "}, "hash": "5f055e69632d6261de58a5ba5d9b38f9664f2fe9e4fc38a421f68cde37948027", "class_name": "RelatedNodeInfo"}}, "text": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "start_char_idx": 2012, "end_char_idx": 2202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bc50d30-2681-4f2f-95fc-ad4d90c15d54": {"__data__": {"id_": "0bc50d30-2681-4f2f-95fc-ad4d90c15d54", "embedding": null, "metadata": {"window": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "original_text": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5aec7777-8729-47a4-916f-adb71b169c97", "node_type": "1", "metadata": {"window": "This \nassumes an approximate $475 million gross impact from in flation and global supply chain constraints, \npartially offset by $175 million of mitigation actions, including pricing and evolving our commercial \ncontracting .  \n \n While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "original_text": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a3ab1069131815c819b01839ebaea82a3c9165ce41babb5b5e54cdc32145803", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "424b579b-a7c3-4d28-9eca-98f9231897f2", "node_type": "1", "metadata": {"window": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "original_text": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n"}, "hash": "965ca516fc8074ddc1098ba309e38ff075b012c1f4ae1c4132c88c0bbab25830", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "start_char_idx": 2202, "end_char_idx": 2377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "424b579b-a7c3-4d28-9eca-98f9231897f2": {"__data__": {"id_": "424b579b-a7c3-4d28-9eca-98f9231897f2", "embedding": null, "metadata": {"window": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "original_text": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bc50d30-2681-4f2f-95fc-ad4d90c15d54", "node_type": "1", "metadata": {"window": "While still significantly elevated relative to historical levels, we\u2019re encouraged by the rec ent \nimprovements in spot rates of certain cost drivers such as international freight and some \ncommodities.  As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "original_text": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f00164d3e7aae1e7d6ef723c430a516ead6fd95ae415d2ca58501473a3a4799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2", "node_type": "1", "metadata": {"window": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. "}, "hash": "ec2ebc4dbb19f6e7636cdd114a25ae989be62a20aa92a000e51dd58d6e169793", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "start_char_idx": 2377, "end_char_idx": 2570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2": {"__data__": {"id_": "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2", "embedding": null, "metadata": {"window": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "424b579b-a7c3-4d28-9eca-98f9231897f2", "node_type": "1", "metadata": {"window": "As a reminder, these product costs are capitalized and have historically been reflected \nin our P&L results on a one to two  quarter delay, however, in  the current period of elongated supply \nchains it is closer to two quarters.  Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "original_text": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddef72ca42a3386ce75f78755aa6af14f4caaf25e6b8cc75694a5b3cb0614a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b69a99f3-ae0e-4730-a4e4-0373c7f23d75", "node_type": "1", "metadata": {"window": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n"}, "hash": "a73960e122eee7e57467cb6237d3178bac80be744b96b6bbe0e39a6f3c11c90e", "class_name": "RelatedNodeInfo"}}, "text": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "start_char_idx": 2570, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b69a99f3-ae0e-4730-a4e4-0373c7f23d75": {"__data__": {"id_": "b69a99f3-ae0e-4730-a4e4-0373c7f23d75", "embedding": null, "metadata": {"window": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2", "node_type": "1", "metadata": {"window": "Our current assumption is that the impact of inflation and global \nsupply chain constraints will peak in the first quarter of fiscal \u201823 and gradually decrease over the next \ncouple  years.  Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins. ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0e8a543434aa0f3fbc80b3b9b32f3625813fb7d4276c3c9caa188b35724d494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca28a5ea-196e-4cc7-b826-051c8bf8edcd", "node_type": "1", "metadata": {"window": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n"}, "hash": "a7330812a6e21a9b8d0b1ed5cad6ed5ef1d97954f4e5a4869479cd597c2b2ace", "class_name": "RelatedNodeInfo"}}, "text": "We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "start_char_idx": 2772, "end_char_idx": 2919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca28a5ea-196e-4cc7-b826-051c8bf8edcd": {"__data__": {"id_": "ca28a5ea-196e-4cc7-b826-051c8bf8edcd", "embedding": null, "metadata": {"window": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b69a99f3-ae0e-4730-a4e4-0373c7f23d75", "node_type": "1", "metadata": {"window": "Additionally, along with the pricing actions that went into effect at the start of the year, \nwe are implementing additional waves of increases over the course of fiscal \u201823.  We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "772cd141601026f8baad7935225a2bc0325bfe88bf0c7a9d62618c22cb8658f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7", "node_type": "1", "metadata": {"window": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  "}, "hash": "cf7f41e9943f25de39d981bd24953162c2eebfd4819c13105925d9f5725c8418", "class_name": "RelatedNodeInfo"}}, "text": "We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "start_char_idx": 2919, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7": {"__data__": {"id_": "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7", "embedding": null, "metadata": {"window": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b9f86132-8431-4532-8b36-81be49b4c509", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79cebfd07bd3da9f2a3e38836e2333e3a62918dd2d8880a3346b2888c4a28033", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca28a5ea-196e-4cc7-b826-051c8bf8edcd", "node_type": "1", "metadata": {"window": "We continue to \nexpect that as we exit fiscal \u201823, the run rate of our miti gation actions will offset at least 50% of the \ngross impact from inflation and global supply chain constraints.  \n \n In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b50bfb7ec292b4ad1be6bf321478d7035493a00a89cbe47bcec184f5c47f12d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f6d4d8e-9ca7-454e-9903-0e86d09baad4", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "original_text": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n"}, "hash": "dd288df80743209b4b7e2b570baf02265182ae4b2508d8167d99b9a1907443ca", "class_name": "RelatedNodeInfo"}}, "text": "We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "start_char_idx": 3018, "end_char_idx": 3161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f6d4d8e-9ca7-454e-9903-0e86d09baad4": {"__data__": {"id_": "9f6d4d8e-9ca7-454e-9903-0e86d09baad4", "embedding": null, "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "original_text": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7", "node_type": "1", "metadata": {"window": "In terms of other key assumptions for Medical in fiscal \u201823\u2026  \n \nAs the operating environment continues to normalize, we expect an approximate $50  million tailwind \nfrom an improvement in PPE margins.  We plan to sell -through the majority of higher cost PPE in the \nfirst half of the year, and for PPE margins to normalize as we exit the year.  \n \n We expect the PPE tailwind to be offset by a similar headwin d from lower lab testing volumes.  \n \n We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "original_text": "We also anticipate a headwind of approximately $50 million from re -baselining incentive \ncompensation following fiscal \u201822 underperformance.  ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb1aa69da15759972f7cce2b09add19afa0a59ddbf09b219f9f465d62ec29efb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95be8c6a-bae8-4318-b22c-439491b0c01e", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "original_text": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year. "}, "hash": "a26f720a46bf6099bfb6541473500e7b00933529cf6dafb24f28946574eca124", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n", "start_char_idx": 0, "end_char_idx": 133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95be8c6a-bae8-4318-b22c-439491b0c01e": {"__data__": {"id_": "95be8c6a-bae8-4318-b22c-439491b0c01e", "embedding": null, "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "original_text": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f6d4d8e-9ca7-454e-9903-0e86d09baad4", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "original_text": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5023bfdd5886cf19401dc304d4823b0c386f1f7a55cd810edbff8fb53ddbe01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "original_text": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million. "}, "hash": "df3c560162fea86fcd431d9f08fcfd5e4eb0f6ae8fd3b2aa49488244b923c02f", "class_name": "RelatedNodeInfo"}}, "text": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year. ", "start_char_idx": 133, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d": {"__data__": {"id_": "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d", "embedding": null, "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "original_text": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95be8c6a-bae8-4318-b22c-439491b0c01e", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "original_text": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e37718951528860ff0a22817b93afe14fbd941cd810e8f1e5b09294dfbfa725f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ab7416-5392-4f44-8cd8-8b70aaeb435d", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "original_text": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n"}, "hash": "4f01b15e735c9cd9a90fc27b570666bb238b4469bd572e3c3885c436c56a8e60", "class_name": "RelatedNodeInfo"}}, "text": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million. ", "start_char_idx": 318, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ab7416-5392-4f44-8cd8-8b70aaeb435d": {"__data__": {"id_": "56ab7416-5392-4f44-8cd8-8b70aaeb435d", "embedding": null, "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "original_text": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "original_text": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22679d3f7222c76d1f2f15a0d716c02c5190fc6262a08c0633f9c2fd22e07c37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed234f12-ef85-4567-9f63-ee243911acf8", "node_type": "1", "metadata": {"window": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "original_text": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. "}, "hash": "9e098e5924150fa96eaa5c088cbfec146665ae8da4e232eae817c25ff64855fc", "class_name": "RelatedNodeInfo"}}, "text": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "start_char_idx": 442, "end_char_idx": 651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed234f12-ef85-4567-9f63-ee243911acf8": {"__data__": {"id_": "ed234f12-ef85-4567-9f63-ee243911acf8", "embedding": null, "metadata": {"window": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "original_text": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ab7416-5392-4f44-8cd8-8b70aaeb435d", "node_type": "1", "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "original_text": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dda17bef8ea22f541176afcdc62d46ea8fea89dcdd57b6d3c7c6bb36dc7e049", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ccd4ad5-1665-4b3d-85d2-0043a24f355c", "node_type": "1", "metadata": {"window": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "original_text": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n"}, "hash": "e5e1ca9c6bb09a9a4574fdace5190cbd85269569a38c3354cd7a42ae01a2faea", "class_name": "RelatedNodeInfo"}}, "text": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "start_char_idx": 651, "end_char_idx": 812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ccd4ad5-1665-4b3d-85d2-0043a24f355c": {"__data__": {"id_": "6ccd4ad5-1665-4b3d-85d2-0043a24f355c", "embedding": null, "metadata": {"window": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "original_text": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed234f12-ef85-4567-9f63-ee243911acf8", "node_type": "1", "metadata": {"window": "On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "original_text": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0092af7f13854835ddbee27173ef6ba63fc3aec88976fc4d18371122e94d05ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba", "node_type": "1", "metadata": {"window": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.  ", "original_text": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. "}, "hash": "b4490ac455f9314108165673aa2598462068546bf693614b27ad93aee65069f6", "class_name": "RelatedNodeInfo"}}, "text": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "start_char_idx": 812, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba": {"__data__": {"id_": "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba", "embedding": null, "metadata": {"window": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.  ", "original_text": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ccd4ad5-1665-4b3d-85d2-0043a24f355c", "node_type": "1", "metadata": {"window": "Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "original_text": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8225e5555d439901ef3e49ba53a67cd88bb5d2937ab0c87d771a799ab0884c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19d9dc38-1ec9-4679-a560-6a993224224f", "node_type": "1", "metadata": {"window": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "original_text": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n"}, "hash": "07ff5d0f4519956889d95e294051a0f67fefbd0daa2457123cfa90991c302df9", "class_name": "RelatedNodeInfo"}}, "text": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "start_char_idx": 951, "end_char_idx": 1222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19d9dc38-1ec9-4679-a560-6a993224224f": {"__data__": {"id_": "19d9dc38-1ec9-4679-a560-6a993224224f", "embedding": null, "metadata": {"window": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "original_text": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba", "node_type": "1", "metadata": {"window": "We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.  ", "original_text": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87e9059ee8c83dff9a9fe4a55f4e3ee0465753cb912b0ef49797aa58a2d9c4ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bf91eb6-c35d-49bf-8b8c-b860dd09285b", "node_type": "1", "metadata": {"window": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "original_text": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. "}, "hash": "605d799fc0ab6af9b299273b31a8c285468640c3d637d80fc0b10f8e55ea1dd1", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "start_char_idx": 1222, "end_char_idx": 1411, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bf91eb6-c35d-49bf-8b8c-b860dd09285b": {"__data__": {"id_": "5bf91eb6-c35d-49bf-8b8c-b860dd09285b", "embedding": null, "metadata": {"window": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "original_text": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19d9dc38-1ec9-4679-a560-6a993224224f", "node_type": "1", "metadata": {"window": "As for the rest of the year, we expect the substantial majority of segment profit to come in the second \nhalf of fiscal \u201823, particularly in the fourth quarter.  This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "original_text": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f38f36ae78844458573ad92eb87a5ba9dad7d5727371a86c8d556f0020b5f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aea0568d-1d26-4d22-ae67-1275fc7ac7f4", "node_type": "1", "metadata": {"window": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "original_text": "Mitigate inflation and global supply chain constraints.  "}, "hash": "72aa1ba4b2e450354b1d994b39a894528a5dd5f865c0519173d5431b9590ef49", "class_name": "RelatedNodeInfo"}}, "text": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "start_char_idx": 1411, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aea0568d-1d26-4d22-ae67-1275fc7ac7f4": {"__data__": {"id_": "aea0568d-1d26-4d22-ae67-1275fc7ac7f4", "embedding": null, "metadata": {"window": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "original_text": "Mitigate inflation and global supply chain constraints.  ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bf91eb6-c35d-49bf-8b8c-b860dd09285b", "node_type": "1", "metadata": {"window": "This sequencing primarily reflects our assumptions \naround inflation, gl obal supply chain constraints, inflation mitigation, and PPE.  \n \n While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "original_text": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4cf5a3d7d40a4f315e8697f86abae932334ed7d7985e9fee06f48b2a55015619", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65620a6b-335d-4821-b673-d520f56f0d9e", "node_type": "1", "metadata": {"window": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two. ", "original_text": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n"}, "hash": "9e384a7fdacafe4450ddfa6c4e8875dd242b59e55ba513ee1f6d12d437fa52a5", "class_name": "RelatedNodeInfo"}}, "text": "Mitigate inflation and global supply chain constraints.  ", "start_char_idx": 1503, "end_char_idx": 1560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65620a6b-335d-4821-b673-d520f56f0d9e": {"__data__": {"id_": "65620a6b-335d-4821-b673-d520f56f0d9e", "embedding": null, "metadata": {"window": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two. ", "original_text": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aea0568d-1d26-4d22-ae67-1275fc7ac7f4", "node_type": "1", "metadata": {"window": "While there are many moving parts in fiscal \u201823, we are confident in our long -term outlook and are \nreiterating our previously announced long -term targets for our businesses and for double -digit \ncombined EPS growth and dividend yield over longer, normalized periods.  Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "original_text": "Mitigate inflation and global supply chain constraints.  ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc23352fce53921ccbcb2904bc11b242d57bee69d9310bf9f00dd42b844355d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10006d25-89c4-4489-92b5-db868d9de085", "node_type": "1", "metadata": {"window": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio . ", "original_text": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n"}, "hash": "d61e9627e5cae44d5fda955acd9560c162ffc702bbb0217c8469726e9b893a72", "class_name": "RelatedNodeInfo"}}, "text": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "start_char_idx": 1560, "end_char_idx": 1814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10006d25-89c4-4489-92b5-db868d9de085": {"__data__": {"id_": "10006d25-89c4-4489-92b5-db868d9de085", "embedding": null, "metadata": {"window": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio . ", "original_text": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65620a6b-335d-4821-b673-d520f56f0d9e", "node_type": "1", "metadata": {"window": "Additionally, we are \nintroducing a new target for at least $650 million in Medical segment profit by fiscal \u201825, driven by the \nMedical Improvement Plan that we are introducing today.  \n \n Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two. ", "original_text": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33ea5e814e45c66d781e8ad908f96d4c4fa98b4944f671aab036ad620aff94ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67060987-9cd9-40b6-9cb1-2bc70e819494", "node_type": "1", "metadata": {"window": "Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "original_text": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n"}, "hash": "382dd519452ebc38b177cdcb059b98b69ebbb37d2257b4aa5ef4f167686962f7", "class_name": "RelatedNodeInfo"}}, "text": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "start_char_idx": 1814, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67060987-9cd9-40b6-9cb1-2bc70e819494": {"__data__": {"id_": "67060987-9cd9-40b6-9cb1-2bc70e819494", "embedding": null, "metadata": {"window": "Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "original_text": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10006d25-89c4-4489-92b5-db868d9de085", "node_type": "1", "metadata": {"window": "Slide 17 highlights our four areas of focus to improve Medical performance:  \n \nNumber one.  Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio . ", "original_text": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f62c527fc3880a12cf1147577032891c7420e2edb8d3946a30c11c14667180c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c898dec-7ed9-44e2-95d5-864ed15bd192", "node_type": "1", "metadata": {"window": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "original_text": "Two. "}, "hash": "bd425bdf4d3c3c80c92c1f844eb18271f5206681153179751020f8428f0fbb65", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "start_char_idx": 1965, "end_char_idx": 2274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c898dec-7ed9-44e2-95d5-864ed15bd192": {"__data__": {"id_": "9c898dec-7ed9-44e2-95d5-864ed15bd192", "embedding": null, "metadata": {"window": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "original_text": "Two. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67060987-9cd9-40b6-9cb1-2bc70e819494", "node_type": "1", "metadata": {"window": "Mitigate inflation and global supply chain constraints.   We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "original_text": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a43d92739e6e332b1c6196b4a12607a963b040555b3382894a20565dcf904ccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e350a6d-9987-4d65-923f-f5e827bf4fef", "node_type": "1", "metadata": {"window": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus. ", "original_text": "Optimize and grow the Cardinal Health Brand portfolio . "}, "hash": "e2318598d23ad283b7865c119d16facaf9b4a24210b95e364702cbf7c9a42137", "class_name": "RelatedNodeInfo"}}, "text": "Two. ", "start_char_idx": 2274, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e350a6d-9987-4d65-923f-f5e827bf4fef": {"__data__": {"id_": "3e350a6d-9987-4d65-923f-f5e827bf4fef", "embedding": null, "metadata": {"window": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus. ", "original_text": "Optimize and grow the Cardinal Health Brand portfolio . ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c898dec-7ed9-44e2-95d5-864ed15bd192", "node_type": "1", "metadata": {"window": "We plan to fully address the \nimpact of inflation and global supply chain constraints through mitigation initiatives by the time we exit \nfiscal \u201824, and are targeting to exit fiscal \u201823 offsetting at least half of the gross impact on our \nbusiness.  \n \n Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "original_text": "Two. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9609f07262fb3d5829d568eae3ad5ac98bdaf0ae2fef37d4a9e376a80ec4f068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "297de1b1-ec5f-495f-810e-648f4fc10c21", "node_type": "1", "metadata": {"window": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n", "original_text": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. "}, "hash": "2a75f162852409a674d77fd1fa5b486ce94ca2c4abcc09e06ae3b585f1c596f1", "class_name": "RelatedNodeInfo"}}, "text": "Optimize and grow the Cardinal Health Brand portfolio . ", "start_char_idx": 2279, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "297de1b1-ec5f-495f-810e-648f4fc10c21": {"__data__": {"id_": "297de1b1-ec5f-495f-810e-648f4fc10c21", "embedding": null, "metadata": {"window": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n", "original_text": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e350a6d-9987-4d65-923f-f5e827bf4fef", "node_type": "1", "metadata": {"window": "Our sec ond wave of price increases went into effect on July 1st on four more categories, and we plan \non the next wave commencing on October 1st.  \n \n In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus. ", "original_text": "Optimize and grow the Cardinal Health Brand portfolio . ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f229bda0059bd01ff28b325558a2c47d93e7e953eae5fa26ab8d5f29fcbb1595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bb13d19-de20-4971-bd3d-64374403dddc", "node_type": "1", "metadata": {"window": "Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "original_text": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n"}, "hash": "168bdda283dbf2a75e91015ce408d73da016990b170ca334a0421e58f7fb4312", "class_name": "RelatedNodeInfo"}}, "text": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "start_char_idx": 2335, "end_char_idx": 2507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bb13d19-de20-4971-bd3d-64374403dddc": {"__data__": {"id_": "5bb13d19-de20-4971-bd3d-64374403dddc", "embedding": null, "metadata": {"window": "Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "original_text": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "297de1b1-ec5f-495f-810e-648f4fc10c21", "node_type": "1", "metadata": {"window": "In addition, we\u2019ve executed distribution fee increases for certain suppliers\u2026and we are actively \nworking with custom ers and GPOs to adjust language in our Product and Distribution contracts as \nthey renew, allowing for greater price flexibility to respond to current and future macroeconomic \ndynamics.  \n \n Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n", "original_text": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f37f618ed8d187abaac6e642ad16fb78e60da93bb5a745491e41fca7540957f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b", "node_type": "1", "metadata": {"window": "Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "This growth will be achieved through two key areas of focus. "}, "hash": "484a0c243d8aa8ca303b82f60809463f6ef260279b460b601e5003463306016e", "class_name": "RelatedNodeInfo"}}, "text": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "start_char_idx": 2507, "end_char_idx": 2704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b": {"__data__": {"id_": "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b", "embedding": null, "metadata": {"window": "Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "This growth will be achieved through two key areas of focus. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bb13d19-de20-4971-bd3d-64374403dddc", "node_type": "1", "metadata": {"window": "Two.  Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "original_text": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f3e931d3b14d7fa26a86c50263bd58e7b981612021341a6c683518655ac876e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1f0f083-3a59-462d-9231-289f59322250", "node_type": "1", "metadata": {"window": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "First, R&D and new product innovation. \n"}, "hash": "5c147b32c2d79277d0dd0157cc3fb01f75288b995c1f6ec9e80c57881a342045", "class_name": "RelatedNodeInfo"}}, "text": "This growth will be achieved through two key areas of focus. ", "start_char_idx": 2704, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1f0f083-3a59-462d-9231-289f59322250": {"__data__": {"id_": "c1f0f083-3a59-462d-9231-289f59322250", "embedding": null, "metadata": {"window": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "First, R&D and new product innovation. \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b", "node_type": "1", "metadata": {"window": "Optimize and grow the Cardinal Health Brand portfolio .  Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "This growth will be achieved through two key areas of focus. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dac337546835d00fd0761a74d86b41585d40035b9b1231d067f7e29b0ddaeb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75c5f6e7-727e-4e05-aab0-0f706e448a09", "node_type": "1", "metadata": {"window": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. "}, "hash": "d702345d5cb71558d4a96136f87ddf133638f125b472524bf0d09ea498dabbf8", "class_name": "RelatedNodeInfo"}}, "text": "First, R&D and new product innovation. \n", "start_char_idx": 2765, "end_char_idx": 2805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75c5f6e7-727e-4e05-aab0-0f706e448a09": {"__data__": {"id_": "75c5f6e7-727e-4e05-aab0-0f706e448a09", "embedding": null, "metadata": {"window": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1f0f083-3a59-462d-9231-289f59322250", "node_type": "1", "metadata": {"window": "Our $4.6 billion Cardinal Health Brand \nportfolio, which includes nearly $4 billion of non -PPE categories, offers leading brands and clinically -\ndifferentiated products.  We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "First, R&D and new product innovation. \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "465a08bfe66f8188e3e41a06b5971b3bf4a1098679add63106d06d3947fd125e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15a9de53-f1d0-4a44-8ee0-5656c2ac151f", "node_type": "1", "metadata": {"window": "This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "Second , is increased product availability as a "}, "hash": "647de00e659efadd051ea66398c98a22aa4a1b32731acbb9fe5f3c9d061f4ca0", "class_name": "RelatedNodeInfo"}}, "text": "We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "start_char_idx": 2805, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15a9de53-f1d0-4a44-8ee0-5656c2ac151f": {"__data__": {"id_": "15a9de53-f1d0-4a44-8ee0-5656c2ac151f", "embedding": null, "metadata": {"window": "This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "Second , is increased product availability as a ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "28621069-0622-4966-b60c-1feb6586ae7c", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88285c9db7f1ce3b3e46e080444cbbd59a3c42e34cb644998f58763e5df94794", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75c5f6e7-727e-4e05-aab0-0f706e448a09", "node_type": "1", "metadata": {"window": "We plan to grow Cardinal Health Brand sales by a compounded annual \ngrowth rate of at lea st 3%, which will generate $75  million  or more of incremental segment profit over \nthe next 3 years.  \n \n This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform. ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa6d1062d109c05d4a65316a153e26fa967130fc61e16abf980e194463f08445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d034ea41-182d-4dcd-ac50-9141bab7bba5", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "original_text": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes. "}, "hash": "e5161b6141b61ea052caf3bfcf4bfba6a6f0f970f007650bb1579242654efaaf", "class_name": "RelatedNodeInfo"}}, "text": "Second , is increased product availability as a ", "start_char_idx": 2958, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d034ea41-182d-4dcd-ac50-9141bab7bba5": {"__data__": {"id_": "d034ea41-182d-4dcd-ac50-9141bab7bba5", "embedding": null, "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "original_text": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15a9de53-f1d0-4a44-8ee0-5656c2ac151f", "node_type": "1", "metadata": {"window": "This growth will be achieved through two key areas of focus.  First, R&D and new product innovation. \n We see opportunities in key categories, such as nutritional delivery, where we will be launching the \nnext generation Kangaroo Enteral Feeding platform.  Second , is increased product availability as a ", "original_text": "Second , is increased product availability as a ", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f70a9c2aaa7f1fc0387af978eb46dde84efa97fe1c5a74749503fa922356e76a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8fae56e-f6a8-475b-affa-8c7fd79e1036", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "original_text": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n"}, "hash": "57cd3de0347323d5911eeaeb555a359a25fc905a705bcb98811c63a0f0fa3f13", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes. ", "start_char_idx": 0, "end_char_idx": 107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8fae56e-f6a8-475b-affa-8c7fd79e1036": {"__data__": {"id_": "a8fae56e-f6a8-475b-affa-8c7fd79e1036", "embedding": null, "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "original_text": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d034ea41-182d-4dcd-ac50-9141bab7bba5", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "original_text": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2a75ee80a286a3c6e257b7a6dd9a7f8e0c3ad391c79cd03a4c5973989df3317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "original_text": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.  "}, "hash": "ab4628789273760a79191b8f1f2545fa35458ee662f5cc23329c9306fa10830a", "class_name": "RelatedNodeInfo"}}, "text": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n", "start_char_idx": 107, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47": {"__data__": {"id_": "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47", "embedding": null, "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "original_text": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.  ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8fae56e-f6a8-475b-affa-8c7fd79e1036", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "original_text": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b5ef0e04f318fc6d7c4c5bae6ad096be05a244c8e4643a0feab441d81c6b89a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71fce01f-fb21-4282-a2f3-d2ecf3705e39", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "original_text": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. "}, "hash": "4540bbab5c6ba0a9edce53141490968956b994d3b5a2255e56ab4ed54f77e8b6", "class_name": "RelatedNodeInfo"}}, "text": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.  ", "start_char_idx": 305, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71fce01f-fb21-4282-a2f3-d2ecf3705e39": {"__data__": {"id_": "71fce01f-fb21-4282-a2f3-d2ecf3705e39", "embedding": null, "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "original_text": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "original_text": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.  ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c27bdd54f040f1fe38460348d0bf6cbdb88118ed2fa164d237bea504a276df2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02ee8c60-5406-4cf1-9b45-90912b0f2268", "node_type": "1", "metadata": {"window": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "original_text": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n"}, "hash": "51a3bff8843794d6ed2ff5d588abbc74bbeb3ee7ae2de5e2b3a1895ca041fac8", "class_name": "RelatedNodeInfo"}}, "text": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "start_char_idx": 399, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02ee8c60-5406-4cf1-9b45-90912b0f2268": {"__data__": {"id_": "02ee8c60-5406-4cf1-9b45-90912b0f2268", "embedding": null, "metadata": {"window": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "original_text": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71fce01f-fb21-4282-a2f3-d2ecf3705e39", "node_type": "1", "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "original_text": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad712479bea3993c42a1cd8534020acc30c36cd2ce78992adcb3ef59b3cc34c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25e33a3c-fba4-4676-9fee-3835fde92342", "node_type": "1", "metadata": {"window": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "original_text": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . "}, "hash": "a730c5d4716664c66be5c6fede4cb5d04f987e6a2ce0ed444e5e7405266a3b51", "class_name": "RelatedNodeInfo"}}, "text": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "start_char_idx": 602, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25e33a3c-fba4-4676-9fee-3835fde92342": {"__data__": {"id_": "25e33a3c-fba4-4676-9fee-3835fde92342", "embedding": null, "metadata": {"window": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "original_text": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02ee8c60-5406-4cf1-9b45-90912b0f2268", "node_type": "1", "metadata": {"window": "For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "original_text": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa503495f12191ca36fa503c5cafee938cfb2c52df80794c9d45495b476b1bdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24f9e384-819d-42c1-9c38-74f80c088a36", "node_type": "1", "metadata": {"window": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "original_text": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. "}, "hash": "5b91dec4fa5cec90505c3fdedf481d55120ad2c204bb6e97b4248128b29f8d6d", "class_name": "RelatedNodeInfo"}}, "text": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "start_char_idx": 774, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24f9e384-819d-42c1-9c38-74f80c088a36": {"__data__": {"id_": "24f9e384-819d-42c1-9c38-74f80c088a36", "embedding": null, "metadata": {"window": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "original_text": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25e33a3c-fba4-4676-9fee-3835fde92342", "node_type": "1", "metadata": {"window": "The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "original_text": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts . ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1f08c79e609b4a2d0c3c011abf31c30786431831d41014ad4c83d142fafb48b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe", "node_type": "1", "metadata": {"window": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "original_text": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. "}, "hash": "dbf1b05196878ec0230f5ed0c6b3d353d6ca97146bc2934f240d55f3cce85dfc", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "start_char_idx": 878, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe": {"__data__": {"id_": "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe", "embedding": null, "metadata": {"window": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "original_text": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24f9e384-819d-42c1-9c38-74f80c088a36", "node_type": "1", "metadata": {"window": "These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825.  At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "original_text": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e683f5ece1aecfd863c2f4b4ed40dc3ea7bc0559e913c794d62e352cc60465b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620547c3-71ea-4d25-9781-2cdaf445d449", "node_type": "1", "metadata": {"window": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "original_text": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n"}, "hash": "47de85e29f603b4c24b12390f5070cd0f2f940120bfff8eb243dd50393235390", "class_name": "RelatedNodeInfo"}}, "text": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "start_char_idx": 1067, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620547c3-71ea-4d25-9781-2cdaf445d449": {"__data__": {"id_": "620547c3-71ea-4d25-9781-2cdaf445d449", "embedding": null, "metadata": {"window": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "original_text": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe", "node_type": "1", "metadata": {"window": "At -\nHome Solutions, for example, is n ow a $2.4 billion business, that has consistently grown topline at \naround 10% as patient care continues to shift into the home.  \n \n And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "original_text": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "367077e5ef2cfa89928f43998188e44daee0f86fa67e7b80a6b00d02b75abff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2", "node_type": "1", "metadata": {"window": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "original_text": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. "}, "hash": "c8ed45377cd0ee67318cee19befd925216a897237da1ac32e9f05c082f36d3b0", "class_name": "RelatedNodeInfo"}}, "text": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "start_char_idx": 1270, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2": {"__data__": {"id_": "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2", "embedding": null, "metadata": {"window": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "original_text": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620547c3-71ea-4d25-9781-2cdaf445d449", "node_type": "1", "metadata": {"window": "And finally, our fourth area of focus is to continue our simplification and cost optimization efforts .  We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "original_text": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e9fc542f20fa10401a26a626637949f2db8016ef0420daf986f6600520a1fd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a", "node_type": "1", "metadata": {"window": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "original_text": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. "}, "hash": "e2ef1e062168183c6307af12d9eab38613629a8d99e34c45a0616c93c575ca9f", "class_name": "RelatedNodeInfo"}}, "text": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "start_char_idx": 1399, "end_char_idx": 1548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a": {"__data__": {"id_": "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a", "embedding": null, "metadata": {"window": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "original_text": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2", "node_type": "1", "metadata": {"window": "We \nexpect actions that increase  productivity in our manufacturing plants, distribution centers, supply \nchain, and back -office to yield  at least $50M of net cost savings by fiscal \u201825.  Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "original_text": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "040f0d8dacbd8f9368aad7fcb6a689cd2bcbf6dba47a8a6cb3d6ad7b3dccae46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24fa7907-9873-4474-847c-be24c355aa67", "node_type": "1", "metadata": {"window": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "original_text": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. "}, "hash": "d7901c440f5a202d100082449302f5bc73eb264b1903fc3e25d46563cfd3b953", "class_name": "RelatedNodeInfo"}}, "text": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "start_char_idx": 1548, "end_char_idx": 1708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24fa7907-9873-4474-847c-be24c355aa67": {"__data__": {"id_": "24fa7907-9873-4474-847c-be24c355aa67", "embedding": null, "metadata": {"window": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "original_text": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a", "node_type": "1", "metadata": {"window": "Going forward, we are \nfocused on driving simplification through value improvement projects, tra nsportation management, \nand further optimizing our sourcing and manufacturing footprint, where possible.  We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "original_text": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d7b7f315c847d0137060f54185fc23196a128aa9ca46f3308004d264f8d2529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1daa99fd-861f-47fa-b5d7-2e56888d79c4", "node_type": "1", "metadata": {"window": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "original_text": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n"}, "hash": "d374bacb47898dcf18e4bc6c8e26abba154824ec6c6bb6be04ba5534d100b914", "class_name": "RelatedNodeInfo"}}, "text": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "start_char_idx": 1708, "end_char_idx": 1919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1daa99fd-861f-47fa-b5d7-2e56888d79c4": {"__data__": {"id_": "1daa99fd-861f-47fa-b5d7-2e56888d79c4", "embedding": null, "metadata": {"window": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "original_text": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24fa7907-9873-4474-847c-be24c355aa67", "node_type": "1", "metadata": {"window": "We expect these \ninitiatives to contribute towards exceeding our existing enterprise $750M cost savings goal by fiscal \n\u201823.  \n \n While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "original_text": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a15be21363a5f9403e20ce7026a0e8dc54c6f0877eb80400fefd7d5c32072d68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d763e999-61d1-4556-a712-891d9eb8533b", "node_type": "1", "metadata": {"window": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "original_text": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n"}, "hash": "0738b48f79146d343718bb4c04d16ce358603dfe0de1c2c5061d9a4978334023", "class_name": "RelatedNodeInfo"}}, "text": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "start_char_idx": 1919, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d763e999-61d1-4556-a712-891d9eb8533b": {"__data__": {"id_": "d763e999-61d1-4556-a712-891d9eb8533b", "embedding": null, "metadata": {"window": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "original_text": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1daa99fd-861f-47fa-b5d7-2e56888d79c4", "node_type": "1", "metadata": {"window": "While on the topic of our supply chain, let me take a moment to share some additional color, where \nwe have received a number of investor questions.  We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "original_text": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3380aa6da5d8e6b302d6acfb2d9748c99fe921a19338c45f770bc168d478e992", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a137233e-bd91-4104-98e2-ca117020b5f8", "node_type": "1", "metadata": {"window": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "original_text": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n"}, "hash": "c9b2b73bdc7ea479bc14206f800f18eaaf4f109621b7669fa99aad31d4a668be", "class_name": "RelatedNodeInfo"}}, "text": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "start_char_idx": 2131, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a137233e-bd91-4104-98e2-ca117020b5f8": {"__data__": {"id_": "a137233e-bd91-4104-98e2-ca117020b5f8", "embedding": null, "metadata": {"window": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "original_text": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d763e999-61d1-4556-a712-891d9eb8533b", "node_type": "1", "metadata": {"window": "We operate a highly diverse global supply chain, \nwith approximately two -thirds of our Cardinal Health Brand revenue coming from self -manufactured \nproducts.  We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "original_text": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49f8e5252bd4ad49bce91ed9dfefefd4d93710a6204c8bf552362bf3310903b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9219cb49-3fdf-4d24-a08f-b8ed645b844b", "node_type": "1", "metadata": {"window": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n"}, "hash": "eac49b89a1ff7477aa335edb23b26199ec202c9d42bcae8c5cf0b5c16ce41a1d", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "start_char_idx": 2313, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9219cb49-3fdf-4d24-a08f-b8ed645b844b": {"__data__": {"id_": "9219cb49-3fdf-4d24-a08f-b8ed645b844b", "embedding": null, "metadata": {"window": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a137233e-bd91-4104-98e2-ca117020b5f8", "node_type": "1", "metadata": {"window": "We have invested in additional self -manufacturing capabilities, many in our own North \nAmerican facilities and today, approximately half of our Cardinal Health Brand revenue comes from \nNorth America in total.  To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "original_text": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1de5ca64b9540f913ca7c15d924e042d67a7d860a2c64250415bdbd07940dc2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac6c135b-3a96-42fb-833f-8d75fd1d1faa", "node_type": "1", "metadata": {"window": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n"}, "hash": "590c11afda405f4927a40a05b156975149d72eb64b80d8a515703baaf1a2d350", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "start_char_idx": 2491, "end_char_idx": 2783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac6c135b-3a96-42fb-833f-8d75fd1d1faa": {"__data__": {"id_": "ac6c135b-3a96-42fb-833f-8d75fd1d1faa", "embedding": null, "metadata": {"window": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9219cb49-3fdf-4d24-a08f-b8ed645b844b", "node_type": "1", "metadata": {"window": "To best serve our customer s, we continue to believe in the importance of a \ndiverse global supply chain, and we are focused on responding to any global supply chain disruptions \nwith resilience and agility.  \n \n In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "813fcde9d4571dee506a7a2ea9afa68de55d1aa4936d900008f5552bd17ba55c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcafdbc2-6981-43e6-8aff-b397d9884fdf", "node_type": "1", "metadata": {"window": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. "}, "hash": "23bdce7d326150dbe5f75a73fec8f172f9c024588cf080279f2d96c4b8a5bb1e", "class_name": "RelatedNodeInfo"}}, "text": "With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "start_char_idx": 2783, "end_char_idx": 2966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcafdbc2-6981-43e6-8aff-b397d9884fdf": {"__data__": {"id_": "fcafdbc2-6981-43e6-8aff-b397d9884fdf", "embedding": null, "metadata": {"window": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac6c135b-3a96-42fb-833f-8d75fd1d1faa", "node_type": "1", "metadata": {"window": "In summary, we believe the introduction of measurable proof points in each of these four areas of \nfocus provides visibility to measure progress against our plans going forward.  \n \n Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c809b72fb0e588b4e81d28335ee85b4be1759201ceb6c0db0345d28972dd3b3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee", "node_type": "1", "metadata": {"window": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n "}, "hash": "7943f2e7a6c5e763e457932edb3ccac596ad1b34fbdce795c57f16da1681cacf", "class_name": "RelatedNodeInfo"}}, "text": "We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "start_char_idx": 2966, "end_char_idx": 3156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee": {"__data__": {"id_": "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee", "embedding": null, "metadata": {"window": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfcad2c202ad1188eedd24e77e20fc8b5f16e622370d51e3ebcec0cdb7b452d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcafdbc2-6981-43e6-8aff-b397d9884fdf", "node_type": "1", "metadata": {"window": "Let\u2019s now turn to the Pharmaceutical segment, where we continue to focus on strengthening our Core \nPD business and investing in our growth businesses, pr imarily Specialty.  \n \n In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd1a9217bb25f3be6b79585371ae52dc1baa026d35aa89d68a5853a13ded918d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e049061f-c8a1-48a3-8f24-ca2032d73656", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "original_text": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n"}, "hash": "d8de44c94a4e04fbef859902cd37f0628532eb4319e8de864184193e9ca8199d", "class_name": "RelatedNodeInfo"}}, "text": "They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "start_char_idx": 3156, "end_char_idx": 3359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e049061f-c8a1-48a3-8f24-ca2032d73656": {"__data__": {"id_": "e049061f-c8a1-48a3-8f24-ca2032d73656", "embedding": null, "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "original_text": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee", "node_type": "1", "metadata": {"window": "In Pharma distribution, with our significant technology enhancements that we\u2019ve been working on \nover the past several years substantially completed, we now focus our attention on increasing \nproductivity, maximizing working capital effic iency, and prioritizing the customer experience.  \n \n With our generics program, anchored by the scale and expertise of Red Oak, we continue to further \nenhance our capabilities as we focus on share of wallet and maximizing margins.  \n \n We recently held our Retai l Business Conference where over 4,000 customers attended live for the \nfirst time in 3 years and had an opportunity to see and experience our latest innovations.  They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "original_text": "They also \nhad the chance to register for services that would help them create an online shoppi ng portal, \nadvisory support to optimize reimbursement, and central fill compliance packaging services.  \n ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfb5c6f491b49bbe7151d75bc31d02753908ec4e8145a2c50c92f53f43d55af0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd2d866f-8e65-4926-937f-c8f13703115f", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "original_text": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization. "}, "hash": "415de22dcfb89ea706e4b806b40f6ffa07d41f3cce461e8483073934b846a43c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n", "start_char_idx": 0, "end_char_idx": 174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd2d866f-8e65-4926-937f-c8f13703115f": {"__data__": {"id_": "fd2d866f-8e65-4926-937f-c8f13703115f", "embedding": null, "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "original_text": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e049061f-c8a1-48a3-8f24-ca2032d73656", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "original_text": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "682dbdf1f62da4e8d8292114d5d2953bcfa43948407392841fcd8e1c40066b7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2be9ce14-7a5a-46fa-924e-46b288780bc0", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "original_text": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n"}, "hash": "ad86dc84f4c8d47bc4bdc1f3d9b758662540de787d6b5d72b3d2cf8895352219", "class_name": "RelatedNodeInfo"}}, "text": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization. ", "start_char_idx": 174, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2be9ce14-7a5a-46fa-924e-46b288780bc0": {"__data__": {"id_": "2be9ce14-7a5a-46fa-924e-46b288780bc0", "embedding": null, "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "original_text": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd2d866f-8e65-4926-937f-c8f13703115f", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "original_text": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7d4fdc11fc861ff20f6b67ecbdf1667985043bc0d8a4f34fa6c52047f4fc8f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f189c81f-6b55-4c87-bce1-c08e3fc19ac0", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "original_text": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n"}, "hash": "5c00e2d8bad2f19fd99114f92a737944c766ba2eacead6e068288ccfbcdf63ee", "class_name": "RelatedNodeInfo"}}, "text": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n", "start_char_idx": 298, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f189c81f-6b55-4c87-bce1-c08e3fc19ac0": {"__data__": {"id_": "f189c81f-6b55-4c87-bce1-c08e3fc19ac0", "embedding": null, "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "original_text": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2be9ce14-7a5a-46fa-924e-46b288780bc0", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "original_text": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8443e6102ac28b7ef5192f1e207b4243f557c51ee13a2c906762414024bf4f58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca18d6c9-19c4-439c-b43a-1b85a99c8a27", "node_type": "1", "metadata": {"window": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "original_text": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n"}, "hash": "14d0f116a05a0972679f0915e19c2ba9cb40c0c6c6d317837021913d6b4e3da4", "class_name": "RelatedNodeInfo"}}, "text": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "start_char_idx": 520, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca18d6c9-19c4-439c-b43a-1b85a99c8a27": {"__data__": {"id_": "ca18d6c9-19c4-439c-b43a-1b85a99c8a27", "embedding": null, "metadata": {"window": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "original_text": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f189c81f-6b55-4c87-bce1-c08e3fc19ac0", "node_type": "1", "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "original_text": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de08f1cbbe0c2982a0a8b1734f795025cd424409befe461b842dbbd06015e541", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2db6b07-5549-4746-9164-5234e75df8ce", "node_type": "1", "metadata": {"window": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n", "original_text": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. "}, "hash": "dcc8060f02ec28f15299fa2508f8ac9fcc43d4c0b772edebe01298557b76c427", "class_name": "RelatedNodeInfo"}}, "text": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "start_char_idx": 720, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2db6b07-5549-4746-9164-5234e75df8ce": {"__data__": {"id_": "d2db6b07-5549-4746-9164-5234e75df8ce", "embedding": null, "metadata": {"window": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n", "original_text": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca18d6c9-19c4-439c-b43a-1b85a99c8a27", "node_type": "1", "metadata": {"window": "We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "original_text": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d22b9f5bdd49461b5ffe8280812211f51b8ad90a1d5fa99eb0e648af4898715f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa08349-7f4c-4e66-a003-1b5b9076e781", "node_type": "1", "metadata": {"window": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you . ", "original_text": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n"}, "hash": "adb0c456464bccd9629b2cde526d9093d13ace560b961c9ebece6ee63cf96633", "class_name": "RelatedNodeInfo"}}, "text": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "start_char_idx": 880, "end_char_idx": 1062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa08349-7f4c-4e66-a003-1b5b9076e781": {"__data__": {"id_": "dfa08349-7f4c-4e66-a003-1b5b9076e781", "embedding": null, "metadata": {"window": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you . ", "original_text": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2db6b07-5549-4746-9164-5234e75df8ce", "node_type": "1", "metadata": {"window": "These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n", "original_text": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4e895cfa5a49f0ef2ccd9222f05f9c37b574696f439ab2090c68055b53a5849", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a80b5ff-bfe8-486f-a800-e1e9747d9681", "node_type": "1", "metadata": {"window": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "original_text": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n"}, "hash": "4360ab628c33dfebafd4cdcc5b9d1d80c52bb5359e5f7bb011d23ef3c2e83288", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "start_char_idx": 1062, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a80b5ff-bfe8-486f-a800-e1e9747d9681": {"__data__": {"id_": "0a80b5ff-bfe8-486f-a800-e1e9747d9681", "embedding": null, "metadata": {"window": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "original_text": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa08349-7f4c-4e66-a003-1b5b9076e781", "node_type": "1", "metadata": {"window": "Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you . ", "original_text": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "582fea02f585a209e9e1cf9b45e7f1a15cc90d6d9193bae5434294e11c5b48d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4146cc9d-c8b3-48c4-96a5-acf673b7b24c", "node_type": "1", "metadata": {"window": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "original_text": "With that, I will take your questions.  \n \n"}, "hash": "3ee472cef3e0bfdf1552308e521c758720ac103833eb9604c9d47b9759c52dec", "class_name": "RelatedNodeInfo"}}, "text": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "start_char_idx": 1194, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4146cc9d-c8b3-48c4-96a5-acf673b7b24c": {"__data__": {"id_": "4146cc9d-c8b3-48c4-96a5-acf673b7b24c", "embedding": null, "metadata": {"window": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "original_text": "With that, I will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a80b5ff-bfe8-486f-a800-e1e9747d9681", "node_type": "1", "metadata": {"window": "We also continue to see strong growth in Sonexus, our patient hub where our technology solutions \nhelp biopharma customers remove barriers to patient care.  \n \n And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "original_text": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ebdc6fb39d526e32aa2a81e99979ea6ceb4b8d205d7b5d34624bac9001e6742", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84276a58-05c3-44ea-a242-73cc3805cce8", "node_type": "1", "metadata": {"window": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "original_text": "Operator :  Thank you . "}, "hash": "fe79bb308c46e013c52eacc0422477034626e68678ba412efae430db666c53e2", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will take your questions.  \n \n", "start_char_idx": 1356, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84276a58-05c3-44ea-a242-73cc3805cce8": {"__data__": {"id_": "84276a58-05c3-44ea-a242-73cc3805cce8", "embedding": null, "metadata": {"window": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "original_text": "Operator :  Thank you . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4146cc9d-c8b3-48c4-96a5-acf673b7b24c", "node_type": "1", "metadata": {"window": "And with biosimilars, we are proactively addressing common barriers to adoption  by investing in \neducation campaigns to build awareness, clinical comfort, and ensure accessibility.  We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "original_text": "With that, I will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69e084d5c5157b9298f67e0531a2d49b55cbf53d978666b00ab91dad4779320a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a", "node_type": "1", "metadata": {"window": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question . ", "original_text": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . "}, "hash": "4f859e0b03032a06ddf07dbe86e2e5b1ba2749cba6ba491479bdd9fbd9dd1b38", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 1399, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a": {"__data__": {"id_": "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a", "embedding": null, "metadata": {"window": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question . ", "original_text": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84276a58-05c3-44ea-a242-73cc3805cce8", "node_type": "1", "metadata": {"window": "We continue to \nbe excited about the future growth in this space and remain well positioned as new biosimilars come \nto market.  \n \n In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "original_text": "Operator :  Thank you . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fffbc6c3bd1ddedb2204204b62f5c3ea5f32a397d87dfdde1b8eaaf00045063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f3aacb0-9878-4302-97ca-c66dbfbf02dc", "node_type": "1", "metadata": {"window": "With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P. ", "original_text": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . "}, "hash": "9da0e1eeb480855a73b0b1e0cc578bcf41fc4775dae01fdde0443396dbb089eb", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "start_char_idx": 1423, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f3aacb0-9878-4302-97ca-c66dbfbf02dc": {"__data__": {"id_": "8f3aacb0-9878-4302-97ca-c66dbfbf02dc", "embedding": null, "metadata": {"window": "With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P. ", "original_text": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a", "node_type": "1", "metadata": {"window": "In closing, while there is a lot of work to be done, I am excited to work with our 44,000 teammates in \nexecuting our plans to grow in fiscal \u201823 and beyond.  \n \n With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question . ", "original_text": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbe7641741fc266bbac1cea8fd3ba447c40ea60089edc428f248020e236d808c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939780d6-e1ac-41ec-aab2-39e1cc7da9a7", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan . ", "original_text": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . "}, "hash": "0e6f5596b8a7efca0521a8aef674af3260c41d6a3d3c2cc569352a4400278145", "class_name": "RelatedNodeInfo"}}, "text": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "start_char_idx": 1568, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939780d6-e1ac-41ec-aab2-39e1cc7da9a7": {"__data__": {"id_": "939780d6-e1ac-41ec-aab2-39e1cc7da9a7", "embedding": null, "metadata": {"window": "Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan . ", "original_text": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f3aacb0-9878-4302-97ca-c66dbfbf02dc", "node_type": "1", "metadata": {"window": "With that, I will take your questions.  \n \n Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P. ", "original_text": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8570a65215569fdc0b19a2f10f799073ee0f5208505b4cc0b48af353a16eb5a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5f602b3-843f-4c99-bfd4-5de2caced4e6", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n", "original_text": "Once \nagain, please press star one to ask a question . "}, "hash": "30fa17c0148462ebbb86fa8be2dcf87588b11b5036fff0f965e863797295e022", "class_name": "RelatedNodeInfo"}}, "text": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "start_char_idx": 1686, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5f602b3-843f-4c99-bfd4-5de2caced4e6": {"__data__": {"id_": "a5f602b3-843f-4c99-bfd4-5de2caced4e6", "embedding": null, "metadata": {"window": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n", "original_text": "Once \nagain, please press star one to ask a question . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939780d6-e1ac-41ec-aab2-39e1cc7da9a7", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan . ", "original_text": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b424d622ef24fb429313821e2c8010634dc273c77fc08a082ede4ee449ff13f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b717dc42-181f-4b5a-af42-658567b1387b", "node_type": "1", "metadata": {"window": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "original_text": "We will take our first question today from Lisa Gill of \nJ.P. "}, "hash": "7e7582c3c8b829cbc11f26eb595b9f14363cd6ac218b567d85be004383843cc8", "class_name": "RelatedNodeInfo"}}, "text": "Once \nagain, please press star one to ask a question . ", "start_char_idx": 1808, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b717dc42-181f-4b5a-af42-658567b1387b": {"__data__": {"id_": "b717dc42-181f-4b5a-af42-658567b1387b", "embedding": null, "metadata": {"window": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "original_text": "We will take our first question today from Lisa Gill of \nJ.P. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5f602b3-843f-4c99-bfd4-5de2caced4e6", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if you would  like to ask a question, please press the star \nor asterisk key followed by the digit one on your telephone .  Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n", "original_text": "Once \nagain, please press star one to ask a question . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "999b9b58e046465c226ce8db57e2875ad529456e3b4014e30b38a05db3fa098a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18ff74af-861c-4811-a923-5d4318a2337b", "node_type": "1", "metadata": {"window": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "original_text": "Morgan . "}, "hash": "3b325faf4accce6e6c8020a80ef245423e0d1fbfa64429ba54d7aa98328dec2e", "class_name": "RelatedNodeInfo"}}, "text": "We will take our first question today from Lisa Gill of \nJ.P. ", "start_char_idx": 1863, "end_char_idx": 1925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18ff74af-861c-4811-a923-5d4318a2337b": {"__data__": {"id_": "18ff74af-861c-4811-a923-5d4318a2337b", "embedding": null, "metadata": {"window": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "original_text": "Morgan . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b717dc42-181f-4b5a-af42-658567b1387b", "node_type": "1", "metadata": {"window": "Please ensure that the mute function on \nyour telephone is switched off to allow your signal to reach our equipment .  If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "original_text": "We will take our first question today from Lisa Gill of \nJ.P. ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9bbe9aa8b12701ef0fbd7c5bfbca7169b4930cc2c2954562fecb2b389906cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "487de5a2-2fcb-4340-944b-8b50a704af56", "node_type": "1", "metadata": {"window": "Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n", "original_text": "Please go ahead .  \n \n"}, "hash": "d33afc8e4f8ecb9e6b85dc5efdf9e4f6de8b4737e6dce1c832e72cc04ded4552", "class_name": "RelatedNodeInfo"}}, "text": "Morgan . ", "start_char_idx": 1925, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "487de5a2-2fcb-4340-944b-8b50a704af56": {"__data__": {"id_": "487de5a2-2fcb-4340-944b-8b50a704af56", "embedding": null, "metadata": {"window": "Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n", "original_text": "Please go ahead .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18ff74af-861c-4811-a923-5d4318a2337b", "node_type": "1", "metadata": {"window": "If you find that your question  \nhas already been answered, you may remove yourself from the queue by pressing star two .  Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "original_text": "Morgan . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d51e6627be7f688b1cbc94c56022e6fdf6878b07f4b4053c95f39b7e20428170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1", "node_type": "1", "metadata": {"window": "We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "original_text": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman . "}, "hash": "adcf330a10d5d26f7a6541130981198d9ec8adecbfaaa3dcdafb918f83bf1217", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead .  \n \n", "start_char_idx": 1934, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1": {"__data__": {"id_": "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1", "embedding": null, "metadata": {"window": "We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "original_text": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "487de5a2-2fcb-4340-944b-8b50a704af56", "node_type": "1", "metadata": {"window": "Once \nagain, please press star one to ask a question .  We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n", "original_text": "Please go ahead .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91a3ea386155bd31b6a68ae42748423cbc59574962b80c31edab6f155fdc6cf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "624d06ed-119d-47d4-82af-c1f4e77f0f0b", "node_type": "1", "metadata": {"window": "Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas . ", "original_text": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . "}, "hash": "3e180a2acb5b7bf82cccdb934501d751b99d0b6fdf20afa616c6258bfaaff177", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "start_char_idx": 1956, "end_char_idx": 2019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "624d06ed-119d-47d4-82af-c1f4e77f0f0b": {"__data__": {"id_": "624d06ed-119d-47d4-82af-c1f4e77f0f0b", "embedding": null, "metadata": {"window": "Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas . ", "original_text": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1", "node_type": "1", "metadata": {"window": "We will take our first question today from Lisa Gill of \nJ.P.  Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "original_text": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f490ca360049d76d80887226c903c4b3d54c3221785946656b1988d2b69bb06e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "original_text": "And congratulations, Jason, on becoming CEO .  \n \n"}, "hash": "63b7ca329b89b44dc19cb392105f09d5418e3af32f0f1830a4ba934ab476a97d", "class_name": "RelatedNodeInfo"}}, "text": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "start_char_idx": 2019, "end_char_idx": 2121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a": {"__data__": {"id_": "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a", "embedding": null, "metadata": {"window": "Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "original_text": "And congratulations, Jason, on becoming CEO .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "624d06ed-119d-47d4-82af-c1f4e77f0f0b", "node_type": "1", "metadata": {"window": "Morgan .  Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas . ", "original_text": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "773ec8bc5103694c62015770e2080430d171f33fbdee9b408d38fd7141c2acd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c2ad050-a164-4a62-aae2-7a49060482d4", "node_type": "1", "metadata": {"window": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "original_text": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . "}, "hash": "28fbdd07046d60720a091b91cb4c36eb147a3fd67a55326f4c360d543c2416d4", "class_name": "RelatedNodeInfo"}}, "text": "And congratulations, Jason, on becoming CEO .  \n \n", "start_char_idx": 2121, "end_char_idx": 2171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c2ad050-a164-4a62-aae2-7a49060482d4": {"__data__": {"id_": "8c2ad050-a164-4a62-aae2-7a49060482d4", "embedding": null, "metadata": {"window": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "original_text": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "original_text": "And congratulations, Jason, on becoming CEO .  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf2d7eb7a126073812d93b11c2a1573a205e4596c02924707e03f7e7a3cd7993", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d84cbfc2-fe08-4a87-85e9-b3de45f962c3", "node_type": "1", "metadata": {"window": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "original_text": "And Jason, you just talked about four different areas . "}, "hash": "da59d749d40ef96c95f2698d4f87cc3c92928a7cae223956bf1f435658b23228", "class_name": "RelatedNodeInfo"}}, "text": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "start_char_idx": 2171, "end_char_idx": 2328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d84cbfc2-fe08-4a87-85e9-b3de45f962c3": {"__data__": {"id_": "d84cbfc2-fe08-4a87-85e9-b3de45f962c3", "embedding": null, "metadata": {"window": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "original_text": "And Jason, you just talked about four different areas . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c2ad050-a164-4a62-aae2-7a49060482d4", "node_type": "1", "metadata": {"window": "Lisa Gill :  I want to say best of luck to you, Mike Kaufman .  It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "original_text": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d33a9f5712f7aea81bdcaf3ca032729864c90a57611decc0a38b583db1e85bb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92811701-c730-47a6-bd3b-cf4e4fa30d94", "node_type": "1", "metadata": {"window": "And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional . ", "original_text": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . "}, "hash": "8d3ffa26a3a40f1bbcdb5da0091cd8baf94b56723499fdaf0f4ab923afd403a1", "class_name": "RelatedNodeInfo"}}, "text": "And Jason, you just talked about four different areas . ", "start_char_idx": 2328, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92811701-c730-47a6-bd3b-cf4e4fa30d94": {"__data__": {"id_": "92811701-c730-47a6-bd3b-cf4e4fa30d94", "embedding": null, "metadata": {"window": "And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional . ", "original_text": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d84cbfc2-fe08-4a87-85e9-b3de45f962c3", "node_type": "1", "metadata": {"window": "It's been great working with you all these \nyears, and I look forward to hopefully staying in touch .  And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "original_text": "And Jason, you just talked about four different areas . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7605f7ea94374eb548ef466dfe517c9f01fda4906d1314878c333e81897bc154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c130caf-ea6e-4263-adef-8958ecd43a4a", "node_type": "1", "metadata": {"window": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?  ", "original_text": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . "}, "hash": "404333c60dccd1383f01b5dbe1455a7c07ace3baf25decfb8efb88d3dc009539", "class_name": "RelatedNodeInfo"}}, "text": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "start_char_idx": 2384, "end_char_idx": 2488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c130caf-ea6e-4263-adef-8958ecd43a4a": {"__data__": {"id_": "1c130caf-ea6e-4263-adef-8958ecd43a4a", "embedding": null, "metadata": {"window": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?  ", "original_text": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92811701-c730-47a6-bd3b-cf4e4fa30d94", "node_type": "1", "metadata": {"window": "And congratulations, Jason, on becoming CEO .  \n \n I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional . ", "original_text": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aef6560925eb6a7fd015bca0c8753c9ac4de0be7ece174ee11fd7e3307e79c92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47c49868-079e-4cc8-ac23-d4d9999f0800", "node_type": "1", "metadata": {"window": "And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into? ", "original_text": "Can you talk about, one, why now you think that \nyou can really accelerate that?  "}, "hash": "6a77184d0a758423895684510146be929008e4cfe76cefa06a684b5431b650d3", "class_name": "RelatedNodeInfo"}}, "text": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "start_char_idx": 2488, "end_char_idx": 2653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47c49868-079e-4cc8-ac23-d4d9999f0800": {"__data__": {"id_": "47c49868-079e-4cc8-ac23-d4d9999f0800", "embedding": null, "metadata": {"window": "And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into? ", "original_text": "Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c130caf-ea6e-4263-adef-8958ecd43a4a", "node_type": "1", "metadata": {"window": "I really want t o start with, you know, obviously you talk about this huge ramp, getting the medical side \nof the business back to $650  million of profit .  And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?  ", "original_text": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a541dcbb65a680f9489b2004d915df631fb3d332b1fae4ae64c9cfd9b98ff087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357", "node_type": "1", "metadata": {"window": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "original_text": "Two, I think you talked about nutritional . "}, "hash": "874b82443238dd448c17bf8cc49852c3b505474c3dcb42203d0b2a0f537b1cb5", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "start_char_idx": 2653, "end_char_idx": 2735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357": {"__data__": {"id_": "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357", "embedding": null, "metadata": {"window": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "original_text": "Two, I think you talked about nutritional . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47c49868-079e-4cc8-ac23-d4d9999f0800", "node_type": "1", "metadata": {"window": "And Jason, you just talked about four different areas .  I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into? ", "original_text": "Can you talk about, one, why now you think that \nyou can really accelerate that?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27b4048d84e08d41c7101b13b540193f108256006a65a165d83ce2ed3d8ca050", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21", "node_type": "1", "metadata": {"window": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "original_text": "You know, we've had others \nthat have had problems in that area, right?  "}, "hash": "da1e0cee8c7433df6f2014b2ccd362f5252972e1ec6f59f924c56a279be09742", "class_name": "RelatedNodeInfo"}}, "text": "Two, I think you talked about nutritional . ", "start_char_idx": 2735, "end_char_idx": 2779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21": {"__data__": {"id_": "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21", "embedding": null, "metadata": {"window": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "original_text": "You know, we've had others \nthat have had problems in that area, right?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357", "node_type": "1", "metadata": {"window": "I \nreally want to just focus on the first area and that's grow ing, you know, Cardinal brand products .  And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "original_text": "Two, I think you talked about nutritional . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b11bc33121a3e4daf19966e889c9a7e20e5b501d13cbf1cfd785b82739e1a16a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d32947f6-1270-4553-bdee-b82d049b43e5", "node_type": "1", "metadata": {"window": "Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, why do you think that that that's a good area for \nCardinal to go into? "}, "hash": "0d3f3ddd97df98ccf92c11b2edd7357e5f15a9d25dd43bee5f5bc42a76c50283", "class_name": "RelatedNodeInfo"}}, "text": "You know, we've had others \nthat have had problems in that area, right?  ", "start_char_idx": 2779, "end_char_idx": 2852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d32947f6-1270-4553-bdee-b82d049b43e5": {"__data__": {"id_": "d32947f6-1270-4553-bdee-b82d049b43e5", "embedding": null, "metadata": {"window": "Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, why do you think that that that's a good area for \nCardinal to go into? ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21", "node_type": "1", "metadata": {"window": "And \nobviously for someone like myself, that's followed the company for a long time, you know, that's kind of \nebbed and flowed as far as the focus of the company .  Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "original_text": "You know, we've had others \nthat have had problems in that area, right?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d31a73b3f70e367ac01499ee9db3a761f8c0edfeaeacc3e212ab178b8a23f280", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c1d49db-26f6-494f-aae2-53f754048748", "node_type": "1", "metadata": {"window": "Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  "}, "hash": "7aa36af294b4bf3d5ef154b53acbf9e404688d0c05d8f66275553b8741e07981", "class_name": "RelatedNodeInfo"}}, "text": "You know, why do you think that that that's a good area for \nCardinal to go into? ", "start_char_idx": 2852, "end_char_idx": 2934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c1d49db-26f6-494f-aae2-53f754048748": {"__data__": {"id_": "3c1d49db-26f6-494f-aae2-53f754048748", "embedding": null, "metadata": {"window": "Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d32947f6-1270-4553-bdee-b82d049b43e5", "node_type": "1", "metadata": {"window": "Can you talk about, one, why now you think that \nyou can really accelerate that?   Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, why do you think that that that's a good area for \nCardinal to go into? ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fe3e3e48db4b812a01dc1471fdce792882d73ebc0dea288452d42d93aae7e2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b551a71-f483-4c51-be6b-af2b9b8fd9ca", "node_type": "1", "metadata": {"window": "You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . "}, "hash": "f82ad70edfa4ae80592af8c13a981af164f0ecebf6d9b410ea5a65a4dfe303c5", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "start_char_idx": 2934, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b551a71-f483-4c51-be6b-af2b9b8fd9ca": {"__data__": {"id_": "2b551a71-f483-4c51-be6b-af2b9b8fd9ca", "embedding": null, "metadata": {"window": "You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c1d49db-26f6-494f-aae2-53f754048748", "node_type": "1", "metadata": {"window": "Two, I think you talked about nutritional .  You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?  ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6da503b283417bab1588e6d87218f657ac54dccef1cf52776bb792082c0d2ca1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f", "node_type": "1", "metadata": {"window": "You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "So I'll stop there.  \n "}, "hash": "ddae34019b107cb0ac50a8941b033736e214b2d3511c017cd90eb81923f09d2a", "class_name": "RelatedNodeInfo"}}, "text": "You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "start_char_idx": 3080, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f": {"__data__": {"id_": "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f", "embedding": null, "metadata": {"window": "You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "So I'll stop there.  \n ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28977d30fce4fa57e7d8ef9a5a919289cb23a1acbb3c97e9d986d229e6940dd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b551a71-f483-4c51-be6b-af2b9b8fd9ca", "node_type": "1", "metadata": {"window": "You know, we've had others \nthat have had problems in that area, right?   You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products . ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d2024d83826d66798e8472fc1fbce2a24ea1c3c417fac34dbccdca37b30f2ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b1a3978-18ed-4da0-a129-0ca6c1e24eb2", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "original_text": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion . "}, "hash": "625b8c51c7ce50b0c0d52aa597c804c8d03bd61558bf1de6841ad92f1ddd1f7b", "class_name": "RelatedNodeInfo"}}, "text": "So I'll stop there.  \n ", "start_char_idx": 3204, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b1a3978-18ed-4da0-a129-0ca6c1e24eb2": {"__data__": {"id_": "8b1a3978-18ed-4da0-a129-0ca6c1e24eb2", "embedding": null, "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "original_text": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f", "node_type": "1", "metadata": {"window": "You know, why do you think that that that's a good area for \nCardinal to go into?  And then secondly, when we thi nk about, you know, physician preference, etc., \nwhat are you hearing in the market around private label product?   You know, to give you some of the \ninsights as to the opportunities that you see here specific to Cardinal brand products .  So I'll stop there.  \n ", "original_text": "So I'll stop there.  \n ", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e18063d7cd551a0740f7c8ea9d00cc8cd71874f0f353331492417f5db5c0283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6383d63-eacf-41c2-b94e-293e059a9863", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "original_text": "Thanks, Lisa . "}, "hash": "9efaf65d3f71ec8db36a02a4c6faeb899663545f178ad5918b6e66db7d303761", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion . ", "start_char_idx": 0, "end_char_idx": 82, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6383d63-eacf-41c2-b94e-293e059a9863": {"__data__": {"id_": "d6383d63-eacf-41c2-b94e-293e059a9863", "embedding": null, "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "original_text": "Thanks, Lisa . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b1a3978-18ed-4da0-a129-0ca6c1e24eb2", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "original_text": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef9413e34b87278cbf1c07de71719b7c77facb7d3a853f332c08c7b358495433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "original_text": "So first of all, let's start with your \nfirst one there about why now . "}, "hash": "597500051190ec779ce1accb62a3e443023a4f132325fb14192d691f4820e19a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Lisa . ", "start_char_idx": 82, "end_char_idx": 97, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f": {"__data__": {"id_": "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f", "embedding": null, "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "original_text": "So first of all, let's start with your \nfirst one there about why now . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6383d63-eacf-41c2-b94e-293e059a9863", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "original_text": "Thanks, Lisa . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a466a61e01217f437a325a1f8c19cc5f19d827372e14b37ccf1aebbe162ae537", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0342688-f935-454c-bbc1-4c33a4f810df", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "original_text": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. "}, "hash": "932f862f854690b13d934519cf494773bbef3099ce3f1b5bac562df5a0daea49", "class_name": "RelatedNodeInfo"}}, "text": "So first of all, let's start with your \nfirst one there about why now . ", "start_char_idx": 97, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0342688-f935-454c-bbc1-4c33a4f810df": {"__data__": {"id_": "f0342688-f935-454c-bbc1-4c33a4f810df", "embedding": null, "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "original_text": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "original_text": "So first of all, let's start with your \nfirst one there about why now . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e49a2287bcbfe780bb2e54778b060c1a30c76c88b8c85b3b5bf21b7d73db42a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce", "node_type": "1", "metadata": {"window": "Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "original_text": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . "}, "hash": "91dd9db6f977faa126436e16edebf51d485df1fb77d0cbfe37594ba85a12cb0a", "class_name": "RelatedNodeInfo"}}, "text": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "start_char_idx": 169, "end_char_idx": 449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce": {"__data__": {"id_": "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce", "embedding": null, "metadata": {"window": "Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "original_text": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0342688-f935-454c-bbc1-4c33a4f810df", "node_type": "1", "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "original_text": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0388de18fe902cfc70ce49cbee1c76c7343207031c7a4649fa09b19cfde74ee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f82226e-1dfb-45ef-8b51-04bc42270e1b", "node_type": "1", "metadata": {"window": "So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "original_text": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . "}, "hash": "4f7b971c3a205d7dcbf11aedc1a8f5f61fc57633d1b7e15bc6543a0f2e66417d", "class_name": "RelatedNodeInfo"}}, "text": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "start_char_idx": 449, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f82226e-1dfb-45ef-8b51-04bc42270e1b": {"__data__": {"id_": "6f82226e-1dfb-45ef-8b51-04bc42270e1b", "embedding": null, "metadata": {"window": "So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "original_text": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce", "node_type": "1", "metadata": {"window": "Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "original_text": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8f96bb639d70137facf18809f2f44ea930c1b964c2e3997c68b0ab930d1cd73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad", "node_type": "1", "metadata": {"window": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "original_text": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n"}, "hash": "5d5615d11818915311b30cb7292901cc325b9085a14943c7d4e29ca78bf9fe14", "class_name": "RelatedNodeInfo"}}, "text": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "start_char_idx": 554, "end_char_idx": 742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad": {"__data__": {"id_": "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad", "embedding": null, "metadata": {"window": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "original_text": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f82226e-1dfb-45ef-8b51-04bc42270e1b", "node_type": "1", "metadata": {"window": "So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "original_text": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57ecf15f5050b969a65247b00fc46dee19d73702d39112d2a84ef15926fd642d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d156036-227c-41d2-aa7e-5ad242174677", "node_type": "1", "metadata": {"window": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n", "original_text": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . "}, "hash": "647ed4b2a49c15797246c22661b48c9db0812cbb2a93bd3fd4f1a655fac6ab0f", "class_name": "RelatedNodeInfo"}}, "text": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "start_char_idx": 742, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d156036-227c-41d2-aa7e-5ad242174677": {"__data__": {"id_": "9d156036-227c-41d2-aa7e-5ad242174677", "embedding": null, "metadata": {"window": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n", "original_text": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad", "node_type": "1", "metadata": {"window": "So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix.  And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "original_text": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c58d31de34bea9e02268b2cdcfd9c6863c4526d36a76592bd192a548b08eaa20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f60abac-f775-4b8f-a7de-294c5b968148", "node_type": "1", "metadata": {"window": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional . ", "original_text": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . "}, "hash": "ec9e0ab4bea5bdf7b3a0f17bb6668219343914e07159d991d118093e96191251", "class_name": "RelatedNodeInfo"}}, "text": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "start_char_idx": 922, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f60abac-f775-4b8f-a7de-294c5b968148": {"__data__": {"id_": "5f60abac-f775-4b8f-a7de-294c5b968148", "embedding": null, "metadata": {"window": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional . ", "original_text": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d156036-227c-41d2-aa7e-5ad242174677", "node_type": "1", "metadata": {"window": "And then COVID occurred , and it went from a sales focused challenge to now a supply c hain \nchallenge .  And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n", "original_text": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90431c8e2507bed1381e333d2106dc157f2ad0f5cc60f93f9b605adbaa731b16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3adb4f7-cd34-46cf-902e-33ff93f788f1", "node_type": "1", "metadata": {"window": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?  ", "original_text": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . "}, "hash": "270fec1d1484bc42fcce279076932283f5e6fd7897784dd65ccaff92d17e1de5", "class_name": "RelatedNodeInfo"}}, "text": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "start_char_idx": 1244, "end_char_idx": 1529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3adb4f7-cd34-46cf-902e-33ff93f788f1": {"__data__": {"id_": "e3adb4f7-cd34-46cf-902e-33ff93f788f1", "embedding": null, "metadata": {"window": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?  ", "original_text": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f60abac-f775-4b8f-a7de-294c5b968148", "node_type": "1", "metadata": {"window": "And of course, our sales team, as well as our customers, were very much focused on PPE \nand getting care to COVID patients and the change in the mix was not exactly the highest priority .  So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional . ", "original_text": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0bc82b65502b847ffd9258f5b68c6ca9b030fa704cabe1954eef442d162ff54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5546a29-a3f6-4510-9eb6-85edafd06808", "node_type": "1", "metadata": {"window": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line . ", "original_text": "But of course we need the capacity and the products to allow them to be successful.  \n \n"}, "hash": "5dd2c47013f391d51e34dc43ec5bb81c96c4e279a77fa930922e0c1597c7b447", "class_name": "RelatedNodeInfo"}}, "text": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "start_char_idx": 1529, "end_char_idx": 1658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5546a29-a3f6-4510-9eb6-85edafd06808": {"__data__": {"id_": "b5546a29-a3f6-4510-9eb6-85edafd06808", "embedding": null, "metadata": {"window": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line . ", "original_text": "But of course we need the capacity and the products to allow them to be successful.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3adb4f7-cd34-46cf-902e-33ff93f788f1", "node_type": "1", "metadata": {"window": "So I \nthink it's always been a focus of Cardinal, but  we recognize that we needed to change our priority to \nalign with our customers' priority over the last couple of years.  \n \n But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?  ", "original_text": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "227bdffb58a012a9eb889f5fb8a05e6699a0947e6a5ac97daebd4899fcc60063", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4c545e5-44ea-49be-9bf2-aace5ea6bc72", "node_type": "1", "metadata": {"window": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today . ", "original_text": "You asked a specific question about nutritional . "}, "hash": "80bc3383bb2aaff9a2840d2d13f3c30066e7ccdc92794def0708dc0394218bb9", "class_name": "RelatedNodeInfo"}}, "text": "But of course we need the capacity and the products to allow them to be successful.  \n \n", "start_char_idx": 1658, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4c545e5-44ea-49be-9bf2-aace5ea6bc72": {"__data__": {"id_": "c4c545e5-44ea-49be-9bf2-aace5ea6bc72", "embedding": null, "metadata": {"window": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today . ", "original_text": "You asked a specific question about nutritional . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5546a29-a3f6-4510-9eb6-85edafd06808", "node_type": "1", "metadata": {"window": "But behind the scenes, especially with the pandemic, our Medical team realized that we needed to \ninvest in our own supply chain capab ilities, our own products, and a lot of the capacity that was \nnecessary for the manufacturing, either, whether it's our own products or sourced products, to ensure \nfurther resiliency .  So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line . ", "original_text": "But of course we need the capacity and the products to allow them to be successful.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31db4350116588225a733c8acfb575463b35a97a4933c81f740acc378e667cba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "719f960f-663c-4275-973e-001e178d03ab", "node_type": "1", "metadata": {"window": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader . ", "original_text": "You know, that's just one area, right?  "}, "hash": "6c1ea3570eb5caeff5fd700219be2adeb26329017751e39d52e451dcc9b52ae8", "class_name": "RelatedNodeInfo"}}, "text": "You asked a specific question about nutritional . ", "start_char_idx": 1746, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "719f960f-663c-4275-973e-001e178d03ab": {"__data__": {"id_": "719f960f-663c-4275-973e-001e178d03ab", "embedding": null, "metadata": {"window": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader . ", "original_text": "You know, that's just one area, right?  ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4c545e5-44ea-49be-9bf2-aace5ea6bc72", "node_type": "1", "metadata": {"window": "So now that we are getting a little bit more normalized and we see that  we have to \ninvest in that supply chain, it not only helps provide resiliency to our customers, but it also allows us to \ngrow high margin products where we have the right to win and expand our margins further .  So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today . ", "original_text": "You asked a specific question about nutritional . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59894c46e005c042c8fbc1014fb907dc97b057b3dd16168fe3e30882ba993977", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37a4d36b-2c49-4d0d-9bdb-bac47ff21282", "node_type": "1", "metadata": {"window": "But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "original_text": "We have a very \nbroad, diverse product line . "}, "hash": "13daac49f4ab48bc1b6639f5d682b904fb7190b6860e6bd0f9dff205bc90fda9", "class_name": "RelatedNodeInfo"}}, "text": "You know, that's just one area, right?  ", "start_char_idx": 1796, "end_char_idx": 1836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37a4d36b-2c49-4d0d-9bdb-bac47ff21282": {"__data__": {"id_": "37a4d36b-2c49-4d0d-9bdb-bac47ff21282", "embedding": null, "metadata": {"window": "But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "original_text": "We have a very \nbroad, diverse product line . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "719f960f-663c-4275-973e-001e178d03ab", "node_type": "1", "metadata": {"window": "So now is \nthe right time as we start to move on and allow our sales team to get re -engaged and focus on driving \nthat volume .  But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader . ", "original_text": "You know, that's just one area, right?  ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6ff1c5ad88d7d19a034afd506ced78b2e94a45a2d419c714eafde69573d0f90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "333c53b7-8b44-404d-8837-68ac20d43a15", "node_type": "1", "metadata": {"window": "You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "original_text": "We are successful in the category today . "}, "hash": "58a0c3c36a01eefa543ac49f473b1ea5f8e0b1cd624a79daed2fe6dccac8c14b", "class_name": "RelatedNodeInfo"}}, "text": "We have a very \nbroad, diverse product line . ", "start_char_idx": 1836, "end_char_idx": 1882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "333c53b7-8b44-404d-8837-68ac20d43a15": {"__data__": {"id_": "333c53b7-8b44-404d-8837-68ac20d43a15", "embedding": null, "metadata": {"window": "You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "original_text": "We are successful in the category today . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37a4d36b-2c49-4d0d-9bdb-bac47ff21282", "node_type": "1", "metadata": {"window": "But of course we need the capacity and the products to allow them to be successful.  \n \n You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "original_text": "We have a very \nbroad, diverse product line . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "463f597aefd2f00515b783ec8f2bb364cf2745bac15460bd9f832cda52d9a9b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08793620-bb16-45d7-9ae7-27d30c21cb1b", "node_type": "1", "metadata": {"window": "You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth . ", "original_text": "The Kangaroo brand is a market \nleader . "}, "hash": "794b92a3822346e12710136d972b820fe02e12825516e532f2d7ad3f99474018", "class_name": "RelatedNodeInfo"}}, "text": "We are successful in the category today . ", "start_char_idx": 1882, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08793620-bb16-45d7-9ae7-27d30c21cb1b": {"__data__": {"id_": "08793620-bb16-45d7-9ae7-27d30c21cb1b", "embedding": null, "metadata": {"window": "You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth . ", "original_text": "The Kangaroo brand is a market \nleader . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "333c53b7-8b44-404d-8837-68ac20d43a15", "node_type": "1", "metadata": {"window": "You asked a specific question about nutritional .  You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "original_text": "We are successful in the category today . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f79ace3ba2f8f50f938c8fb6ecd98b8f5e886aef0ce258b1f4dc538e1721f3a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35c47bdc-4c26-407c-a8bf-3fdc63342e6e", "node_type": "1", "metadata": {"window": "We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "original_text": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. "}, "hash": "b52431ceaa982900ef715bb27712be6fe5fbf7bbad2f47d4c8a5014504f5fa03", "class_name": "RelatedNodeInfo"}}, "text": "The Kangaroo brand is a market \nleader . ", "start_char_idx": 1924, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35c47bdc-4c26-407c-a8bf-3fdc63342e6e": {"__data__": {"id_": "35c47bdc-4c26-407c-a8bf-3fdc63342e6e", "embedding": null, "metadata": {"window": "We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "original_text": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08793620-bb16-45d7-9ae7-27d30c21cb1b", "node_type": "1", "metadata": {"window": "You know, that's just one area, right?   We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth . ", "original_text": "The Kangaroo brand is a market \nleader . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4bb24d44f0011ecd0ba553e596efb349cd4a7199e060082389e668ba7b3a2f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7628c771-536b-4e61-83cc-50b1a9cc0fdb", "node_type": "1", "metadata": {"window": "We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n", "original_text": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . "}, "hash": "8e7e35adec3c179d4bb64ac5fc30e98e6288a7fda19fc79253ac0290d7c5f80a", "class_name": "RelatedNodeInfo"}}, "text": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "start_char_idx": 1965, "end_char_idx": 2099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7628c771-536b-4e61-83cc-50b1a9cc0fdb": {"__data__": {"id_": "7628c771-536b-4e61-83cc-50b1a9cc0fdb", "embedding": null, "metadata": {"window": "We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n", "original_text": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35c47bdc-4c26-407c-a8bf-3fdc63342e6e", "node_type": "1", "metadata": {"window": "We have a very \nbroad, diverse product line .  We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "original_text": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty. ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8330b23d57be75ff77dd3bdb5f0fd84c7ccee45f2fe6bdbc3da5081477b22b02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac056211-4c01-490e-80dd-1d19b79c49ff", "node_type": "1", "metadata": {"window": "The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "original_text": "We are with good margins, good growth . "}, "hash": "a69e32d6c74f4a7e727956011c983aaf1b353b5d6574f6f8d61eab105d32ea95", "class_name": "RelatedNodeInfo"}}, "text": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "start_char_idx": 2099, "end_char_idx": 2216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac056211-4c01-490e-80dd-1d19b79c49ff": {"__data__": {"id_": "ac056211-4c01-490e-80dd-1d19b79c49ff", "embedding": null, "metadata": {"window": "The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "original_text": "We are with good margins, good growth . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7628c771-536b-4e61-83cc-50b1a9cc0fdb", "node_type": "1", "metadata": {"window": "We are successful in the category today .  The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n", "original_text": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae0531ecce0da85d2c315b514989d6024aeb44560a5250764585e503a5a73d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bbe3dd9-2462-4757-95ea-72989d6b8924", "node_type": "1", "metadata": {"window": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n", "original_text": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . "}, "hash": "3a343b6cb05adf9fda8a74157fbd1ff6701b123d0fe6bb5c40c56d267a1d414f", "class_name": "RelatedNodeInfo"}}, "text": "We are with good margins, good growth . ", "start_char_idx": 2216, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bbe3dd9-2462-4757-95ea-72989d6b8924": {"__data__": {"id_": "9bbe3dd9-2462-4757-95ea-72989d6b8924", "embedding": null, "metadata": {"window": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n", "original_text": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac056211-4c01-490e-80dd-1d19b79c49ff", "node_type": "1", "metadata": {"window": "The Kangaroo brand is a market \nleader .  So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "original_text": "We are with good margins, good growth . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecf077293d5fc0dd8cfabb2039b242707887b6ae2402a3f13d745613ecbc2b43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e9b316-894c-4e1d-a07d-8b922da3f03e", "node_type": "1", "metadata": {"window": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you . ", "original_text": "So it's \nactually a lower risk strategy than entering in separately.  \n \n"}, "hash": "7f5b7e77eef5af8430205b6a232dd38180768ce2a18e18d9aed044f091ca5d73", "class_name": "RelatedNodeInfo"}}, "text": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "start_char_idx": 2256, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8e9b316-894c-4e1d-a07d-8b922da3f03e": {"__data__": {"id_": "d8e9b316-894c-4e1d-a07d-8b922da3f03e", "embedding": null, "metadata": {"window": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you . ", "original_text": "So it's \nactually a lower risk strategy than entering in separately.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bbe3dd9-2462-4757-95ea-72989d6b8924", "node_type": "1", "metadata": {"window": "So this is not necessarily we're getting into it, in fact, that's that's what gets me so excited about \nthis item, this opportuni ty.  The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n", "original_text": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f064f40000bf814b53ce483f434b6d775d61a0be9d0980d289e20d9033c7c3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9df61988-5e06-4893-ba62-b69d2015a3ab", "node_type": "1", "metadata": {"window": "We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank . ", "original_text": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n"}, "hash": "980a0904a20e972b9fa3a6b30ad790dff6bcb77a78fe94c678bee900dbe928be", "class_name": "RelatedNodeInfo"}}, "text": "So it's \nactually a lower risk strategy than entering in separately.  \n \n", "start_char_idx": 2368, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9df61988-5e06-4893-ba62-b69d2015a3ab": {"__data__": {"id_": "9df61988-5e06-4893-ba62-b69d2015a3ab", "embedding": null, "metadata": {"window": "We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank . ", "original_text": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e9b316-894c-4e1d-a07d-8b922da3f03e", "node_type": "1", "metadata": {"window": "The two items I referenced, the surgical gloves and nutritional are already \nareas where we're significant leaders .  We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you . ", "original_text": "So it's \nactually a lower risk strategy than entering in separately.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "634d591c0387302382ab90da39e62df709532efb2a7211fda3680af10106a75a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5", "node_type": "1", "metadata": {"window": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n", "original_text": "Kevin Moran :  Next question, please.   \n \n"}, "hash": "1b5e0614d3c78187b44f7a0c22e6bd924363663239d6456e5ea0652f56ceba9a", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "start_char_idx": 2441, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5": {"__data__": {"id_": "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5", "embedding": null, "metadata": {"window": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n", "original_text": "Kevin Moran :  Next question, please.   \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9df61988-5e06-4893-ba62-b69d2015a3ab", "node_type": "1", "metadata": {"window": "We are with good margins, good growth .  We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank . ", "original_text": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71b773d7eb4e85ed200bce1a8c83d423ff81a5e12f66ba9e3fc5b3aaf2dd2087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce830ded-4672-43f8-8dc1-1d6b77f0a28c", "node_type": "1", "metadata": {"window": "So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "original_text": "Operator :  Thank you . "}, "hash": "3e8d6e7d6f6cc0528ef93d34e2d00681ff41bcce91b54fe0c7b32dcbe5dcbbac", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Next question, please.   \n \n", "start_char_idx": 2839, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce830ded-4672-43f8-8dc1-1d6b77f0a28c": {"__data__": {"id_": "ce830ded-4672-43f8-8dc1-1d6b77f0a28c", "embedding": null, "metadata": {"window": "So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "original_text": "Operator :  Thank you . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5", "node_type": "1", "metadata": {"window": "We have the \nopportunity to just continue our leadership through additional products and additio nal capacity .  So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n", "original_text": "Kevin Moran :  Next question, please.   \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6e1c05c5179466fc779a4a535d8ae07f9cbbd7fc3e3af08fd8ba2e4974c6053", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3abd137b-25f1-45e6-b038-0f69eafe5b9e", "node_type": "1", "metadata": {"window": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "original_text": "Our next question comes from George Hill of Deutsche Bank . "}, "hash": "7ea5cd6b0cec730c182a2a7b433a6b1ba8a3fad7877f304c2a9f72a4fa636c7c", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 2882, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3abd137b-25f1-45e6-b038-0f69eafe5b9e": {"__data__": {"id_": "3abd137b-25f1-45e6-b038-0f69eafe5b9e", "embedding": null, "metadata": {"window": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "original_text": "Our next question comes from George Hill of Deutsche Bank . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce830ded-4672-43f8-8dc1-1d6b77f0a28c", "node_type": "1", "metadata": {"window": "So it's \nactually a lower risk strategy than entering in separately.  \n \n As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "original_text": "Operator :  Thank you . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c18b6886393892b5bd5a665553403023809de09e449b5e90d32765d708eb0d0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2c1017-0a06-41ba-93fa-23d93dbe3411", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "original_text": "Please go ahead .  \n \n"}, "hash": "d245b00063c65f53b181de5fe6e5a12e566f27e61c3d1dc748d35a50d0310139", "class_name": "RelatedNodeInfo"}}, "text": "Our next question comes from George Hill of Deutsche Bank . ", "start_char_idx": 2906, "end_char_idx": 2966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2c1017-0a06-41ba-93fa-23d93dbe3411": {"__data__": {"id_": "0a2c1017-0a06-41ba-93fa-23d93dbe3411", "embedding": null, "metadata": {"window": "Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "original_text": "Please go ahead .  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3abd137b-25f1-45e6-b038-0f69eafe5b9e", "node_type": "1", "metadata": {"window": "As it relates to your last question, again, we have very broad, diverse products and we can manufacture, \nwe can source, and we're going to use all tools available to us an d and use that diverse capability, \ninternal or external, with partners or ourselves, and just continue to adapt and evolve as the market \ndemands  it and when we look at the supply chain constraints that go behind that.  \n \n Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "original_text": "Our next question comes from George Hill of Deutsche Bank . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5c655c3dd5d506a1d7949a915cd7a85532575f9ecdc944444ebf9a6b98adec6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c49f6a9-6a76-46cb-aabb-e930acc067d0", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . "}, "hash": "4e355289d599df5b850e79c84009b7381395fc6854bab486229ee425e4926523", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead .  \n \n", "start_char_idx": 2966, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c49f6a9-6a76-46cb-aabb-e930acc067d0": {"__data__": {"id_": "9c49f6a9-6a76-46cb-aabb-e930acc067d0", "embedding": null, "metadata": {"window": "Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2c1017-0a06-41ba-93fa-23d93dbe3411", "node_type": "1", "metadata": {"window": "Kevin Moran :  Next question, please.   \n \n Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "original_text": "Please go ahead .  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f91f047c30e59c38393ceeb27ac9731e71b1b801ef68e996408a015da4f897a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8939bdda-3e87-4963-86e2-16d04e74160c", "node_type": "1", "metadata": {"window": "Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? "}, "hash": "e781e7c62b7a46b8f6077700359c48865e04a2535e377277cac4f38563d68fd8", "class_name": "RelatedNodeInfo"}}, "text": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "start_char_idx": 2988, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8939bdda-3e87-4963-86e2-16d04e74160c": {"__data__": {"id_": "8939bdda-3e87-4963-86e2-16d04e74160c", "embedding": null, "metadata": {"window": "Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c49f6a9-6a76-46cb-aabb-e930acc067d0", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "006ba1ea2eedf53e0e6c197c6111d916b180737e6fb0fc042e643a1a6e5eb445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e77de87-929e-4d67-bd93-7f856ea83dc9", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n"}, "hash": "e8e9de33cccbd112edece220fa0800dc542d18e4902cc8445f7c58564fd383ea", "class_name": "RelatedNodeInfo"}}, "text": "And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "start_char_idx": 3080, "end_char_idx": 3330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e77de87-929e-4d67-bd93-7f856ea83dc9": {"__data__": {"id_": "8e77de87-929e-4d67-bd93-7f856ea83dc9", "embedding": null, "metadata": {"window": "Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8939bdda-3e87-4963-86e2-16d04e74160c", "node_type": "1", "metadata": {"window": "Our next question comes from George Hill of Deutsche Bank .  Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ? ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56027b724bcb014699129e952cce886ffa1b45770ad47247d255a3290292adca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2102d64e-86e7-4107-bf9c-4bf610a9726d", "node_type": "1", "metadata": {"window": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational "}, "hash": "f05389adb718f30d97f02be590fa4c9c15e49271744308079879905dce081ebc", "class_name": "RelatedNodeInfo"}}, "text": "And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "start_char_idx": 3330, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2102d64e-86e7-4107-bf9c-4bf610a9726d": {"__data__": {"id_": "2102d64e-86e7-4107-bf9c-4bf610a9726d", "embedding": null, "metadata": {"window": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "311c4650ec9357b3d2f8e772bd1892c945ac2ca8f855bb041bce3a2fbeef3f96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e77de87-929e-4d67-bd93-7f856ea83dc9", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f66adc08e6fdaeb62e08c3b8502c0c816689b6a862732ea8de5eb51169374f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d982b89b-8b80-4f25-98ef-42d785f79e6b", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "original_text": " \nPage 11 of 18 \n \nperformance within the business . "}, "hash": "40be15362801aa8a90a7d711efe516f4ba2d3ad1f8275a0bd3ded1737507bc63", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "start_char_idx": 3527, "end_char_idx": 3738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d982b89b-8b80-4f25-98ef-42d785f79e6b": {"__data__": {"id_": "d982b89b-8b80-4f25-98ef-42d785f79e6b", "embedding": null, "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "original_text": " \nPage 11 of 18 \n \nperformance within the business . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2102d64e-86e7-4107-bf9c-4bf610a9726d", "node_type": "1", "metadata": {"window": "George Hill :  Good morning, guys and Mike, I'll echo Lisa's comments in wishing you well .  And Jason I \ndon't mean this question to sound insensitive but I guess given the company's recent performance, \ncould you talk about why the board chose to not run a process to replace Mike and why you guys kind \nof went with an internal promotion ?  And just kind of, I don't know if you're able to comment  at all, just \nkind of on the board's perception of company performance and how it kind of wants to evaluate \nmanagement going forward.  \n \n Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "original_text": "Jason Hollar:  Well I certainly will not attempt to speak for the board , but what I will say is that my time \nboth here , as well as elsewhere in industry, I'm very focused, very tenured on driving operational ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32b8752dfa9379815e258b6042ea2e3d848ad041689d8dce6fbc7d6c9ac6d7b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1374bc3c-4b28-4c12-aad0-471b746b97d3", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture . ", "original_text": "I have made a mark within this or ganization . "}, "hash": "bd8bca4f28c4b7e0353331337dd0d841226978d5bd534fba21b1707616e6e929", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 18 \n \nperformance within the business . ", "start_char_idx": 0, "end_char_idx": 53, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1374bc3c-4b28-4c12-aad0-471b746b97d3": {"__data__": {"id_": "1374bc3c-4b28-4c12-aad0-471b746b97d3", "embedding": null, "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture . ", "original_text": "I have made a mark within this or ganization . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d982b89b-8b80-4f25-98ef-42d785f79e6b", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "original_text": " \nPage 11 of 18 \n \nperformance within the business . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8e63870fa2a1173355f5e2aed0630b7e11bcabe5a57da352313111c0a261163", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f6f5033-a6f0-4493-9112-d90dcf98b48f", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.  ", "original_text": "I've been very focused \non capital deployment, driving cash in the company and have made that impact . "}, "hash": "6d688edd271abf1cd04f158a52ca98677d6ba9fd7dc369273ab491a7140c4acf", "class_name": "RelatedNodeInfo"}}, "text": "I have made a mark within this or ganization . ", "start_char_idx": 53, "end_char_idx": 100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f6f5033-a6f0-4493-9112-d90dcf98b48f": {"__data__": {"id_": "3f6f5033-a6f0-4493-9112-d90dcf98b48f", "embedding": null, "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.  ", "original_text": "I've been very focused \non capital deployment, driving cash in the company and have made that impact . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1374bc3c-4b28-4c12-aad0-471b746b97d3", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture . ", "original_text": "I have made a mark within this or ganization . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b765279fbf03f411cfd81b7076ab58cb8a885294b8e1bb307516b59d7b7d569", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "original_text": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . "}, "hash": "49e504945f9340966faced48db795faaabf174d353f09bdf321461953ffea748", "class_name": "RelatedNodeInfo"}}, "text": "I've been very focused \non capital deployment, driving cash in the company and have made that impact . ", "start_char_idx": 100, "end_char_idx": 203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a": {"__data__": {"id_": "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a", "embedding": null, "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "original_text": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f6f5033-a6f0-4493-9112-d90dcf98b48f", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.  ", "original_text": "I've been very focused \non capital deployment, driving cash in the company and have made that impact . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "885603ea9de7f4e35b961f936544be5fe58aa36b271c86524a591d0c8364cff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17eca2e7-efb9-453a-98e3-c856d22a84af", "node_type": "1", "metadata": {"window": "I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better . ", "original_text": "We have a wonderful culture . "}, "hash": "248da225f8c00b77ff62e730860c180a45c7ab30ca321eb6767ba86fbcb99299", "class_name": "RelatedNodeInfo"}}, "text": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "start_char_idx": 203, "end_char_idx": 345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17eca2e7-efb9-453a-98e3-c856d22a84af": {"__data__": {"id_": "17eca2e7-efb9-453a-98e3-c856d22a84af", "embedding": null, "metadata": {"window": "I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better . ", "original_text": "We have a wonderful culture . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a", "node_type": "1", "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "original_text": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0e5e055b5fe56c54facb1acfd3236e0648fcd62f06641d52b15ace42076c500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a378d6f4-9b27-42e3-812b-a47382f0363b", "node_type": "1", "metadata": {"window": "I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "original_text": "We have wonderful products, leading positions, great \ngrowth areas.  "}, "hash": "706146d8ba7644731aae9131e07ed8f41cd1bf7387098b32cd10e9c325d30b19", "class_name": "RelatedNodeInfo"}}, "text": "We have a wonderful culture . ", "start_char_idx": 345, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a378d6f4-9b27-42e3-812b-a47382f0363b": {"__data__": {"id_": "a378d6f4-9b27-42e3-812b-a47382f0363b", "embedding": null, "metadata": {"window": "I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "original_text": "We have wonderful products, leading positions, great \ngrowth areas.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17eca2e7-efb9-453a-98e3-c856d22a84af", "node_type": "1", "metadata": {"window": "I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better . ", "original_text": "We have a wonderful culture . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e6404d8b7dd8cb5968e644686a3fea8323e225e3a8ff8f1bf99a27dc405b0db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64fe58d2-0b9d-43c0-9fda-bf547028cec0", "node_type": "1", "metadata": {"window": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient . ", "original_text": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . "}, "hash": "e594f743db8c3d498ce43fa3950c239b011f5223bef304a15e1d7f179474e262", "class_name": "RelatedNodeInfo"}}, "text": "We have wonderful products, leading positions, great \ngrowth areas.  ", "start_char_idx": 375, "end_char_idx": 444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64fe58d2-0b9d-43c0-9fda-bf547028cec0": {"__data__": {"id_": "64fe58d2-0b9d-43c0-9fda-bf547028cec0", "embedding": null, "metadata": {"window": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient . ", "original_text": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a378d6f4-9b27-42e3-812b-a47382f0363b", "node_type": "1", "metadata": {"window": "I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "original_text": "We have wonderful products, leading positions, great \ngrowth areas.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b2df326715f700a8b91d1e866a8557d0cbef049563eb671782d2709cd97a5ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "933af036-4ad4-427a-8ab6-6f843b647eca", "node_type": "1", "metadata": {"window": "We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year . ", "original_text": "So probably \ndoing fewer things but doing them better . "}, "hash": "aaa84a1634d69ab4051df6561aad1a1950b8647736a98846e5a5de616ed26ae6", "class_name": "RelatedNodeInfo"}}, "text": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "start_char_idx": 444, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "933af036-4ad4-427a-8ab6-6f843b647eca": {"__data__": {"id_": "933af036-4ad4-427a-8ab6-6f843b647eca", "embedding": null, "metadata": {"window": "We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year . ", "original_text": "So probably \ndoing fewer things but doing them better . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64fe58d2-0b9d-43c0-9fda-bf547028cec0", "node_type": "1", "metadata": {"window": "When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization .  We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient . ", "original_text": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a3055016b4b9a53eb6015c2796efe0c185e472df10948d2327f56a50ddcbaf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1eada1e2-a679-4702-873b-bf815f148baf", "node_type": "1", "metadata": {"window": "We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "original_text": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . "}, "hash": "8541b6df8541b96d0a39ff4b536f42d76da7f45e317f96c042f03c5aa71821b6", "class_name": "RelatedNodeInfo"}}, "text": "So probably \ndoing fewer things but doing them better . ", "start_char_idx": 626, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1eada1e2-a679-4702-873b-bf815f148baf": {"__data__": {"id_": "1eada1e2-a679-4702-873b-bf815f148baf", "embedding": null, "metadata": {"window": "We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "original_text": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "933af036-4ad4-427a-8ab6-6f843b647eca", "node_type": "1", "metadata": {"window": "We have a wonderful culture .  We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year . ", "original_text": "So probably \ndoing fewer things but doing them better . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b1d24dac1177e3c0a4d4b8924a09d6c1d415fa43d1a7900642611a83591e98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa4f16f2-c5f3-4523-889c-586b5ddebed2", "node_type": "1", "metadata": {"window": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.  ", "original_text": "The Pharma business has been very \nresilient . "}, "hash": "f619ce5dc16e56b5d2d1e59e7e8cf474b45c31a1f41978ba79aa9029871eec10", "class_name": "RelatedNodeInfo"}}, "text": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "start_char_idx": 682, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa4f16f2-c5f3-4523-889c-586b5ddebed2": {"__data__": {"id_": "fa4f16f2-c5f3-4523-889c-586b5ddebed2", "embedding": null, "metadata": {"window": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.  ", "original_text": "The Pharma business has been very \nresilient . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1eada1e2-a679-4702-873b-bf815f148baf", "node_type": "1", "metadata": {"window": "We have wonderful products, leading positions, great \ngrowth areas.   But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "original_text": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99c94ab0493d40202297c31a4cebec3bde1876e0519014347d848512c0a66c30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58aedb05-e456-43ea-a01b-8176cf49a3a9", "node_type": "1", "metadata": {"window": "So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "original_text": "We hit our both short and long term goals this year . "}, "hash": "c2af95464836ae2ef58662600dd86362cb5525080a8b681eec7049ac0a8b7874", "class_name": "RelatedNodeInfo"}}, "text": "The Pharma business has been very \nresilient . ", "start_char_idx": 810, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58aedb05-e456-43ea-a01b-8176cf49a3a9": {"__data__": {"id_": "58aedb05-e456-43ea-a01b-8176cf49a3a9", "embedding": null, "metadata": {"window": "So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "original_text": "We hit our both short and long term goals this year . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa4f16f2-c5f3-4523-889c-586b5ddebed2", "node_type": "1", "metadata": {"window": "But what the pandemic has shown us is that we need to go back to some some level of \nbasics here in terms of the operational core  \u2013 in driving efficiency, driving  simplification .  So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.  ", "original_text": "The Pharma business has been very \nresilient . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb02504c8ec19599a82eb8d65a8b8a3a8a395744c3516b3ea021495a0ee1c175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c31c71f-a130-4a9f-b117-0f628d12e522", "node_type": "1", "metadata": {"window": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "original_text": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . "}, "hash": "9021b0f97c504366c9971ca1e47dcbfbc4321c9b9113eef85acbe2c562e2e33d", "class_name": "RelatedNodeInfo"}}, "text": "We hit our both short and long term goals this year . ", "start_char_idx": 857, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c31c71f-a130-4a9f-b117-0f628d12e522": {"__data__": {"id_": "0c31c71f-a130-4a9f-b117-0f628d12e522", "embedding": null, "metadata": {"window": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "original_text": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58aedb05-e456-43ea-a01b-8176cf49a3a9", "node_type": "1", "metadata": {"window": "So probably \ndoing fewer things but doing them better .  And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "original_text": "We hit our both short and long term goals this year . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86d740937cc74007a786206d4f689878a05b07993c9dba7cb3505c3e196fdfc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60338c1b-2e27-4497-89ea-6f3ae945a8c0", "node_type": "1", "metadata": {"window": "The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n", "original_text": "So \nwe're in a very different phase there.  "}, "hash": "9c76e2448586ed2da2013ccee56aab050a15be4c689cde29063c9e3c657848da", "class_name": "RelatedNodeInfo"}}, "text": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "start_char_idx": 911, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60338c1b-2e27-4497-89ea-6f3ae945a8c0": {"__data__": {"id_": "60338c1b-2e27-4497-89ea-6f3ae945a8c0", "embedding": null, "metadata": {"window": "The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n", "original_text": "So \nwe're in a very different phase there.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c31c71f-a130-4a9f-b117-0f628d12e522", "node_type": "1", "metadata": {"window": "And that focus and that attention to de -risking the model and \ndriving this profit improvement plan for the Medical business .  The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "original_text": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f1be0bcbe4aaa18e1b9937e2ccb583be271a7a0bc90869ecc69da8b3e2a04c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b881a63-425e-4815-96cf-c913a01d150c", "node_type": "1", "metadata": {"window": "We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n", "original_text": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . "}, "hash": "c251fea8d66ff61ab1f7a47591b7d93ee7f86adf654d7d1710a0001b354b1720", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe're in a very different phase there.  ", "start_char_idx": 1054, "end_char_idx": 1098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b881a63-425e-4815-96cf-c913a01d150c": {"__data__": {"id_": "8b881a63-425e-4815-96cf-c913a01d150c", "embedding": null, "metadata": {"window": "We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n", "original_text": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60338c1b-2e27-4497-89ea-6f3ae945a8c0", "node_type": "1", "metadata": {"window": "The Pharma business has been very \nresilient .  We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n", "original_text": "So \nwe're in a very different phase there.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c35cbcb4f6bd41b2aef673ff5baf858bcd088e45806bd19ea07b3d58f657d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80bbd855-64bc-4ccd-a18c-8dea4c649eb3", "node_type": "1", "metadata": {"window": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you . ", "original_text": "I'm well positioned to take us through those those challenges \nthat we've be en faced with . "}, "hash": "3d567efd3ca57ba03b19ad254028b00bb720ccf04e72593a408530bcc1dee144", "class_name": "RelatedNodeInfo"}}, "text": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "start_char_idx": 1098, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80bbd855-64bc-4ccd-a18c-8dea4c649eb3": {"__data__": {"id_": "80bbd855-64bc-4ccd-a18c-8dea4c649eb3", "embedding": null, "metadata": {"window": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you . ", "original_text": "I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b881a63-425e-4815-96cf-c913a01d150c", "node_type": "1", "metadata": {"window": "We hit our both short and long term goals this year .  We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n", "original_text": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d6f57e324a5f22f06ae0cd91e3868db283fb451f9b15a382d5a6a3bc0b85c3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78d5725d-37c2-43c6-9048-8c57fb5a8ee2", "node_type": "1", "metadata": {"window": "So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J. ", "original_text": "And I am going to absolutely focus on taking the next steps here.  \n \n"}, "hash": "58a3df0e1a61cf1e233ef637dfb5514f4d779f80e0c696c01bb63bea86227d3b", "class_name": "RelatedNodeInfo"}}, "text": "I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "start_char_idx": 1313, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78d5725d-37c2-43c6-9048-8c57fb5a8ee2": {"__data__": {"id_": "78d5725d-37c2-43c6-9048-8c57fb5a8ee2", "embedding": null, "metadata": {"window": "So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J. ", "original_text": "And I am going to absolutely focus on taking the next steps here.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80bbd855-64bc-4ccd-a18c-8dea4c649eb3", "node_type": "1", "metadata": {"window": "We need to keep doing more of the same , \nwhile also continuing to grow those growth areas of which of course specialty , is the largest one .  So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you . ", "original_text": "I'm well positioned to take us through those those challenges \nthat we've be en faced with . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afaf13413f5d596ae570b17804721fce2f6984f59580f45c2610416daea5b8fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea392b4d-8dd2-48d8-be52-73a86b8882a7", "node_type": "1", "metadata": {"window": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse . ", "original_text": "Kevin Moran :  Operator , next question please.  \n \n"}, "hash": "f311a5c199fe6d32f040b35c39da54babfac64c099f47eacd00d6563058080ce", "class_name": "RelatedNodeInfo"}}, "text": "And I am going to absolutely focus on taking the next steps here.  \n \n", "start_char_idx": 1406, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea392b4d-8dd2-48d8-be52-73a86b8882a7": {"__data__": {"id_": "ea392b4d-8dd2-48d8-be52-73a86b8882a7", "embedding": null, "metadata": {"window": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse . ", "original_text": "Kevin Moran :  Operator , next question please.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78d5725d-37c2-43c6-9048-8c57fb5a8ee2", "node_type": "1", "metadata": {"window": "So \nwe're in a very different phase there.   And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J. ", "original_text": "And I am going to absolutely focus on taking the next steps here.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5770b836ec44128733033cdff9e29785342653f11c702e533702ab17a31cb4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01073702-f57d-4126-8898-14541ddb3435", "node_type": "1", "metadata": {"window": "I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n", "original_text": "Operator :  Thank you . "}, "hash": "cc20ad0bf05555e8567cd24b75306302d87566b5c205793dfc7a470e4633ffb9", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran :  Operator , next question please.  \n \n", "start_char_idx": 1476, "end_char_idx": 1528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01073702-f57d-4126-8898-14541ddb3435": {"__data__": {"id_": "01073702-f57d-4126-8898-14541ddb3435", "embedding": null, "metadata": {"window": "I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n", "original_text": "Operator :  Thank you . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea392b4d-8dd2-48d8-be52-73a86b8882a7", "node_type": "1", "metadata": {"window": "And then with this plan today, we're really highlighting how \naggressive we're going to be with our capital deployment, that when we generate that cash, $3.1  billion \nin \u201822, we're going to deploy it effectively .  I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse . ", "original_text": "Kevin Moran :  Operator , next question please.  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06551cff0294475d20902567eb97f83488aa9db76eb6f79fa062cadf73404ae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "467f234b-fe59-446a-8c16-0b49b0e7ee6f", "node_type": "1", "metadata": {"window": "And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "original_text": "We now move to A.J. "}, "hash": "a8b1a187c571565f9ed24f49ca37e86833e761d421507a400f91a0ce9c7c4905", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 1528, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "467f234b-fe59-446a-8c16-0b49b0e7ee6f": {"__data__": {"id_": "467f234b-fe59-446a-8c16-0b49b0e7ee6f", "embedding": null, "metadata": {"window": "And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "original_text": "We now move to A.J. ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01073702-f57d-4126-8898-14541ddb3435", "node_type": "1", "metadata": {"window": "I'm well positioned to take us through those those challenges \nthat we've be en faced with .  And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n", "original_text": "Operator :  Thank you . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c9fd7afcd8431bb05139410cca732f427fcc623dbca1d44f4f61c76c839ac9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1328339a-9fe4-4da3-a0e1-7ea5b565528b", "node_type": "1", "metadata": {"window": "Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well . ", "original_text": "Rice of Credit Suisse . "}, "hash": "06b0760966c866a58715108481a608cd5878d1abed6247e84656f553a7ba7f1f", "class_name": "RelatedNodeInfo"}}, "text": "We now move to A.J. ", "start_char_idx": 1552, "end_char_idx": 1572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1328339a-9fe4-4da3-a0e1-7ea5b565528b": {"__data__": {"id_": "1328339a-9fe4-4da3-a0e1-7ea5b565528b", "embedding": null, "metadata": {"window": "Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well . ", "original_text": "Rice of Credit Suisse . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "467f234b-fe59-446a-8c16-0b49b0e7ee6f", "node_type": "1", "metadata": {"window": "And I am going to absolutely focus on taking the next steps here.  \n \n Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "original_text": "We now move to A.J. ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b632bdf779e62c8aa7d2a7266081eca285bfa6064a0be126c070b97c12ca310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f7dcbde-d06d-417f-8c04-5d71820fdff3", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "original_text": "Please go ahead .  \n \n"}, "hash": "cb9f215119380b563eaac8500de09f65624412f3e6e78da5c7b8e2330e02d562", "class_name": "RelatedNodeInfo"}}, "text": "Rice of Credit Suisse . ", "start_char_idx": 1572, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f7dcbde-d06d-417f-8c04-5d71820fdff3": {"__data__": {"id_": "1f7dcbde-d06d-417f-8c04-5d71820fdff3", "embedding": null, "metadata": {"window": "Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "original_text": "Please go ahead .  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1328339a-9fe4-4da3-a0e1-7ea5b565528b", "node_type": "1", "metadata": {"window": "Kevin Moran :  Operator , next question please.  \n \n Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well . ", "original_text": "Rice of Credit Suisse . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09816e0d7e6e25cc08538603231f563d574c9c010816840fac9aa01f372acaf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce", "node_type": "1", "metadata": {"window": "We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "original_text": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . "}, "hash": "bcb9ce33963580167d27af863d1efa47c63eac70415ba10d4d93c47b3bb95271", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead .  \n \n", "start_char_idx": 1596, "end_char_idx": 1618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce": {"__data__": {"id_": "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce", "embedding": null, "metadata": {"window": "We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "original_text": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f7dcbde-d06d-417f-8c04-5d71820fdff3", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "original_text": "Please go ahead .  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27f78e25a35a5f358f189d4e5c2f65c5c9926bc14e87f2b73cd3bf1b1a831883", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69675c15-03c6-4890-9ca6-4499069ef558", "node_type": "1", "metadata": {"window": "Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "original_text": "I just want to echo my congrats to Jason and Mike \nas well . "}, "hash": "ad038484685f268e4eb564b677ee40eca29e9f3b78a7c13cdbb2f4dec6e4c162", "class_name": "RelatedNodeInfo"}}, "text": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "start_char_idx": 1618, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69675c15-03c6-4890-9ca6-4499069ef558": {"__data__": {"id_": "69675c15-03c6-4890-9ca6-4499069ef558", "embedding": null, "metadata": {"window": "Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "original_text": "I just want to echo my congrats to Jason and Mike \nas well . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce", "node_type": "1", "metadata": {"window": "We now move to A.J.  Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "original_text": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44252e20cc2d85812017a934961e9e848023afcb96a44f39ec35370a695031e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0170d41a-778c-4f75-a556-e033b1335d14", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "original_text": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . "}, "hash": "da1d1bb2006a509eb7d5738896cf92a01b79840e5deb3015f2d75c60ed6eec6a", "class_name": "RelatedNodeInfo"}}, "text": "I just want to echo my congrats to Jason and Mike \nas well . ", "start_char_idx": 1671, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0170d41a-778c-4f75-a556-e033b1335d14": {"__data__": {"id_": "0170d41a-778c-4f75-a556-e033b1335d14", "embedding": null, "metadata": {"window": "Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "original_text": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69675c15-03c6-4890-9ca6-4499069ef558", "node_type": "1", "metadata": {"window": "Rice of Credit Suisse .  Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "original_text": "I just want to echo my congrats to Jason and Mike \nas well . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f81640268ef82636343e94e47278120e9000b1950845040530439558bdb859f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "470d2ed0-ba69-48b5-9f45-55e61585f0d8", "node_type": "1", "metadata": {"window": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?  ", "original_text": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  "}, "hash": "5038cc285b0ed25fa2bbd884b7e47493718ac9c9a5754bb6e09bbf260e4ea3d4", "class_name": "RelatedNodeInfo"}}, "text": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "start_char_idx": 1732, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "470d2ed0-ba69-48b5-9f45-55e61585f0d8": {"__data__": {"id_": "470d2ed0-ba69-48b5-9f45-55e61585f0d8", "embedding": null, "metadata": {"window": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?  ", "original_text": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0170d41a-778c-4f75-a556-e033b1335d14", "node_type": "1", "metadata": {"window": "Please go ahead .  \n \n Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "original_text": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b252b6020801f981ced0ac0f6e9cc0f88b4fdf52010056b5bde1938f07722e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5177268-9f9d-428e-9820-0719e4f37732", "node_type": "1", "metadata": {"window": "I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n", "original_text": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . "}, "hash": "51df54f881d63bfe5c903063a9f83725b88e99b2c65f1fd5afa1153c2b3d1c62", "class_name": "RelatedNodeInfo"}}, "text": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "start_char_idx": 1931, "end_char_idx": 2058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5177268-9f9d-428e-9820-0719e4f37732": {"__data__": {"id_": "f5177268-9f9d-428e-9820-0719e4f37732", "embedding": null, "metadata": {"window": "I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n", "original_text": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "470d2ed0-ba69-48b5-9f45-55e61585f0d8", "node_type": "1", "metadata": {"window": "Jonathan Yong :  Hi, it's Jonathan Yong on for A.J .  I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?  ", "original_text": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff7bc31111c08ed10e352d361f48885e7467e5316463a09f2d3550d19ae9a58d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1719eac8-bc5e-4944-8c49-6254d98e0102", "node_type": "1", "metadata": {"window": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "original_text": "I guess, what are you assuming in terms of pricing growth moving \nforward ? "}, "hash": "0138bb5619f04a3b8424d9ff48e21189a38524e920f837e471708b9a3331a01d", "class_name": "RelatedNodeInfo"}}, "text": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "start_char_idx": 2058, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1719eac8-bc5e-4944-8c49-6254d98e0102": {"__data__": {"id_": "1719eac8-bc5e-4944-8c49-6254d98e0102", "embedding": null, "metadata": {"window": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "original_text": "I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5177268-9f9d-428e-9820-0719e4f37732", "node_type": "1", "metadata": {"window": "I just want to echo my congrats to Jason and Mike \nas well .  So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n", "original_text": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "949379728322b9a28b27c4b449f795ebd3d9c85bf46a936778e48c8c68c60f1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b6a6dab-a62e-4d86-9e76-29257e6c624a", "node_type": "1", "metadata": {"window": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "original_text": "And alongside that , utilization?  "}, "hash": "27705ec4804149b9c8cc422080603b32b501de23c7be48d9444c5eefab57af6a", "class_name": "RelatedNodeInfo"}}, "text": "I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "start_char_idx": 2163, "end_char_idx": 2239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b6a6dab-a62e-4d86-9e76-29257e6c624a": {"__data__": {"id_": "1b6a6dab-a62e-4d86-9e76-29257e6c624a", "embedding": null, "metadata": {"window": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "original_text": "And alongside that , utilization?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1719eac8-bc5e-4944-8c49-6254d98e0102", "node_type": "1", "metadata": {"window": "So you mentioned the various costs have been coming down within the Medical segment and \nunderstanding there is a lag between when the spot prices come down vers us when it flows through \nyour P&L .  Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "original_text": "I guess, what are you assuming in terms of pricing growth moving \nforward ? ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f198f251ea210637db2825e0763339eb1abe8fe36b24ce81411424d583884414", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0487795a-fe00-40c0-9b89-988edd10f90b", "node_type": "1", "metadata": {"window": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "original_text": "Thanks .  \n \n"}, "hash": "5f4ba2a2807218fc4e79eda94ea74733873b908e53083d5bb4045e2e5a933669", "class_name": "RelatedNodeInfo"}}, "text": "And alongside that , utilization?  ", "start_char_idx": 2239, "end_char_idx": 2274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0487795a-fe00-40c0-9b89-988edd10f90b": {"__data__": {"id_": "0487795a-fe00-40c0-9b89-988edd10f90b", "embedding": null, "metadata": {"window": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "original_text": "Thanks .  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b6a6dab-a62e-4d86-9e76-29257e6c624a", "node_type": "1", "metadata": {"window": "Should we take it that any further decline in the spot prices would be upside to the medical \noutlook for FY  \u201823 and beyond?   And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "original_text": "And alongside that , utilization?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e0c64768ae344aba485660b504be0e0970fdf9822ba3e8b51bfaa77484cc032", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "150505f3-cc8a-43f7-a7b1-67e44217e59d", "node_type": "1", "metadata": {"window": "I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "original_text": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . "}, "hash": "32949e010b808a5ae481edffd57d47a779c5c1cbedf9d98f938ce2cdb8627470", "class_name": "RelatedNodeInfo"}}, "text": "Thanks .  \n \n", "start_char_idx": 2274, "end_char_idx": 2287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "150505f3-cc8a-43f7-a7b1-67e44217e59d": {"__data__": {"id_": "150505f3-cc8a-43f7-a7b1-67e44217e59d", "embedding": null, "metadata": {"window": "I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "original_text": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0487795a-fe00-40c0-9b89-988edd10f90b", "node_type": "1", "metadata": {"window": "And then alongside that, you talked about the 3% revenue CAGR for \nthe Cardinal Health brand pro ducts .  I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "original_text": "Thanks .  \n \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42fb398b383d655d8b9cc47368a5e19480206beac7384bbf0839621f2f9b9885", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab945228-ca19-4b31-b766-8ff60081e80a", "node_type": "1", "metadata": {"window": "And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n", "original_text": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  "}, "hash": "294fef0b0459ad8b926477c573e4976095b20653ae51172ac70edd9b82bda7c8", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "start_char_idx": 2287, "end_char_idx": 2521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab945228-ca19-4b31-b766-8ff60081e80a": {"__data__": {"id_": "ab945228-ca19-4b31-b766-8ff60081e80a", "embedding": null, "metadata": {"window": "And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n", "original_text": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "150505f3-cc8a-43f7-a7b1-67e44217e59d", "node_type": "1", "metadata": {"window": "I guess, what are you assuming in terms of pricing growth moving \nforward ?  And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "original_text": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e730cb141ca28ffdc57a731141d65172077680d24ea19fc1e1c0de5d3f60a55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf", "node_type": "1", "metadata": {"window": "Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "original_text": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n"}, "hash": "056bccdfab1b9f9b50f819be0a098e7172c78d960ecb09d1d32b433e4460dcab", "class_name": "RelatedNodeInfo"}}, "text": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "start_char_idx": 2521, "end_char_idx": 2652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf": {"__data__": {"id_": "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf", "embedding": null, "metadata": {"window": "Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "original_text": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab945228-ca19-4b31-b766-8ff60081e80a", "node_type": "1", "metadata": {"window": "And alongside that , utilization?   Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n", "original_text": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8657eb53624dd28dc202abc7585d3390e5c844aa0a5d6a3a801d0be418e760f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b11519a5-c811-4110-a295-e1ac1c1b609e", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "original_text": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . "}, "hash": "7785cb681a2606decbce49e1bb3e23ef2fdbccdc5c48a5882663fd761301995a", "class_name": "RelatedNodeInfo"}}, "text": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "start_char_idx": 2652, "end_char_idx": 2830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b11519a5-c811-4110-a295-e1ac1c1b609e": {"__data__": {"id_": "b11519a5-c811-4110-a295-e1ac1c1b609e", "embedding": null, "metadata": {"window": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "original_text": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf", "node_type": "1", "metadata": {"window": "Thanks .  \n \n Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "original_text": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08dfaeb5d6c1026a63829c40997c30f5a4ffed1b0fb994eb5411079037ad5223", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07c9530a-aba6-468c-9e51-35a795f85138", "node_type": "1", "metadata": {"window": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change . ", "original_text": "So it kind of depends on what cost you're talking about.  \n"}, "hash": "d90291ee3f9edf497a50b4d7a91553cb63ebdd1d5d9dca2e80b810c5f4b570cc", "class_name": "RelatedNodeInfo"}}, "text": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "start_char_idx": 2830, "end_char_idx": 2993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07c9530a-aba6-468c-9e51-35a795f85138": {"__data__": {"id_": "07c9530a-aba6-468c-9e51-35a795f85138", "embedding": null, "metadata": {"window": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change . ", "original_text": "So it kind of depends on what cost you're talking about.  \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b11519a5-c811-4110-a295-e1ac1c1b609e", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay , so to start with  \u2013 on the spot prices, well, that's why we always talk about the net \nimpact   because obviousl y there's a gross impact in and then a pricing in other contracting items that \ncreate that net .  And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "original_text": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73a53bf041479e65ae8e4ae001bc42ad1f1058d5d973d65c8b0ab4a41b7771dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a480579-b271-4725-800e-c44182f263cd", "node_type": "1", "metadata": {"window": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "original_text": "Long term, we believe there's going to be a parity to pre -pandemic levels for this . "}, "hash": "f2762564c7108054895f4199b04887aeec28b82a9291d4ad4ae2f7ce2c41f462", "class_name": "RelatedNodeInfo"}}, "text": "So it kind of depends on what cost you're talking about.  \n", "start_char_idx": 2993, "end_char_idx": 3052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a480579-b271-4725-800e-c44182f263cd": {"__data__": {"id_": "2a480579-b271-4725-800e-c44182f263cd", "embedding": null, "metadata": {"window": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "original_text": "Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07c9530a-aba6-468c-9e51-35a795f85138", "node_type": "1", "metadata": {"window": "And so as I think about that dynamic in the short term, as as I think you indicate and \nunderstand, depends on what it is, right?   If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change . ", "original_text": "So it kind of depends on what cost you're talking about.  \n", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5255fc64470946e18c15a9baebce08c64b9e76b49d349dcd9a6099c32799e3dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72f86a08-7dd3-489e-9e86-683540daba91", "node_type": "1", "metadata": {"window": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "original_text": "So if costs weaken, \nget lower, then some of the pricing actions  may change . "}, "hash": "f829e2c2b20507287844df4025f2d6feb2ebae45cc395600a486f046e779c2b9", "class_name": "RelatedNodeInfo"}}, "text": "Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "start_char_idx": 3052, "end_char_idx": 3138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72f86a08-7dd3-489e-9e86-683540daba91": {"__data__": {"id_": "72f86a08-7dd3-489e-9e86-683540daba91", "embedding": null, "metadata": {"window": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "original_text": "So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a480579-b271-4725-800e-c44182f263cd", "node_type": "1", "metadata": {"window": "If it's inventory costs like the freight, international freight, the \nproduct freight or the commodities, that will be rolled in and that will be more of that two quarter lag . \n But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "original_text": "Long term, we believe there's going to be a parity to pre -pandemic levels for this . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "102562ccf9ecbbdcad7cee6561ab211fe333c85acc11a8ffbe9d7f3d354e589a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dec2ff41-0113-4c77-9c03-0d60af25f621", "node_type": "1", "metadata": {"window": "So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.  ", "original_text": "In the near term, I don't think pricing is going \nto change . "}, "hash": "17a84f9581f22ee0b0aba576e55abb3b6ee88e2d39b0114f33c3a9857b11ebf7", "class_name": "RelatedNodeInfo"}}, "text": "So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "start_char_idx": 3138, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dec2ff41-0113-4c77-9c03-0d60af25f621": {"__data__": {"id_": "dec2ff41-0113-4c77-9c03-0d60af25f621", "embedding": null, "metadata": {"window": "So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.  ", "original_text": "In the near term, I don't think pricing is going \nto change . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72f86a08-7dd3-489e-9e86-683540daba91", "node_type": "1", "metadata": {"window": "But as it relates to the domestic transportation, that piece, which hasn't moved  you know, very much in \neithe r direction, that is a little bit more real time .  So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "original_text": "So if costs weaken, \nget lower, then some of the pricing actions  may change . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23c68982a686ee435ca91acd70fa5ffdf69eb35ebc910714b8ba3ff3b64aae1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "751e2230-fed6-4028-940f-3b4c939b2f42", "node_type": "1", "metadata": {"window": "Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "original_text": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . "}, "hash": "52a6123b66eb210ec7913afa01a6b234fb29c72c53f768a0bf92fd236598d1e9", "class_name": "RelatedNodeInfo"}}, "text": "In the near term, I don't think pricing is going \nto change . ", "start_char_idx": 3217, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "751e2230-fed6-4028-940f-3b4c939b2f42": {"__data__": {"id_": "751e2230-fed6-4028-940f-3b4c939b2f42", "embedding": null, "metadata": {"window": "Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "original_text": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dec2ff41-0113-4c77-9c03-0d60af25f621", "node_type": "1", "metadata": {"window": "So it kind of depends on what cost you're talking about.  \n Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.  ", "original_text": "In the near term, I don't think pricing is going \nto change . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a37e70323c16237fdb3af0dd32450391a1bbf3b1fbc0751584f5b9a143042b61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2", "node_type": "1", "metadata": {"window": "So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "original_text": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . "}, "hash": "dd420a31db600b06bce52636c400e94f60df9ce08f045eaa866370bc7b25eb35", "class_name": "RelatedNodeInfo"}}, "text": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "start_char_idx": 3279, "end_char_idx": 3394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2": {"__data__": {"id_": "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2", "embedding": null, "metadata": {"window": "So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "original_text": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "751e2230-fed6-4028-940f-3b4c939b2f42", "node_type": "1", "metadata": {"window": "Long term, we believe there's going to be a parity to pre -pandemic levels for this .  So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "original_text": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25810c7c415107e4b8178cac0b22bf5b6ab453e8510124001f0943c7ead58376", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83900a24-e963-4b19-903b-44f532b35727", "node_type": "1", "metadata": {"window": "In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "original_text": "But again, that would be most likely in the second half of the \nyear.  "}, "hash": "c74041b7908d5a9926c24bf9dec9cb715bdee3ca1a217cfef53eaa7b9881a2c6", "class_name": "RelatedNodeInfo"}}, "text": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "start_char_idx": 3394, "end_char_idx": 3518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83900a24-e963-4b19-903b-44f532b35727": {"__data__": {"id_": "83900a24-e963-4b19-903b-44f532b35727", "embedding": null, "metadata": {"window": "In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "original_text": "But again, that would be most likely in the second half of the \nyear.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2", "node_type": "1", "metadata": {"window": "So if costs weaken, \nget lower, then some of the pricing actions  may change .  In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "original_text": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41d80fafa2f4264ca5b3313cf680c13188dc892ba6cceb45cefeda39471b25eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "665f6d76-5eca-45ac-aaef-e2c67b56b100", "node_type": "1", "metadata": {"window": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions . ", "original_text": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there . "}, "hash": "37dc93276a860704fb14c9f9cf02bdaa26d909842df4f997ce066da7fa33d484", "class_name": "RelatedNodeInfo"}}, "text": "But again, that would be most likely in the second half of the \nyear.  ", "start_char_idx": 3518, "end_char_idx": 3589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "665f6d76-5eca-45ac-aaef-e2c67b56b100": {"__data__": {"id_": "665f6d76-5eca-45ac-aaef-e2c67b56b100", "embedding": null, "metadata": {"window": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions . ", "original_text": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83900a24-e963-4b19-903b-44f532b35727", "node_type": "1", "metadata": {"window": "In the near term, I don't think pricing is going \nto change .  Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "original_text": "But again, that would be most likely in the second half of the \nyear.  ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22a98a58d0c18d1140d80bad4e1ce8d71177bea1b38a1e78bdffe5250f769735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1967b0fd-c351-4f14-bff6-8b824178084b", "node_type": "1", "metadata": {"window": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . "}, "hash": "e17bd54ddf2455275b1f0a4a97066404ed60dbb5cee11faac0e1630d88e69fc0", "class_name": "RelatedNodeInfo"}}, "text": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "start_char_idx": 3589, "end_char_idx": 3673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1967b0fd-c351-4f14-bff6-8b824178084b": {"__data__": {"id_": "1967b0fd-c351-4f14-bff6-8b824178084b", "embedding": null, "metadata": {"window": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "665f6d76-5eca-45ac-aaef-e2c67b56b100", "node_type": "1", "metadata": {"window": "Under all these pricing scenarios, we're still not covering \u2013 expected to cover \u2013 more than \nhalf of that impact .  So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions . ", "original_text": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b55f628d25918953a1cf92e374ccb37d0314b835a21c9225288f58b6a0ae0d26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0", "node_type": "1", "metadata": {"window": "But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . "}, "hash": "695104069132e1e2a18fdad67a9099eaafafda8bc995b367c2cb10ff77b45426", "class_name": "RelatedNodeInfo"}}, "text": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "start_char_idx": 3673, "end_char_idx": 3851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0": {"__data__": {"id_": "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0", "embedding": null, "metadata": {"window": "But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1967b0fd-c351-4f14-bff6-8b824178084b", "node_type": "1", "metadata": {"window": "So overall, we think in the short term, yeah, the costs are going t o flow more to \nminimizing the impact of what we have .  But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c269c37d1c4976ee4bd56d5849f3c330697a5059ce52c22ad1e2c7e713c8d3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60b1d59a-2bc1-4436-8ee6-924601979425", "node_type": "1", "metadata": {"window": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "It's not double \ndipping on on the pricing actions . "}, "hash": "dd1aea7fc01047319b42b183854044576cb044948d7266de9a44354febbcb18b", "class_name": "RelatedNodeInfo"}}, "text": "There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "start_char_idx": 3851, "end_char_idx": 3997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60b1d59a-2bc1-4436-8ee6-924601979425": {"__data__": {"id_": "60b1d59a-2bc1-4436-8ee6-924601979425", "embedding": null, "metadata": {"window": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "It's not double \ndipping on on the pricing actions . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0", "node_type": "1", "metadata": {"window": "But again, that would be most likely in the second half of the \nyear.   In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "012a37dab1f965ccd7536a7b64cd2deeb8ed27ac6cd05fdd40e9a8ac07eb5a07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47960c3d-65b4-413e-9fcd-5936c77a0263", "node_type": "1", "metadata": {"window": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   "}, "hash": "bfc20df3fb8069db775cdf89477da70d71071b6f206a9da3a66e6dea96e48e29", "class_name": "RelatedNodeInfo"}}, "text": "It's not double \ndipping on on the pricing actions . ", "start_char_idx": 3997, "end_char_idx": 4050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47960c3d-65b4-413e-9fcd-5936c77a0263": {"__data__": {"id_": "47960c3d-65b4-413e-9fcd-5936c77a0263", "embedding": null, "metadata": {"window": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ea66d9b879d4bec661ca10ac4e288c8e82a9ce4ed318330612736317a3bcf1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60b1d59a-2bc1-4436-8ee6-924601979425", "node_type": "1", "metadata": {"window": "In terms of the 3% CAGR, I'm not sure I fully understand the price question there .  But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "It's not double \ndipping on on the pricing actions . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e2c7d317fd713847004fb2562cfb3ca736e97162b0f6558c9df323772c0d9b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2738ebd-3eb8-457d-832e-c7f704aaf7bd", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n", "original_text": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n"}, "hash": "b56236f9380431c16314ae70e8dca0f7e2ecafcdcc6e5a580d9d7b5ea341c343", "class_name": "RelatedNodeInfo"}}, "text": "That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "start_char_idx": 4050, "end_char_idx": 4186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2738ebd-3eb8-457d-832e-c7f704aaf7bd": {"__data__": {"id_": "d2738ebd-3eb8-457d-832e-c7f704aaf7bd", "embedding": null, "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n", "original_text": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47960c3d-65b4-413e-9fcd-5936c77a0263", "node_type": "1", "metadata": {"window": "But within our \nCardinal Health, it's specificall y related to that $4  billion bucket that I referenced in my comments , that \nthe underlying volume is what that's related to .  There is pricing that goes along with that but I would \nsay it's more on the volume side and the pricing side that's driving that ty pe of CAGR .  It's not double \ndipping on on the pricing actions .  That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "original_text": "That is presuming a normalized level of inflation and pricing and so \nthen it would be more of volume driving that incremental value.   ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b27cc341577f56703ec4fa1d1f1e497724a9bbb91a05f518ef4c293fd15cfaea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf51af5e-b8da-4952-b1bf-6725a67776dd", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning . ", "original_text": "Operator :  Thank you . "}, "hash": "4e0e8eb56b54fe690dec66c468ab634680d758fc2f0cd9cad8a00351431db58c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n", "start_char_idx": 0, "end_char_idx": 54, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf51af5e-b8da-4952-b1bf-6725a67776dd": {"__data__": {"id_": "cf51af5e-b8da-4952-b1bf-6725a67776dd", "embedding": null, "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning . ", "original_text": "Operator :  Thank you . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2738ebd-3eb8-457d-832e-c7f704aaf7bd", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n", "original_text": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "feedc4a0cb8b82f22f16b859bd43a371d62a9e5fc09441f2b34f3e4d30991baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cb64771-51c5-4e1b-a5f2-dabf86b049c5", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "original_text": "Moving to Michael Cherny of Bank of America . "}, "hash": "30d258cd5ed0f27f1a9a2d274cb7ed16692b8133472ad7d222b3b181f6ae208e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 54, "end_char_idx": 78, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cb64771-51c5-4e1b-a5f2-dabf86b049c5": {"__data__": {"id_": "0cb64771-51c5-4e1b-a5f2-dabf86b049c5", "embedding": null, "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "original_text": "Moving to Michael Cherny of Bank of America . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf51af5e-b8da-4952-b1bf-6725a67776dd", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning . ", "original_text": "Operator :  Thank you . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3198ac7738dd4190cb3598ad869d0fecf5421b322ad6bc8cf2080848910f5efc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years . ", "original_text": "Please go ahead.   \n \n"}, "hash": "889ee056fe88e2e55e9371176e5726557af0174b531049e0c832f8c09e5291a9", "class_name": "RelatedNodeInfo"}}, "text": "Moving to Michael Cherny of Bank of America . ", "start_char_idx": 78, "end_char_idx": 124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117": {"__data__": {"id_": "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117", "embedding": null, "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years . ", "original_text": "Please go ahead.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cb64771-51c5-4e1b-a5f2-dabf86b049c5", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "original_text": "Moving to Michael Cherny of Bank of America . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98c6c44540cb4bc5d006dfd707105cf5c9bdfaadf9ed5394a3888818335a22db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddf13643-7081-4de8-b470-8f7c0236e1a1", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "original_text": "Michael Cherny :  Good morning . "}, "hash": "2c78e131527e9109e9ca49c222a600031381ee59ad737053ecef5b53ad1d38c4", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n \n", "start_char_idx": 124, "end_char_idx": 146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddf13643-7081-4de8-b470-8f7c0236e1a1": {"__data__": {"id_": "ddf13643-7081-4de8-b470-8f7c0236e1a1", "embedding": null, "metadata": {"window": "Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "original_text": "Michael Cherny :  Good morning . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117", "node_type": "1", "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years . ", "original_text": "Please go ahead.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a62e9eac4f110fba9d48e0cb6ead52c3fd8961034e4a1987327f282bed300bf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef", "node_type": "1", "metadata": {"window": "Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "original_text": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on . "}, "hash": "6175a0219b9bbf027a7fadbc2e7bf13c7c6654cd75dc12a70f3ad736eb351fc8", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny :  Good morning . ", "start_char_idx": 146, "end_char_idx": 179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef": {"__data__": {"id_": "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef", "embedding": null, "metadata": {"window": "Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "original_text": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddf13643-7081-4de8-b470-8f7c0236e1a1", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "original_text": "Michael Cherny :  Good morning . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1bf4ca0d01e91b6091677265fadefc80a0e63719b04aa1df93c52e5e3d7e233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66169882-127f-45c4-a776-caf19d0e1f61", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "original_text": "It's been a pleasure working with you over the years . "}, "hash": "3135659030918b6ad9d825760e96c9e25ed66a893cc320feae79b3291ebcf60b", "class_name": "RelatedNodeInfo"}}, "text": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "start_char_idx": 179, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66169882-127f-45c4-a776-caf19d0e1f61": {"__data__": {"id_": "66169882-127f-45c4-a776-caf19d0e1f61", "embedding": null, "metadata": {"window": "Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "original_text": "It's been a pleasure working with you over the years . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef", "node_type": "1", "metadata": {"window": "Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "original_text": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "297ef72432c44740fa5c02baaf48da10e70339f84abf3738823a5b51d5656cc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d848ddcc-c9c3-43f1-8d69-689b8a63f888", "node_type": "1", "metadata": {"window": "Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah . ", "original_text": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . "}, "hash": "2caa0db7fc27b625acc19888f77d2cd6118f3ef570741b289ab575053fd11719", "class_name": "RelatedNodeInfo"}}, "text": "It's been a pleasure working with you over the years . ", "start_char_idx": 256, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d848ddcc-c9c3-43f1-8d69-689b8a63f888": {"__data__": {"id_": "d848ddcc-c9c3-43f1-8d69-689b8a63f888", "embedding": null, "metadata": {"window": "Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah . ", "original_text": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66169882-127f-45c4-a776-caf19d0e1f61", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "original_text": "It's been a pleasure working with you over the years . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "beb4d4c538cd51b0e4efd9c4b2799b2142783844a3b45b0578d6a4b1b7384746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a00ae6-2492-4440-96e3-775af60b6268", "node_type": "1", "metadata": {"window": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "original_text": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  "}, "hash": "0badca385f87dfc960595dd16d4004df2682cd2e00408df51d32b66715cf4f1b", "class_name": "RelatedNodeInfo"}}, "text": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "start_char_idx": 311, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99a00ae6-2492-4440-96e3-775af60b6268": {"__data__": {"id_": "99a00ae6-2492-4440-96e3-775af60b6268", "embedding": null, "metadata": {"window": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "original_text": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d848ddcc-c9c3-43f1-8d69-689b8a63f888", "node_type": "1", "metadata": {"window": "Michael Cherny :  Good morning .  And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah . ", "original_text": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cbb9f10b41cda09ba0a4299cf28ca5ed6cae72c9791ee975e81ebadf7bcb201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5743eb27-c97f-4067-bda4-67a64e899acc", "node_type": "1", "metadata": {"window": "It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization . ", "original_text": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n"}, "hash": "ec2d35a429bd55ad4024160bf0cdd0eb84659c73905b4e239ff83986b8ea516d", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "start_char_idx": 468, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5743eb27-c97f-4067-bda4-67a64e899acc": {"__data__": {"id_": "5743eb27-c97f-4067-bda4-67a64e899acc", "embedding": null, "metadata": {"window": "It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization . ", "original_text": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99a00ae6-2492-4440-96e3-775af60b6268", "node_type": "1", "metadata": {"window": "And Mike, obviously a theme here, but wish you best wishes as you \nmove on .  It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "original_text": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40fbc9c374b20211515b3eba868e1ed2707176ea24ea10082f4d507204af0e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e2acd3-ef61-41ba-b400-685cfaeacd85", "node_type": "1", "metadata": {"window": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "original_text": "Jason Hollar :  Yeah . "}, "hash": "5517d5fc6ef3e332d7f9a64753b3c632571055e2efad73a70a0847e7207ef994", "class_name": "RelatedNodeInfo"}}, "text": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "start_char_idx": 734, "end_char_idx": 865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e2acd3-ef61-41ba-b400-685cfaeacd85": {"__data__": {"id_": "34e2acd3-ef61-41ba-b400-685cfaeacd85", "embedding": null, "metadata": {"window": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "original_text": "Jason Hollar :  Yeah . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5743eb27-c97f-4067-bda4-67a64e899acc", "node_type": "1", "metadata": {"window": "It's been a pleasure working with you over the years .  Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization . ", "original_text": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2008418934d3f8b9dac09efd336a795ddc24df75b69e3d90d3c604c3fbaa8ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87831237-90fa-4424-83b5-fb5dffcba2e7", "node_type": "1", "metadata": {"window": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "original_text": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . "}, "hash": "f3a0421dba483f6f15c4a260092754bb404f0c9f2ac7d3bb3fa4e92426beebd6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yeah . ", "start_char_idx": 865, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87831237-90fa-4424-83b5-fb5dffcba2e7": {"__data__": {"id_": "87831237-90fa-4424-83b5-fb5dffcba2e7", "embedding": null, "metadata": {"window": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "original_text": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e2acd3-ef61-41ba-b400-685cfaeacd85", "node_type": "1", "metadata": {"window": "Maybe, Jason, to dive a little bit also \ninto the Medical transformation plan, as you think about the totality of Cardinal, as you step into the \nCEO seat .  As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "original_text": "Jason Hollar :  Yeah . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c39f2b5c27cfa888dc07167294f47183bedeaea9546487b8c1a225e8abb6d88", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17f79297-e729-404f-bea5-a2c508efcf15", "node_type": "1", "metadata": {"window": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "original_text": "Probably the first one is the simplification \nand continued cost optimization . "}, "hash": "b24371d9f4cd459026001f1379cbc3f2297843cd31741fa6a285fb00b6a0cf6f", "class_name": "RelatedNodeInfo"}}, "text": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "start_char_idx": 888, "end_char_idx": 1036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17f79297-e729-404f-bea5-a2c508efcf15": {"__data__": {"id_": "17f79297-e729-404f-bea5-a2c508efcf15", "embedding": null, "metadata": {"window": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "original_text": "Probably the first one is the simplification \nand continued cost optimization . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87831237-90fa-4424-83b5-fb5dffcba2e7", "node_type": "1", "metadata": {"window": "As you think about the moving pieces that you have and the drivers to push back towards \ngrowth, can you give us a sense as well on how much the linkage between the Pharma and Medical \nside will be able to help al low you to hit these targets that you've laid out?   And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "original_text": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "333b8f345e3b65cf9d9f7a8454d3c1b9d012556681e96fded6c848fd9834e874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55ea9310-c28d-41e3-a1ee-c66a9e13e96b", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.  ", "original_text": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . "}, "hash": "4c14f69dbe2ffd35c36b5bc91664b36250324befdeb86c97ae69a166598a2808", "class_name": "RelatedNodeInfo"}}, "text": "Probably the first one is the simplification \nand continued cost optimization . ", "start_char_idx": 1036, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55ea9310-c28d-41e3-a1ee-c66a9e13e96b": {"__data__": {"id_": "55ea9310-c28d-41e3-a1ee-c66a9e13e96b", "embedding": null, "metadata": {"window": "Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.  ", "original_text": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17f79297-e729-404f-bea5-a2c508efcf15", "node_type": "1", "metadata": {"window": "And how do you view the \nsynergies, especially among this revamped Medical outlook between these two segments going \nforward?   \n \n Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "original_text": "Probably the first one is the simplification \nand continued cost optimization . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87880fa0c3cec5d102694f14e4c7ab5afd65a64be6faf091045a933e3aaf49dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc", "node_type": "1", "metadata": {"window": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "original_text": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . "}, "hash": "f010102ed83445817cf4d1295ce74b4e6ec0a41ea5db56f1e5bb0566a18a308a", "class_name": "RelatedNodeInfo"}}, "text": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "start_char_idx": 1116, "end_char_idx": 1300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc": {"__data__": {"id_": "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc", "embedding": null, "metadata": {"window": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "original_text": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55ea9310-c28d-41e3-a1ee-c66a9e13e96b", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah .  So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.  ", "original_text": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "833ef3d25844f214fb834fb8fc40f2e63a18a113d560bbe4695a5ae947920123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "179f2260-96af-4988-8783-df3e61c6ff58", "node_type": "1", "metadata": {"window": "Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "original_text": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . "}, "hash": "b373317008773e58a67b90468df1e63d74f826d587964d09a217bca5b3def845", "class_name": "RelatedNodeInfo"}}, "text": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "start_char_idx": 1300, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "179f2260-96af-4988-8783-df3e61c6ff58": {"__data__": {"id_": "179f2260-96af-4988-8783-df3e61c6ff58", "embedding": null, "metadata": {"window": "Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "original_text": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc", "node_type": "1", "metadata": {"window": "So when I step back and think about that plan, the area that is \u2013 there's a couple \nof areas that could be impacted, that have connectivity there .  Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "original_text": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06e40f00af2eaf46bb931b34ecc52f324d6dcf6b609844cb5054ddd6ffcaeeaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e49a92dd-7bc4-4dc1-847d-19cbdef4d113", "node_type": "1", "metadata": {"window": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "original_text": "So that's certainly \na piece of it.  "}, "hash": "03b72c3daf109cf3ae2e22aa14ddc6ede163604bcbbdc7c384bbefc6a845476f", "class_name": "RelatedNodeInfo"}}, "text": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "start_char_idx": 1416, "end_char_idx": 1686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e49a92dd-7bc4-4dc1-847d-19cbdef4d113": {"__data__": {"id_": "e49a92dd-7bc4-4dc1-847d-19cbdef4d113", "embedding": null, "metadata": {"window": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "original_text": "So that's certainly \na piece of it.  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "179f2260-96af-4988-8783-df3e61c6ff58", "node_type": "1", "metadata": {"window": "Probably the first one is the simplification \nand continued cost optimization .  Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "original_text": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35f1c57217fcba708ca74a94a8b6f485292b998384d64abf0c91ce623bde5275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d33700-97f5-4edd-95cf-a2e0c4700edf", "node_type": "1", "metadata": {"window": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "original_text": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. "}, "hash": "8b0817f2785e33704ae494a2425336759e1dc33a58be539c55695b8a38ffd09b", "class_name": "RelatedNodeInfo"}}, "text": "So that's certainly \na piece of it.  ", "start_char_idx": 1686, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d33700-97f5-4edd-95cf-a2e0c4700edf": {"__data__": {"id_": "e8d33700-97f5-4edd-95cf-a2e0c4700edf", "embedding": null, "metadata": {"window": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "original_text": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e49a92dd-7bc4-4dc1-847d-19cbdef4d113", "node_type": "1", "metadata": {"window": "Those types of initiatives are wide ranging and as we implement a \nparticular project t o reduce cost, it's a lot of cherry picking between the segments and the corporate \nfunctions .  When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "original_text": "So that's certainly \na piece of it.  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "87c53b66fa6ffcbd34bcc184fbde86bb1459100e5daf5d21aa04487eda608378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dad53a7-5623-474b-8da4-1c08bc05bc00", "node_type": "1", "metadata": {"window": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "So that's not a huge enabler of \nthat type of item, but it could be a component of it . "}, "hash": "b2ffd9b85db0585d2b97f8d7d7e0a1d02ed7708f1c92937b3978a17c6a165674", "class_name": "RelatedNodeInfo"}}, "text": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "start_char_idx": 1723, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dad53a7-5623-474b-8da4-1c08bc05bc00": {"__data__": {"id_": "7dad53a7-5623-474b-8da4-1c08bc05bc00", "embedding": null, "metadata": {"window": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d33700-97f5-4edd-95cf-a2e0c4700edf", "node_type": "1", "metadata": {"window": "When one person has a good idea, we push those across all of them, and in some cases \nwe're leveraging that scale .  We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "original_text": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b233685096e21f84f33455fcdb8ca45319ef974d94101ac6438caf2a4165551", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd893f9b-ffc8-4375-bec6-6ee62fe7d312", "node_type": "1", "metadata": {"window": "So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n"}, "hash": "dc0f733298981fa30678d9c7833bbf64db275d1948688b9c087ac87ae6a53c13", "class_name": "RelatedNodeInfo"}}, "text": "So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "start_char_idx": 1987, "end_char_idx": 2075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd893f9b-ffc8-4375-bec6-6ee62fe7d312": {"__data__": {"id_": "bd893f9b-ffc8-4375-bec6-6ee62fe7d312", "embedding": null, "metadata": {"window": "So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dad53a7-5623-474b-8da4-1c08bc05bc00", "node_type": "1", "metadata": {"window": "We're doing a lot of centralization of work to  standardize and offshore back \noffice activities, things of that nature, using digital tools that when we can invest in those types of \ntechnologies and capabilities centrally and blow that out to the whole organization .  So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys . ", "original_text": "So that's not a huge enabler of \nthat type of item, but it could be a component of it . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a204f2fd58bdf60e33c47f3ccb897f567fe1846a4f80025ba790052d81e3cc6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d1e90dc-a811-436f-839d-bdcf83cf08a2", "node_type": "1", "metadata": {"window": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "original_text": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n"}, "hash": "2754aed7cffc063360cff162afe05089d959b1fd4404609ba5b57d936e1dfb5c", "class_name": "RelatedNodeInfo"}}, "text": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "start_char_idx": 2075, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d1e90dc-a811-436f-839d-bdcf83cf08a2": {"__data__": {"id_": "7d1e90dc-a811-436f-839d-bdcf83cf08a2", "embedding": null, "metadata": {"window": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "original_text": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd893f9b-ffc8-4375-bec6-6ee62fe7d312", "node_type": "1", "metadata": {"window": "So that's certainly \na piece of it.   And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question . ", "original_text": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e11473494a4251ebc984a304377589da3c3b402fec2a4374e360fa383ca6eb91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ab3a169-ccf2-4450-a4c3-987d1ae3570f", "node_type": "1", "metadata": {"window": "So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "original_text": "Elizabeth Anderson :  Hi, guys . "}, "hash": "5aa5667221fadfbd728c3d997077d104538b2c67d899735aae09081ba3ba8af1", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "start_char_idx": 2159, "end_char_idx": 2223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ab3a169-ccf2-4450-a4c3-987d1ae3570f": {"__data__": {"id_": "2ab3a169-ccf2-4450-a4c3-987d1ae3570f", "embedding": null, "metadata": {"window": "So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "original_text": "Elizabeth Anderson :  Hi, guys . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d1e90dc-a811-436f-839d-bdcf83cf08a2", "node_type": "1", "metadata": {"window": "And then when we talk about the the growing our Cardinal Health brand portfolio, while \nthere's not a lot of crossover selling, and we do have the same customers, and so those relationships, \nthose discussions can spawn into a variety of different opportunit ies.  So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "original_text": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6b22c33275cb6ece2a9d26ca09eba22619a447d7665a6cf2461cef9df75db99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66956909-3cd4-49e1-a23d-f9e9e5a0519b", "node_type": "1", "metadata": {"window": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "original_text": "Thanks so much for the question . "}, "hash": "14ef9f067bb26dd66d2dbe423f8af87ba1eecd9e6323a759762c63fc87f75a4a", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson :  Hi, guys . ", "start_char_idx": 2223, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66956909-3cd4-49e1-a23d-f9e9e5a0519b": {"__data__": {"id_": "66956909-3cd4-49e1-a23d-f9e9e5a0519b", "embedding": null, "metadata": {"window": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "original_text": "Thanks so much for the question . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ab3a169-ccf2-4450-a4c3-987d1ae3570f", "node_type": "1", "metadata": {"window": "So that's not a huge enabler of \nthat type of item, but it could be a component of it .  And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "original_text": "Elizabeth Anderson :  Hi, guys . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "188571bd5c8d6f1132037c6e0953badf889838a7295b0db2659b9bdb4222f710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cafc0e69-980f-4d2f-bd7e-8230c26893f7", "node_type": "1", "metadata": {"window": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there . ", "original_text": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason . "}, "hash": "f956a60f318e9609774d235bf65ee7ab550b181ac48cabfd5fa524111db454de", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question . ", "start_char_idx": 2256, "end_char_idx": 2290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cafc0e69-980f-4d2f-bd7e-8230c26893f7": {"__data__": {"id_": "cafc0e69-980f-4d2f-bd7e-8230c26893f7", "embedding": null, "metadata": {"window": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there . ", "original_text": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66956909-3cd4-49e1-a23d-f9e9e5a0519b", "node_type": "1", "metadata": {"window": "And I would say that that's probably the areas that \nthere's the most overlap.   \n \n Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "original_text": "Thanks so much for the question . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f8853446600a987ef9dc24eade35dcbf247064e01f5540b91233c07ef31727d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1270ac96-9775-4b56-a287-20230defa564", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n", "original_text": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . "}, "hash": "d1a585ba74c52c282a0fac34f6f7a449596312337cdb08d983633c22fb42b1ca", "class_name": "RelatedNodeInfo"}}, "text": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "start_char_idx": 2290, "end_char_idx": 2365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1270ac96-9775-4b56-a287-20230defa564": {"__data__": {"id_": "1270ac96-9775-4b56-a287-20230defa564", "embedding": null, "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n", "original_text": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cafc0e69-980f-4d2f-bd7e-8230c26893f7", "node_type": "1", "metadata": {"window": "Operator :  We move now to Elizabeth Anderson of Evercore.   \n \n Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there . ", "original_text": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "063c88dcc9e50ef7c82940473292654f8e479afb79c6854b6dcb60169839f8c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "601fa7bb-abc2-486f-a521-eca1145b5ceb", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah . ", "original_text": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. "}, "hash": "327fe62cfd4fac3b6c9d0af0e6d3ee05e4e93126254961a3e368d41d9abe1a0b", "class_name": "RelatedNodeInfo"}}, "text": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "start_char_idx": 2365, "end_char_idx": 2559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "601fa7bb-abc2-486f-a521-eca1145b5ceb": {"__data__": {"id_": "601fa7bb-abc2-486f-a521-eca1145b5ceb", "embedding": null, "metadata": {"window": "Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah . ", "original_text": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1270ac96-9775-4b56-a287-20230defa564", "node_type": "1", "metadata": {"window": "Elizabeth Anderson :  Hi, guys .  Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n", "original_text": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac7dddc956fe100262b42d91968a34699e0d7882cd1faeef273a9c69bd7d9bf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fafe797-bc26-4395-94bc-3cdd8b7967e1", "node_type": "1", "metadata": {"window": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "original_text": "And I know there \nare a variety of things in there . "}, "hash": "8732f6eb298b41d426f238065e8301e01d06b581021a43e26057ec82aaa110f4", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "start_char_idx": 2559, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fafe797-bc26-4395-94bc-3cdd8b7967e1": {"__data__": {"id_": "4fafe797-bc26-4395-94bc-3cdd8b7967e1", "embedding": null, "metadata": {"window": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "original_text": "And I know there \nare a variety of things in there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "601fa7bb-abc2-486f-a521-eca1145b5ceb", "node_type": "1", "metadata": {"window": "Thanks so much for the question .  Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah . ", "original_text": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abfe2a65fdb20146cf441e33007fbb174f759a11a1b06521c611f58874ede8a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d8c9563-0699-4fb9-b1bc-1aa02a43deab", "node_type": "1", "metadata": {"window": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st . ", "original_text": "So just wondering if you could update us on that?  \n \n"}, "hash": "869a647955e975d8a195f5199f58826db0655051e097491935424d2da56a51c7", "class_name": "RelatedNodeInfo"}}, "text": "And I know there \nare a variety of things in there . ", "start_char_idx": 2727, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d8c9563-0699-4fb9-b1bc-1aa02a43deab": {"__data__": {"id_": "5d8c9563-0699-4fb9-b1bc-1aa02a43deab", "embedding": null, "metadata": {"window": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st . ", "original_text": "So just wondering if you could update us on that?  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fafe797-bc26-4395-94bc-3cdd8b7967e1", "node_type": "1", "metadata": {"window": "Best wishes, Mike, and excited to \nwork with you in your new role, Jason .  I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "original_text": "And I know there \nare a variety of things in there . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12f9ca5b246316f7b1a823f5e012fe80f9900c62c6ba7f8d4027df6be3243c48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c843a705-d066-44f1-b5e9-290bddce00fe", "node_type": "1", "metadata": {"window": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "original_text": "Jason Hollar :  Yeah . "}, "hash": "7f4e016ab517e758fe19b5d8fbb57ccf23329b2c5691682dc700ecce1b49254b", "class_name": "RelatedNodeInfo"}}, "text": "So just wondering if you could update us on that?  \n \n", "start_char_idx": 2780, "end_char_idx": 2834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c843a705-d066-44f1-b5e9-290bddce00fe": {"__data__": {"id_": "c843a705-d066-44f1-b5e9-290bddce00fe", "embedding": null, "metadata": {"window": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "original_text": "Jason Hollar :  Yeah . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d8c9563-0699-4fb9-b1bc-1aa02a43deab", "node_type": "1", "metadata": {"window": "I had a question just in terms of you talked about, I think, on the \nlast call that you had gotten sort of 50% of SKUs sort of at a higher \u2013 you'd been able to pass through \nhigher cost there .  I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st . ", "original_text": "So just wondering if you could update us on that?  \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09fd383d342f597aba1b3126ddbffd032850b9b761943656766f5e714ab26db6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfb0a393-7e78-4739-ac51-85065fcdfc39", "node_type": "1", "metadata": {"window": "And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "original_text": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . "}, "hash": "b51f3594301928f7d82feb80cf9a08c18264b49e21a1b6068e4e390fe50acb07", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yeah . ", "start_char_idx": 865, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfb0a393-7e78-4739-ac51-85065fcdfc39": {"__data__": {"id_": "cfb0a393-7e78-4739-ac51-85065fcdfc39", "embedding": null, "metadata": {"window": "And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "original_text": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c843a705-d066-44f1-b5e9-290bddce00fe", "node_type": "1", "metadata": {"window": "I was wondering if you could update that, because I know you said in your slides, \nobviously, you were going to have offset about 50% of that gross impact exiting \u201923.  And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "original_text": "Jason Hollar :  Yeah . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b338d04169e03afec15e50c84cdbbda4d0f99eacece8ab625292251ec5ff77c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99c1b11-1f1c-45c4-a242-d60647a82cf0", "node_type": "1", "metadata": {"window": "So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "original_text": "So that is effective July 1st . "}, "hash": "3df2b6a2eb1689d586c0d3c74a2f7ff6e3c56ae8e352d30fbf812eefab2e8938", "class_name": "RelatedNodeInfo"}}, "text": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "start_char_idx": 2857, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99c1b11-1f1c-45c4-a242-d60647a82cf0": {"__data__": {"id_": "d99c1b11-1f1c-45c4-a242-d60647a82cf0", "embedding": null, "metadata": {"window": "So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "original_text": "So that is effective July 1st . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfb0a393-7e78-4739-ac51-85065fcdfc39", "node_type": "1", "metadata": {"window": "And I know there \nare a variety of things in there .  So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "original_text": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7abefe9e19abc5b80201c560e7b6c59a2ba947dc04939ea7affd62f8ef1edb80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "497a5e5d-ea00-4156-a0f1-0e76bf940582", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "original_text": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . "}, "hash": "097ef966d7e27c62511b57f62197e49f04f9edd712157288279739d732530050", "class_name": "RelatedNodeInfo"}}, "text": "So that is effective July 1st . ", "start_char_idx": 2949, "end_char_idx": 2981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "497a5e5d-ea00-4156-a0f1-0e76bf940582": {"__data__": {"id_": "497a5e5d-ea00-4156-a0f1-0e76bf940582", "embedding": null, "metadata": {"window": "Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "original_text": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99c1b11-1f1c-45c4-a242-d60647a82cf0", "node_type": "1", "metadata": {"window": "So just wondering if you could update us on that?  \n \n Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "original_text": "So that is effective July 1st . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0a84b8b50ec10079377e0b4aaa360ba12a97398a4c392718b8ad439405ebe73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4c9b15-4bc1-4a09-8253-c63184ed18b6", "node_type": "1", "metadata": {"window": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "original_text": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . "}, "hash": "5ae444f03b8d18ecf2662faeb83f3e62a944d9453ffb38f041614bfce1e103aa", "class_name": "RelatedNodeInfo"}}, "text": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "start_char_idx": 2981, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4c9b15-4bc1-4a09-8253-c63184ed18b6": {"__data__": {"id_": "fc4c9b15-4bc1-4a09-8253-c63184ed18b6", "embedding": null, "metadata": {"window": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "original_text": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "497a5e5d-ea00-4156-a0f1-0e76bf940582", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah .  So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "original_text": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7f9fd70f5f09c891a46913e0ae529ae4fc2c173371fd38ba96aee9df3c269f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "526eeaf6-0850-4fe6-9f43-6440c42689a5", "node_type": "1", "metadata": {"window": "So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "original_text": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . "}, "hash": "01547e773658f2c67b0dd96833142cca4a95ddeb947e2c0e6485a5d7f3db797b", "class_name": "RelatedNodeInfo"}}, "text": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "start_char_idx": 3078, "end_char_idx": 3186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "526eeaf6-0850-4fe6-9f43-6440c42689a5": {"__data__": {"id_": "526eeaf6-0850-4fe6-9f43-6440c42689a5", "embedding": null, "metadata": {"window": "So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "original_text": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4c9b15-4bc1-4a09-8253-c63184ed18b6", "node_type": "1", "metadata": {"window": "So that reference to 50% of SKUs was reflective of the expected July 1st price \nincreases .  So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "original_text": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d2641b3cb8d7583218e3ca3dfae86c05196d9ff160d07fb6cecb300ca9f25f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab", "node_type": "1", "metadata": {"window": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation . ", "original_text": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  "}, "hash": "8db7c99f4823eec693dc3f9682e7610a93156cba9d0b9ee80afba432073abc7d", "class_name": "RelatedNodeInfo"}}, "text": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "start_char_idx": 3186, "end_char_idx": 3292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab": {"__data__": {"id_": "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab", "embedding": null, "metadata": {"window": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation . ", "original_text": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "526eeaf6-0850-4fe6-9f43-6440c42689a5", "node_type": "1", "metadata": {"window": "So that is effective July 1st .  Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "original_text": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3f1610a202dd65c6ce4fa36f99973631b1c31e9634f783383a5eee5c183877a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa29760-d276-4e3a-85a0-219dd8a3ff17", "node_type": "1", "metadata": {"window": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. "}, "hash": "316d243fff06483337956d60076976defb80e11210dd8a11ab43df72e26804a1", "class_name": "RelatedNodeInfo"}}, "text": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "start_char_idx": 3292, "end_char_idx": 3400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa29760-d276-4e3a-85a0-219dd8a3ff17": {"__data__": {"id_": "dfa29760-d276-4e3a-85a0-219dd8a3ff17", "embedding": null, "metadata": {"window": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab", "node_type": "1", "metadata": {"window": "Now, since then, we've now disc ussed and are informing \neveryone of the October 1st increases .  I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation . ", "original_text": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.  ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45ae84cf2044d73ac9d1a43963c353ec33f9081ea32d9f088abbed7fb2061b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a02159d4-8490-42bf-9736-cceaba703747", "node_type": "1", "metadata": {"window": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So we indicated there \nwas $125  million gross impact with $25  million of pricing . "}, "hash": "7afb5b2a653c09ef49db69dddc14f6da00b5d3dc17707b0b4067729081f20292", "class_name": "RelatedNodeInfo"}}, "text": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "start_char_idx": 3400, "end_char_idx": 3537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a02159d4-8490-42bf-9736-cceaba703747": {"__data__": {"id_": "a02159d4-8490-42bf-9736-cceaba703747", "embedding": null, "metadata": {"window": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa29760-d276-4e3a-85a0-219dd8a3ff17", "node_type": "1", "metadata": {"window": "I didn't provide that exact number, but remember, that's just the \npercentage of SKUs that we're touching .  I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on. ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6560d40242e2e470d89916c2f58f58580f5c00a30e26ddf0a446889a78e3cdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "597f6b04-5676-42d1-b260-aae04b76d60f", "node_type": "1", "metadata": {"window": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So it's a 20% mitigation . "}, "hash": "198d11e62e0de005eee8286c3fe80ce20e6ebac99a922ddcf1d0ebbf909e19ca", "class_name": "RelatedNodeInfo"}}, "text": "So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "start_char_idx": 3537, "end_char_idx": 3622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "597f6b04-5676-42d1-b260-aae04b76d60f": {"__data__": {"id_": "597f6b04-5676-42d1-b260-aae04b76d60f", "embedding": null, "metadata": {"window": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So it's a 20% mitigation . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a02159d4-8490-42bf-9736-cceaba703747", "node_type": "1", "metadata": {"window": "I think the more important way to think about it is the \npercentage of mitigation that  we're targeting .  So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So we indicated there \nwas $125  million gross impact with $25  million of pricing . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca4473c35ba52cb02088e369af0d5b1a9cf9926f2f24cfb09e360beaa450b4c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea84f927-bac8-4d87-a38c-43bc3df4cf2a", "node_type": "1", "metadata": {"window": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average "}, "hash": "442fc9fa1803811f62e4b78e6c11054e4ce952e4a6d55ca978457835214687c2", "class_name": "RelatedNodeInfo"}}, "text": "So it's a 20% mitigation . ", "start_char_idx": 3622, "end_char_idx": 3649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea84f927-bac8-4d87-a38c-43bc3df4cf2a": {"__data__": {"id_": "ea84f927-bac8-4d87-a38c-43bc3df4cf2a", "embedding": null, "metadata": {"window": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10bbabf6d21debca3289fba4d0d0c095b8b0ff873a7175319ec07c2b8021634d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "597f6b04-5676-42d1-b260-aae04b76d60f", "node_type": "1", "metadata": {"window": "So let me kind of walk through the flow and how I think \nyou should think about it for this upcoming year.   So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "So it's a 20% mitigation . ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "503b9fde4e1b607731af059df85549dfefa3cae8ae12dd189e1ab3d555c00350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb1f3df9-daf0-4318-b8a3-15b67c6f1a28", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too . ", "original_text": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823. "}, "hash": "956af6a843364ff2f0ce9f909dbccada3d135836efa86330d5db88d39cfe06f0", "class_name": "RelatedNodeInfo"}}, "text": "We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "start_char_idx": 3649, "end_char_idx": 3776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb1f3df9-daf0-4318-b8a3-15b67c6f1a28": {"__data__": {"id_": "bb1f3df9-daf0-4318-b8a3-15b67c6f1a28", "embedding": null, "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too . ", "original_text": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea84f927-bac8-4d87-a38c-43bc3df4cf2a", "node_type": "1", "metadata": {"window": "So just as an anchor point, I just walked it through in \nthe prepared comments, in Q4 \u201822 what we just spent is about a 20% mitigati on.  So we indicated there \nwas $125  million gross impact with $25  million of pricing .  So it's a 20% mitigation .  We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "original_text": "We expect that 20% \nwith the July increases and phasing that in over the quarter, that's going to increase that to 25% average ", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89a5feb677291525d8222ed1b27233cff9cb23b3066e00a197f189816533bdd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04e8843c-98c1-4f25-a718-b5c706d7aeb0", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823. ", "original_text": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases . "}, "hash": "8ff85e9f18837fe7c55adf6342ec38a71ae2801e0ae0723921fed1e96d91d2c0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823. ", "start_char_idx": 0, "end_char_idx": 51, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04e8843c-98c1-4f25-a718-b5c706d7aeb0": {"__data__": {"id_": "04e8843c-98c1-4f25-a718-b5c706d7aeb0", "embedding": null, "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823. ", "original_text": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb1f3df9-daf0-4318-b8a3-15b67c6f1a28", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too . ", "original_text": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5772f3f9de5c05e244099dce65b64d44e564226033545c2f8aae568e5121360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8712560-79d1-43e4-996f-5921d4575f19", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "original_text": "I mean, these are the big waves, \nbut there's always going to be other increases along the way . "}, "hash": "2b70dc58c39f0beb297a0516d4e40673a86d32a21bae64208d3dd977205a9e3e", "class_name": "RelatedNodeInfo"}}, "text": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases . ", "start_char_idx": 51, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8712560-79d1-43e4-996f-5921d4575f19": {"__data__": {"id_": "c8712560-79d1-43e4-996f-5921d4575f19", "embedding": null, "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "original_text": "I mean, these are the big waves, \nbut there's always going to be other increases along the way . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04e8843c-98c1-4f25-a718-b5c706d7aeb0", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823. ", "original_text": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be65f16f45c860eea30ee94da7f6f99622906e34b4709b39dd62bb23f6174713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "original_text": "And our supplier fees that go along with \nthis too . "}, "hash": "76db5166ad21786ffcad67751477e72f38379bbcf7d65da44faa1bc14f7ae936", "class_name": "RelatedNodeInfo"}}, "text": "I mean, these are the big waves, \nbut there's always going to be other increases along the way . ", "start_char_idx": 198, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43": {"__data__": {"id_": "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43", "embedding": null, "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "original_text": "And our supplier fees that go along with \nthis too . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8712560-79d1-43e4-996f-5921d4575f19", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "original_text": "I mean, these are the big waves, \nbut there's always going to be other increases along the way . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d48d547fd002e62d95bab202eb338bc408f99f36bd4987a4b85444ea1885ec22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62f4f7ba-e24f-49ec-b2b0-96680696375d", "node_type": "1", "metadata": {"window": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "original_text": "And then that 25% we expect to double by the time we exit fiscal \u201823. "}, "hash": "24e43e863c37ac00a44139b10ae20d00da8858441ab04ae67ed89e5bbc79963a", "class_name": "RelatedNodeInfo"}}, "text": "And our supplier fees that go along with \nthis too . ", "start_char_idx": 295, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62f4f7ba-e24f-49ec-b2b0-96680696375d": {"__data__": {"id_": "62f4f7ba-e24f-49ec-b2b0-96680696375d", "embedding": null, "metadata": {"window": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "original_text": "And then that 25% we expect to double by the time we exit fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43", "node_type": "1", "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "original_text": "And our supplier fees that go along with \nthis too . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6820dc6c3fe1665e59c8d3d51dc257c7aa2038c62ebfeb099c7273fcee1acbaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff714d89-7fbc-4900-8ef5-cc90567e0450", "node_type": "1", "metadata": {"window": "I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "original_text": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. "}, "hash": "9bd7ebb4356d588b275a551918c8f416376cbb7ebc21e9d19f1fc5b123d295c2", "class_name": "RelatedNodeInfo"}}, "text": "And then that 25% we expect to double by the time we exit fiscal \u201823. ", "start_char_idx": 348, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff714d89-7fbc-4900-8ef5-cc90567e0450": {"__data__": {"id_": "ff714d89-7fbc-4900-8ef5-cc90567e0450", "embedding": null, "metadata": {"window": "I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "original_text": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62f4f7ba-e24f-49ec-b2b0-96680696375d", "node_type": "1", "metadata": {"window": "Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "original_text": "And then that 25% we expect to double by the time we exit fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02abff55d8928987b2269b9a568b58ea70cbc712e6e22de4cc61e1bb08fb7188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "184747cf-56d3-42be-af3a-b61391ff9751", "node_type": "1", "metadata": {"window": "And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you . ", "original_text": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . "}, "hash": "f59a19be2b1bfcba8a9077460e4db13ace02c753f6c27bafbe973d480ac1777d", "class_name": "RelatedNodeInfo"}}, "text": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "start_char_idx": 418, "end_char_idx": 488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "184747cf-56d3-42be-af3a-b61391ff9751": {"__data__": {"id_": "184747cf-56d3-42be-af3a-b61391ff9751", "embedding": null, "metadata": {"window": "And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you . ", "original_text": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff714d89-7fbc-4900-8ef5-cc90567e0450", "node_type": "1", "metadata": {"window": "I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "original_text": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36da6ebe03f630d2f66b785f21011c2918b637530ddbd6e1a2b927df6274f1d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5453fe51-e646-40b2-863c-5501a9fabe39", "node_type": "1", "metadata": {"window": "And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays . ", "original_text": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . "}, "hash": "54e96ab8bb26441e82b9a301b5bbe691ea915ed19fc0bb9f46941be281032c35", "class_name": "RelatedNodeInfo"}}, "text": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "start_char_idx": 488, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5453fe51-e646-40b2-863c-5501a9fabe39": {"__data__": {"id_": "5453fe51-e646-40b2-863c-5501a9fabe39", "embedding": null, "metadata": {"window": "And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays . ", "original_text": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "184747cf-56d3-42be-af3a-b61391ff9751", "node_type": "1", "metadata": {"window": "And our supplier fees that go along with \nthis too .  And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you . ", "original_text": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64097358b8f425d513c21461f07717ee9ee2e944e8b2e442ff7390af8fa470ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dafc3286-829b-4796-8ab7-35dc23f04152", "node_type": "1", "metadata": {"window": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n", "original_text": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n"}, "hash": "ac139a51138db6a2f632deb9ca345b6ca8558563035e7a45d299be29767566f9", "class_name": "RelatedNodeInfo"}}, "text": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "start_char_idx": 587, "end_char_idx": 696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dafc3286-829b-4796-8ab7-35dc23f04152": {"__data__": {"id_": "dafc3286-829b-4796-8ab7-35dc23f04152", "embedding": null, "metadata": {"window": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n", "original_text": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5453fe51-e646-40b2-863c-5501a9fabe39", "node_type": "1", "metadata": {"window": "And then that 25% we expect to double by the time we exit fiscal \u201823.  So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays . ", "original_text": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8daa2807f6a8d1cb1c093f5fa1ddaad6057722aeb069cd87a0210502939ae8a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bad40d9c-4172-4137-891e-e04b40cbcc28", "node_type": "1", "metadata": {"window": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks . ", "original_text": "Operator :  Thank you . "}, "hash": "db1f4bbc80f6b125231228a166fcc538233478dfb4dd97c53599f5b49f547ccd", "class_name": "RelatedNodeInfo"}}, "text": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "start_char_idx": 696, "end_char_idx": 840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bad40d9c-4172-4137-891e-e04b40cbcc28": {"__data__": {"id_": "bad40d9c-4172-4137-891e-e04b40cbcc28", "embedding": null, "metadata": {"window": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks . ", "original_text": "Operator :  Thank you . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dafc3286-829b-4796-8ab7-35dc23f04152", "node_type": "1", "metadata": {"window": "So we expect a run rate \nof about 50% by the time we exit fiscal \u201823.  And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n", "original_text": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c92a9c88fc3617e08ee33e38df7fbb5a0802737135136831b97509e877c163f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214", "node_type": "1", "metadata": {"window": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "original_text": "We now move to Stephen Valiquette of Barclays . "}, "hash": "4fe1599855dd2681f17bf5c1aad932722cdefc3e0662956f59612fba5803b7df", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 840, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214": {"__data__": {"id_": "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214", "embedding": null, "metadata": {"window": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "original_text": "We now move to Stephen Valiquette of Barclays . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bad40d9c-4172-4137-891e-e04b40cbcc28", "node_type": "1", "metadata": {"window": "And then as I indicated in my comments, we would expect \nto exit fiscal \u201824 with 100% mitigation .  By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks . ", "original_text": "Operator :  Thank you . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "870a913b142f5e39293497d1cc23bebe3211cb65e2f228f5ed75d99cd2a4605d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b5c43f1-e90b-4df4-a442-c1ed780a04d5", "node_type": "1", "metadata": {"window": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "original_text": "Please go ahead.   \n \n"}, "hash": "1ed84b26378ac7ab8c71eacc674429d97f7ed5529a800eaaee053c9784438903", "class_name": "RelatedNodeInfo"}}, "text": "We now move to Stephen Valiquette of Barclays . ", "start_char_idx": 864, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b5c43f1-e90b-4df4-a442-c1ed780a04d5": {"__data__": {"id_": "6b5c43f1-e90b-4df4-a442-c1ed780a04d5", "embedding": null, "metadata": {"window": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "original_text": "Please go ahead.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214", "node_type": "1", "metadata": {"window": "By the time you get to the end of \u201824, we would expect that part \nof this inflation continues to come down .  So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "original_text": "We now move to Stephen Valiquette of Barclays . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7c18b6d4d05ac8b3b823ceabf7b43b0aa0ae94ac95e97e432e21d50fa60e8ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "original_text": "Stephen Valiquette :  Yeah, thanks . "}, "hash": "38ec232d16918021ec153f77ed027e82f9afaca2d89c7ae976ddea1d44f53d7e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n \n", "start_char_idx": 912, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c": {"__data__": {"id_": "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c", "embedding": null, "metadata": {"window": "Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "original_text": "Stephen Valiquette :  Yeah, thanks . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b5c43f1-e90b-4df4-a442-c1ed780a04d5", "node_type": "1", "metadata": {"window": "So our gross impact in \u201824 would trend lower and t hen our \npricing would trend higher until , until effectively those two numbers offset .  \n \n Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "original_text": "Please go ahead.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1e4c4d2d42a9aa2bfe4376872ac5eac36302f064a691829082aa0a69b96dd48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "795808fd-72ef-4cd2-bc93-edb3c974d759", "node_type": "1", "metadata": {"window": "We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "original_text": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . "}, "hash": "ca04e2904009d86face6a51455a3b7752518c86dc60c17d49692bebb3bfd62f1", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Valiquette :  Yeah, thanks . ", "start_char_idx": 934, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "795808fd-72ef-4cd2-bc93-edb3c974d759": {"__data__": {"id_": "795808fd-72ef-4cd2-bc93-edb3c974d759", "embedding": null, "metadata": {"window": "We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "original_text": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "original_text": "Stephen Valiquette :  Yeah, thanks . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "691738418a5eb7794db720dffb561382b9aaea0d9ad1c9a66686d097de2a94da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb9850a5-52b2-4a5b-9eb1-334bea65d434", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "original_text": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . "}, "hash": "98f8e32ebb1e266957d43f1df727c92ad1b636b6b565140f2ebfaeb2b28128c3", "class_name": "RelatedNodeInfo"}}, "text": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "start_char_idx": 971, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb9850a5-52b2-4a5b-9eb1-334bea65d434": {"__data__": {"id_": "fb9850a5-52b2-4a5b-9eb1-334bea65d434", "embedding": null, "metadata": {"window": "Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "original_text": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "795808fd-72ef-4cd2-bc93-edb3c974d759", "node_type": "1", "metadata": {"window": "We now move to Stephen Valiquette of Barclays .  Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "original_text": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29fed8c82e05f41f17f58d272ca7f296877897c568daf3317e8c8380d21fe055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "046bd9ca-bb3d-400b-aee6-40d72019939c", "node_type": "1", "metadata": {"window": "Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that . ", "original_text": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n"}, "hash": "80ca94ba68b6d9c2ee19ac1e03a5d6e5eb88023eefbba95b777d84e0c64beb86", "class_name": "RelatedNodeInfo"}}, "text": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "start_char_idx": 1054, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "046bd9ca-bb3d-400b-aee6-40d72019939c": {"__data__": {"id_": "046bd9ca-bb3d-400b-aee6-40d72019939c", "embedding": null, "metadata": {"window": "Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that . ", "original_text": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb9850a5-52b2-4a5b-9eb1-334bea65d434", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "original_text": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf50ab7f3ac5d3ec8f7d6eea9cda3dcb4ed291e05d6bb752996ad7019957c17e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9724c6a3-ce12-4c10-8819-8e259c0fd53a", "node_type": "1", "metadata": {"window": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n", "original_text": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n"}, "hash": "57084b06266d297b510facc1e69efaba767504201a6b37eb5f75430681407778", "class_name": "RelatedNodeInfo"}}, "text": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "start_char_idx": 1135, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9724c6a3-ce12-4c10-8819-8e259c0fd53a": {"__data__": {"id_": "9724c6a3-ce12-4c10-8819-8e259c0fd53a", "embedding": null, "metadata": {"window": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n", "original_text": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "046bd9ca-bb3d-400b-aee6-40d72019939c", "node_type": "1", "metadata": {"window": "Stephen Valiquette :  Yeah, thanks .  I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that . ", "original_text": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a972cbe85345a9ded31a8c7bb2ccb595292d1856049d285cbb5d38693adaa508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0969fa8b-6af0-4227-b59c-c77ee135a4eb", "node_type": "1", "metadata": {"window": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n", "original_text": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . "}, "hash": "c8bd7dc2315a974639448e5ee14022b15c6d63c8b360091257b30d9465e29389", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "start_char_idx": 1223, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0969fa8b-6af0-4227-b59c-c77ee135a4eb": {"__data__": {"id_": "0969fa8b-6af0-4227-b59c-c77ee135a4eb", "embedding": null, "metadata": {"window": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n", "original_text": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9724c6a3-ce12-4c10-8819-8e259c0fd53a", "node_type": "1", "metadata": {"window": "I also just want to congratulate Mike on a  rewarding 30 plus years \nat Cardinal .  And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n", "original_text": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e36bb6004413f21757b2a7883577953e1f216b342408f49a1bed540ddbf823c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de", "node_type": "1", "metadata": {"window": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah . ", "original_text": "I \nguess I was curious for more color on the drivers of growth within that . "}, "hash": "dbe50d4505e463cfec1effb5bc216ef07e55fdf557051a82c27e58d277457fd4", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "start_char_idx": 1291, "end_char_idx": 1387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de": {"__data__": {"id_": "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de", "embedding": null, "metadata": {"window": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah . ", "original_text": "I \nguess I was curious for more color on the drivers of growth within that . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0969fa8b-6af0-4227-b59c-c77ee135a4eb", "node_type": "1", "metadata": {"window": "And Jason, here's to you, hoping you'll have 30 plus years at Cardinal as well .  That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n", "original_text": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cb9237326fbbae8b094ac1e051ea8566340a766e22d35709c17d05857e62d7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80dec3cd-706d-4bf5-b8b4-a5395c452fdb", "node_type": "1", "metadata": {"window": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay . ", "original_text": "That's for fiscal \u201823, obviously . \n"}, "hash": "ff68542bfc4a911a4ef009e034d3eda584c782bc104200ab9b96b469511e3ec6", "class_name": "RelatedNodeInfo"}}, "text": "I \nguess I was curious for more color on the drivers of growth within that . ", "start_char_idx": 1387, "end_char_idx": 1464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80dec3cd-706d-4bf5-b8b4-a5395c452fdb": {"__data__": {"id_": "80dec3cd-706d-4bf5-b8b4-a5395c452fdb", "embedding": null, "metadata": {"window": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay . ", "original_text": "That's for fiscal \u201823, obviously . \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de", "node_type": "1", "metadata": {"window": "That would \nput you in your late seventies , but I think you can do it  (laughter).  \n \n Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah . ", "original_text": "I \nguess I was curious for more color on the drivers of growth within that . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2b382341368e88cce13b40ec6387232a3241d05f4b3624eac06c27f51d99f5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2", "node_type": "1", "metadata": {"window": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it . ", "original_text": "Just want more color around the double di git top line within Pharma.   \n \n"}, "hash": "2ba75b595175fb9f6c71b262b4d766f03ebaba0cb70fe051ac5f9c82dc8ecb2c", "class_name": "RelatedNodeInfo"}}, "text": "That's for fiscal \u201823, obviously . \n", "start_char_idx": 1464, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2": {"__data__": {"id_": "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2", "embedding": null, "metadata": {"window": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it . ", "original_text": "Just want more color around the double di git top line within Pharma.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80dec3cd-706d-4bf5-b8b4-a5395c452fdb", "node_type": "1", "metadata": {"window": "Jason Hollar :  I'm not sure the math works for me  (laughter).  \n \n Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay . ", "original_text": "That's for fiscal \u201823, obviously . \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a51360ca3d041741491613811d07bcc7116eb84ea2ee2ca9b129050ef6180d99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1905d7-2d1c-4782-9c43-a179ba09a937", "node_type": "1", "metadata": {"window": "I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points . ", "original_text": "Jason Hollar :  Well, yeah . "}, "hash": "f3bf6c65e19b6bdd74ff03c679545159db865c28e9a23189de9a9f3b254a17e9", "class_name": "RelatedNodeInfo"}}, "text": "Just want more color around the double di git top line within Pharma.   \n \n", "start_char_idx": 1500, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1905d7-2d1c-4782-9c43-a179ba09a937": {"__data__": {"id_": "4d1905d7-2d1c-4782-9c43-a179ba09a937", "embedding": null, "metadata": {"window": "I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points . ", "original_text": "Jason Hollar :  Well, yeah . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2", "node_type": "1", "metadata": {"window": "Stephen Valiquette :  Just the 10% to 14% revenue growth and Pharma jumped out is pretty high .  I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it . ", "original_text": "Just want more color around the double di git top line within Pharma.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d288c13854b7bd20d9f1237dda7009d1a2f1987f9d393a6f80f21507594a19b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c31712f-b362-4ed3-91d0-75a5a2a2673e", "node_type": "1", "metadata": {"window": "That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year . ", "original_text": "Okay . "}, "hash": "06d2475678d3a7737520cd11d1faa7358f4e4cab3f1d7bd96ac44a96a21f74ac", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Well, yeah . ", "start_char_idx": 1575, "end_char_idx": 1604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c31712f-b362-4ed3-91d0-75a5a2a2673e": {"__data__": {"id_": "8c31712f-b362-4ed3-91d0-75a5a2a2673e", "embedding": null, "metadata": {"window": "That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year . ", "original_text": "Okay . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1905d7-2d1c-4782-9c43-a179ba09a937", "node_type": "1", "metadata": {"window": "I \nguess I was curious for more color on the drivers of growth within that .  That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points . ", "original_text": "Jason Hollar :  Well, yeah . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcef85a835ef535460f34cfe378ad4f32eda293b7ed0ae2399a45a98d39cfdcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2bb731-21cc-40e1-a97b-b6f5868c07a7", "node_type": "1", "metadata": {"window": "Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers . ", "original_text": "Got it . "}, "hash": "c0018a2d5070e470dcd5836155c2113cab5b770b1e3249a1a550cb92b63e4e40", "class_name": "RelatedNodeInfo"}}, "text": "Okay . ", "start_char_idx": 1604, "end_char_idx": 1611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2bb731-21cc-40e1-a97b-b6f5868c07a7": {"__data__": {"id_": "af2bb731-21cc-40e1-a97b-b6f5868c07a7", "embedding": null, "metadata": {"window": "Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers . ", "original_text": "Got it . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c31712f-b362-4ed3-91d0-75a5a2a2673e", "node_type": "1", "metadata": {"window": "That's for fiscal \u201823, obviously . \n Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year . ", "original_text": "Okay . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7048d723dbddfc091d23a9f0b8ba0b2954fe93f28a6ea70fe702d525d280d547", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60811646-47e3-43bc-b02e-81fdae97da6c", "node_type": "1", "metadata": {"window": "Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "original_text": "I think there's a couple of key points . "}, "hash": "374279e689b488de4289a70e7cc9e29b5bf40bbb636202b64ea03d1a1fd4ca20", "class_name": "RelatedNodeInfo"}}, "text": "Got it . ", "start_char_idx": 1611, "end_char_idx": 1620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60811646-47e3-43bc-b02e-81fdae97da6c": {"__data__": {"id_": "60811646-47e3-43bc-b02e-81fdae97da6c", "embedding": null, "metadata": {"window": "Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "original_text": "I think there's a couple of key points . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2bb731-21cc-40e1-a97b-b6f5868c07a7", "node_type": "1", "metadata": {"window": "Just want more color around the double di git top line within Pharma.   \n \n Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers . ", "original_text": "Got it . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d491fbf44682bc1a87f6c1cda89b71f37fb9478633444062d182f6aae45ad0c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d2b939c-dcb2-4902-9f6f-7383b144cb56", "node_type": "1", "metadata": {"window": "Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "original_text": "First of all, it's very \nconsistent with what we've done this past year . "}, "hash": "3cc78a7a4271ba7d7a531726479e15fb64405a9c89dbb082eeaf9a3a023428f1", "class_name": "RelatedNodeInfo"}}, "text": "I think there's a couple of key points . ", "start_char_idx": 1620, "end_char_idx": 1661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d2b939c-dcb2-4902-9f6f-7383b144cb56": {"__data__": {"id_": "4d2b939c-dcb2-4902-9f6f-7383b144cb56", "embedding": null, "metadata": {"window": "Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "original_text": "First of all, it's very \nconsistent with what we've done this past year . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60811646-47e3-43bc-b02e-81fdae97da6c", "node_type": "1", "metadata": {"window": "Jason Hollar :  Well, yeah .  Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "original_text": "I think there's a couple of key points . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c312319d9044d631fb4c637e06c595a65fb50db1dbf2985251e0597b99d08ef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59d8adda-f568-4030-9215-d41f6a2f5c06", "node_type": "1", "metadata": {"window": "Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "original_text": "And that was driven by a couple of key drivers . "}, "hash": "69de334bbc68dffcdeac5cb3c85061a8f3fca04fb7c4217325733e2915badcf8", "class_name": "RelatedNodeInfo"}}, "text": "First of all, it's very \nconsistent with what we've done this past year . ", "start_char_idx": 1661, "end_char_idx": 1735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59d8adda-f568-4030-9215-d41f6a2f5c06": {"__data__": {"id_": "59d8adda-f568-4030-9215-d41f6a2f5c06", "embedding": null, "metadata": {"window": "Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "original_text": "And that was driven by a couple of key drivers . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d2b939c-dcb2-4902-9f6f-7383b144cb56", "node_type": "1", "metadata": {"window": "Okay .  Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "original_text": "First of all, it's very \nconsistent with what we've done this past year . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5db7439219d357f7675f20338a7eee6d268e207a8776361b2ddddb524a197ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee60b070-0b6a-4248-8a46-2986248fd2e5", "node_type": "1", "metadata": {"window": "I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "original_text": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n"}, "hash": "285aab11b5a4dce7140d8e8bb041892165a1332e8df31623725798e97dac3e9d", "class_name": "RelatedNodeInfo"}}, "text": "And that was driven by a couple of key drivers . ", "start_char_idx": 1735, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee60b070-0b6a-4248-8a46-2986248fd2e5": {"__data__": {"id_": "ee60b070-0b6a-4248-8a46-2986248fd2e5", "embedding": null, "metadata": {"window": "I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "original_text": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59d8adda-f568-4030-9215-d41f6a2f5c06", "node_type": "1", "metadata": {"window": "Got it .  I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "original_text": "And that was driven by a couple of key drivers . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "937ca8fc1d535c9231624460d38c546acdffc45ce3d9f2936c89c677f571e70d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2104bab-0a8f-4fba-af9e-d15afce4c8b0", "node_type": "1", "metadata": {"window": "First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "original_text": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. "}, "hash": "e0bb3949e3f9be4ca9a8efa4395b6f27a9397f3bab059910fc960c4cb60b94ba", "class_name": "RelatedNodeInfo"}}, "text": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "start_char_idx": 1784, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2104bab-0a8f-4fba-af9e-d15afce4c8b0": {"__data__": {"id_": "b2104bab-0a8f-4fba-af9e-d15afce4c8b0", "embedding": null, "metadata": {"window": "First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "original_text": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee60b070-0b6a-4248-8a46-2986248fd2e5", "node_type": "1", "metadata": {"window": "I think there's a couple of key points .  First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "original_text": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d1ec896fef5c97cf5a71eafab75fcfe955445b3f4852957a539c7813573afcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0835b4f3-bf55-46c1-a1f1-0e5443392c88", "node_type": "1", "metadata": {"window": "And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n", "original_text": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . "}, "hash": "695e118872a8c9b7eb1586597fc11531421ebc823813f0748b46a4bff895e1e2", "class_name": "RelatedNodeInfo"}}, "text": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "start_char_idx": 2001, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0835b4f3-bf55-46c1-a1f1-0e5443392c88": {"__data__": {"id_": "0835b4f3-bf55-46c1-a1f1-0e5443392c88", "embedding": null, "metadata": {"window": "And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n", "original_text": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2104bab-0a8f-4fba-af9e-d15afce4c8b0", "node_type": "1", "metadata": {"window": "First of all, it's very \nconsistent with what we've done this past year .  And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "original_text": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8248454e35c08f7514e5248a9bf1c3888a9dbc6d5b3b92ec2a01639f5bbf9884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dbaed9d-7410-4aed-88b3-a38c8d03f786", "node_type": "1", "metadata": {"window": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you . ", "original_text": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . "}, "hash": "744a78ad1ec117dcd1cdc6c596f74fe0d56da2cfcb1d5d70710ebf284dd199c1", "class_name": "RelatedNodeInfo"}}, "text": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "start_char_idx": 2111, "end_char_idx": 2275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dbaed9d-7410-4aed-88b3-a38c8d03f786": {"__data__": {"id_": "6dbaed9d-7410-4aed-88b3-a38c8d03f786", "embedding": null, "metadata": {"window": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you . ", "original_text": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0835b4f3-bf55-46c1-a1f1-0e5443392c88", "node_type": "1", "metadata": {"window": "And that was driven by a couple of key drivers .  And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n", "original_text": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edbabb1a8c94254e128ee427767d2a8b4713e2e8e6a7acaa9c8cfbd3be19de38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e", "node_type": "1", "metadata": {"window": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley . ", "original_text": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . "}, "hash": "2764b93dc1cbe8e33473ba88aabd6d8db0c6342bdaafbff6f5c3549fc81a2257", "class_name": "RelatedNodeInfo"}}, "text": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "start_char_idx": 2275, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e": {"__data__": {"id_": "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e", "embedding": null, "metadata": {"window": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley . ", "original_text": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dbaed9d-7410-4aed-88b3-a38c8d03f786", "node_type": "1", "metadata": {"window": "And I \nthink you should think about the drivers as being similar, because one of those drivers we've referenced \na few times is some net new business that we referenced came in beginning of the third quarter of \u201822. \n So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you . ", "original_text": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3420c4ab77c13e6f9a7f11605ae17be000a2325a3aa92930acab5c60cc3e62f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ffde1fd-4af4-450e-9174-a524dce7b260", "node_type": "1", "metadata": {"window": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n", "original_text": "But those are the \nbigge st drivers.   \n \n"}, "hash": "23ef990cc97ab1cc86b89220188f760b0c0eb9b592f0a836ad49a04c614957f8", "class_name": "RelatedNodeInfo"}}, "text": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "start_char_idx": 2419, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ffde1fd-4af4-450e-9174-a524dce7b260": {"__data__": {"id_": "8ffde1fd-4af4-450e-9174-a524dce7b260", "embedding": null, "metadata": {"window": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n", "original_text": "But those are the \nbigge st drivers.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e", "node_type": "1", "metadata": {"window": "So that would be a little bit more of a front end loaded type of revenue benefit as we as we see fiscal \n\u201823.  And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley . ", "original_text": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f61bffb5e738ac601187912122a1f11936d1e00dab20d23bf6cd9af686a17fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8004bc41-723a-43b0-94bb-e9109e762a59", "node_type": "1", "metadata": {"window": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah . ", "original_text": "Operator :  Thank you . "}, "hash": "0dcb119a57daa79ee7269cc1c9463937143738dd3718c438502250e988324362", "class_name": "RelatedNodeInfo"}}, "text": "But those are the \nbigge st drivers.   \n \n", "start_char_idx": 2602, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8004bc41-723a-43b0-94bb-e9109e762a59": {"__data__": {"id_": "8004bc41-723a-43b0-94bb-e9109e762a59", "embedding": null, "metadata": {"window": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah . ", "original_text": "Operator :  Thank you . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ffde1fd-4af4-450e-9174-a524dce7b260", "node_type": "1", "metadata": {"window": "And then we've also been highlighting the strength in our large customers, large PD specialty, and \nwe've seen some some really good volume in the brand category .  And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n", "original_text": "But those are the \nbigge st drivers.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99ca9013ba77f601401933e5dd7349371fcbde40bc57f9671465e7147c7011d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd27b1eb-1d34-4dc7-9300-a70554f1a28d", "node_type": "1", "metadata": {"window": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi. ", "original_text": "Next, we move to Ricky Goldwasser of Morgan Stanley . "}, "hash": "0cc97627215b710d7026e3bb2af9e132dccb86d65752ff973603f11d08b68948", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 840, "end_char_idx": 864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd27b1eb-1d34-4dc7-9300-a70554f1a28d": {"__data__": {"id_": "fd27b1eb-1d34-4dc7-9300-a70554f1a28d", "embedding": null, "metadata": {"window": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi. ", "original_text": "Next, we move to Ricky Goldwasser of Morgan Stanley . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8004bc41-723a-43b0-94bb-e9109e762a59", "node_type": "1", "metadata": {"window": "And so, as you know, some of that \nlarger customers and some of the brand volume doesn't a lways bring with it a tremendous amount of \nmargin .  But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah . ", "original_text": "Operator :  Thank you . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21348acadb6e11f3adb90a0e585e72c445cf235f77b8284d43e902d2e143f5b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89d4b50a-7153-43bb-9c4b-a12d4d1214b0", "node_type": "1", "metadata": {"window": "But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning . ", "original_text": "Please go ahead.   \n \n"}, "hash": "0762e6eab4e59f94d8f163e953179f3d847a75981ca9acbeccda3c8ea9f4b51b", "class_name": "RelatedNodeInfo"}}, "text": "Next, we move to Ricky Goldwasser of Morgan Stanley . ", "start_char_idx": 2668, "end_char_idx": 2722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89d4b50a-7153-43bb-9c4b-a12d4d1214b0": {"__data__": {"id_": "89d4b50a-7153-43bb-9c4b-a12d4d1214b0", "embedding": null, "metadata": {"window": "But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning . ", "original_text": "Please go ahead.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd27b1eb-1d34-4dc7-9300-a70554f1a28d", "node_type": "1", "metadata": {"window": "But that's one of the reasons why you see very robust revenue growth , and still profit growth \nwell within the range of what we've indicated for both our short and long term goals .  But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi. ", "original_text": "Next, we move to Ricky Goldwasser of Morgan Stanley . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cd106aeb1c1e5c00fe0a6c23e779d5a805e2c24f12d67e1aa52dd8fbdcdc1be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2052f3b2-97db-49f9-8966-f088c1331719", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes . ", "original_text": "Ricky Goldwasser :  Yeah . "}, "hash": "84d2ac7ca5ac9f1294d8a0a379d9bbb1cd361dc6147cb038be6b82513a477a8b", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.   \n \n", "start_char_idx": 912, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2052f3b2-97db-49f9-8966-f088c1331719": {"__data__": {"id_": "2052f3b2-97db-49f9-8966-f088c1331719", "embedding": null, "metadata": {"window": "Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes . ", "original_text": "Ricky Goldwasser :  Yeah . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89d4b50a-7153-43bb-9c4b-a12d4d1214b0", "node_type": "1", "metadata": {"window": "But those are the \nbigge st drivers.   \n \n Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning . ", "original_text": "Please go ahead.   \n \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9526f18149573cd15bcc9aae7072be0e683480c054bd909902bb65caef018ef6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5", "node_type": "1", "metadata": {"window": "Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck . ", "original_text": "Hi. "}, "hash": "d00c47989c39b8ee4227bec92b77d9f8e003d7ea3a7aa69b459ce0af6600ad2b", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser :  Yeah . ", "start_char_idx": 2744, "end_char_idx": 2771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5": {"__data__": {"id_": "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5", "embedding": null, "metadata": {"window": "Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck . ", "original_text": "Hi. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2052f3b2-97db-49f9-8966-f088c1331719", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes . ", "original_text": "Ricky Goldwasser :  Yeah . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a27c33e64f0deba1815c8225e59327f7c47e06570a486cd1aa323ccecc51cd7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddb55fbb-ef52-4117-bf6e-bf176df5fa08", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "original_text": "Good morning . "}, "hash": "93095a116127e38b580226b9948023e8206f7c7cb0569f7430b2bb1971c587f1", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 2771, "end_char_idx": 2775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddb55fbb-ef52-4117-bf6e-bf176df5fa08": {"__data__": {"id_": "ddb55fbb-ef52-4117-bf6e-bf176df5fa08", "embedding": null, "metadata": {"window": "Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "original_text": "Good morning . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5", "node_type": "1", "metadata": {"window": "Next, we move to Ricky Goldwasser of Morgan Stanley .  Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck . ", "original_text": "Hi. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01d2c2c4ebe84767d3d45f1f091a155e911cbe5fcf4468fcb051bc2cf32d1ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b78b392f-67dc-479b-b1c2-33e2ae9f56f3", "node_type": "1", "metadata": {"window": "Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "original_text": "And Mike, all my very best wishes . "}, "hash": "60d9c007bc188d50d86e070a45c18119f4067a16c03cd45388cd3338ca2c493b", "class_name": "RelatedNodeInfo"}}, "text": "Good morning . ", "start_char_idx": 2775, "end_char_idx": 2790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b78b392f-67dc-479b-b1c2-33e2ae9f56f3": {"__data__": {"id_": "b78b392f-67dc-479b-b1c2-33e2ae9f56f3", "embedding": null, "metadata": {"window": "Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "original_text": "And Mike, all my very best wishes . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddb55fbb-ef52-4117-bf6e-bf176df5fa08", "node_type": "1", "metadata": {"window": "Please go ahead.   \n \n Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "original_text": "Good morning . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b545895f552f286f84a13736e2116f0bb1bbabf6eaec5a74e18ee3cdd9ced00a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2", "node_type": "1", "metadata": {"window": "Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly . ", "original_text": "And Jason, congrats \nand good luck . "}, "hash": "fdb34805a94491e6fb246f979a19464416849c476d908b1dcd1b14d312f9ff6e", "class_name": "RelatedNodeInfo"}}, "text": "And Mike, all my very best wishes . ", "start_char_idx": 2790, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2": {"__data__": {"id_": "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2", "embedding": null, "metadata": {"window": "Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly . ", "original_text": "And Jason, congrats \nand good luck . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b78b392f-67dc-479b-b1c2-33e2ae9f56f3", "node_type": "1", "metadata": {"window": "Ricky Goldwasser :  Yeah .  Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "original_text": "And Mike, all my very best wishes . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18c5bb51ed45d7ea456374bd750217c1653f88784fe178157cbe0cea189357b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6f55b24-22c6-4b90-a70c-e1bb58277915", "node_type": "1", "metadata": {"window": "Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year . ", "original_text": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . "}, "hash": "14441306085fa7442ff7e40d8bd45078f49a547ab52332b0a3bc260c34f4986e", "class_name": "RelatedNodeInfo"}}, "text": "And Jason, congrats \nand good luck . ", "start_char_idx": 2826, "end_char_idx": 2863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6f55b24-22c6-4b90-a70c-e1bb58277915": {"__data__": {"id_": "c6f55b24-22c6-4b90-a70c-e1bb58277915", "embedding": null, "metadata": {"window": "Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year . ", "original_text": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2", "node_type": "1", "metadata": {"window": "Hi.  Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly . ", "original_text": "And Jason, congrats \nand good luck . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29f0cce1d9a3f4abd9a30b8671ee9fe9742d61f43522bbb8fabdde93ac431999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3", "node_type": "1", "metadata": {"window": "And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "original_text": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . "}, "hash": "2fa0bd935bb6069dc68bc0e2e3b03f69a6f5db9763f24adc94b33343941fd477", "class_name": "RelatedNodeInfo"}}, "text": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "start_char_idx": 2863, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3": {"__data__": {"id_": "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3", "embedding": null, "metadata": {"window": "And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "original_text": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6f55b24-22c6-4b90-a70c-e1bb58277915", "node_type": "1", "metadata": {"window": "Good morning .  And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year . ", "original_text": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f65aeeb2548aa9b7a8b99d974f53d81331c8d12aabfed140c4411f381a4281ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4bbda4f-db47-4d20-bae4-878be10dfcbd", "node_type": "1", "metadata": {"window": "And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?  ", "original_text": "I just want to make sure that I'm \nthinking about this correctly . "}, "hash": "dcb239eec87c77e1020a70316ac6c2ee0e6a974edf4982a4f38d3e20cef75bb0", "class_name": "RelatedNodeInfo"}}, "text": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "start_char_idx": 3041, "end_char_idx": 3233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4bbda4f-db47-4d20-bae4-878be10dfcbd": {"__data__": {"id_": "c4bbda4f-db47-4d20-bae4-878be10dfcbd", "embedding": null, "metadata": {"window": "And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?  ", "original_text": "I just want to make sure that I'm \nthinking about this correctly . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3", "node_type": "1", "metadata": {"window": "And Mike, all my very best wishes .  And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "original_text": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b5379e552d92a56af677da73259c2ffc58ca3ec01e23152f29f1fb42e6188c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff37c70e-cb7d-4660-9ba5-659cbba7c912", "node_type": "1", "metadata": {"window": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n", "original_text": "And then we'll slowly improve throughout the year . "}, "hash": "6add763c7d3ded5e99eaa540d25ccd09dc8576ec2f94dcbfd04d602d7b44c47c", "class_name": "RelatedNodeInfo"}}, "text": "I just want to make sure that I'm \nthinking about this correctly . ", "start_char_idx": 3233, "end_char_idx": 3300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff37c70e-cb7d-4660-9ba5-659cbba7c912": {"__data__": {"id_": "ff37c70e-cb7d-4660-9ba5-659cbba7c912", "embedding": null, "metadata": {"window": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n", "original_text": "And then we'll slowly improve throughout the year . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4bbda4f-db47-4d20-bae4-878be10dfcbd", "node_type": "1", "metadata": {"window": "And Jason, congrats \nand good luck .  So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?  ", "original_text": "I just want to make sure that I'm \nthinking about this correctly . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d2cd6e55c54b0ccd4a7e016d8da1a054dc08d92573f59eb73448a7a71bbd621", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0e95903-e8b4-483f-866d-5f6975196e4e", "node_type": "1", "metadata": {"window": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.  ", "original_text": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . "}, "hash": "1e34a678a3d7d8bc711a45d455de628f6d32f6ada4eaa1b93506f2a2fbc9059f", "class_name": "RelatedNodeInfo"}}, "text": "And then we'll slowly improve throughout the year . ", "start_char_idx": 3300, "end_char_idx": 3352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0e95903-e8b4-483f-866d-5f6975196e4e": {"__data__": {"id_": "c0e95903-e8b4-483f-866d-5f6975196e4e", "embedding": null, "metadata": {"window": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.  ", "original_text": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff37c70e-cb7d-4660-9ba5-659cbba7c912", "node_type": "1", "metadata": {"window": "So a couple of questions her e. So just to get a sense \u2013 and Jason, thank you for \nclarifying the $150  million in gross headwind in the first quarter versus the $125  million .  So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n", "original_text": "And then we'll slowly improve throughout the year . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "808a95acb53943b552006cf486d88ef3e5392765bdec85f845b22b809b395545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926461e9-5510-4475-bef1-91ec7b7c8e32", "node_type": "1", "metadata": {"window": "I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "When you're saying 50%, should we assume basically a double from that?  "}, "hash": "358246258490835c964992cf8c2226603679db1d9f5f20bd0c8d98e6b5891ba6", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "start_char_idx": 3352, "end_char_idx": 3500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926461e9-5510-4475-bef1-91ec7b7c8e32": {"__data__": {"id_": "926461e9-5510-4475-bef1-91ec7b7c8e32", "embedding": null, "metadata": {"window": "I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "When you're saying 50%, should we assume basically a double from that?  ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0e95903-e8b4-483f-866d-5f6975196e4e", "node_type": "1", "metadata": {"window": "So as we think \nabout, it seems like you're, in your guidance, right, you're assuming that the headwinds are g oing to \nget worse in the first quarter versus the run rate, the exit run rate .  I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.  ", "original_text": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "feb898d54e5ed28a8d5f60dbbaa500041af10d690da7b42bdb902326ded655b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6662cd1-3366-4ed5-9850-3f71e5c17b27", "node_type": "1", "metadata": {"window": "And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "So $75  million . \n"}, "hash": "99fabdf80a415a83c5210fae396203ce6c12864d94051aae014c90e6b1bed4ff", "class_name": "RelatedNodeInfo"}}, "text": "When you're saying 50%, should we assume basically a double from that?  ", "start_char_idx": 3500, "end_char_idx": 3572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6662cd1-3366-4ed5-9850-3f71e5c17b27": {"__data__": {"id_": "b6662cd1-3366-4ed5-9850-3f71e5c17b27", "embedding": null, "metadata": {"window": "And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "So $75  million . \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926461e9-5510-4475-bef1-91ec7b7c8e32", "node_type": "1", "metadata": {"window": "I just want to make sure that I'm \nthinking about this correctly .  And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "When you're saying 50%, should we assume basically a double from that?  ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22effca6e68187df2cf0e368846aeb633156653e6974a281773556d1c1022111", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b99e2c2e-6e6f-4124-a97d-de6181ff3676", "node_type": "1", "metadata": {"window": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "I just want to kind of like understand the reference of that 50%.  "}, "hash": "af613aac58fd1cf00dd9b94b49d85cafbf66f6efaf2ece548dea05d09529d803", "class_name": "RelatedNodeInfo"}}, "text": "So $75  million . \n", "start_char_idx": 3572, "end_char_idx": 3591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b99e2c2e-6e6f-4124-a97d-de6181ff3676": {"__data__": {"id_": "b99e2c2e-6e6f-4124-a97d-de6181ff3676", "embedding": null, "metadata": {"window": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "I just want to kind of like understand the reference of that 50%.  ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6662cd1-3366-4ed5-9850-3f71e5c17b27", "node_type": "1", "metadata": {"window": "And then we'll slowly improve throughout the year .  As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "So $75  million . \n", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dba88c588ea667a1259f1d20c03dc4a4819f4e39c0b92fb4f5ddd12213f8f7cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08d6ebac-a5df-4a9c-a3a0-eb07bc556366", "node_type": "1", "metadata": {"window": "When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . "}, "hash": "abc0486cb64007ec2937de9ce6189242abf136e41e14706bb6dfd3afb9aabbc4", "class_name": "RelatedNodeInfo"}}, "text": "I just want to kind of like understand the reference of that 50%.  ", "start_char_idx": 3591, "end_char_idx": 3658, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08d6ebac-a5df-4a9c-a3a0-eb07bc556366": {"__data__": {"id_": "08d6ebac-a5df-4a9c-a3a0-eb07bc556366", "embedding": null, "metadata": {"window": "When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34cab507cb2f4f896ec18b9976e855bab1cf2c0082a1610e09d7782d238fa0aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b99e2c2e-6e6f-4124-a97d-de6181ff3676", "node_type": "1", "metadata": {"window": "As we think about the \nmitigation, I think your numbers imp ly about $38  million, right, in mitigation from better pricing in the \nfirst quarter .  When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "I just want to kind of like understand the reference of that 50%.  ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1598aaaa950559f3ca1ef77ad5ea74f3437a1acf9b9be45f3f26f37e7541d8bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4008a047-b46e-4d9c-8c1d-fa2df4908d00", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue . ", "original_text": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand . "}, "hash": "919d6b9f6a3fe5509a2cb29744656b3120af15f64613ab5a4155bc05d1bb11c1", "class_name": "RelatedNodeInfo"}}, "text": "And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "start_char_idx": 3658, "end_char_idx": 3806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4008a047-b46e-4d9c-8c1d-fa2df4908d00": {"__data__": {"id_": "4008a047-b46e-4d9c-8c1d-fa2df4908d00", "embedding": null, "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue . ", "original_text": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08d6ebac-a5df-4a9c-a3a0-eb07bc556366", "node_type": "1", "metadata": {"window": "When you're saying 50%, should we assume basically a double from that?   So $75  million . \n I just want to kind of like understand the reference of that 50%.   And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "original_text": "And then an add itional question on the \nthe Cardinal brand, because it seems that that's a really important part of sort of the longer term plan . ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcd409e7c296bcb7f9cfd0de1e9f3b1327f111a0d258e05d708dfe08eecdcfe1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "130e5868-8815-4f04-a588-f13b974c410b", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?  ", "original_text": "So \none, how do you envision t his revenue mix, what it will be by 2025?  "}, "hash": "7f58be45658f0e79f55eb151612ead9e4a12c9e3e5d44dbb74b5c46df00cb9d7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand . ", "start_char_idx": 0, "end_char_idx": 115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "130e5868-8815-4f04-a588-f13b974c410b": {"__data__": {"id_": "130e5868-8815-4f04-a588-f13b974c410b", "embedding": null, "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?  ", "original_text": "So \none, how do you envision t his revenue mix, what it will be by 2025?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4008a047-b46e-4d9c-8c1d-fa2df4908d00", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue . ", "original_text": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7043adba349d1c354e2d3013f659f613ed860f6bc9e28a35b3e9e832bb7bddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db356b52-9965-4bff-aec6-d4d2b096b8a0", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n", "original_text": "And then how should we think \nabout sort of the the EBIT mix?  "}, "hash": "aa61206871cda41f7834ac3c9375805b4f9146ccef9317f62c1bf8f49d7dfd82", "class_name": "RelatedNodeInfo"}}, "text": "So \none, how do you envision t his revenue mix, what it will be by 2025?  ", "start_char_idx": 115, "end_char_idx": 189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db356b52-9965-4bff-aec6-d4d2b096b8a0": {"__data__": {"id_": "db356b52-9965-4bff-aec6-d4d2b096b8a0", "embedding": null, "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n", "original_text": "And then how should we think \nabout sort of the the EBIT mix?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "130e5868-8815-4f04-a588-f13b974c410b", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?  ", "original_text": "So \none, how do you envision t his revenue mix, what it will be by 2025?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d8b1c29263e91b5dad2aeb70d6f6d643bcd8985144b714ca4c00d39eb943109", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26af46d5-bebc-45f2-9520-c5eaa277daae", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay . ", "original_text": "It's 29% of revenue . "}, "hash": "207071a4a28730ee030d1b3c5b9b9cd8bf340ce7c35a8c7973c866fc1b37ba3c", "class_name": "RelatedNodeInfo"}}, "text": "And then how should we think \nabout sort of the the EBIT mix?  ", "start_char_idx": 189, "end_char_idx": 252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26af46d5-bebc-45f2-9520-c5eaa277daae": {"__data__": {"id_": "26af46d5-bebc-45f2-9520-c5eaa277daae", "embedding": null, "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay . ", "original_text": "It's 29% of revenue . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db356b52-9965-4bff-aec6-d4d2b096b8a0", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n", "original_text": "And then how should we think \nabout sort of the the EBIT mix?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34f2fc089d8aa5b3be8e775bf794a6b26103d1cf09a02efd289fb030f07f0a22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f83bf4fa-6a26-4287-a4a3-2a93c3495115", "node_type": "1", "metadata": {"window": "So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay . ", "original_text": "What percentage of profits today?  "}, "hash": "b06a68edfc1fc91c81478cc5a7583fab08faef27d9f73c4c37483992a8ef3baf", "class_name": "RelatedNodeInfo"}}, "text": "It's 29% of revenue . ", "start_char_idx": 252, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f83bf4fa-6a26-4287-a4a3-2a93c3495115": {"__data__": {"id_": "f83bf4fa-6a26-4287-a4a3-2a93c3495115", "embedding": null, "metadata": {"window": "So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay . ", "original_text": "What percentage of profits today?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26af46d5-bebc-45f2-9520-c5eaa277daae", "node_type": "1", "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay . ", "original_text": "It's 29% of revenue . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da7e5b95be6806bd11d661fa6259c3a199e7b7659b03c3c197f5cb9fec9a9919", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffc927bf-0fd0-4f78-9144-510ad3e0a498", "node_type": "1", "metadata": {"window": "And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "original_text": "Thank you.   \n \n"}, "hash": "4f742a58df87a64cd9db9d805eaeb00d91d19a34e9615095537bd091f7cc10f7", "class_name": "RelatedNodeInfo"}}, "text": "What percentage of profits today?  ", "start_char_idx": 274, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffc927bf-0fd0-4f78-9144-510ad3e0a498": {"__data__": {"id_": "ffc927bf-0fd0-4f78-9144-510ad3e0a498", "embedding": null, "metadata": {"window": "And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "original_text": "Thank you.   \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f83bf4fa-6a26-4287-a4a3-2a93c3495115", "node_type": "1", "metadata": {"window": "So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay . ", "original_text": "What percentage of profits today?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e382f53fb2cf34cffd5e4b50be8992779716508f70e0b2bcaa9ef28156c08e14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bff9e035-9fda-486c-b57e-70c5bb41bd43", "node_type": "1", "metadata": {"window": "It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes. ", "original_text": "Jason Hollar :  Okay . "}, "hash": "c71f30e464836802421498428117eec4dbccdda3fb960b6c07e83c301718efc1", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.   \n \n", "start_char_idx": 309, "end_char_idx": 325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bff9e035-9fda-486c-b57e-70c5bb41bd43": {"__data__": {"id_": "bff9e035-9fda-486c-b57e-70c5bb41bd43", "embedding": null, "metadata": {"window": "It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes. ", "original_text": "Jason Hollar :  Okay . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffc927bf-0fd0-4f78-9144-510ad3e0a498", "node_type": "1", "metadata": {"window": "And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "original_text": "Thank you.   \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6830d7121491cb1d70c1308bb1cae36035504b3020d4bd3425d3e72172ab1702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df5d6e30-47c7-4b9e-8566-522ea7950864", "node_type": "1", "metadata": {"window": "What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "original_text": "Okay . "}, "hash": "6a00f7aa746d2c2653c64e3cce513fcdd35aa658917416a2da61938cd9dae7d1", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Okay . ", "start_char_idx": 325, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df5d6e30-47c7-4b9e-8566-522ea7950864": {"__data__": {"id_": "df5d6e30-47c7-4b9e-8566-522ea7950864", "embedding": null, "metadata": {"window": "What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "original_text": "Okay . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bff9e035-9fda-486c-b57e-70c5bb41bd43", "node_type": "1", "metadata": {"window": "It's 29% of revenue .  What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes. ", "original_text": "Jason Hollar :  Okay . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "303e507d92ca79278f3375943c18892f84100f30710d0735c910287ad8a439cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fcac4af-db12-4b16-be5b-2dd4b5e3f106", "node_type": "1", "metadata": {"window": "Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "original_text": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . "}, "hash": "a4886bcf2971cc3ea5fb6b4f2833362a086948589dffa692e481fac7fe4a6b64", "class_name": "RelatedNodeInfo"}}, "text": "Okay . ", "start_char_idx": 341, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fcac4af-db12-4b16-be5b-2dd4b5e3f106": {"__data__": {"id_": "2fcac4af-db12-4b16-be5b-2dd4b5e3f106", "embedding": null, "metadata": {"window": "Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "original_text": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df5d6e30-47c7-4b9e-8566-522ea7950864", "node_type": "1", "metadata": {"window": "What percentage of profits today?   Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "original_text": "Okay . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1303d78bbc7353eec56260f48701c34229daf7ce752cddc460d51a0219eb85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0258e207-4185-4aad-b97d-383ec1915b0d", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots . ", "original_text": "Yes. "}, "hash": "0a5f44318aa0db3b1a7f53a8702bd130cb2f806ebcb14ca6b88906d3292f9f81", "class_name": "RelatedNodeInfo"}}, "text": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "start_char_idx": 355, "end_char_idx": 451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0258e207-4185-4aad-b97d-383ec1915b0d": {"__data__": {"id_": "0258e207-4185-4aad-b97d-383ec1915b0d", "embedding": null, "metadata": {"window": "Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots . ", "original_text": "Yes. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fcac4af-db12-4b16-be5b-2dd4b5e3f106", "node_type": "1", "metadata": {"window": "Thank you.   \n \n Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "original_text": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b45b6039305f252835c141fbf659909dee9e5a8a7cfbde0d661c7c4862523d2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "407e0340-65c9-4fb2-9de6-43b244c935d9", "node_type": "1", "metadata": {"window": "Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas . ", "original_text": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . "}, "hash": "7d03fb63993a589490f6e97634913250fb4fb9b4dd82aa4e25b9d2f25ddc2b0d", "class_name": "RelatedNodeInfo"}}, "text": "Yes. ", "start_char_idx": 451, "end_char_idx": 456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "407e0340-65c9-4fb2-9de6-43b244c935d9": {"__data__": {"id_": "407e0340-65c9-4fb2-9de6-43b244c935d9", "embedding": null, "metadata": {"window": "Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas . ", "original_text": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0258e207-4185-4aad-b97d-383ec1915b0d", "node_type": "1", "metadata": {"window": "Jason Hollar :  Okay .  Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots . ", "original_text": "Yes. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35e0b1eaac0443817befc8e7f5b6ca238f3b330ea438720487d4909c485c4442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8371396b-dee8-4436-bbf4-b3c5a8edee84", "node_type": "1", "metadata": {"window": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too . ", "original_text": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n"}, "hash": "da434babd5b33f431d44e0f9f8e7e8422d1cfc07fc58381f10df8287e3764454", "class_name": "RelatedNodeInfo"}}, "text": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "start_char_idx": 456, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8371396b-dee8-4436-bbf4-b3c5a8edee84": {"__data__": {"id_": "8371396b-dee8-4436-bbf4-b3c5a8edee84", "embedding": null, "metadata": {"window": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too . ", "original_text": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "407e0340-65c9-4fb2-9de6-43b244c935d9", "node_type": "1", "metadata": {"window": "Okay .  So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas . ", "original_text": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c1db5e755e7a521a932b8b0c1ad3b4ca6c1abcb2dbb76610d0f3ff7d72c34af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f", "node_type": "1", "metadata": {"window": "Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "original_text": "And that is \u2013 just make sure we connect all the dots . "}, "hash": "09d9e8dd453386a7b9cda4eaca3954c95a95b616f89f55468b6c92079ae2f3f0", "class_name": "RelatedNodeInfo"}}, "text": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "start_char_idx": 562, "end_char_idx": 656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f": {"__data__": {"id_": "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f", "embedding": null, "metadata": {"window": "Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "original_text": "And that is \u2013 just make sure we connect all the dots . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8371396b-dee8-4436-bbf4-b3c5a8edee84", "node_type": "1", "metadata": {"window": "So starting with the pricing, I think you get fairly c lose, but let me clarify a \nfew points .  Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too . ", "original_text": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8bac9a191653833740be1c6d653251edca9028bb3521385e1db1fc80647f2169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9b024aa-b88c-4764-888e-df27c6ab392d", "node_type": "1", "metadata": {"window": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "original_text": "Yes, spot prices we see are starting to soften in a \nfew areas . "}, "hash": "1d945502882618207e4526ffd605bed84916dbeef100ca930e15efd256a90376", "class_name": "RelatedNodeInfo"}}, "text": "And that is \u2013 just make sure we connect all the dots . ", "start_char_idx": 656, "end_char_idx": 711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9b024aa-b88c-4764-888e-df27c6ab392d": {"__data__": {"id_": "b9b024aa-b88c-4764-888e-df27c6ab392d", "embedding": null, "metadata": {"window": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "original_text": "Yes, spot prices we see are starting to soften in a \nfew areas . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f", "node_type": "1", "metadata": {"window": "Yes.  On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "original_text": "And that is \u2013 just make sure we connect all the dots . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31abc507697b1ca01e05c47ca76a7623364df855774a964378d52d70c3ce8b73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e89030e1-0d78-4ce7-9696-a75cd73b997a", "node_type": "1", "metadata": {"window": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "original_text": "Not all areas, there are some going the opposite direction too . "}, "hash": "84545979c5aa2245422f7cda4b919ead22165e76ab55eea6ff800c31afb70705", "class_name": "RelatedNodeInfo"}}, "text": "Yes, spot prices we see are starting to soften in a \nfew areas . ", "start_char_idx": 711, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e89030e1-0d78-4ce7-9696-a75cd73b997a": {"__data__": {"id_": "e89030e1-0d78-4ce7-9696-a75cd73b997a", "embedding": null, "metadata": {"window": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "original_text": "Not all areas, there are some going the opposite direction too . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9b024aa-b88c-4764-888e-df27c6ab392d", "node_type": "1", "metadata": {"window": "On \u2013 you got the math right for Q1, that would be pretty pretty close to how you should \nthink about it .  So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "original_text": "Yes, spot prices we see are starting to soften in a \nfew areas . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42302d9575a6b924680609f5e3266b22ffd2000e8f54c09edf7b0e4e60b193a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05daebd8-ea1f-4473-abdb-3f2044aa35be", "node_type": "1", "metadata": {"window": "And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through . ", "original_text": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. "}, "hash": "d4b2f21af65b1de8aa0a6f3500a6ce3de8a8b86ec90f55a7addc463f25f29648", "class_name": "RelatedNodeInfo"}}, "text": "Not all areas, there are some going the opposite direction too . ", "start_char_idx": 776, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05daebd8-ea1f-4473-abdb-3f2044aa35be": {"__data__": {"id_": "05daebd8-ea1f-4473-abdb-3f2044aa35be", "embedding": null, "metadata": {"window": "And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through . ", "original_text": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e89030e1-0d78-4ce7-9696-a75cd73b997a", "node_type": "1", "metadata": {"window": "So, yes, the gross impact is increasing a little bit from the $125 in Q4 to the $150 in Q1 . \n And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "original_text": "Not all areas, there are some going the opposite direction too . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d72ff8330f7d49590103a983bd32c38f653557d0ff98c5a378cfdfdc5c0e9959", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94328f26-243e-412b-8e76-fba52cca218a", "node_type": "1", "metadata": {"window": "Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit . ", "original_text": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . "}, "hash": "4d80a7caf68c7e6044d384944dcbbc9f00a27189e4ece468c34c7598c18a3476", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "start_char_idx": 841, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94328f26-243e-412b-8e76-fba52cca218a": {"__data__": {"id_": "94328f26-243e-412b-8e76-fba52cca218a", "embedding": null, "metadata": {"window": "Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit . ", "original_text": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05daebd8-ea1f-4473-abdb-3f2044aa35be", "node_type": "1", "metadata": {"window": "And that is \u2013 just make sure we connect all the dots .  Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through . ", "original_text": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbbacfd041fe2be962b878c4485fe596cc972481cdbcad149f3aedad4455e888", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c730cf0b-bfe1-4b19-81ee-29680b4c135e", "node_type": "1", "metadata": {"window": "Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "original_text": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . "}, "hash": "8d025be3a3c93a99759cef586f2c3fbc8e076be35a8145ef79ae9fa61ee2f72d", "class_name": "RelatedNodeInfo"}}, "text": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "start_char_idx": 978, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c730cf0b-bfe1-4b19-81ee-29680b4c135e": {"__data__": {"id_": "c730cf0b-bfe1-4b19-81ee-29680b4c135e", "embedding": null, "metadata": {"window": "Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "original_text": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94328f26-243e-412b-8e76-fba52cca218a", "node_type": "1", "metadata": {"window": "Yes, spot prices we see are starting to soften in a \nfew areas .  Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit . ", "original_text": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e7ab5bc08f30a460f365332792743abfe7125e30d2883df11c8ca20e3a1b450", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f43da9f7-bf27-4392-be1e-5ac99a8d55cd", "node_type": "1", "metadata": {"window": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "original_text": "So \nit's going to take some time for that to flow through . "}, "hash": "f630caac39e36aa98e928a531c5b8d3ed8d33fb07e745aeae650680c8f39e226", "class_name": "RelatedNodeInfo"}}, "text": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "start_char_idx": 1164, "end_char_idx": 1283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f43da9f7-bf27-4392-be1e-5ac99a8d55cd": {"__data__": {"id_": "f43da9f7-bf27-4392-be1e-5ac99a8d55cd", "embedding": null, "metadata": {"window": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "original_text": "So \nit's going to take some time for that to flow through . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c730cf0b-bfe1-4b19-81ee-29680b4c135e", "node_type": "1", "metadata": {"window": "Not all areas, there are some going the opposite direction too .  But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "original_text": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45b9d30b67eadf4a78df47888380c6dd6f006113824745c054ee36e7aa4a413d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16f591ea-dc5c-414c-8f3a-084d207ac9d7", "node_type": "1", "metadata": {"window": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "original_text": "So certainly Q1 is not going to see any of that \nbenefit . "}, "hash": "63967487f12a7ee395eedc00b9e66c19c2dd312468683860ff02bd2ce6a6cdbc", "class_name": "RelatedNodeInfo"}}, "text": "So \nit's going to take some time for that to flow through . ", "start_char_idx": 1283, "end_char_idx": 1343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16f591ea-dc5c-414c-8f3a-084d207ac9d7": {"__data__": {"id_": "16f591ea-dc5c-414c-8f3a-084d207ac9d7", "embedding": null, "metadata": {"window": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "original_text": "So certainly Q1 is not going to see any of that \nbenefit . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f43da9f7-bf27-4392-be1e-5ac99a8d55cd", "node_type": "1", "metadata": {"window": "But generally speaking, \nthere's some some benefit there which \u2013 but it's not impacti ng our P&L because it's got that two quarter \nlag.  So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "original_text": "So \nit's going to take some time for that to flow through . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f5da74e4b651a011201f725878e0bee29220e2a9b3e9ff66b465e5e0b5c9b9ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0122552c-276e-4d2e-b74b-e0e3b3071976", "node_type": "1", "metadata": {"window": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight . ", "original_text": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. "}, "hash": "8d5019b09c0ce67c5e5d9f0150917218c767e0d9958f3bf76dcc2d9be5393846", "class_name": "RelatedNodeInfo"}}, "text": "So certainly Q1 is not going to see any of that \nbenefit . ", "start_char_idx": 1343, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0122552c-276e-4d2e-b74b-e0e3b3071976": {"__data__": {"id_": "0122552c-276e-4d2e-b74b-e0e3b3071976", "embedding": null, "metadata": {"window": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight . ", "original_text": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16f591ea-dc5c-414c-8f3a-084d207ac9d7", "node_type": "1", "metadata": {"window": "So when you think about when, the international freight specifically, it started reducing dramatically \nabout two months ago, two or three months ago, there was a really big reduction .  So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "original_text": "So certainly Q1 is not going to see any of that \nbenefit . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1690fd4db16faabcc9917054846c8e4883cc77f0f1d6c78116256c09b34e44cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbd0c1e8-cc84-4983-a348-7c05544b666e", "node_type": "1", "metadata": {"window": "So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up . ", "original_text": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  "}, "hash": "997037c8f42c367353b604cab30d1440ac06753b4291ad48895038b755307de6", "class_name": "RelatedNodeInfo"}}, "text": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "start_char_idx": 1402, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbd0c1e8-cc84-4983-a348-7c05544b666e": {"__data__": {"id_": "dbd0c1e8-cc84-4983-a348-7c05544b666e", "embedding": null, "metadata": {"window": "So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up . ", "original_text": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0122552c-276e-4d2e-b74b-e0e3b3071976", "node_type": "1", "metadata": {"window": "So you wouldn't \nexpe ct that and it didn't reduce \u2013 there's been a consistent reduction over the last several weeks .  So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight . ", "original_text": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbb348984a439c8178c46d34b52d3411bf346d693f31517a546f842458450420", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad7785bc-edbc-4416-990a-caa14197da36", "node_type": "1", "metadata": {"window": "So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "original_text": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . "}, "hash": "bfa365d698ad941f181df3273c54594b9e4237a6248f050c096b742e264a6705", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "start_char_idx": 1515, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad7785bc-edbc-4416-990a-caa14197da36": {"__data__": {"id_": "ad7785bc-edbc-4416-990a-caa14197da36", "embedding": null, "metadata": {"window": "So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "original_text": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbd0c1e8-cc84-4983-a348-7c05544b666e", "node_type": "1", "metadata": {"window": "So \nit's going to take some time for that to flow through .  So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up . ", "original_text": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbfedafdd08f72171269fe9687ea2a09c4a8d051280a6afbd98cafab9ac2416c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb7cf1aa-09da-4aaf-9188-7637629cd7f2", "node_type": "1", "metadata": {"window": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say . ", "original_text": "We are anticipating it will come down, in part \nbecause of that international freight . "}, "hash": "5cd006b91b5fc3d9f1bd4e462dfc2f1bad4ce347010e6c1312354e5ec56b383a", "class_name": "RelatedNodeInfo"}}, "text": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "start_char_idx": 1640, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb7cf1aa-09da-4aaf-9188-7637629cd7f2": {"__data__": {"id_": "bb7cf1aa-09da-4aaf-9188-7637629cd7f2", "embedding": null, "metadata": {"window": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say . ", "original_text": "We are anticipating it will come down, in part \nbecause of that international freight . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad7785bc-edbc-4416-990a-caa14197da36", "node_type": "1", "metadata": {"window": "So certainly Q1 is not going to see any of that \nbenefit .  And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "original_text": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc2b1925f7d4a28acd1e42495733bdadd05351f63e99e81b7c951d131c3a1b01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "403f3605-5340-4a16-b1cf-091eed4b7a08", "node_type": "1", "metadata": {"window": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically . ", "original_text": "So that will begin to come down and then pricing will continue to \ngo up . "}, "hash": "ef4a27e9913c7e48183d204d94e1524d7cdfccc362d8ce0ab681b007e0b3af0e", "class_name": "RelatedNodeInfo"}}, "text": "We are anticipating it will come down, in part \nbecause of that international freight . ", "start_char_idx": 1772, "end_char_idx": 1860, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "403f3605-5340-4a16-b1cf-091eed4b7a08": {"__data__": {"id_": "403f3605-5340-4a16-b1cf-091eed4b7a08", "embedding": null, "metadata": {"window": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically . ", "original_text": "So that will begin to come down and then pricing will continue to \ngo up . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb7cf1aa-09da-4aaf-9188-7637629cd7f2", "node_type": "1", "metadata": {"window": "And that's why you see the gross impact st ill increasing, is because that's from five, six months \nago as well.  As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say . ", "original_text": "We are anticipating it will come down, in part \nbecause of that international freight . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c44830085411727d819bbc11391ad83748d2e17d30e3b057cad0c752a77fb3d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "152feb8d-114f-41be-b28a-b7112c46a01d", "node_type": "1", "metadata": {"window": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "original_text": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  "}, "hash": "2a9c180b2958e9d5f11643d7bbad7f87a8e37f1ab8e84adc3b0f4d63bd579d20", "class_name": "RelatedNodeInfo"}}, "text": "So that will begin to come down and then pricing will continue to \ngo up . ", "start_char_idx": 1860, "end_char_idx": 1935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "152feb8d-114f-41be-b28a-b7112c46a01d": {"__data__": {"id_": "152feb8d-114f-41be-b28a-b7112c46a01d", "embedding": null, "metadata": {"window": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "original_text": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "403f3605-5340-4a16-b1cf-091eed4b7a08", "node_type": "1", "metadata": {"window": "As you think about the exit, and you're trying to get the math on the pricing, does the pricing \ndouble from that $37, $38?   Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically . ", "original_text": "So that will begin to come down and then pricing will continue to \ngo up . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee3a40a4259bc182229483ff080fa37d678865ccff427814490e9b9db1e81814", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b6da42b-7feb-4aa5-9132-cef750466183", "node_type": "1", "metadata": {"window": "We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "original_text": "As it relates to the revenue mix, you know, that's hard \nto say . "}, "hash": "a02bff073896b2753f7d743ca614e65191ece74239e4b177d0d393ac6fc3c7f4", "class_name": "RelatedNodeInfo"}}, "text": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "start_char_idx": 1935, "end_char_idx": 2082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b6da42b-7feb-4aa5-9132-cef750466183": {"__data__": {"id_": "7b6da42b-7feb-4aa5-9132-cef750466183", "embedding": null, "metadata": {"window": "We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "original_text": "As it relates to the revenue mix, you know, that's hard \nto say . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "152feb8d-114f-41be-b28a-b7112c46a01d", "node_type": "1", "metadata": {"window": "Probably not, because what you're missing, I think, in your mat h is that that \n$150 should come down over the course of the year .  We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "original_text": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7749fb047f9fe9a0ce05248315e913415befc1bf9b288f63dc8404200aae625c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a52d05e8-0b38-4970-8d48-158daee72380", "node_type": "1", "metadata": {"window": "So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "original_text": "I'm not ready to answer that specifically . "}, "hash": "00d316f8344b3cf657ba49678cd39f49f7dda3e7ef9911f4079cd5fb8b6cf995", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the revenue mix, you know, that's hard \nto say . ", "start_char_idx": 2082, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a52d05e8-0b38-4970-8d48-158daee72380": {"__data__": {"id_": "a52d05e8-0b38-4970-8d48-158daee72380", "embedding": null, "metadata": {"window": "So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "original_text": "I'm not ready to answer that specifically . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b6da42b-7feb-4aa5-9132-cef750466183", "node_type": "1", "metadata": {"window": "We are anticipating it will come down, in part \nbecause of that international freight .  So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "original_text": "As it relates to the revenue mix, you know, that's hard \nto say . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "970a37ca18ab83bf9412c576f012c2a1e0dfbd99e319848606fb7b94de639646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "846cf9ba-b4f9-42ae-b035-def750af0f0a", "node_type": "1", "metadata": {"window": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly . ", "original_text": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . "}, "hash": "6a17031d00a475720f993daa63973955bbb1f1e3882be6173674aae33cc31297", "class_name": "RelatedNodeInfo"}}, "text": "I'm not ready to answer that specifically . ", "start_char_idx": 2148, "end_char_idx": 2192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "846cf9ba-b4f9-42ae-b035-def750af0f0a": {"__data__": {"id_": "846cf9ba-b4f9-42ae-b035-def750af0f0a", "embedding": null, "metadata": {"window": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly . ", "original_text": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a52d05e8-0b38-4970-8d48-158daee72380", "node_type": "1", "metadata": {"window": "So that will begin to come down and then pricing will continue to \ngo up .  But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "original_text": "I'm not ready to answer that specifically . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "753e5bac36d096a086a247066bf8896ffee70b3754e23bc98f5517057747bd2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35add517-718c-485c-8857-548542f18750", "node_type": "1", "metadata": {"window": "As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect . ", "original_text": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  "}, "hash": "80571b29a9d255363b7c01556ee2fe2a62f6992daaacbe0315c7ec9b8ff39696", "class_name": "RelatedNodeInfo"}}, "text": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "start_char_idx": 2192, "end_char_idx": 2337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35add517-718c-485c-8857-548542f18750": {"__data__": {"id_": "35add517-718c-485c-8857-548542f18750", "embedding": null, "metadata": {"window": "As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect . ", "original_text": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "846cf9ba-b4f9-42ae-b035-def750af0f0a", "node_type": "1", "metadata": {"window": "But by the time we exit agai n, that exit rate would be around 50%, but lower than the $150 and \nhigher than the $37, $38 from the first quarter.   As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly . ", "original_text": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7ab3d4cef55632946321df2aa61dd626fb87478399663405d1a6ddcbc78868e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "832d2d96-d5bd-4b46-b3ea-c388b541b27c", "node_type": "1", "metadata": {"window": "I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "original_text": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% . "}, "hash": "e56e2b660e485a06a11a640d7020d7df28ed0581cff2996f9480a40155aacd3e", "class_name": "RelatedNodeInfo"}}, "text": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "start_char_idx": 2337, "end_char_idx": 2452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "832d2d96-d5bd-4b46-b3ea-c388b541b27c": {"__data__": {"id_": "832d2d96-d5bd-4b46-b3ea-c388b541b27c", "embedding": null, "metadata": {"window": "I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "original_text": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35add517-718c-485c-8857-548542f18750", "node_type": "1", "metadata": {"window": "As it relates to the revenue mix, you know, that's hard \nto say .  I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect . ", "original_text": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "643473034a2065b4db30b06e4e4003ff97818ce0edf5de1554dd60fc23c537a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaa5dac5-9964-4c74-a71d-036e7eecdf1f", "node_type": "1", "metadata": {"window": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "original_text": "We expect it to continue growing robustly . "}, "hash": "4bbad04a980bfd360f562b64794ff8fe4a7222179096865887f1d1456bda6326", "class_name": "RelatedNodeInfo"}}, "text": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "start_char_idx": 2452, "end_char_idx": 2523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaa5dac5-9964-4c74-a71d-036e7eecdf1f": {"__data__": {"id_": "aaa5dac5-9964-4c74-a71d-036e7eecdf1f", "embedding": null, "metadata": {"window": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "original_text": "We expect it to continue growing robustly . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "832d2d96-d5bd-4b46-b3ea-c388b541b27c", "node_type": "1", "metadata": {"window": "I'm not ready to answer that specifically .  The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "original_text": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d50df6432edc9347d150434365d6b91b4f176a07e0528e23bc8401395f36fae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfa944d6-786e-4831-a225-a5d2b423a383", "node_type": "1", "metadata": {"window": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you . ", "original_text": "And so \nthat will, in a way, have a mix effect . "}, "hash": "dbadde73e58cc97b9276f19c5be7d8e35ee71455239770416e6e890158c94d5d", "class_name": "RelatedNodeInfo"}}, "text": "We expect it to continue growing robustly . ", "start_char_idx": 2523, "end_char_idx": 2567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfa944d6-786e-4831-a225-a5d2b423a383": {"__data__": {"id_": "dfa944d6-786e-4831-a225-a5d2b423a383", "embedding": null, "metadata": {"window": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you . ", "original_text": "And so \nthat will, in a way, have a mix effect . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaa5dac5-9964-4c74-a71d-036e7eecdf1f", "node_type": "1", "metadata": {"window": "The one thing I'll highlight is , as we indicated $2.4  billion \nof revenue for at -Home is a meaningful number when you when you look at that .  So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "original_text": "We expect it to continue growing robustly . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac255928f4a3e64cc07be44ca4d679c56e5690218024f01653d2feadb30f3b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb0a9ac-f003-4248-8681-79fce599f3be", "node_type": "1", "metadata": {"window": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research. ", "original_text": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . "}, "hash": "149b0316278695a17c9c107954d988090b63129a7085b53dc2010ef90bcb14bd", "class_name": "RelatedNodeInfo"}}, "text": "And so \nthat will, in a way, have a mix effect . ", "start_char_idx": 2567, "end_char_idx": 2616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb0a9ac-f003-4248-8681-79fce599f3be": {"__data__": {"id_": "1bb0a9ac-f003-4248-8681-79fce599f3be", "embedding": null, "metadata": {"window": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research. ", "original_text": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfa944d6-786e-4831-a225-a5d2b423a383", "node_type": "1", "metadata": {"window": "So it's a matter of are \nyou doing calculations on the full segment or only on medical products and distribution?   At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you . ", "original_text": "And so \nthat will, in a way, have a mix effect . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b61f1c8d13a92a4429ea44ccf577ef755100a2bb770649e2fca6d966c7c7505d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77d61f82-71d4-4404-80db-76c295d4a952", "node_type": "1", "metadata": {"window": "We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n", "original_text": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n"}, "hash": "41f788b2395e0b38851c92794356cbb20f1d8af9d75221b9677bda7decb9ee18", "class_name": "RelatedNodeInfo"}}, "text": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "start_char_idx": 2616, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77d61f82-71d4-4404-80db-76c295d4a952": {"__data__": {"id_": "77d61f82-71d4-4404-80db-76c295d4a952", "embedding": null, "metadata": {"window": "We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n", "original_text": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb0a9ac-f003-4248-8681-79fce599f3be", "node_type": "1", "metadata": {"window": "At $2.4  billion \nof revenue, it's  been growing consistently at 10% .  We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research. ", "original_text": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c72a0a06a1a4a210cbd499b56923e20fb55aff31c86e1a55c8ef7cfc3089bba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64194f12-4162-4967-b6de-10e7f273829b", "node_type": "1", "metadata": {"window": "And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr. ", "original_text": "Operator :  Thank you . "}, "hash": "2ed2a907acc5262cc51bbbdeec77ddc2a0c2e3d64831985ec15d88ffb3858a28", "class_name": "RelatedNodeInfo"}}, "text": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "start_char_idx": 2765, "end_char_idx": 2854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64194f12-4162-4967-b6de-10e7f273829b": {"__data__": {"id_": "64194f12-4162-4967-b6de-10e7f273829b", "embedding": null, "metadata": {"window": "And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr. ", "original_text": "Operator :  Thank you . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77d61f82-71d4-4404-80db-76c295d4a952", "node_type": "1", "metadata": {"window": "We expect it to continue growing robustly .  And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n", "original_text": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b3772af9eca62e60cdb250f4ebbcfb014df2c01ccdb36df2f86d70cf93f4acd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75a04cfc-e435-4614-8b9e-d485d61a6432", "node_type": "1", "metadata": {"window": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open . ", "original_text": "We now move to Eric Percher of Nephron Research. "}, "hash": "33286a4316c3f046e8954f6d1d912071cba52dfed1de82599fdda98ac22e9449", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 2854, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75a04cfc-e435-4614-8b9e-d485d61a6432": {"__data__": {"id_": "75a04cfc-e435-4614-8b9e-d485d61a6432", "embedding": null, "metadata": {"window": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open . ", "original_text": "We now move to Eric Percher of Nephron Research. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64194f12-4162-4967-b6de-10e7f273829b", "node_type": "1", "metadata": {"window": "And so \nthat will, in a way, have a mix effect .  So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr. ", "original_text": "Operator :  Thank you . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be56d4096a6f9b9d25769f0115e4ee483e65348a5e053f8532648d182287843b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dccc76f9-0a68-4d37-be28-a893c80fa60c", "node_type": "1", "metadata": {"window": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question . ", "original_text": "Please go ahead.  \n \n"}, "hash": "712cdf160d002856af6b7a0e9ff049f3cd1fa05237b6deb98e08a5e30b076610", "class_name": "RelatedNodeInfo"}}, "text": "We now move to Eric Percher of Nephron Research. ", "start_char_idx": 2878, "end_char_idx": 2927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dccc76f9-0a68-4d37-be28-a893c80fa60c": {"__data__": {"id_": "dccc76f9-0a68-4d37-be28-a893c80fa60c", "embedding": null, "metadata": {"window": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question . ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75a04cfc-e435-4614-8b9e-d485d61a6432", "node_type": "1", "metadata": {"window": "So percentage of revenue in the total segment, that will be a bigger \npiece and medical product distribution will most likely be the smaller piece .  So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open . ", "original_text": "We now move to Eric Percher of Nephron Research. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ba7437b76eb16519c494bc439b96ce1b9ecba1927b5009f253c6675b5064be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eec74176-b1a8-49f8-a583-fd9a4415edc7", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen . ", "original_text": "Mr. "}, "hash": "3e531502ac31c4f8018e993ce395f8d365200c0df7e39e77a616342b7a4fcf2c", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 2927, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eec74176-b1a8-49f8-a583-fd9a4415edc7": {"__data__": {"id_": "eec74176-b1a8-49f8-a583-fd9a4415edc7", "embedding": null, "metadata": {"window": "Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen . ", "original_text": "Mr. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dccc76f9-0a68-4d37-be28-a893c80fa60c", "node_type": "1", "metadata": {"window": "So we'll need to do a bit \nmore math before we can respond more clearly on that one.  \n \n Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question . ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f28ee78ca01ffe4f5f5cb8a2793b6d764524f539a866a22cc057d96932a19a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d041cf87-586a-4330-a205-058205b59256", "node_type": "1", "metadata": {"window": "We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n", "original_text": "Percher, your line is open . "}, "hash": "142da716d51e39c80d92fab864505281b3a65647d907f0f3b97b6331990be5df", "class_name": "RelatedNodeInfo"}}, "text": "Mr. ", "start_char_idx": 2948, "end_char_idx": 2952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d041cf87-586a-4330-a205-058205b59256": {"__data__": {"id_": "d041cf87-586a-4330-a205-058205b59256", "embedding": null, "metadata": {"window": "We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n", "original_text": "Percher, your line is open . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eec74176-b1a8-49f8-a583-fd9a4415edc7", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen . ", "original_text": "Mr. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eb060a15663bd8ddc33f71824f779a904a0a2315ac5adc9b2bc6b22415a5acb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80530559-fed8-40ab-b5c3-6f53a5e15e38", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question . ", "original_text": "We move to our next question . "}, "hash": "7accd6a4d22e858f1b6b2ab90c4976133e6d3acda5d2aa4cab49bc1692f00249", "class_name": "RelatedNodeInfo"}}, "text": "Percher, your line is open . ", "start_char_idx": 2952, "end_char_idx": 2981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80530559-fed8-40ab-b5c3-6f53a5e15e38": {"__data__": {"id_": "80530559-fed8-40ab-b5c3-6f53a5e15e38", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question . ", "original_text": "We move to our next question . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d041cf87-586a-4330-a205-058205b59256", "node_type": "1", "metadata": {"window": "We now move to Eric Percher of Nephron Research.  Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n", "original_text": "Percher, your line is open . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fd79412dec2218d06f667ea26fc2f04d74ea713eb49aad2e9fe185ae1dd92db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6adc80d-7788-49cc-b7af-89cc7b105ac9", "node_type": "1", "metadata": {"window": "Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything . ", "original_text": "Charles Rhyee of Cowen . "}, "hash": "30add8b62ead6413824306f5f1a642ab56906e545288f47e40a09f628bad3e56", "class_name": "RelatedNodeInfo"}}, "text": "We move to our next question . ", "start_char_idx": 2981, "end_char_idx": 3012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6adc80d-7788-49cc-b7af-89cc7b105ac9": {"__data__": {"id_": "b6adc80d-7788-49cc-b7af-89cc7b105ac9", "embedding": null, "metadata": {"window": "Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything . ", "original_text": "Charles Rhyee of Cowen . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80530559-fed8-40ab-b5c3-6f53a5e15e38", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question . ", "original_text": "We move to our next question . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91d45582d50fdf323a7b25bdb3e2942b259a5abd6f8dffd2dbcd09aefc206ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6192e916-226b-45cb-8647-fe7c84c46f0e", "node_type": "1", "metadata": {"window": "Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you . ", "original_text": "Please go \nahead.   \n \n"}, "hash": "888b6bf700301f237cec724a285ae03e07c4afa4cd3760910a89139a5ce91ad5", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee of Cowen . ", "start_char_idx": 3012, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6192e916-226b-45cb-8647-fe7c84c46f0e": {"__data__": {"id_": "6192e916-226b-45cb-8647-fe7c84c46f0e", "embedding": null, "metadata": {"window": "Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you . ", "original_text": "Please go \nahead.   \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6adc80d-7788-49cc-b7af-89cc7b105ac9", "node_type": "1", "metadata": {"window": "Mr.  Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything . ", "original_text": "Charles Rhyee of Cowen . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f990020975884c69174251f58492a93b222e800e66f81c5720dcc9a23dd45a66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ba958b-960a-470a-98d8-96d34068c2fb", "node_type": "1", "metadata": {"window": "We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "original_text": "Charles Rhyee :  Yeah, thanks for taking the question . "}, "hash": "09510ab70fa0b62e31dc00b8864d5640a2a0b8f02f0eb542c73c55f1d249bd57", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.   \n \n", "start_char_idx": 3037, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ba958b-960a-470a-98d8-96d34068c2fb": {"__data__": {"id_": "90ba958b-960a-470a-98d8-96d34068c2fb", "embedding": null, "metadata": {"window": "We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "original_text": "Charles Rhyee :  Yeah, thanks for taking the question . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6192e916-226b-45cb-8647-fe7c84c46f0e", "node_type": "1", "metadata": {"window": "Percher, your line is open .  We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you . ", "original_text": "Please go \nahead.   \n \n", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd32573f2d94c65667ec41909df0d4ae2c09b9e7058ac7a84a20de5eaa7731fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd3fb0bc-ed66-4d02-8d34-9126e97284c7", "node_type": "1", "metadata": {"window": "Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase . ", "original_text": "And Mike, congratulations and best wishes with \neverything . "}, "hash": "a4b850bb323eb1db838e7c344c4d354feda049111ac3d8e092dbb3f6a7b70e9d", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee :  Yeah, thanks for taking the question . ", "start_char_idx": 3060, "end_char_idx": 3116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd3fb0bc-ed66-4d02-8d34-9126e97284c7": {"__data__": {"id_": "bd3fb0bc-ed66-4d02-8d34-9126e97284c7", "embedding": null, "metadata": {"window": "Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase . ", "original_text": "And Mike, congratulations and best wishes with \neverything . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ba958b-960a-470a-98d8-96d34068c2fb", "node_type": "1", "metadata": {"window": "We move to our next question .  Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "original_text": "Charles Rhyee :  Yeah, thanks for taking the question . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a07ed704667ef3fb9da68ef48d6e302c353cd643c38e2215d8f87665d5a20091", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c2cdc5c-7450-44f9-8999-4f46e1177324", "node_type": "1", "metadata": {"window": "Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "original_text": "And Jason, I look forward to workin g \u2013 continue working with you . "}, "hash": "b0406fbb485ddb37cc7fd194bd26f27d4178cff6f1f09f7976aa894803c3e146", "class_name": "RelatedNodeInfo"}}, "text": "And Mike, congratulations and best wishes with \neverything . ", "start_char_idx": 3116, "end_char_idx": 3177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c2cdc5c-7450-44f9-8999-4f46e1177324": {"__data__": {"id_": "0c2cdc5c-7450-44f9-8999-4f46e1177324", "embedding": null, "metadata": {"window": "Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "original_text": "And Jason, I look forward to workin g \u2013 continue working with you . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd3fb0bc-ed66-4d02-8d34-9126e97284c7", "node_type": "1", "metadata": {"window": "Charles Rhyee of Cowen .  Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase . ", "original_text": "And Mike, congratulations and best wishes with \neverything . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0adf8f9d4958bcbfa8ea00382e0f01b4d7e6e69ac158c44f6f27a1dcbaeee26c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22a9d222-27c6-4347-8ff9-aff6d066817b", "node_type": "1", "metadata": {"window": "Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "original_text": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. "}, "hash": "4794721a70de8cb6bdec7117b56d3ecb1effc3fa1849b9c97329ff21ffff87ab", "class_name": "RelatedNodeInfo"}}, "text": "And Jason, I look forward to workin g \u2013 continue working with you . ", "start_char_idx": 3177, "end_char_idx": 3245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22a9d222-27c6-4347-8ff9-aff6d066817b": {"__data__": {"id_": "22a9d222-27c6-4347-8ff9-aff6d066817b", "embedding": null, "metadata": {"window": "Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "original_text": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c2cdc5c-7450-44f9-8999-4f46e1177324", "node_type": "1", "metadata": {"window": "Please go \nahead.   \n \n Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "original_text": "And Jason, I look forward to workin g \u2013 continue working with you . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2c5ec13fb905db576098111525a97bb816f66e11f08288b4665bb7379677137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a563ed62-0705-45fd-8293-ec76e7cff961", "node_type": "1", "metadata": {"window": "And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "original_text": "And obviously, you outlined an amount for share repurchase . "}, "hash": "377691e3db29c099c2b85ae91c459b28c8b408e566d3442bf7c005a3ea60428c", "class_name": "RelatedNodeInfo"}}, "text": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "start_char_idx": 3245, "end_char_idx": 3377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a563ed62-0705-45fd-8293-ec76e7cff961": {"__data__": {"id_": "a563ed62-0705-45fd-8293-ec76e7cff961", "embedding": null, "metadata": {"window": "And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "original_text": "And obviously, you outlined an amount for share repurchase . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22a9d222-27c6-4347-8ff9-aff6d066817b", "node_type": "1", "metadata": {"window": "Charles Rhyee :  Yeah, thanks for taking the question .  And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "original_text": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit. ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ce113336c5383ac0d14b673e066dd74558896fab48391717854b2a502ac108b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db1e4601-8f55-4cbb-9180-f42efb196379", "node_type": "1", "metadata": {"window": "And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "original_text": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  "}, "hash": "b0ab03bbc70f39deb78fbfd143ef8aae319f4a17d917f5e34c1fddfc42ce314e", "class_name": "RelatedNodeInfo"}}, "text": "And obviously, you outlined an amount for share repurchase . ", "start_char_idx": 3377, "end_char_idx": 3438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db1e4601-8f55-4cbb-9180-f42efb196379": {"__data__": {"id_": "db1e4601-8f55-4cbb-9180-f42efb196379", "embedding": null, "metadata": {"window": "And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "original_text": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a563ed62-0705-45fd-8293-ec76e7cff961", "node_type": "1", "metadata": {"window": "And Mike, congratulations and best wishes with \neverything .  And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "original_text": "And obviously, you outlined an amount for share repurchase . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c12eaa8e9f4c690f8f9991441ec92cbf424f5e752c5570e4ad0a9d360027b64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91062fcf-d4c4-456a-bc51-1c2ab063d494", "node_type": "1", "metadata": {"window": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  "}, "hash": "8681e3057e542cc14ed04e0bc4ab94e7aaf2da028f2fae3d1214a6aee5856937", "class_name": "RelatedNodeInfo"}}, "text": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "start_char_idx": 3438, "end_char_idx": 3653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91062fcf-d4c4-456a-bc51-1c2ab063d494": {"__data__": {"id_": "91062fcf-d4c4-456a-bc51-1c2ab063d494", "embedding": null, "metadata": {"window": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db1e4601-8f55-4cbb-9180-f42efb196379", "node_type": "1", "metadata": {"window": "And Jason, I look forward to workin g \u2013 continue working with you .  You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "original_text": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a799ac26ab67ca5b47b7dca533494415c57340a1d218cd07bac678648960a0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0", "node_type": "1", "metadata": {"window": "And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . "}, "hash": "e8db1c89ee13895d99f4313ccfc3726eaf58c72e6555d799921c8fb8481b8c79", "class_name": "RelatedNodeInfo"}}, "text": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "start_char_idx": 3653, "end_char_idx": 3780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0": {"__data__": {"id_": "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0", "embedding": null, "metadata": {"window": "And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91062fcf-d4c4-456a-bc51-1c2ab063d494", "node_type": "1", "metadata": {"window": "You know, I want to just \nto maybe follow up, you know, Jason, you talked about, you know, really using the cash and deploying \nit.  And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a39666e82103df4437bf2fa3290c463e9d7ba44e074c4477af4558c0a71abaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d770a0f-94d2-43cd-a18e-539002be3a47", "node_type": "1", "metadata": {"window": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  "}, "hash": "56b266c34b70fc5bac9a43620a8c34b645349f0c0ddb86f87d1d596e6966e614", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "start_char_idx": 3780, "end_char_idx": 3894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d770a0f-94d2-43cd-a18e-539002be3a47": {"__data__": {"id_": "3d770a0f-94d2-43cd-a18e-539002be3a47", "embedding": null, "metadata": {"window": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0", "node_type": "1", "metadata": {"window": "And obviously, you outlined an amount for share repurchase .  You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "411c2442efceca92d56cf73084d323c49685fc02d137e18b02c85559b81faff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dd5bee4-c86c-49de-a558-00f944835b7a", "node_type": "1", "metadata": {"window": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "Thanks.   "}, "hash": "ec340d626f8113bc8253ca0579d2dc556266ad1dde93943b3f22f47a0c1998da", "class_name": "RelatedNodeInfo"}}, "text": "When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "start_char_idx": 3894, "end_char_idx": 4047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dd5bee4-c86c-49de-a558-00f944835b7a": {"__data__": {"id_": "7dd5bee4-c86c-49de-a558-00f944835b7a", "embedding": null, "metadata": {"window": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "Thanks.   ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1967416014f7be95799b691fffad80374ec9a3757ccbca371921688f704314a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d770a0f-94d2-43cd-a18e-539002be3a47", "node_type": "1", "metadata": {"window": "You know, when you think about gett ing \nto this $650  million sort of target in medical operating profit, you know, can you talk about maybe sort \nof M&A and other kind of capabilities that you might want to add?   I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?  ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ba7dade0bfcc6e17e0089914f8711a6e32ad8d5c10af97df051c755c40b3e4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27d4793f-2900-486d-86da-91c2ade01204", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "original_text": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no . "}, "hash": "77405345dd02fa347962c69e5fc3352572f7196e60131081b8f2770919d694f8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.   ", "start_char_idx": 4047, "end_char_idx": 4057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27d4793f-2900-486d-86da-91c2ade01204": {"__data__": {"id_": "27d4793f-2900-486d-86da-91c2ade01204", "embedding": null, "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "original_text": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dd5bee4-c86c-49de-a558-00f944835b7a", "node_type": "1", "metadata": {"window": "I know that, you know, we spent the \nlast few years actually divesting assets, bu t is part of that growth inorganic as well?   And then secondly, \nyou know, producer price index kind of fell below, you know, was below what people expected .  When \nwe think about the gross impact from inflationary pressures, are you starting to see some of t hat ease \nas well, given sort of this July report?   Thanks.   ", "original_text": "Thanks.   ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2db9bfbb81ab5950fd60c51545d2d6dc406a71f348a97b784f06cb2420a4a381", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "183f8861-8164-4945-b18e-3bfd301eb00e", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity . ", "original_text": "M&A is not a \ncornerstone of that plan . "}, "hash": "7ba974a28b47dc55eea5d49fecb872b268c619f2c9dffad0d705d356201a095b", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no . ", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "183f8861-8164-4945-b18e-3bfd301eb00e": {"__data__": {"id_": "183f8861-8164-4945-b18e-3bfd301eb00e", "embedding": null, "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity . ", "original_text": "M&A is not a \ncornerstone of that plan . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27d4793f-2900-486d-86da-91c2ade01204", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "original_text": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d83c554c0270ec88563419c97ec48628c9e99dd8e070b262f90d6a6446f4d36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25069839-7bd5-4554-88ee-3fc9e89e6f08", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "original_text": "We will be looking to always augment, especially our growth businesses . "}, "hash": "0ae9f80da48c4420af752bf3ff0e8e866205dc758bd6f4612decf520633b8f25", "class_name": "RelatedNodeInfo"}}, "text": "M&A is not a \ncornerstone of that plan . ", "start_char_idx": 101, "end_char_idx": 142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25069839-7bd5-4554-88ee-3fc9e89e6f08": {"__data__": {"id_": "25069839-7bd5-4554-88ee-3fc9e89e6f08", "embedding": null, "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "original_text": "We will be looking to always augment, especially our growth businesses . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "183f8861-8164-4945-b18e-3bfd301eb00e", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity . ", "original_text": "M&A is not a \ncornerstone of that plan . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7529acc05cc8b34c8abc70835a9660d9abb8e274677cfcc30483650b15418a57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone . ", "original_text": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . "}, "hash": "ddb4f50855f8b56a664ac5c91db58a0637ad6395f4b23fe59fae2cd9e92baa33", "class_name": "RelatedNodeInfo"}}, "text": "We will be looking to always augment, especially our growth businesses . ", "start_char_idx": 142, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca": {"__data__": {"id_": "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca", "embedding": null, "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone . ", "original_text": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25069839-7bd5-4554-88ee-3fc9e89e6f08", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "original_text": "We will be looking to always augment, especially our growth businesses . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb6719b797074b7f5b482b1a0daeecf54bb6243aa27f21aa5ca9f03b362d7fd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7d55395-673e-4740-a4e5-37e6c22cd053", "node_type": "1", "metadata": {"window": "M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.  ", "original_text": "We are investing in distribution capacity . "}, "hash": "4f65d4d00af0fad4e1fa22580af3156f1f8fa064faa05ef5076fcb95c7ee1a64", "class_name": "RelatedNodeInfo"}}, "text": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "start_char_idx": 215, "end_char_idx": 378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7d55395-673e-4740-a4e5-37e6c22cd053": {"__data__": {"id_": "c7d55395-673e-4740-a4e5-37e6c22cd053", "embedding": null, "metadata": {"window": "M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.  ", "original_text": "We are investing in distribution capacity . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca", "node_type": "1", "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone . ", "original_text": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f19f3e23e1c54bfbde46f1dee0fc0532f43fa5bf2b69d9ae211103e8397bcb89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f1db7a3-fcff-490e-b173-8108a78ea571", "node_type": "1", "metadata": {"window": "We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core . ", "original_text": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . "}, "hash": "eae7f948eeb59c70d7b131b1c602386faacee7531453c7c9f9dbc1baa67398df", "class_name": "RelatedNodeInfo"}}, "text": "We are investing in distribution capacity . ", "start_char_idx": 378, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f1db7a3-fcff-490e-b173-8108a78ea571": {"__data__": {"id_": "9f1db7a3-fcff-490e-b173-8108a78ea571", "embedding": null, "metadata": {"window": "We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core . ", "original_text": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7d55395-673e-4740-a4e5-37e6c22cd053", "node_type": "1", "metadata": {"window": "M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.  ", "original_text": "We are investing in distribution capacity . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecb25b9b3fdec15d2647ffa16e3e6274858c0ab9c5a81a5d1b5b70e528131a94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eaf5966e-a969-4a7c-ae55-6293749029d2", "node_type": "1", "metadata": {"window": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "original_text": "So that is not a cornerstone . "}, "hash": "bb82f376794a2136b996acc21fec410684b03306e1f6ae9793339718f35c10ab", "class_name": "RelatedNodeInfo"}}, "text": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "start_char_idx": 422, "end_char_idx": 574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eaf5966e-a969-4a7c-ae55-6293749029d2": {"__data__": {"id_": "eaf5966e-a969-4a7c-ae55-6293749029d2", "embedding": null, "metadata": {"window": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "original_text": "So that is not a cornerstone . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f1db7a3-fcff-490e-b173-8108a78ea571", "node_type": "1", "metadata": {"window": "We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core . ", "original_text": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7f0495d72834b5fcf2a51db633a6c952683eee8a30bdb5e58ba1d9931564e4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fa2ef08-c47c-484d-bc26-a578607e4fc8", "node_type": "1", "metadata": {"window": "We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "original_text": "In fact, I would say maybe a little \nbit of the opposite.  "}, "hash": "f99f10fdf14b701fb8158b285b9d0ad1a568dace83a23eadfd0b5034ee030d98", "class_name": "RelatedNodeInfo"}}, "text": "So that is not a cornerstone . ", "start_char_idx": 574, "end_char_idx": 605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fa2ef08-c47c-484d-bc26-a578607e4fc8": {"__data__": {"id_": "0fa2ef08-c47c-484d-bc26-a578607e4fc8", "embedding": null, "metadata": {"window": "We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "original_text": "In fact, I would say maybe a little \nbit of the opposite.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eaf5966e-a969-4a7c-ae55-6293749029d2", "node_type": "1", "metadata": {"window": "So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story .  We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "original_text": "So that is not a cornerstone . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98b47256a5452744a46b826873a9a02ee517de9fa5d45e06bf9069666e6d2d6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "088dc78a-815c-4df5-8fd4-92a541b51548", "node_type": "1", "metadata": {"window": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "original_text": "A lot of what this plan is, is very focused on the core . "}, "hash": "127b47631e7f3b50b8eee8b6f574378ee5dbdbac8a5d5cf2162fc5882c3daf03", "class_name": "RelatedNodeInfo"}}, "text": "In fact, I would say maybe a little \nbit of the opposite.  ", "start_char_idx": 605, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "088dc78a-815c-4df5-8fd4-92a541b51548": {"__data__": {"id_": "088dc78a-815c-4df5-8fd4-92a541b51548", "embedding": null, "metadata": {"window": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "original_text": "A lot of what this plan is, is very focused on the core . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fa2ef08-c47c-484d-bc26-a578607e4fc8", "node_type": "1", "metadata": {"window": "We are investing in distribution capacity .  That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "original_text": "In fact, I would say maybe a little \nbit of the opposite.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4edb777535fdb91483a068d2bea4043d31efc2931a9929d951c54fa3b4c7d347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9842b21b-6c13-4ff8-8e73-f9f5853d9aec", "node_type": "1", "metadata": {"window": "So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it . ", "original_text": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . "}, "hash": "1514d5c97cb7662295f6bf1a8745f48da1bb2a074cb56af11be30bcd4996bd91", "class_name": "RelatedNodeInfo"}}, "text": "A lot of what this plan is, is very focused on the core . ", "start_char_idx": 664, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9842b21b-6c13-4ff8-8e73-f9f5853d9aec": {"__data__": {"id_": "9842b21b-6c13-4ff8-8e73-f9f5853d9aec", "embedding": null, "metadata": {"window": "So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it . ", "original_text": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "088dc78a-815c-4df5-8fd4-92a541b51548", "node_type": "1", "metadata": {"window": "That \n10% growth does mean that we have some constraints  and we need to invest in that to ensure that that \nbusiness can continue to grow profitably .  So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "original_text": "A lot of what this plan is, is very focused on the core . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dab16f18aa2f8058a4e3191ea836c9efb2c860bcb420bb5eeb0b77ab67913731", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8", "node_type": "1", "metadata": {"window": "In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "original_text": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . "}, "hash": "0ac1e467f7ae5fcb78d447ddd0101ff30b6206fdaea4553d41ff0c7beb8701aa", "class_name": "RelatedNodeInfo"}}, "text": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "start_char_idx": 722, "end_char_idx": 843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8": {"__data__": {"id_": "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8", "embedding": null, "metadata": {"window": "In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "original_text": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9842b21b-6c13-4ff8-8e73-f9f5853d9aec", "node_type": "1", "metadata": {"window": "So that is not a cornerstone .  In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it . ", "original_text": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daca914c01ec8f8b20244cf71adf0c36bfdcbec16978b59d5893139990b8668c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13fd4d8e-9560-4c43-809e-bdde10d02994", "node_type": "1", "metadata": {"window": "A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.  ", "original_text": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . "}, "hash": "1e975d828582bf60cc99232e3e1851d07e360534172f919ebd74d43b840b3be5", "class_name": "RelatedNodeInfo"}}, "text": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "start_char_idx": 843, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13fd4d8e-9560-4c43-809e-bdde10d02994": {"__data__": {"id_": "13fd4d8e-9560-4c43-809e-bdde10d02994", "embedding": null, "metadata": {"window": "A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.  ", "original_text": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8", "node_type": "1", "metadata": {"window": "In fact, I would say maybe a little \nbit of the opposite.   A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "original_text": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a22a9db52088ac19ec9d0d37dc5481a8a97492bad25900ad8a93765464954044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc4ecd11-0086-4f52-b717-71ce15476155", "node_type": "1", "metadata": {"window": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "original_text": "We won't \never ignore it . "}, "hash": "6131393ea595326d6e2d3b9c8a2515acaedfbeaecdf6f0cfb0c4a5aae6344f59", "class_name": "RelatedNodeInfo"}}, "text": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "start_char_idx": 1012, "end_char_idx": 1166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc4ecd11-0086-4f52-b717-71ce15476155": {"__data__": {"id_": "cc4ecd11-0086-4f52-b717-71ce15476155", "embedding": null, "metadata": {"window": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "original_text": "We won't \never ignore it . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13fd4d8e-9560-4c43-809e-bdde10d02994", "node_type": "1", "metadata": {"window": "A lot of what this plan is, is very focused on the core .  It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.  ", "original_text": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a69c2a0e5719728fe1251c22640a7ebbf066d716c4813bf0ea346010291b851", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b499cc1-a8e9-4b0b-9161-5a4c2f798246", "node_type": "1", "metadata": {"window": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down . ", "original_text": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . "}, "hash": "8cbe7f217fa49a7114424b65012eab43639cb19759855a1f932d1a0ac6f22457", "class_name": "RelatedNodeInfo"}}, "text": "We won't \never ignore it . ", "start_char_idx": 1166, "end_char_idx": 1193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b499cc1-a8e9-4b0b-9161-5a4c2f798246": {"__data__": {"id_": "2b499cc1-a8e9-4b0b-9161-5a4c2f798246", "embedding": null, "metadata": {"window": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down . ", "original_text": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc4ecd11-0086-4f52-b717-71ce15476155", "node_type": "1", "metadata": {"window": "It's very focuse d on, you know, \nwe have just increased our CapEx guidance this year from where it's been in the past .  That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "original_text": "We won't \never ignore it . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ef2afc9432251cc237c4df8a5c21939ff178f062fb62349319603e24a16f9c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f07082c-63d1-48be-8d24-26e8086a704c", "node_type": "1", "metadata": {"window": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to . ", "original_text": "But it's not \nthe focus and not necessary for what we're doing.  "}, "hash": "43e1fc701ec74780fcf7602bbaaecf5bec9266aba36c3841607e29b59de7c14f", "class_name": "RelatedNodeInfo"}}, "text": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "start_char_idx": 1193, "end_char_idx": 1277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f07082c-63d1-48be-8d24-26e8086a704c": {"__data__": {"id_": "1f07082c-63d1-48be-8d24-26e8086a704c", "embedding": null, "metadata": {"window": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to . ", "original_text": "But it's not \nthe focus and not necessary for what we're doing.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b499cc1-a8e9-4b0b-9161-5a4c2f798246", "node_type": "1", "metadata": {"window": "That was hinted \nat and signaled last quarter where we talked about some of these capacity investments that, again, we \nfeel are relatively low risk and a good return .  So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down . ", "original_text": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bde8519103444f04713e3beec46892283a0633f673f8b2cd9c310c9e558e1897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c904c0-427e-45d8-ad5f-78d15d38f02a", "node_type": "1", "metadata": {"window": "We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day . ", "original_text": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . "}, "hash": "96b3b0e1eb0d178b7e91554d40c7c9cf08dff70c50611d1feb5925661571ed92", "class_name": "RelatedNodeInfo"}}, "text": "But it's not \nthe focus and not necessary for what we're doing.  ", "start_char_idx": 1277, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c904c0-427e-45d8-ad5f-78d15d38f02a": {"__data__": {"id_": "74c904c0-427e-45d8-ad5f-78d15d38f02a", "embedding": null, "metadata": {"window": "We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day . ", "original_text": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f07082c-63d1-48be-8d24-26e8086a704c", "node_type": "1", "metadata": {"window": "So it's more of that type of investment that we're focused \non and that we believe is a better balance of risk and return as we drive this plan forward .  We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to . ", "original_text": "But it's not \nthe focus and not necessary for what we're doing.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d27a7df18525171fc9ddff4ca027f4c1b282a2feffc9eb10a7fd6e77448c6516", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cddebe8c-8a51-48ab-a07a-9bf632fe55b2", "node_type": "1", "metadata": {"window": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs . ", "original_text": "That has come down . "}, "hash": "558321936d955344c9ad6655d6728ac97817d02c2d353e4446a0d781fb6f4f69", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "start_char_idx": 1342, "end_char_idx": 1535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cddebe8c-8a51-48ab-a07a-9bf632fe55b2": {"__data__": {"id_": "cddebe8c-8a51-48ab-a07a-9bf632fe55b2", "embedding": null, "metadata": {"window": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs . ", "original_text": "That has come down . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c904c0-427e-45d8-ad5f-78d15d38f02a", "node_type": "1", "metadata": {"window": "We won't \never ignore it .  And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day . ", "original_text": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80003240fb99c7846476a825d844b487ae3b387b4bb179ae889fa26f962d575e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a06371b-eae7-420c-ab2f-2774b3541b76", "node_type": "1", "metadata": {"window": "But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "original_text": "So PPI in general, I don't pay much attention to . "}, "hash": "e8f661547ef78cd2d09fbacda8abeae136220a1d6ad9b2a861a3cfd3fe57cf1b", "class_name": "RelatedNodeInfo"}}, "text": "That has come down . ", "start_char_idx": 1535, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a06371b-eae7-420c-ab2f-2774b3541b76": {"__data__": {"id_": "4a06371b-eae7-420c-ab2f-2774b3541b76", "embedding": null, "metadata": {"window": "But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "original_text": "So PPI in general, I don't pay much attention to . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cddebe8c-8a51-48ab-a07a-9bf632fe55b2", "node_type": "1", "metadata": {"window": "And it could be a pillar \u2013 sorry, it could be an enable , at som e point later on .  But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs . ", "original_text": "That has come down . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01de5cc796273e49156a7d432f34c54aafcdd49f2611534ed4c6f8ac2aab555d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a", "node_type": "1", "metadata": {"window": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it . ", "original_text": "I do look at \nthe price of oil at least two or three times a day . "}, "hash": "bd97a5252e5c394435e5ba29fe4107db173e48b402c467b095a8b1824a00438e", "class_name": "RelatedNodeInfo"}}, "text": "So PPI in general, I don't pay much attention to . ", "start_char_idx": 1556, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a": {"__data__": {"id_": "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a", "embedding": null, "metadata": {"window": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it . ", "original_text": "I do look at \nthe price of oil at least two or three times a day . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a06371b-eae7-420c-ab2f-2774b3541b76", "node_type": "1", "metadata": {"window": "But it's not \nthe focus and not necessary for what we're doing.   As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "original_text": "So PPI in general, I don't pay much attention to . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00b2b8df22cbdc43d3e82fac30ecadef3d86ec866d2c36ad13e7912df56994fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "427711d9-027b-468f-afc9-355f4289bec4", "node_type": "1", "metadata": {"window": "That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "original_text": "It does have an impact on a lot of the input costs . "}, "hash": "7f45e741b98eaa400d7de65bb53061ace2bf87da0fc717b4a015baaf04180689", "class_name": "RelatedNodeInfo"}}, "text": "I do look at \nthe price of oil at least two or three times a day . ", "start_char_idx": 1607, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "427711d9-027b-468f-afc9-355f4289bec4": {"__data__": {"id_": "427711d9-027b-468f-afc9-355f4289bec4", "embedding": null, "metadata": {"window": "That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "original_text": "It does have an impact on a lot of the input costs . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a", "node_type": "1", "metadata": {"window": "As it relates to PPI, I think just one maybe \u2013 I kind of \ntalk about a lot of the pieces, but one area that is often referenced as a key driver for a lot of our costs \nis just oil in general .  That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it . ", "original_text": "I do look at \nthe price of oil at least two or three times a day . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c8886adbff013cabb2ac7ef2d54f038cbbdfb33646dbc952a7c79564b12640e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606103d5-d433-492d-a6fd-fc01aff524f7", "node_type": "1", "metadata": {"window": "So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n", "original_text": "And \nwe talk about polypropylene, polyethylene, p olystyrene . "}, "hash": "f2d59df3006685044e544b156491b54178ab0fa60e7c7ebd0d33b80f54dfe210", "class_name": "RelatedNodeInfo"}}, "text": "It does have an impact on a lot of the input costs . ", "start_char_idx": 1674, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606103d5-d433-492d-a6fd-fc01aff524f7": {"__data__": {"id_": "606103d5-d433-492d-a6fd-fc01aff524f7", "embedding": null, "metadata": {"window": "So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n", "original_text": "And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "427711d9-027b-468f-afc9-355f4289bec4", "node_type": "1", "metadata": {"window": "That has come down .  So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "original_text": "It does have an impact on a lot of the input costs . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8b1964ee7667cdb629a5522d6b1fd8f49e6b93a9b1fd8efa2528f7d6973b139", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d00db7a9-73e5-4284-b78b-f111672056ee", "node_type": "1", "metadata": {"window": "I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much . ", "original_text": "All these polys have some input costs, that are \npetroleum based, that does impact it . "}, "hash": "439427844763c530e05f453bbea85405000d4bcd244c7180370d2647081a82dc", "class_name": "RelatedNodeInfo"}}, "text": "And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "start_char_idx": 1727, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d00db7a9-73e5-4284-b78b-f111672056ee": {"__data__": {"id_": "d00db7a9-73e5-4284-b78b-f111672056ee", "embedding": null, "metadata": {"window": "I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much . ", "original_text": "All these polys have some input costs, that are \npetroleum based, that does impact it . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606103d5-d433-492d-a6fd-fc01aff524f7", "node_type": "1", "metadata": {"window": "So PPI in general, I don't pay much attention to .  I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n", "original_text": "And \nwe talk about polypropylene, polyethylene, p olystyrene . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e29eaaca5c93c7c016261d186e68f10e660eeec9c7a5d6557496a6cf7cb6409", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da865a67-5fac-4dfe-90ce-fcbdacd21e25", "node_type": "1", "metadata": {"window": "It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "original_text": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . "}, "hash": "e054acbfcb62a6eb0ccd9789f5e6e07c8338966dcb36b48fac73aa52915f9931", "class_name": "RelatedNodeInfo"}}, "text": "All these polys have some input costs, that are \npetroleum based, that does impact it . ", "start_char_idx": 1790, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da865a67-5fac-4dfe-90ce-fcbdacd21e25": {"__data__": {"id_": "da865a67-5fac-4dfe-90ce-fcbdacd21e25", "embedding": null, "metadata": {"window": "It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "original_text": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d00db7a9-73e5-4284-b78b-f111672056ee", "node_type": "1", "metadata": {"window": "I do look at \nthe price of oil at least two or three times a day .  It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much . ", "original_text": "All these polys have some input costs, that are \npetroleum based, that does impact it . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97ffa2d66cb1473c502e724238c8b2bce8c694157743599e4009251e3c8fac0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74da753c-7d50-4a7b-ac19-aca899883e76", "node_type": "1", "metadata": {"window": "And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "original_text": "And I think at some point that w ill come through . \n"}, "hash": "94a94be011431b7786a6d4ab705c52a02b6b2f362fcb9647f83712f0972896d2", "class_name": "RelatedNodeInfo"}}, "text": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "start_char_idx": 1878, "end_char_idx": 2004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74da753c-7d50-4a7b-ac19-aca899883e76": {"__data__": {"id_": "74da753c-7d50-4a7b-ac19-aca899883e76", "embedding": null, "metadata": {"window": "And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "original_text": "And I think at some point that w ill come through . \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da865a67-5fac-4dfe-90ce-fcbdacd21e25", "node_type": "1", "metadata": {"window": "It does have an impact on a lot of the input costs .  And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "original_text": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3e90e37f1270cbd13a565b7ad5a0b4ca3deeebf50448b5594a140f478843dda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34adbcaf-c87e-4fca-89d3-36ce84a39052", "node_type": "1", "metadata": {"window": "All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.  ", "original_text": "But we're really not seeing it that much . "}, "hash": "0653a1132b0642803c6ce4595add928a954af74a32f1751611486f8ede88ed52", "class_name": "RelatedNodeInfo"}}, "text": "And I think at some point that w ill come through . \n", "start_char_idx": 2004, "end_char_idx": 2057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34adbcaf-c87e-4fca-89d3-36ce84a39052": {"__data__": {"id_": "34adbcaf-c87e-4fca-89d3-36ce84a39052", "embedding": null, "metadata": {"window": "All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.  ", "original_text": "But we're really not seeing it that much . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74da753c-7d50-4a7b-ac19-aca899883e76", "node_type": "1", "metadata": {"window": "And \nwe talk about polypropylene, polyethylene, p olystyrene .  All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "original_text": "And I think at some point that w ill come through . \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7ac60eeb1553a1a1166f28d315d04f2f416bb53368ca7031910f85f2ef7f266", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570", "node_type": "1", "metadata": {"window": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point . ", "original_text": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. "}, "hash": "11fa4b48e1258c4df9a471606fadbeecb45ecad3337f1c086797e045c309bcf3", "class_name": "RelatedNodeInfo"}}, "text": "But we're really not seeing it that much . ", "start_char_idx": 2057, "end_char_idx": 2100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570": {"__data__": {"id_": "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570", "embedding": null, "metadata": {"window": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point . ", "original_text": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34adbcaf-c87e-4fca-89d3-36ce84a39052", "node_type": "1", "metadata": {"window": "All these polys have some input costs, that are \npetroleum based, that does impact it .  But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.  ", "original_text": "But we're really not seeing it that much . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8996b83e7d7fd6af324b07351bd92519ccc8e7f02291e40e4ea43494a6ebe27b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32f35bba-cb67-4778-b0e9-b439df6f98ee", "node_type": "1", "metadata": {"window": "And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "original_text": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . "}, "hash": "7dbd3fd19438da9dc6b247a5510c2d58df8d22d5c5633f1b447d35de0a783bac", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "start_char_idx": 2100, "end_char_idx": 2302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32f35bba-cb67-4778-b0e9-b439df6f98ee": {"__data__": {"id_": "32f35bba-cb67-4778-b0e9-b439df6f98ee", "embedding": null, "metadata": {"window": "And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "original_text": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570", "node_type": "1", "metadata": {"window": "But the supply -demand dynamics are so wonky right now that it's \nhard to see a one for one transition of these input costs .  And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point . ", "original_text": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts. ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50503131492a8a6f48507bff1d53f1d2dfd1cb8e1c7fd3fe10cef9f1ceb281c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a7efbd1-ea64-48d7-9c4b-856fe3d19297", "node_type": "1", "metadata": {"window": "But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "original_text": "But it's just going to take time for that to run through \nour P&L.  "}, "hash": "06a8c70aa1b63366457b0bf626b44cbc1bd269549afe056342989f35ca377448", "class_name": "RelatedNodeInfo"}}, "text": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "start_char_idx": 2302, "end_char_idx": 2423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a7efbd1-ea64-48d7-9c4b-856fe3d19297": {"__data__": {"id_": "2a7efbd1-ea64-48d7-9c4b-856fe3d19297", "embedding": null, "metadata": {"window": "But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "original_text": "But it's just going to take time for that to run through \nour P&L.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32f35bba-cb67-4778-b0e9-b439df6f98ee", "node_type": "1", "metadata": {"window": "And I think at some point that w ill come through . \n But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "original_text": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "588ae148df423983839d8d849e38d9c7f6fabb51343ed85c198326bcf35418c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4720b41c-6f37-46fc-8ee9-68dd6d092a3b", "node_type": "1", "metadata": {"window": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "original_text": "But I wouldn't call that a inflation driven or input cost driven  point . "}, "hash": "22a880571852aa5c4c008d8e3b3f9827d852909beed13ac34a7e11753d39b07a", "class_name": "RelatedNodeInfo"}}, "text": "But it's just going to take time for that to run through \nour P&L.  ", "start_char_idx": 2423, "end_char_idx": 2491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4720b41c-6f37-46fc-8ee9-68dd6d092a3b": {"__data__": {"id_": "4720b41c-6f37-46fc-8ee9-68dd6d092a3b", "embedding": null, "metadata": {"window": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "original_text": "But I wouldn't call that a inflation driven or input cost driven  point . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a7efbd1-ea64-48d7-9c4b-856fe3d19297", "node_type": "1", "metadata": {"window": "But we're really not seeing it that much .  We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "original_text": "But it's just going to take time for that to run through \nour P&L.  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aaf7789402dbac23e4f8ee91d28878d803397909880c82af0bcdc3a906878421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec8e2a5-a37f-481e-8215-a41e1365ffff", "node_type": "1", "metadata": {"window": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you . ", "original_text": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . "}, "hash": "afb095bca16becbbbc51b0743d5ef4254eb600baa6003f1a5ba9af64bdbe4750", "class_name": "RelatedNodeInfo"}}, "text": "But I wouldn't call that a inflation driven or input cost driven  point . ", "start_char_idx": 2491, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec8e2a5-a37f-481e-8215-a41e1365ffff": {"__data__": {"id_": "5ec8e2a5-a37f-481e-8215-a41e1365ffff", "embedding": null, "metadata": {"window": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you . ", "original_text": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4720b41c-6f37-46fc-8ee9-68dd6d092a3b", "node_type": "1", "metadata": {"window": "We are seeing lower diesel costs, so that's going in the right \ndirection, that I would expect at some point we'll help with the transportation rates, but we're not \nnecessarily seeing those eleme nts.  Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "original_text": "But I wouldn't call that a inflation driven or input cost driven  point . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2f540cbc0d853e6a7446cb98ab742a0b8caeecb466b8db3bfc519e8cb15ce97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef5225db-b017-4bd4-8faa-8ae84fe49a9f", "node_type": "1", "metadata": {"window": "But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n", "original_text": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . "}, "hash": "24ee12dddf1ad036d94548b55b1955e7d30e89d6d04ad7f1ac2cf0bd28d5737c", "class_name": "RelatedNodeInfo"}}, "text": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "start_char_idx": 2565, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef5225db-b017-4bd4-8faa-8ae84fe49a9f": {"__data__": {"id_": "ef5225db-b017-4bd4-8faa-8ae84fe49a9f", "embedding": null, "metadata": {"window": "But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n", "original_text": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec8e2a5-a37f-481e-8215-a41e1365ffff", "node_type": "1", "metadata": {"window": "Where it is most striking is the international freight and that \ncontinues to be the one that is clearly running lower .  But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you . ", "original_text": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb56c28eb6e5ab76bd234c8ed22961fa864f8d9b41387967904d4e510d6c5b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "813d549b-493d-49dd-a2b2-6146c65c149d", "node_type": "1", "metadata": {"window": "But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi. ", "original_text": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n"}, "hash": "835ab43b0b540dedd39dbab30a1148dba399731b4fbead2901ee82356621f5e0", "class_name": "RelatedNodeInfo"}}, "text": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "start_char_idx": 2752, "end_char_idx": 2970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "813d549b-493d-49dd-a2b2-6146c65c149d": {"__data__": {"id_": "813d549b-493d-49dd-a2b2-6146c65c149d", "embedding": null, "metadata": {"window": "But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi. ", "original_text": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef5225db-b017-4bd4-8faa-8ae84fe49a9f", "node_type": "1", "metadata": {"window": "But it's just going to take time for that to run through \nour P&L.   But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n", "original_text": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c52c25cc7ba931c880be7c7ade7630d344aaea562516319027326da8863b5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f40a383f-761d-44ec-9120-b695011c574d", "node_type": "1", "metadata": {"window": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call . ", "original_text": "Operator :  Thank you . "}, "hash": "152615b3b582e89020d41c73accacde0d35e53059ac9f34993e5023e25526b37", "class_name": "RelatedNodeInfo"}}, "text": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "start_char_idx": 2970, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f40a383f-761d-44ec-9120-b695011c574d": {"__data__": {"id_": "f40a383f-761d-44ec-9120-b695011c574d", "embedding": null, "metadata": {"window": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call . ", "original_text": "Operator :  Thank you . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "813d549b-493d-49dd-a2b2-6146c65c149d", "node_type": "1", "metadata": {"window": "But I wouldn't call that a inflation driven or input cost driven  point .  The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi. ", "original_text": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "713af25821c390308e4cdc524f3c5d5a573e38bf63490036bcc3d54b6975d427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d248c887-bb0c-429e-8e89-edfad55057cb", "node_type": "1", "metadata": {"window": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason . ", "original_text": "We now move to Kevin Caliendo of UBS.   \n \n"}, "hash": "59b8c0b7f71672eb54ce780deda91d9eada83deb4f735a67c2c81c0c18c7a4e2", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 3068, "end_char_idx": 3092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d248c887-bb0c-429e-8e89-edfad55057cb": {"__data__": {"id_": "d248c887-bb0c-429e-8e89-edfad55057cb", "embedding": null, "metadata": {"window": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason . ", "original_text": "We now move to Kevin Caliendo of UBS.   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f40a383f-761d-44ec-9120-b695011c574d", "node_type": "1", "metadata": {"window": "The cost of diesel fuel for \nour freight is small, it's the supply and demand dynamics that were all out of whack early on in the \npandemic that appear to be getting a bit more in line .  And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call . ", "original_text": "Operator :  Thank you . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8eb4fc124c72799e0cf1d37614d3bf10b8bb503fb29a3b578e0c3b23b882be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6e45e54-853a-4a8e-ab59-146f73435322", "node_type": "1", "metadata": {"window": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "original_text": "Kevin Caliendo :  Hi. "}, "hash": "29d4f3f72dc3205acbe821462ab1786b25a7e00ccf7740aa9038981ccb86f443", "class_name": "RelatedNodeInfo"}}, "text": "We now move to Kevin Caliendo of UBS.   \n \n", "start_char_idx": 3092, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6e45e54-853a-4a8e-ab59-146f73435322": {"__data__": {"id_": "a6e45e54-853a-4a8e-ab59-146f73435322", "embedding": null, "metadata": {"window": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "original_text": "Kevin Caliendo :  Hi. ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d248c887-bb0c-429e-8e89-edfad55057cb", "node_type": "1", "metadata": {"window": "And that's why at this point, I believe that that \ncost will ma ybe not keep going down at the pace that it's going down, but it does feel like we're seeing \nmore flat and down days for those costs than than up days .  Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason . ", "original_text": "We now move to Kevin Caliendo of UBS.   \n \n", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a5d305906b1c5085ba36cce284b6b8937672a666f91eadc33e0c8536f49fb2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2b8c820-8d8e-435b-9842-a3eac1ce9c32", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?  ", "original_text": "Thanks for taking my call . "}, "hash": "8237a8117119bdcd5cfe066380782f529aa56578cdf35d30c6a15953a6c7b3cf", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo :  Hi. ", "start_char_idx": 3135, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2b8c820-8d8e-435b-9842-a3eac1ce9c32": {"__data__": {"id_": "b2b8c820-8d8e-435b-9842-a3eac1ce9c32", "embedding": null, "metadata": {"window": "Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?  ", "original_text": "Thanks for taking my call . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6e45e54-853a-4a8e-ab59-146f73435322", "node_type": "1", "metadata": {"window": "Everything else, we're going to have to get \nmore data to build to provide additional input.   \n \n Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "original_text": "Kevin Caliendo :  Hi. ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e1c8ab738ead7f2fd7bfb77da6538ddc14c729d0f1149723f9a23cedb008179", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd8515fa-68e3-4729-94b1-f801c113cce5", "node_type": "1", "metadata": {"window": "We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?  ", "original_text": "And again, congrats to both you, Mike and Jason . "}, "hash": "a408b76e969934dc07c803ffc23bd9f99e6362c1c6aec4ed183cc2a03e312173", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call . ", "start_char_idx": 3157, "end_char_idx": 3185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd8515fa-68e3-4729-94b1-f801c113cce5": {"__data__": {"id_": "fd8515fa-68e3-4729-94b1-f801c113cce5", "embedding": null, "metadata": {"window": "We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?  ", "original_text": "And again, congrats to both you, Mike and Jason . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2b8c820-8d8e-435b-9842-a3eac1ce9c32", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?  ", "original_text": "Thanks for taking my call . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1cb224b22fe86190cd06bc0b89f40c7c7c4cd333e32580113347daee4f82f57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f1207c0-577e-4ea6-87b1-ab81005adf1e", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "original_text": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . "}, "hash": "abd2c633251a1f5ee60a9a391073d74fbf3bc6e28c7ab1bbd5686663b9c7d4a2", "class_name": "RelatedNodeInfo"}}, "text": "And again, congrats to both you, Mike and Jason . ", "start_char_idx": 3185, "end_char_idx": 3235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f1207c0-577e-4ea6-87b1-ab81005adf1e": {"__data__": {"id_": "6f1207c0-577e-4ea6-87b1-ab81005adf1e", "embedding": null, "metadata": {"window": "Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "original_text": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd8515fa-68e3-4729-94b1-f801c113cce5", "node_type": "1", "metadata": {"window": "We now move to Kevin Caliendo of UBS.   \n \n Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?  ", "original_text": "And again, congrats to both you, Mike and Jason . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08deceb446b8e6053469be49c18eb5f444d05b56422b35ad52c73775d1d92ff4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5104056b-fc7d-4566-8e86-72997e6f1b38", "node_type": "1", "metadata": {"window": "Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "original_text": "Are you happy with the team in place?  "}, "hash": "4dd46aca207e40e2d4d6d9f62874c5d9a798426c02bbdd735dba02d3a0649b24", "class_name": "RelatedNodeInfo"}}, "text": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "start_char_idx": 3235, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5104056b-fc7d-4566-8e86-72997e6f1b38": {"__data__": {"id_": "5104056b-fc7d-4566-8e86-72997e6f1b38", "embedding": null, "metadata": {"window": "Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "original_text": "Are you happy with the team in place?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f1207c0-577e-4ea6-87b1-ab81005adf1e", "node_type": "1", "metadata": {"window": "Kevin Caliendo :  Hi.  Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "original_text": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69bc26d14363da62fc9c3b78f3193dff5b3f46310ce5ea2007296a621cfe6250", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "604d8a1b-d122-4272-8d5b-a93a459fe66f", "node_type": "1", "metadata": {"window": "And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?  ", "original_text": "How \ndo you enhance your probability of success here internally?  "}, "hash": "60ed8ff76d77d019ed232c57293456da681da0b0a3dd02be9381f95e74a6da41", "class_name": "RelatedNodeInfo"}}, "text": "Are you happy with the team in place?  ", "start_char_idx": 3399, "end_char_idx": 3438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "604d8a1b-d122-4272-8d5b-a93a459fe66f": {"__data__": {"id_": "604d8a1b-d122-4272-8d5b-a93a459fe66f", "embedding": null, "metadata": {"window": "And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?  ", "original_text": "How \ndo you enhance your probability of success here internally?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5104056b-fc7d-4566-8e86-72997e6f1b38", "node_type": "1", "metadata": {"window": "Thanks for taking my call .  And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "original_text": "Are you happy with the team in place?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53b04c88601a6e1dc262e258f046b29cc929121f226039ebb668b958355c43d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71", "node_type": "1", "metadata": {"window": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "original_text": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?  "}, "hash": "29220e466df9cafbdfcc82e7da0adf7fc8de9ab29807a2aa8fbebbe0ddb28015", "class_name": "RelatedNodeInfo"}}, "text": "How \ndo you enhance your probability of success here internally?  ", "start_char_idx": 3438, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71": {"__data__": {"id_": "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71", "embedding": null, "metadata": {"window": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "original_text": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "604d8a1b-d122-4272-8d5b-a93a459fe66f", "node_type": "1", "metadata": {"window": "And again, congrats to both you, Mike and Jason .  I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?  ", "original_text": "How \ndo you enhance your probability of success here internally?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9558da1b4b0bfbdfa5e2738a32d2343814f855aff4ef223f31c28ee4a334908e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6140d053-f048-4368-be20-13a774ce1c77", "node_type": "1", "metadata": {"window": "Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?  ", "original_text": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . "}, "hash": "d84a8a66a28b069caf103cb6e87ecf45994c923ed94b2359aaa0530807f0de7a", "class_name": "RelatedNodeInfo"}}, "text": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "start_char_idx": 3504, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6140d053-f048-4368-be20-13a774ce1c77": {"__data__": {"id_": "6140d053-f048-4368-be20-13a774ce1c77", "embedding": null, "metadata": {"window": "Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?  ", "original_text": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71", "node_type": "1", "metadata": {"window": "I \nguess my question is, going back to the medical segment, there's a lot of execution that needs to ta ke \nplace between now and 2025 to hit these these targets .  Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "original_text": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0728be2610ef97fbb638bc549c38369d103fc738ecff4ed1c804f2ba6b0bb95a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99f0559-49f0-4571-b736-1ce5855943a7", "node_type": "1", "metadata": {"window": "How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?  ", "original_text": "How are you competitively positioned now when it comes to \nprice?  "}, "hash": "c01f08653522036bb7051154eefc6b092b9cd8b26a6f81b2bba36861e43d6a74", "class_name": "RelatedNodeInfo"}}, "text": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "start_char_idx": 3593, "end_char_idx": 3698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99f0559-49f0-4571-b736-1ce5855943a7": {"__data__": {"id_": "d99f0559-49f0-4571-b736-1ce5855943a7", "embedding": null, "metadata": {"window": "How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?  ", "original_text": "How are you competitively positioned now when it comes to \nprice?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6140d053-f048-4368-be20-13a774ce1c77", "node_type": "1", "metadata": {"window": "Are you happy with the team in place?   How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?  ", "original_text": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19ab44a602b00db541ce0f5b2feb64d1e31f2ebc0b99f863d494a97feb82f8e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec1b63d9-b42f-4f39-a52c-671655f97cd2", "node_type": "1", "metadata": {"window": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "original_text": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . "}, "hash": "f4ec5543d14163507c18815b4f024298fcd31b30db1ed2af34771197e912dd9d", "class_name": "RelatedNodeInfo"}}, "text": "How are you competitively positioned now when it comes to \nprice?  ", "start_char_idx": 3698, "end_char_idx": 3765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec1b63d9-b42f-4f39-a52c-671655f97cd2": {"__data__": {"id_": "ec1b63d9-b42f-4f39-a52c-671655f97cd2", "embedding": null, "metadata": {"window": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "original_text": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99f0559-49f0-4571-b736-1ce5855943a7", "node_type": "1", "metadata": {"window": "How \ndo you enhance your probability of success here internally?   Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?  ", "original_text": "How are you competitively positioned now when it comes to \nprice?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "475ba4ee49a8af92b4cf26e08a43af43ddb7c3dd77eedc4accc266d2dfb7dbc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "312efc53-9838-43a1-b0b0-63f2c2274b58", "node_type": "1", "metadata": {"window": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan . ", "original_text": "How are you now positioned competitively when it comes to pricing?  "}, "hash": "bce428a38746a1d8394d8215f407e50a2884de0ba8c4e754b1c53a4fb7711cde", "class_name": "RelatedNodeInfo"}}, "text": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "start_char_idx": 3765, "end_char_idx": 3872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "312efc53-9838-43a1-b0b0-63f2c2274b58": {"__data__": {"id_": "312efc53-9838-43a1-b0b0-63f2c2274b58", "embedding": null, "metadata": {"window": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan . ", "original_text": "How are you now positioned competitively when it comes to pricing?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec1b63d9-b42f-4f39-a52c-671655f97cd2", "node_type": "1", "metadata": {"window": "Is it bringing in new people, more people, \nor do you feel the team in place can do it?   And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "original_text": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2086c301ee1bb994a550252ffd011e4c7e479b23c0d03b99f671832e1d7be33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41e3db85-a3a0-457b-8bb4-80d43f3418b4", "node_type": "1", "metadata": {"window": "How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time . ", "original_text": "And are customers asking \nfor any offsets anywhere else?  "}, "hash": "f96b96decdb43ea872676f9a05145456f9fe71ea6f540c0b4d4429e6c550cfa3", "class_name": "RelatedNodeInfo"}}, "text": "How are you now positioned competitively when it comes to pricing?  ", "start_char_idx": 3872, "end_char_idx": 3940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41e3db85-a3a0-457b-8bb4-80d43f3418b4": {"__data__": {"id_": "41e3db85-a3a0-457b-8bb4-80d43f3418b4", "embedding": null, "metadata": {"window": "How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time . ", "original_text": "And are customers asking \nfor any offsets anywhere else?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "312efc53-9838-43a1-b0b0-63f2c2274b58", "node_type": "1", "metadata": {"window": "And th e second part of that question is, a lot of this is price \nincreases, which you've talked about .  How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan . ", "original_text": "How are you now positioned competitively when it comes to pricing?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b614d8464cf6cad87ab3661df89548d047393a6661eb62d134d5de800f9addc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44a00b16-3559-4b87-840a-0ed72d91bd89", "node_type": "1", "metadata": {"window": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . "}, "hash": "752c9de8fc83da64abc8730f20a8cd08e2df8f20a2972e0713e613a87fffb677", "class_name": "RelatedNodeInfo"}}, "text": "And are customers asking \nfor any offsets anywhere else?  ", "start_char_idx": 3940, "end_char_idx": 3998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44a00b16-3559-4b87-840a-0ed72d91bd89": {"__data__": {"id_": "44a00b16-3559-4b87-840a-0ed72d91bd89", "embedding": null, "metadata": {"window": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41e3db85-a3a0-457b-8bb4-80d43f3418b4", "node_type": "1", "metadata": {"window": "How are you competitively positioned now when it comes to \nprice?   You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time . ", "original_text": "And are customers asking \nfor any offsets anywhere else?  ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd1f876e77989c504b3dfe5398da2bbe6afccff2b197503ec9e4d6ec392c5441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99f2e669-b67f-4d8d-b622-cb94f4efeb79", "node_type": "1", "metadata": {"window": "How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "This is our plan . "}, "hash": "55682108209ec573367f5590b9734d815ddf78bbcc08b4b1b169c5d58339272c", "class_name": "RelatedNodeInfo"}}, "text": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "start_char_idx": 3998, "end_char_idx": 4182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99f2e669-b67f-4d8d-b622-cb94f4efeb79": {"__data__": {"id_": "99f2e669-b67f-4d8d-b622-cb94f4efeb79", "embedding": null, "metadata": {"window": "How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "This is our plan . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44a00b16-3559-4b87-840a-0ed72d91bd89", "node_type": "1", "metadata": {"window": "You talked earlier about losing some share in medical because of PPE capacity and availabilit y \nearlier .  How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8984f00b7652102c44bbb9b1ddb9ae96e5bb14e4c705e628b8cf774d3ec67e33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8dc138-bbde-4f4a-b83b-51232aace9b5", "node_type": "1", "metadata": {"window": "And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "They've been working on this for \nquite some time . "}, "hash": "295cc15f16865ad794ba8180ec07915ef4b547f0a72ec3e288d115299b269c3c", "class_name": "RelatedNodeInfo"}}, "text": "This is our plan . ", "start_char_idx": 4182, "end_char_idx": 4201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8dc138-bbde-4f4a-b83b-51232aace9b5": {"__data__": {"id_": "de8dc138-bbde-4f4a-b83b-51232aace9b5", "embedding": null, "metadata": {"window": "And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "They've been working on this for \nquite some time . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99f2e669-b67f-4d8d-b622-cb94f4efeb79", "node_type": "1", "metadata": {"window": "How are you now positioned competitively when it comes to pricing?   And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "This is our plan . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9ab7d8392a7a0d7e0b2057307556c46ea7a5696d94afaefbdf8d6f44cfe1634", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bb625e7-0895-4fb3-aaae-056341c16333", "node_type": "1", "metadata": {"window": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "We have shared elements of it conceptually with our investors, with you all in the past . "}, "hash": "da5f6c1ed87868d73c4c7d8a9c50cd8b2187c6fac4228bc8de84e4e9799e022a", "class_name": "RelatedNodeInfo"}}, "text": "They've been working on this for \nquite some time . ", "start_char_idx": 4201, "end_char_idx": 4253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bb625e7-0895-4fb3-aaae-056341c16333": {"__data__": {"id_": "4bb625e7-0895-4fb3-aaae-056341c16333", "embedding": null, "metadata": {"window": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "We have shared elements of it conceptually with our investors, with you all in the past . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "304bbfebb8ae8eef2ff077c8e03e3e5ac18c63d15fd99beba673d573739ef0cf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8dc138-bbde-4f4a-b83b-51232aace9b5", "node_type": "1", "metadata": {"window": "And are customers asking \nfor any offsets anywhere else?   I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "They've been working on this for \nquite some time . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "260ea00f0882cf6a16399b30f70113ef67fda464dad0696311e6a09a393237b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc7b6607-5ae7-431f-9ac1-1a38d3902c83", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "original_text": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making . "}, "hash": "0e31a72e887d431ed281643468326828fe1750c293db14eeed20fc1f10126043", "class_name": "RelatedNodeInfo"}}, "text": "We have shared elements of it conceptually with our investors, with you all in the past . ", "start_char_idx": 4253, "end_char_idx": 4343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc7b6607-5ae7-431f-9ac1-1a38d3902c83": {"__data__": {"id_": "bc7b6607-5ae7-431f-9ac1-1a38d3902c83", "embedding": null, "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "original_text": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bb625e7-0895-4fb3-aaae-056341c16333", "node_type": "1", "metadata": {"window": "I know you've talked about some guarantees and the like, but just want \nto understand the competitive positioning as wel l.  \n \nJason Hollar:  Yes, I am happy with the team in place .  This is our plan .  They've been working on this for \nquite some time .  We have shared elements of it conceptually with our investors, with you all in the past . ", "original_text": "We have shared elements of it conceptually with our investors, with you all in the past . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "085404c4d5774709504c7fb25ca310f69b287298d3fbf3c2b7a30f26f02ae1c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2cf4332-52c3-4924-b176-36f67dd938e4", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "original_text": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx . "}, "hash": "75cc6b225341d8e9bd1b9bfa797508325a07a3fd899e019c481d4f95cb3610d5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making . ", "start_char_idx": 0, "end_char_idx": 142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2cf4332-52c3-4924-b176-36f67dd938e4": {"__data__": {"id_": "c2cf4332-52c3-4924-b176-36f67dd938e4", "embedding": null, "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "original_text": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc7b6607-5ae7-431f-9ac1-1a38d3902c83", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "original_text": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d8ab920255f9e24c4a77ad53604713442bea75c0f27a6a11f265de18bb1245d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a31827-e476-41ad-b7b3-d039a0331f52", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "original_text": "I do think that we need to continue to augment some of the capabilities . "}, "hash": "8a85944aba533a62d3ad56fe75c30d9b61dedc8714cb1028e63a5e4368f0b196", "class_name": "RelatedNodeInfo"}}, "text": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx . ", "start_char_idx": 142, "end_char_idx": 233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a31827-e476-41ad-b7b3-d039a0331f52": {"__data__": {"id_": "f0a31827-e476-41ad-b7b3-d039a0331f52", "embedding": null, "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "original_text": "I do think that we need to continue to augment some of the capabilities . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2cf4332-52c3-4924-b176-36f67dd938e4", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "original_text": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91308e8ed79ba8482993e2e6361778826a6117c08714ad9aab58b9fb801adc73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc32c69-11d3-4eb0-b885-da244f0fa21f", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "original_text": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . "}, "hash": "efb0542a98ea5475c94b8e61b62a746bf28c045e99fbf89ad4a848f05cc6935a", "class_name": "RelatedNodeInfo"}}, "text": "I do think that we need to continue to augment some of the capabilities . ", "start_char_idx": 233, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc32c69-11d3-4eb0-b885-da244f0fa21f": {"__data__": {"id_": "0cc32c69-11d3-4eb0-b885-da244f0fa21f", "embedding": null, "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "original_text": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a31827-e476-41ad-b7b3-d039a0331f52", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "original_text": "I do think that we need to continue to augment some of the capabilities . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5aa8effede2039513999faf9916d8a5baf4f6b859aaf46fb11a42da04227bb76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0a16742-ca8f-417c-b181-26ad2776e396", "node_type": "1", "metadata": {"window": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "original_text": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  "}, "hash": "181dd318b0a9518083e52cdb7b1da6ae311a262e50ac1475bfb4bd53a1817b9d", "class_name": "RelatedNodeInfo"}}, "text": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "start_char_idx": 307, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0a16742-ca8f-417c-b181-26ad2776e396": {"__data__": {"id_": "e0a16742-ca8f-417c-b181-26ad2776e396", "embedding": null, "metadata": {"window": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "original_text": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc32c69-11d3-4eb0-b885-da244f0fa21f", "node_type": "1", "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "original_text": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0aba99dd6d918ece3ca9c2babdf9105b0edcc376b44077d8174e71d212dfd5de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06", "node_type": "1", "metadata": {"window": "I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "original_text": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . "}, "hash": "0677fb849cb3f5bbcfc3c4788fd808523433403dd59b6ad2f135d06a5e88d96a", "class_name": "RelatedNodeInfo"}}, "text": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "start_char_idx": 813, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06": {"__data__": {"id_": "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06", "embedding": null, "metadata": {"window": "I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "original_text": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0a16742-ca8f-417c-b181-26ad2776e396", "node_type": "1", "metadata": {"window": "We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "original_text": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.  ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "271de7f2e5b99775b1e774f0eec59016c66d52f58bccce938cd4bf2b03aa21c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72edadaa-1a15-473c-8139-3141caadf839", "node_type": "1", "metadata": {"window": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "original_text": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . "}, "hash": "794366b9347e195f5652816a50ce4e59a067eafbd0a71cbf849a0bdbebbe40ac", "class_name": "RelatedNodeInfo"}}, "text": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "start_char_idx": 946, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72edadaa-1a15-473c-8139-3141caadf839": {"__data__": {"id_": "72edadaa-1a15-473c-8139-3141caadf839", "embedding": null, "metadata": {"window": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "original_text": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06", "node_type": "1", "metadata": {"window": "I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "original_text": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "547bb73f6b6051f64cfab6782be67d43464e2465284a3a821e2320d35f095d71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "468797f5-d305-4af8-9305-c9fc86226e2e", "node_type": "1", "metadata": {"window": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "original_text": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . "}, "hash": "9bfcc2b126481d9b23869860c5d2590191c35e55de795ad6d1be7c997b57f7c7", "class_name": "RelatedNodeInfo"}}, "text": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "start_char_idx": 1109, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "468797f5-d305-4af8-9305-c9fc86226e2e": {"__data__": {"id_": "468797f5-d305-4af8-9305-c9fc86226e2e", "embedding": null, "metadata": {"window": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "original_text": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72edadaa-1a15-473c-8139-3141caadf839", "node_type": "1", "metadata": {"window": "We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line .  So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "original_text": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f06fe10b6fa20cf8258c3ae3d7417a4841b0a1ac5eff6f2062128d4296243d36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe20fcfb-faa7-4b90-af4e-a123218b4502", "node_type": "1", "metadata": {"window": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "original_text": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . "}, "hash": "c0f338ff04c9d99770cf8a66fa4c564b326d334d9ba15b00bda2440f292c266b", "class_name": "RelatedNodeInfo"}}, "text": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "start_char_idx": 1307, "end_char_idx": 1527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe20fcfb-faa7-4b90-af4e-a123218b4502": {"__data__": {"id_": "fe20fcfb-faa7-4b90-af4e-a123218b4502", "embedding": null, "metadata": {"window": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "original_text": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "468797f5-d305-4af8-9305-c9fc86226e2e", "node_type": "1", "metadata": {"window": "So I would not be presenting it this way if I \ndidn't have the confidence that we have the people behind it to actually execute it.   The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "original_text": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2525e751bce6018eadaf453a04127132dd0406a24545d052e7d309889fea0bc9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0732bebe-36b7-45aa-92e2-02f493386429", "node_type": "1", "metadata": {"window": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "original_text": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n"}, "hash": "97174ecfe4859306843275249c8952f5c04fd30872bdc85632872000ca48ae21", "class_name": "RelatedNodeInfo"}}, "text": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "start_char_idx": 1527, "end_char_idx": 1666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0732bebe-36b7-45aa-92e2-02f493386429": {"__data__": {"id_": "0732bebe-36b7-45aa-92e2-02f493386429", "embedding": null, "metadata": {"window": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "original_text": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe20fcfb-faa7-4b90-af4e-a123218b4502", "node_type": "1", "metadata": {"window": "The other thing I'll \nsay about a plan like this is I absolutely understand the intent of your question because there's several \nthings that need to happen here .  And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "original_text": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b173afca97fb6e564152b7f3d99eff2f2b07ae2770eb65e6b1c6cbbe14fc8e3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba", "node_type": "1", "metadata": {"window": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution . ", "original_text": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . "}, "hash": "0055b1e1184da1897ef5ce70af38a1e17616bc8803ec53dadce61d104743d43c", "class_name": "RelatedNodeInfo"}}, "text": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "start_char_idx": 1666, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba": {"__data__": {"id_": "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba", "embedding": null, "metadata": {"window": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution . ", "original_text": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0732bebe-36b7-45aa-92e2-02f493386429", "node_type": "1", "metadata": {"window": "And one thing I've learned in my two years here is that it's not what's \non the piece of paper that ends up taking us sideways, it's the things that are unforeseen, like COVID \nand like inflation .  And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "original_text": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "270a023d9e434cba04b1eea9dc45d2bccddf01a419eb400b80c03d5fb12363f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6139342f-882e-4edf-9ea2-bfa4cd031c1a", "node_type": "1", "metadata": {"window": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation . ", "original_text": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . "}, "hash": "7b43dfbec58af702ffef9bf35e42daca4baa2d6283b6f26005df73949693d693", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "start_char_idx": 1786, "end_char_idx": 1946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6139342f-882e-4edf-9ea2-bfa4cd031c1a": {"__data__": {"id_": "6139342f-882e-4edf-9ea2-bfa4cd031c1a", "embedding": null, "metadata": {"window": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation . ", "original_text": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba", "node_type": "1", "metadata": {"window": "And so with that said, that's why you see, after every single one of these actions, at \nleast, 'or $60  million plus,' 'or $50  million plus ,\u2019 it's because our internal plans are definitely more \naggressive than this .  And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution . ", "original_text": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "247ef181298ad67dbbc0e82280032e31b8723dc4413d4c51d9ce9705e376a5b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc25d01-3b40-42a6-a812-aeb98bdfe566", "node_type": "1", "metadata": {"window": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "original_text": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . "}, "hash": "cd2f835e303ff928daec771f582799db702816bdfb66a0e0d5b9517791d070b3", "class_name": "RelatedNodeInfo"}}, "text": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "start_char_idx": 1946, "end_char_idx": 2109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc25d01-3b40-42a6-a812-aeb98bdfe566": {"__data__": {"id_": "4cc25d01-3b40-42a6-a812-aeb98bdfe566", "embedding": null, "metadata": {"window": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "original_text": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6139342f-882e-4edf-9ea2-bfa4cd031c1a", "node_type": "1", "metadata": {"window": "And we know that there's going to be some unforeseen things that are going to \nmake us exceed some of t hese items so that we can hit it .  So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation . ", "original_text": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "328e4cff4ee5e32cb11ac6cc3a2d8d61f2d4b1cce5da4b908843135912d47f20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "203f30cf-d2cb-4361-9f9f-93c92d2e5b32", "node_type": "1", "metadata": {"window": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process . ", "original_text": "There's not \u2013 especially in distribution . "}, "hash": "53b16e1ed24450c0b512b32d03335c08dd94703e164c5d6ed6221ad586cc5060", "class_name": "RelatedNodeInfo"}}, "text": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "start_char_idx": 2109, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "203f30cf-d2cb-4361-9f9f-93c92d2e5b32": {"__data__": {"id_": "203f30cf-d2cb-4361-9f9f-93c92d2e5b32", "embedding": null, "metadata": {"window": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process . ", "original_text": "There's not \u2013 especially in distribution . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc25d01-3b40-42a6-a812-aeb98bdfe566", "node_type": "1", "metadata": {"window": "So, yes, a lot of execution, but we have the \nteam and we have the plan in place and that's where we have to start.  \n \n As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "original_text": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "352abcaeae7b5156af85f38295dc6f1d4abc06c911d24ec477a5e5b573d19947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a0eb274-cb6c-48cc-8228-97432b631802", "node_type": "1", "metadata": {"window": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years . ", "original_text": "There's not the margin to to absorb inflation . "}, "hash": "c3824fd69ebd82ff11d8ec1510afa4fd0b9402be4c007936431066b39f0a8bfc", "class_name": "RelatedNodeInfo"}}, "text": "There's not \u2013 especially in distribution . ", "start_char_idx": 2221, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a0eb274-cb6c-48cc-8228-97432b631802": {"__data__": {"id_": "5a0eb274-cb6c-48cc-8228-97432b631802", "embedding": null, "metadata": {"window": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years . ", "original_text": "There's not the margin to to absorb inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "203f30cf-d2cb-4361-9f9f-93c92d2e5b32", "node_type": "1", "metadata": {"window": "As it relates to your question on competitiveness, I think I'd like to answer that maybe a little bit m ore \nbroadly, because let's just talk about inflation .  As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process . ", "original_text": "There's not \u2013 especially in distribution . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1885f7163237bcf50c510fea34ac8fa5cbfa41dc244706b91c4e62fa390f1124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b129e73-7814-4647-bbd5-9ac0c6540edf", "node_type": "1", "metadata": {"window": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "original_text": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . "}, "hash": "097c44b15097c11b99b5cfabdf12a8783857e568e486729b52d77e5a513f18cc", "class_name": "RelatedNodeInfo"}}, "text": "There's not the margin to to absorb inflation . ", "start_char_idx": 2264, "end_char_idx": 2312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b129e73-7814-4647-bbd5-9ac0c6540edf": {"__data__": {"id_": "2b129e73-7814-4647-bbd5-9ac0c6540edf", "embedding": null, "metadata": {"window": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "original_text": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a0eb274-cb6c-48cc-8228-97432b631802", "node_type": "1", "metadata": {"window": "As long as we have a cost competitive sourcing, \nmanufacturing footprint, then inflation that we incur absolutely needs to be pushed down to the final \ncustomer .  By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years . ", "original_text": "There's not the margin to to absorb inflation . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8658d8747994c82862d355e3a904eec1c26036dd22e348de80c37a1cd89a8f2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ee3e08-c2ee-4d1a-a898-af296f16de0d", "node_type": "1", "metadata": {"window": "There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "original_text": "But how you get there is a very choppy type of process . "}, "hash": "547580a4bab4e3e3bf39669fcf9dbd8064e3d45adade569ba866dcaada11d529", "class_name": "RelatedNodeInfo"}}, "text": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "start_char_idx": 2312, "end_char_idx": 2451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ee3e08-c2ee-4d1a-a898-af296f16de0d": {"__data__": {"id_": "34ee3e08-c2ee-4d1a-a898-af296f16de0d", "embedding": null, "metadata": {"window": "There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "original_text": "But how you get there is a very choppy type of process . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b129e73-7814-4647-bbd5-9ac0c6540edf", "node_type": "1", "metadata": {"window": "By its nature, inflation in most industr ies and most periods of time don't get absorbed in the \nsupply chain .  There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "original_text": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08feeee5af88daefaf0a79ff7c63ee719819873300f8ecdd1e97b5ce660f4ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb", "node_type": "1", "metadata": {"window": "There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "original_text": "That's why this is \ntaking two, three years . "}, "hash": "5213e81dbada4c04ce3744f3a8404bd5679deb13f76d64df9028fb417020ef16", "class_name": "RelatedNodeInfo"}}, "text": "But how you get there is a very choppy type of process . ", "start_char_idx": 2451, "end_char_idx": 2508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb": {"__data__": {"id_": "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb", "embedding": null, "metadata": {"window": "There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "original_text": "That's why this is \ntaking two, three years . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ee3e08-c2ee-4d1a-a898-af296f16de0d", "node_type": "1", "metadata": {"window": "There's not \u2013 especially in distribution .  There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "original_text": "But how you get there is a very choppy type of process . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f838476b748361e19c238ce50a12408c314178de74c481ad44dc8eff15ac6d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "821c982a-1ba2-4d43-bc94-8eef85022a76", "node_type": "1", "metadata": {"window": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "original_text": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  "}, "hash": "8f67a1a6e80af89065679f7b80b18d7a04dcc6a4dc2fa63b65b8895a03206d8a", "class_name": "RelatedNodeInfo"}}, "text": "That's why this is \ntaking two, three years . ", "start_char_idx": 2508, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "821c982a-1ba2-4d43-bc94-8eef85022a76": {"__data__": {"id_": "821c982a-1ba2-4d43-bc94-8eef85022a76", "embedding": null, "metadata": {"window": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "original_text": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb", "node_type": "1", "metadata": {"window": "There's not the margin to to absorb inflation .  And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "original_text": "That's why this is \ntaking two, three years . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1bae31a9bb079832a6f54ce4d3cb4753a5cc374b5e3a7ffc07dffed68b4ef19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71176fda-7be4-49a4-942a-6ca7ed5f1a89", "node_type": "1", "metadata": {"window": "But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you . ", "original_text": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . "}, "hash": "152a4265e13093be8294ad36981503e6bc48145848b999ebfa69790175260eb4", "class_name": "RelatedNodeInfo"}}, "text": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "start_char_idx": 2554, "end_char_idx": 2718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71176fda-7be4-49a4-942a-6ca7ed5f1a89": {"__data__": {"id_": "71176fda-7be4-49a4-942a-6ca7ed5f1a89", "embedding": null, "metadata": {"window": "But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you . ", "original_text": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "821c982a-1ba2-4d43-bc94-8eef85022a76", "node_type": "1", "metadata": {"window": "And \nso when that higher cost lifts the industry's costs over longer periods of time, we would e xpect that to \nflow, generally speaking .  But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "original_text": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.  ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23a1f0e3a90852c38e34b494e7008c5228a40dda0ca2456faeb077aa9a40d78d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e96c40cd-beed-4565-bad0-172eb949eac7", "node_type": "1", "metadata": {"window": "That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n", "original_text": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. "}, "hash": "58089fa6db9ba92cfee49254ce1b4bfca1542174460dd54dbce44215ea3e24a4", "class_name": "RelatedNodeInfo"}}, "text": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "start_char_idx": 2718, "end_char_idx": 2861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e96c40cd-beed-4565-bad0-172eb949eac7": {"__data__": {"id_": "e96c40cd-beed-4565-bad0-172eb949eac7", "embedding": null, "metadata": {"window": "That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n", "original_text": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71176fda-7be4-49a4-942a-6ca7ed5f1a89", "node_type": "1", "metadata": {"window": "But how you get there is a very choppy type of process .  That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you . ", "original_text": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38ab1a1464f3911e94fcacd9ed3f7cd7eee0c0cde0bf5acda048e7c123e43131", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069", "node_type": "1", "metadata": {"window": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n", "original_text": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n"}, "hash": "73e318938c5b33f6b98721158106d2f2fe9eea52ee933c8e28667edc087f9c7c", "class_name": "RelatedNodeInfo"}}, "text": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "start_char_idx": 2861, "end_char_idx": 2958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069": {"__data__": {"id_": "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069", "embedding": null, "metadata": {"window": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n", "original_text": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e96c40cd-beed-4565-bad0-172eb949eac7", "node_type": "1", "metadata": {"window": "That's why this is \ntaking two, three years .  It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n", "original_text": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea. ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7919df5a8a0c944b31bbda236b448f4a1768cda6ee6f0436fb7b44130418670e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cc2f625-c869-4d78-9a83-609da5a65aff", "node_type": "1", "metadata": {"window": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you . ", "original_text": "Operator :  Thank you . "}, "hash": "6023880b7f316f2691a8da2d4d888444d9153b9f78f2c754474d236de1a48d07", "class_name": "RelatedNodeInfo"}}, "text": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "start_char_idx": 2958, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cc2f625-c869-4d78-9a83-609da5a65aff": {"__data__": {"id_": "1cc2f625-c869-4d78-9a83-609da5a65aff", "embedding": null, "metadata": {"window": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you . ", "original_text": "Operator :  Thank you . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069", "node_type": "1", "metadata": {"window": "It's also certainly because of the contracting nature where a lot of this is rolling \nover into more permanent con tracts in addition to the shorter term actions.   So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n", "original_text": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "746021d55750f3040860980c449ed14afa0437986ee719426ad41549ca1be04b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a2ca8c-101a-4302-bb33-cf95810e9e12", "node_type": "1", "metadata": {"window": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n", "original_text": "We now take our last question today from Eric Percher of Nephron Research . \n"}, "hash": "42a63ce39035ec4bbcc496a4256dbad92ef21380fd7461b697405d25ee8fbb4e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you . ", "start_char_idx": 3076, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a2ca8c-101a-4302-bb33-cf95810e9e12": {"__data__": {"id_": "35a2ca8c-101a-4302-bb33-cf95810e9e12", "embedding": null, "metadata": {"window": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n", "original_text": "We now take our last question today from Eric Percher of Nephron Research . \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cc2f625-c869-4d78-9a83-609da5a65aff", "node_type": "1", "metadata": {"window": "So there's nothing about \nindustry dynamics, there's nothing about our competitiveness, that indicates that we should be losing \nmargin here .  We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you . ", "original_text": "Operator :  Thank you . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58cfa0fb0e57a42ac7d676b4744200680a66a9b4ed6531973edb7d7cf3132119", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddf0a2b1-8273-4889-8deb-e870c2a0be50", "node_type": "1", "metadata": {"window": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n", "original_text": "Please go ahe ad.  \n \n"}, "hash": "1bb5ddce36b3215be092057f873adc4d3d26e6cff3314f465ab9102a76638ec1", "class_name": "RelatedNodeInfo"}}, "text": "We now take our last question today from Eric Percher of Nephron Research . \n", "start_char_idx": 3100, "end_char_idx": 3177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddf0a2b1-8273-4889-8deb-e870c2a0be50": {"__data__": {"id_": "ddf0a2b1-8273-4889-8deb-e870c2a0be50", "embedding": null, "metadata": {"window": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n", "original_text": "Please go ahe ad.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a2ca8c-101a-4302-bb33-cf95810e9e12", "node_type": "1", "metadata": {"window": "We have to be versatile and move our supply chain if we're uncom petitive in a particular \narea.  But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n", "original_text": "We now take our last question today from Eric Percher of Nephron Research . \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d8b85ac28e725ceb93d99b81568a2693e6adf8a93ac5a6e5ff91781220cd0c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbb740c9-01f2-4724-a762-f2a16be01bb5", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect . ", "original_text": "Eric Percher :  Thank you . "}, "hash": "87334261fb7982bb1266e472e1d06a9fe188227aca0c8fc95925cda6dcafc803", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahe ad.  \n \n", "start_char_idx": 3177, "end_char_idx": 3199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbb740c9-01f2-4724-a762-f2a16be01bb5": {"__data__": {"id_": "bbb740c9-01f2-4724-a762-f2a16be01bb5", "embedding": null, "metadata": {"window": "Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect . ", "original_text": "Eric Percher :  Thank you . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddf0a2b1-8273-4889-8deb-e870c2a0be50", "node_type": "1", "metadata": {"window": "But if we're competitive from a cost perspective, there's no reason we shouldn't go back to \nhistorical margins.   \n \n Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n", "original_text": "Please go ahe ad.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00cbda25639e23ccfbf077cd0daad776c5c132c292e2dfe56d951f296f95a129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba", "node_type": "1", "metadata": {"window": "We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "original_text": "Am I coming through this time?   \n \n"}, "hash": "fe770f0560e7352836606ac669055d3b84d32d7e5ac73bb16a7df95e703e7023", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :  Thank you . ", "start_char_idx": 3199, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba": {"__data__": {"id_": "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba", "embedding": null, "metadata": {"window": "We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "original_text": "Am I coming through this time?   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbb740c9-01f2-4724-a762-f2a16be01bb5", "node_type": "1", "metadata": {"window": "Operator :  Thank you .  We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect . ", "original_text": "Eric Percher :  Thank you . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2b5e74960b56f499c54660f6e0a420205533af45d46369a2d63a2abd525201a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9084b08-8e80-433b-9f49-54009727b7a2", "node_type": "1", "metadata": {"window": "Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "original_text": "Jason Hollar :  Yes.  \n \n"}, "hash": "4ca7af2c97d7dbe4495062eeb6d61dca8c3afa5103943598faf1be049c7b67ea", "class_name": "RelatedNodeInfo"}}, "text": "Am I coming through this time?   \n \n", "start_char_idx": 3227, "end_char_idx": 3263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9084b08-8e80-433b-9f49-54009727b7a2": {"__data__": {"id_": "a9084b08-8e80-433b-9f49-54009727b7a2", "embedding": null, "metadata": {"window": "Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "original_text": "Jason Hollar :  Yes.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba", "node_type": "1", "metadata": {"window": "We now take our last question today from Eric Percher of Nephron Research . \n Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "original_text": "Am I coming through this time?   \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "121bcdfa4edf43001c3783a2f4524ee17beae048d052da7a33c85bd86dc652fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ee3bdea-27e4-4398-9854-1a3582be4b2b", "node_type": "1", "metadata": {"window": "Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management . ", "original_text": "Eric Percher :  Perfect . "}, "hash": "fd0f3502046b84036a97619f529767b0e092b58b121e43017214de5cdd1e4b26", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yes.  \n \n", "start_char_idx": 3263, "end_char_idx": 3288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ee3bdea-27e4-4398-9854-1a3582be4b2b": {"__data__": {"id_": "3ee3bdea-27e4-4398-9854-1a3582be4b2b", "embedding": null, "metadata": {"window": "Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management . ", "original_text": "Eric Percher :  Perfect . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9084b08-8e80-433b-9f49-54009727b7a2", "node_type": "1", "metadata": {"window": "Please go ahe ad.  \n \n Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "original_text": "Jason Hollar :  Yes.  \n \n", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "559b55878e65479123b0aad30c9e671706792baf696ce26e2f0a123143a7b012", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e", "node_type": "1", "metadata": {"window": "Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand . ", "original_text": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . "}, "hash": "4316d9ca1b30d6d3829afd4d3ca8830d66488b41f4797b20ca1fb1d7a3e8adb2", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher :  Perfect . ", "start_char_idx": 3288, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e": {"__data__": {"id_": "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e", "embedding": null, "metadata": {"window": "Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand . ", "original_text": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ee3bdea-27e4-4398-9854-1a3582be4b2b", "node_type": "1", "metadata": {"window": "Eric Percher :  Thank you .  Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management . ", "original_text": "Eric Percher :  Perfect . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a8e378c76d47e9a3bb0c0bf8d066136c52ff5d46d83095f524a64599aa9c325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9fcb55f-22ea-4306-84b7-031188691673", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . "}, "hash": "4338be8d6445cc4fe09aa936bec663ab9bc6804d5910c6bbb85e99592682334b", "class_name": "RelatedNodeInfo"}}, "text": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "start_char_idx": 3314, "end_char_idx": 3427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9fcb55f-22ea-4306-84b7-031188691673": {"__data__": {"id_": "f9fcb55f-22ea-4306-84b7-031188691673", "embedding": null, "metadata": {"window": "Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e", "node_type": "1", "metadata": {"window": "Am I coming through this time?   \n \n Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand . ", "original_text": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b297243c1f85c77451caf57b90688979775a8389921ce17750033a5d806cf9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46899054-50fa-4a53-ac83-3c65cdbd9736", "node_type": "1", "metadata": {"window": "Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I heard the focus on cost management . "}, "hash": "96d8394906ebf99f86dd24f60b3ebda9fdd34078c67877437515658a24adcb98", "class_name": "RelatedNodeInfo"}}, "text": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "start_char_idx": 3427, "end_char_idx": 3629, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46899054-50fa-4a53-ac83-3c65cdbd9736": {"__data__": {"id_": "46899054-50fa-4a53-ac83-3c65cdbd9736", "embedding": null, "metadata": {"window": "Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I heard the focus on cost management . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9fcb55f-22ea-4306-84b7-031188691673", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yes.  \n \n Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93b1d38394209957ba071aacc68e19cacc59864f14fc821d8346faef946f6922", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a64570de-ab77-40fd-9551-d7bb69a8297b", "node_type": "1", "metadata": {"window": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I want to ask if there are other \nelements that you think are important for us to understand . "}, "hash": "6373548e6f2267897f7257b02aceb12507300d84b8d72329a7ac6211bf05f402", "class_name": "RelatedNodeInfo"}}, "text": "I heard the focus on cost management . ", "start_char_idx": 3629, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a64570de-ab77-40fd-9551-d7bb69a8297b": {"__data__": {"id_": "a64570de-ab77-40fd-9551-d7bb69a8297b", "embedding": null, "metadata": {"window": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I want to ask if there are other \nelements that you think are important for us to understand . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46899054-50fa-4a53-ac83-3c65cdbd9736", "node_type": "1", "metadata": {"window": "Eric Percher :  Perfect .  So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I heard the focus on cost management . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a84ad9a0c4380231fb7e8bfb8549075d43af9f263c76070e1d3b4d8dda87e33a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aee14e89-26e4-4fa1-8829-5e3b3896b8e9", "node_type": "1", "metadata": {"window": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And then I want to also ask pointedly, will "}, "hash": "1c427c9d4d86c74dfc2fbf2f7b1ee398000732acbe0973cf26346b694c6157b5", "class_name": "RelatedNodeInfo"}}, "text": "I want to ask if there are other \nelements that you think are important for us to understand . ", "start_char_idx": 3668, "end_char_idx": 3763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aee14e89-26e4-4fa1-8829-5e3b3896b8e9": {"__data__": {"id_": "aee14e89-26e4-4fa1-8829-5e3b3896b8e9", "embedding": null, "metadata": {"window": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And then I want to also ask pointedly, will ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ebafefb4-f90a-427a-8f97-d2734c97672a", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f35bddf7f392a770e8a9dc6fe742666234eb6ae68163690beac759f9e7244718", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a64570de-ab77-40fd-9551-d7bb69a8297b", "node_type": "1", "metadata": {"window": "So, Jason, as you take on the new role, I think a couple of questions came down \nto what you will do different .  And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "I want to ask if there are other \nelements that you think are important for us to understand . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5d8b3355cd0a6be9be1dad83b64e88435c71dc1c87b8de6e081dc61d6c0100d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5fa6482-0203-46e3-861f-a38aa7a5fac1", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?  ", "original_text": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n"}, "hash": "2d31dac3c01341686df07c63bd01f47aca564f97e6052769d13c45cf0f57fb14", "class_name": "RelatedNodeInfo"}}, "text": "And then I want to also ask pointedly, will ", "start_char_idx": 3763, "end_char_idx": 3807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5fa6482-0203-46e3-861f-a38aa7a5fac1": {"__data__": {"id_": "d5fa6482-0203-46e3-861f-a38aa7a5fac1", "embedding": null, "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?  ", "original_text": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aee14e89-26e4-4fa1-8829-5e3b3896b8e9", "node_type": "1", "metadata": {"window": "And what I heard during the call was you've had a desire to be more \naggressive on returning capital to shareholders and, opioid settle ment behind you, strong balance \nsheet, we're going to see that .  I heard the focus on cost management .  I want to ask if there are other \nelements that you think are important for us to understand .  And then I want to also ask pointedly, will ", "original_text": "And then I want to also ask pointedly, will ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccca31c5eebea2ced0634676dff49c42cac2aa1335921acc45feec4d516ba856", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3887cb9-3cb1-45c5-8609-587db162c5fa", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?  ", "original_text": "Jason Hollar:  Yeah . "}, "hash": "292ead18a959731670d1936104548f914c682e0ae5042e8d558c4de17e4a6d12", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n", "start_char_idx": 0, "end_char_idx": 136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3887cb9-3cb1-45c5-8609-587db162c5fa": {"__data__": {"id_": "f3887cb9-3cb1-45c5-8609-587db162c5fa", "embedding": null, "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?  ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5fa6482-0203-46e3-861f-a38aa7a5fac1", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?  ", "original_text": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb44a1ae2ed75950ce4178b625072675fca0f4c314eed9ec627b575f75e888ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20360fc-3cac-4e28-9fdb-ef605c1daac8", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "original_text": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value . "}, "hash": "c61111c104c19f05a3c9fd98d9dd2dc143156219211fcf687790652b9275f5e5", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah . ", "start_char_idx": 136, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20360fc-3cac-4e28-9fdb-ef605c1daac8": {"__data__": {"id_": "c20360fc-3cac-4e28-9fdb-ef605c1daac8", "embedding": null, "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "original_text": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3887cb9-3cb1-45c5-8609-587db162c5fa", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?  ", "original_text": "Jason Hollar:  Yeah . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2761ecad59d674ba9c0bc06ef4e484d94ce4179dd97124068b57520d900cd30f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd10b001-154a-440c-ae37-e518c58b760e", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan . ", "original_text": "Where is the opportunities?  "}, "hash": "00ddfd11ec9a5f4a3e42244572877ea6e7b5f9d48072a055ba2ded5be2fa10c4", "class_name": "RelatedNodeInfo"}}, "text": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value . ", "start_char_idx": 158, "end_char_idx": 313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd10b001-154a-440c-ae37-e518c58b760e": {"__data__": {"id_": "bd10b001-154a-440c-ae37-e518c58b760e", "embedding": null, "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan . ", "original_text": "Where is the opportunities?  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20360fc-3cac-4e28-9fdb-ef605c1daac8", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "original_text": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10d0ca888bebfd8a495c7430ce00fa01a2be11a25054bf4c1b78a7023a357ed4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a107fe3d-987e-4c1a-ad27-cd45351bde62", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "original_text": "Where the \nchallenge is?  "}, "hash": "4f847cbc5446478c8dba0a359ae2a9e4e2db475a2b34af76e7fc08548e537cff", "class_name": "RelatedNodeInfo"}}, "text": "Where is the opportunities?  ", "start_char_idx": 313, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a107fe3d-987e-4c1a-ad27-cd45351bde62": {"__data__": {"id_": "a107fe3d-987e-4c1a-ad27-cd45351bde62", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "original_text": "Where the \nchallenge is?  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd10b001-154a-440c-ae37-e518c58b760e", "node_type": "1", "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan . ", "original_text": "Where is the opportunities?  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd6e49e8e0bda3cc8cf34f4f63655f40fbc5a513f8253f2eacb57943ad1f0de5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8574857e-e51d-456d-8bf2-50897abb36a1", "node_type": "1", "metadata": {"window": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "original_text": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . "}, "hash": "f70dbf497fa1e89dffe720bdc50eaf0145ecc599557577a2cbdb92052ad507db", "class_name": "RelatedNodeInfo"}}, "text": "Where the \nchallenge is?  ", "start_char_idx": 342, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8574857e-e51d-456d-8bf2-50897abb36a1": {"__data__": {"id_": "8574857e-e51d-456d-8bf2-50897abb36a1", "embedding": null, "metadata": {"window": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "original_text": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a107fe3d-987e-4c1a-ad27-cd45351bde62", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "original_text": "Where the \nchallenge is?  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36100d318d7b1d455a49ff1332ee9f69496c747706c42c7d16507031e92593ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18775056-5c27-4a29-93e7-220ee34e35d6", "node_type": "1", "metadata": {"window": "Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment . ", "original_text": "And so that is why I'm so focused on this medica l \nimprovement plan . "}, "hash": "f13af80901c0d29adb3dbd9436cff13e4fb10c5ab567dee816b0d73564fd3299", "class_name": "RelatedNodeInfo"}}, "text": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "start_char_idx": 368, "end_char_idx": 506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18775056-5c27-4a29-93e7-220ee34e35d6": {"__data__": {"id_": "18775056-5c27-4a29-93e7-220ee34e35d6", "embedding": null, "metadata": {"window": "Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment . ", "original_text": "And so that is why I'm so focused on this medica l \nimprovement plan . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8574857e-e51d-456d-8bf2-50897abb36a1", "node_type": "1", "metadata": {"window": "So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "original_text": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e00e5f80fa54e1d1860f8c650b4430b0d8df7bec8ed2dec93ba41e80527ead4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a913ae2-16cf-4118-a237-8a87195594e5", "node_type": "1", "metadata": {"window": "Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "original_text": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . "}, "hash": "5d1bacac7311e4f1e915c5ada85da728850fe7c695be35a74ed4bb96be764412", "class_name": "RelatedNodeInfo"}}, "text": "And so that is why I'm so focused on this medica l \nimprovement plan . ", "start_char_idx": 506, "end_char_idx": 577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a913ae2-16cf-4118-a237-8a87195594e5": {"__data__": {"id_": "1a913ae2-16cf-4118-a237-8a87195594e5", "embedding": null, "metadata": {"window": "Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "original_text": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18775056-5c27-4a29-93e7-220ee34e35d6", "node_type": "1", "metadata": {"window": "Where is the opportunities?   Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment . ", "original_text": "And so that is why I'm so focused on this medica l \nimprovement plan . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be6bc03753dd2e1b3d08541a3763766a6467994730706d45afc516d89f6cb3ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0915b0a1-0901-469b-bef2-259a52d31978", "node_type": "1", "metadata": {"window": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "original_text": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . "}, "hash": "f480c3f489c1343c02c08fc4620bf9a517d31803d778cefa62641d797966fa5a", "class_name": "RelatedNodeInfo"}}, "text": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "start_char_idx": 577, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0915b0a1-0901-469b-bef2-259a52d31978": {"__data__": {"id_": "0915b0a1-0901-469b-bef2-259a52d31978", "embedding": null, "metadata": {"window": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "original_text": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a913ae2-16cf-4118-a237-8a87195594e5", "node_type": "1", "metadata": {"window": "Where the \nchallenge is?   And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "original_text": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d844443570bbec711e18d6a5f47acd98f428c83bfc3da3eda8588661be2ad0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cc02cb9-1a69-4afb-ad6d-30c7beacb922", "node_type": "1", "metadata": {"window": "And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain . ", "original_text": "And I do want to step back for a moment . "}, "hash": "7125726671cbc21c9989273ab867b19d99406b9789cd5bf8605f102ca6bedad1", "class_name": "RelatedNodeInfo"}}, "text": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "start_char_idx": 707, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cc02cb9-1a69-4afb-ad6d-30c7beacb922": {"__data__": {"id_": "4cc02cb9-1a69-4afb-ad6d-30c7beacb922", "embedding": null, "metadata": {"window": "And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain . ", "original_text": "And I do want to step back for a moment . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0915b0a1-0901-469b-bef2-259a52d31978", "node_type": "1", "metadata": {"window": "And what is clear to me is that until we can get better evidence of the progress on our \nmedical business, we're going to be challenged .  And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "original_text": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b319b121736f0637403d0492b5a11519ffba2a378b3fd0364b539e59c84a5695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4df449b-e980-4dc9-a19f-a6227ffe2379", "node_type": "1", "metadata": {"window": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "original_text": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . "}, "hash": "e3d7199dd45445c71581f9e0a9c1c69dfdd6cb4ac23293c5ba2aff840996c9af", "class_name": "RelatedNodeInfo"}}, "text": "And I do want to step back for a moment . ", "start_char_idx": 836, "end_char_idx": 878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4df449b-e980-4dc9-a19f-a6227ffe2379": {"__data__": {"id_": "d4df449b-e980-4dc9-a19f-a6227ffe2379", "embedding": null, "metadata": {"window": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "original_text": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cc02cb9-1a69-4afb-ad6d-30c7beacb922", "node_type": "1", "metadata": {"window": "And so that is why I'm so focused on this medica l \nimprovement plan .  Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain . ", "original_text": "And I do want to step back for a moment . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c478673062bf382c4ced7436c8659c780ec01ea4abae6ca8c733307c903ee553", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd", "node_type": "1", "metadata": {"window": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "original_text": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . "}, "hash": "dd212c48121bfa5f417df48bd2b12ab16aab6059e894df401b0e134b5ac34fe6", "class_name": "RelatedNodeInfo"}}, "text": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "start_char_idx": 878, "end_char_idx": 1014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd": {"__data__": {"id_": "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd", "embedding": null, "metadata": {"window": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "original_text": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4df449b-e980-4dc9-a19f-a6227ffe2379", "node_type": "1", "metadata": {"window": "Why we've provided such clarity on it, is that it is absolutely one of, if not my greatest  \nfocus, especially in the near term .  And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "original_text": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b51c71a25e38afc711434eb9065d9134f8cf01c6c7deacd157189a38e85362f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8", "node_type": "1", "metadata": {"window": "And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight . ", "original_text": "It is related to the supply chain . "}, "hash": "b98b0f22c858ce9431efb49b060edce1934e5175c43fac8c44447de584f6c453", "class_name": "RelatedNodeInfo"}}, "text": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "start_char_idx": 1014, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8": {"__data__": {"id_": "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8", "embedding": null, "metadata": {"window": "And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight . ", "original_text": "It is related to the supply chain . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd", "node_type": "1", "metadata": {"window": "And when you think about any type of process to fix anything, it has \nto be first and foremost defining wha t the challenge is .  And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "original_text": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6b9c99516db9ae84852163c99cf14411f69a9e6e1c1260ddcecb989a962e7e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b74cc7-01fb-44a4-8623-df4c97307693", "node_type": "1", "metadata": {"window": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that . ", "original_text": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . "}, "hash": "b343c727eaa11b457122811194d777e725aea3b82dd8ff630ee8eedf7c33e170", "class_name": "RelatedNodeInfo"}}, "text": "It is related to the supply chain . ", "start_char_idx": 1116, "end_char_idx": 1152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b74cc7-01fb-44a4-8623-df4c97307693": {"__data__": {"id_": "e3b74cc7-01fb-44a4-8623-df4c97307693", "embedding": null, "metadata": {"window": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that . ", "original_text": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8", "node_type": "1", "metadata": {"window": "And I do want to step back for a moment .  The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight . ", "original_text": "It is related to the supply chain . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3dd622adfcc61997c0d6a758100eed423232d4af8a35f2ac1a1adfa96c7b38c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04699087-0811-4897-9f93-198155bec3bb", "node_type": "1", "metadata": {"window": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about . ", "original_text": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . "}, "hash": "b285b00c4ee3ac6941e208079ef647f89615da1d75ad3d8981bea185c66764ff", "class_name": "RelatedNodeInfo"}}, "text": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "start_char_idx": 1152, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04699087-0811-4897-9f93-198155bec3bb": {"__data__": {"id_": "04699087-0811-4897-9f93-198155bec3bb", "embedding": null, "metadata": {"window": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about . ", "original_text": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b74cc7-01fb-44a4-8623-df4c97307693", "node_type": "1", "metadata": {"window": "The \u2013 \nwhen you think about the challenges of Medical, I know there's been a lot of adjustments , I know there's \nbeen a lot of noise .  But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that . ", "original_text": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90a9d4fe109781ad78c204791fed23c1946ad5b5c295eb39d51c7b2da913163f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee", "node_type": "1", "metadata": {"window": "It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "original_text": "What went \nfrom a strength to a challenge pretty much overnight . "}, "hash": "91cd18ccb5bf71f1ba8f2dfb9573ec21b3aaef1722e4f24fdaff2cafe04033f2", "class_name": "RelatedNodeInfo"}}, "text": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "start_char_idx": 1417, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee": {"__data__": {"id_": "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee", "embedding": null, "metadata": {"window": "It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "original_text": "What went \nfrom a strength to a challenge pretty much overnight . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04699087-0811-4897-9f93-198155bec3bb", "node_type": "1", "metadata": {"window": "But when you think about the vast majority of the issues,  they do stem from one \nvery common theme .  It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about . ", "original_text": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a8601e61c28403c39d61fda06c3ff4c32a2a8cf3d8f6767c0e3125974373251", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11c5d621-de09-4ff5-907d-d500a2717a98", "node_type": "1", "metadata": {"window": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories . ", "original_text": "So now we've learned from that . "}, "hash": "9e2cd5b6fe76c342e26687118a1e6da2d63a632057e93e9e9a31b311d2b514de", "class_name": "RelatedNodeInfo"}}, "text": "What went \nfrom a strength to a challenge pretty much overnight . ", "start_char_idx": 1710, "end_char_idx": 1776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11c5d621-de09-4ff5-907d-d500a2717a98": {"__data__": {"id_": "11c5d621-de09-4ff5-907d-d500a2717a98", "embedding": null, "metadata": {"window": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories . ", "original_text": "So now we've learned from that . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee", "node_type": "1", "metadata": {"window": "It is related to the supply chain .  Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "original_text": "What went \nfrom a strength to a challenge pretty much overnight . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a6107c3728f252d746326be39cb5c6913c35821156640a17f22e2f246f62344", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8d3ca26-ecf8-402b-b9da-ae4197374d55", "node_type": "1", "metadata": {"window": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus . ", "original_text": "That's what this \nplan is talking about . "}, "hash": "9a6bc7a4472ef037bd4a443b5adb5fa12dfd20bcfd314795c91096986cc09e2d", "class_name": "RelatedNodeInfo"}}, "text": "So now we've learned from that . ", "start_char_idx": 1776, "end_char_idx": 1809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8d3ca26-ecf8-402b-b9da-ae4197374d55": {"__data__": {"id_": "e8d3ca26-ecf8-402b-b9da-ae4197374d55", "embedding": null, "metadata": {"window": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus . ", "original_text": "That's what this \nplan is talking about . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11c5d621-de09-4ff5-907d-d500a2717a98", "node_type": "1", "metadata": {"window": "Now I can start and highlight all the external \ninfluences with that and blame things that have happened to us, and then it's very, very true, but when \nyou think about where we w ere pre -COVID, this type of business, this type of industry was extremely \nstable .  Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories . ", "original_text": "So now we've learned from that . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84460f4bc36d5b267b783b6553976b6d1324b611793b1c032993270464f2d3b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aec910f-15c7-4dad-937a-10943d956d1b", "node_type": "1", "metadata": {"window": "What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost . ", "original_text": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible . "}, "hash": "4358b07049b56c645fd616d6ded04492ba89e2ceae089c665ccf992d5848070a", "class_name": "RelatedNodeInfo"}}, "text": "That's what this \nplan is talking about . ", "start_char_idx": 1809, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aec910f-15c7-4dad-937a-10943d956d1b": {"__data__": {"id_": "1aec910f-15c7-4dad-937a-10943d956d1b", "embedding": null, "metadata": {"window": "What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost . ", "original_text": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8d3ca26-ecf8-402b-b9da-ae4197374d55", "node_type": "1", "metadata": {"window": "Our volume was predictable, especially in areas like PPE, to think about going up 5, 10 x in \nterms of demand overnight and then not having a supply chain that could adjust w ith that, it really \nimpacted our ability to execute in that environment and our diverse, low cost global footprint .  What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus . ", "original_text": "That's what this \nplan is talking about . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "34063b4a9f6492fb18717293b342beff53e7843b43c59a0f2d31e633738af28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cd37a8f-3b37-43ea-8158-4eb2cac449c1", "node_type": "1", "metadata": {"window": "So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "original_text": "We can de -risk the model , while also growing profitable categories . "}, "hash": "5d4afd4951fed416786e7f630298c1a14eeb2b05bd0726b7412834e4c7a4dda2", "class_name": "RelatedNodeInfo"}}, "text": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "start_char_idx": 1851, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cd37a8f-3b37-43ea-8158-4eb2cac449c1": {"__data__": {"id_": "8cd37a8f-3b37-43ea-8158-4eb2cac449c1", "embedding": null, "metadata": {"window": "So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "original_text": "We can de -risk the model , while also growing profitable categories . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aec910f-15c7-4dad-937a-10943d956d1b", "node_type": "1", "metadata": {"window": "What went \nfrom a strength to a challenge pretty much overnight .  So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost . ", "original_text": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef0b48e1112990131b2a2c5d2f3efa700197b2e46ff97c35a3ab6d25bef1be5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df35e488-514d-4812-91b2-0965059ee11e", "node_type": "1", "metadata": {"window": "That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "original_text": "So this is very much a \ncornerstone of what needs to be the focus . "}, "hash": "5efe99143b35757ff1005b011cba4db078557774cf3c715a560454367f122197", "class_name": "RelatedNodeInfo"}}, "text": "We can de -risk the model , while also growing profitable categories . ", "start_char_idx": 1944, "end_char_idx": 2015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df35e488-514d-4812-91b2-0965059ee11e": {"__data__": {"id_": "df35e488-514d-4812-91b2-0965059ee11e", "embedding": null, "metadata": {"window": "That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "original_text": "So this is very much a \ncornerstone of what needs to be the focus . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cd37a8f-3b37-43ea-8158-4eb2cac449c1", "node_type": "1", "metadata": {"window": "So now we've learned from that .  That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "original_text": "We can de -risk the model , while also growing profitable categories . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3710e8684a734ae7498f9d9e2ea2c003e188cb6515fb91f3ca46e6ab686e0c2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64eb969a-3d7f-46df-8686-6efcb6dda70b", "node_type": "1", "metadata": {"window": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "original_text": "But it's not just cost, it' s simplification to reduce cost . "}, "hash": "c21d701ba8e5fac35258f9f9aef17e1555edf99eeda776545ff9ebec2e877ebd", "class_name": "RelatedNodeInfo"}}, "text": "So this is very much a \ncornerstone of what needs to be the focus . ", "start_char_idx": 2015, "end_char_idx": 2083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64eb969a-3d7f-46df-8686-6efcb6dda70b": {"__data__": {"id_": "64eb969a-3d7f-46df-8686-6efcb6dda70b", "embedding": null, "metadata": {"window": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "original_text": "But it's not just cost, it' s simplification to reduce cost . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df35e488-514d-4812-91b2-0965059ee11e", "node_type": "1", "metadata": {"window": "That's what this \nplan is talking about .  It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "original_text": "So this is very much a \ncornerstone of what needs to be the focus . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d42f46f4c19c8c0b0903f51abbbf7d5eea14f09e03dbc87b023bf4ac071841a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe92c004-f4b8-432b-885d-13d66c68686d", "node_type": "1", "metadata": {"window": "We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "original_text": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. "}, "hash": "ed943c45a44c7e511d9db677f3dffffdb896555b1bc89aae843a9bc39be73bc1", "class_name": "RelatedNodeInfo"}}, "text": "But it's not just cost, it' s simplification to reduce cost . ", "start_char_idx": 2083, "end_char_idx": 2145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe92c004-f4b8-432b-885d-13d66c68686d": {"__data__": {"id_": "fe92c004-f4b8-432b-885d-13d66c68686d", "embedding": null, "metadata": {"window": "We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "original_text": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64eb969a-3d7f-46df-8686-6efcb6dda70b", "node_type": "1", "metadata": {"window": "It's building in resiliency and capacity into our system so we can be a lot more \nflexible .  We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "original_text": "But it's not just cost, it' s simplification to reduce cost . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad24556df6b47c9b3af32a33ba0a4be634649e8fab78fdfc1dfe1f1afa2463d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a48b98d6-9df7-458c-9540-7f807fbb3d15", "node_type": "1", "metadata": {"window": "So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "original_text": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . "}, "hash": "c90dfd8dc2208b106e874b477a727668e035c2cccda5b00fd7022006831b8684", "class_name": "RelatedNodeInfo"}}, "text": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "start_char_idx": 2145, "end_char_idx": 2339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a48b98d6-9df7-458c-9540-7f807fbb3d15": {"__data__": {"id_": "a48b98d6-9df7-458c-9540-7f807fbb3d15", "embedding": null, "metadata": {"window": "So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "original_text": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe92c004-f4b8-432b-885d-13d66c68686d", "node_type": "1", "metadata": {"window": "We can de -risk the model , while also growing profitable categories .  So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "original_text": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a132e39683c61302eac6f722059e95d8e62cfdc9aa2491c89971c68164d4323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1748cac-5a6e-4eec-b330-004dd4f6679d", "node_type": "1", "metadata": {"window": "But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "original_text": "What you \nheard me say today was more of an emphasis on specialty and on at -Home . "}, "hash": "91d478db11cc00c4452a761569dcfe7c90bceae9b0ff1534b399428dc4fb1e36", "class_name": "RelatedNodeInfo"}}, "text": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "start_char_idx": 2339, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1748cac-5a6e-4eec-b330-004dd4f6679d": {"__data__": {"id_": "b1748cac-5a6e-4eec-b330-004dd4f6679d", "embedding": null, "metadata": {"window": "But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "original_text": "What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a48b98d6-9df7-458c-9540-7f807fbb3d15", "node_type": "1", "metadata": {"window": "So this is very much a \ncornerstone of what needs to be the focus .  But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "original_text": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b0ad3f13bcb2a6a8f1fb146e6a189251e967a0324f62e0c38c3bf5d4366bbb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792", "node_type": "1", "metadata": {"window": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "original_text": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . "}, "hash": "46c893d2a2babf9b8f3a5f63555c7d01221634bf59704935e8ec19d12f78ae3c", "class_name": "RelatedNodeInfo"}}, "text": "What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "start_char_idx": 2448, "end_char_idx": 2532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792": {"__data__": {"id_": "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792", "embedding": null, "metadata": {"window": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "original_text": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1748cac-5a6e-4eec-b330-004dd4f6679d", "node_type": "1", "metadata": {"window": "But it's not just cost, it' s simplification to reduce cost .  It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "original_text": "What you \nheard me say today was more of an emphasis on specialty and on at -Home . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09b307320ba8028d6464831893ed317da95ef2438e7f6ad876b5106dc76cacb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c47ed845-5a87-4d6a-b8cb-a9661884227e", "node_type": "1", "metadata": {"window": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis . ", "original_text": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . "}, "hash": "31c1c6ea6460783012f4d4c9af0dfbf5448d2f3a7d5c401055c9d3c0fb66e6c0", "class_name": "RelatedNodeInfo"}}, "text": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "start_char_idx": 2532, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c47ed845-5a87-4d6a-b8cb-a9661884227e": {"__data__": {"id_": "c47ed845-5a87-4d6a-b8cb-a9661884227e", "embedding": null, "metadata": {"window": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis . ", "original_text": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792", "node_type": "1", "metadata": {"window": "It's \nalso about driving the right volume, driving organic volume, driving high margin volume and simplifying \neverything about how we operate so that we can be more nimble and we can de -risk.  And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "original_text": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28c5235d773a5fe3a20290b46a9bb515ed0bcba2f507795dd88e0b64c7e6689b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e", "node_type": "1", "metadata": {"window": "What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "original_text": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  "}, "hash": "82ddf07063f221365d49a9398fa5daa87f586bae4405208f3a7e48737493d617", "class_name": "RelatedNodeInfo"}}, "text": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "start_char_idx": 2818, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e": {"__data__": {"id_": "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e", "embedding": null, "metadata": {"window": "What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "original_text": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c47ed845-5a87-4d6a-b8cb-a9661884227e", "node_type": "1", "metadata": {"window": "And then again, \nwithin both segments, there is an absolute need to continue to grow our growth businesses .  What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis . ", "original_text": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c31f0b55a8c10055584548335c875c27ffbd167f08d339ab80602b9db88c1c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f48272f2-a311-40e6-a9ef-81398d3a3d38", "node_type": "1", "metadata": {"window": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "original_text": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . "}, "hash": "a374ec342b91f6cd4667b51f6351bfbc47d670eb29561f09677fc9547a880486", "class_name": "RelatedNodeInfo"}}, "text": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "start_char_idx": 2977, "end_char_idx": 3188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f48272f2-a311-40e6-a9ef-81398d3a3d38": {"__data__": {"id_": "f48272f2-a311-40e6-a9ef-81398d3a3d38", "embedding": null, "metadata": {"window": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "original_text": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e", "node_type": "1", "metadata": {"window": "What you \nheard me say today was more of an emphasis on specialty and on at -Home .  Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "original_text": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.  ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7a7f9a4a6d85872a0c3edbc0ab8e72f4634b9d76b9c48e3d928380be6039813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d031445-6d67-4917-8b9a-ea9641161bef", "node_type": "1", "metadata": {"window": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you. ", "original_text": "You know  about China, naviHealth,  \nand more recently, Cordis . "}, "hash": "457e982adb44bb240d1c77965cfa9038147e0752fbbdb3db6e784d7d1913eed6", "class_name": "RelatedNodeInfo"}}, "text": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "start_char_idx": 3188, "end_char_idx": 3376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d031445-6d67-4917-8b9a-ea9641161bef": {"__data__": {"id_": "1d031445-6d67-4917-8b9a-ea9641161bef", "embedding": null, "metadata": {"window": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you. ", "original_text": "You know  about China, naviHealth,  \nand more recently, Cordis . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f48272f2-a311-40e6-a9ef-81398d3a3d38", "node_type": "1", "metadata": {"window": "Of course, we love all of \nour growth businesses , but what I'm really indicating here is for f or us to achieve that $650  million, what \nwe need are those two businesses to continue to grow the top line and to have a good flow through on \nthat incremental volume that comes with it .  And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "original_text": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3469b963b11e269c3d06a1f721571b19f492cadb5fa3e4a775df687cb44d58fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71dde0e1-667f-42a7-b03c-65ffeac07438", "node_type": "1", "metadata": {"window": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr. ", "original_text": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . "}, "hash": "d6caee22a3fafc8d2da8738b4c156dd2e949178afab68ee587314f669fbdf0c7", "class_name": "RelatedNodeInfo"}}, "text": "You know  about China, naviHealth,  \nand more recently, Cordis . ", "start_char_idx": 3376, "end_char_idx": 3441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71dde0e1-667f-42a7-b03c-65ffeac07438": {"__data__": {"id_": "71dde0e1-667f-42a7-b03c-65ffeac07438", "embedding": null, "metadata": {"window": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr. ", "original_text": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d031445-6d67-4917-8b9a-ea9641161bef", "node_type": "1", "metadata": {"window": "And with that, then we have high confidence that we'll be \nable to get  the pieces of growth for both segments necessary to hit their longer term objectives .  So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you. ", "original_text": "You know  about China, naviHealth,  \nand more recently, Cordis . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c526be2f2ecdb42ff80e237eccec2c05ae6f28cfa3b2ecf82fdaa742a74029d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c710396-95f0-4dd5-8085-c31b783c493d", "node_type": "1", "metadata": {"window": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n"}, "hash": "fe17d058a3f6a74a2cbb28c8cb82372821ad1f8e9dc51425adaefe752aaf6fbb", "class_name": "RelatedNodeInfo"}}, "text": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "start_char_idx": 3441, "end_char_idx": 3597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c710396-95f0-4dd5-8085-c31b783c493d": {"__data__": {"id_": "2c710396-95f0-4dd5-8085-c31b783c493d", "embedding": null, "metadata": {"window": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71dde0e1-667f-42a7-b03c-65ffeac07438", "node_type": "1", "metadata": {"window": "So that \nis very much a growth based story, but it's about, again, prioritization and being really, really focused \non the core of both businesses so that these two growt h businesses can can build from there.   In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr. ", "original_text": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter . ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25ee9b8dc52d7ca53febbd6c10c069b4858e397f792e31177f1e2702ba108538", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3b29a7a-3b02-4e7e-99b1-75b74b45c706", "node_type": "1", "metadata": {"window": "You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Operator :  Thank  you. "}, "hash": "b52d3bb3f8d69583c3f3d5690416a1410f01838f223d3bc3f442a5ea7610e7e0", "class_name": "RelatedNodeInfo"}}, "text": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "start_char_idx": 3597, "end_char_idx": 3939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b29a7a-3b02-4e7e-99b1-75b74b45c706": {"__data__": {"id_": "c3b29a7a-3b02-4e7e-99b1-75b74b45c706", "embedding": null, "metadata": {"window": "You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Operator :  Thank  you. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c710396-95f0-4dd5-8085-c31b783c493d", "node_type": "1", "metadata": {"window": "In terms \nof the portfolio,  \u2013 hey, \u2013 it's something that I believe in continually evaluating our portfolio for all of our \nbusinesses, and the company has demonstrated this in the past .  You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b3728dbd7f06f5159487c7f2eecd6d740e98a4c2f3db0db56771d79fd7541d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e3e6446-7c21-45fb-a165-c36bbfb4b63f", "node_type": "1", "metadata": {"window": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I would now like to turn the call back over to Mr. "}, "hash": "396dce5e010f50b5c2237ba5ebf77198c28c1552f50431643e7b5014be3bf81a", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank  you. ", "start_char_idx": 3939, "end_char_idx": 3963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e3e6446-7c21-45fb-a165-c36bbfb4b63f": {"__data__": {"id_": "0e3e6446-7c21-45fb-a165-c36bbfb4b63f", "embedding": null, "metadata": {"window": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I would now like to turn the call back over to Mr. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3b29a7a-3b02-4e7e-99b1-75b74b45c706", "node_type": "1", "metadata": {"window": "You know  about China, naviHealth,  \nand more recently, Cordis .  We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Operator :  Thank  you. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a7e6266a27d03035861f00f1b9684dd454f4df8598816ba6dfa66d55fee6cd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4279b290-a69c-4599-b6e6-96762234a187", "node_type": "1", "metadata": {"window": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Mike Kaufman n for any additional \nor closing remarks.   \n "}, "hash": "26ca204f05d285d896b6f4cef66936b4f365b449f08c5c2e2b0d751796e5435d", "class_name": "RelatedNodeInfo"}}, "text": "I would now like to turn the call back over to Mr. ", "start_char_idx": 3963, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4279b290-a69c-4599-b6e6-96762234a187": {"__data__": {"id_": "4279b290-a69c-4599-b6e6-96762234a187", "embedding": null, "metadata": {"window": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Mike Kaufman n for any additional \nor closing remarks.   \n ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def785997182c31eb7aa478f3b1b706bb86cee377055c5441008d94eba12fe83", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e3e6446-7c21-45fb-a165-c36bbfb4b63f", "node_type": "1", "metadata": {"window": "We've monetized several  billion dollars over the last several years through \nthose activities and was responsible with the capital deployment thereafter .  I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "I would now like to turn the call back over to Mr. ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e693cd624e9a404f62d4f8ca6d8683efcc9e7214d87d48da9e1ecb969c148ef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eef3d8b-b587-494c-9831-bd8e8f131fc2", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n", "original_text": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you . "}, "hash": "4afb75a54510951a802111aaf7e4ed026990b902237fe52341a9e7a3e9b7a414", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufman n for any additional \nor closing remarks.   \n ", "start_char_idx": 4014, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eef3d8b-b587-494c-9831-bd8e8f131fc2": {"__data__": {"id_": "5eef3d8b-b587-494c-9831-bd8e8f131fc2", "embedding": null, "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n", "original_text": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4279b290-a69c-4599-b6e6-96762234a187", "node_type": "1", "metadata": {"window": "I'm not going to attempt to \ndefine what the appropriate long term course of action is for this business, for the Medical business , \nbut under all scenarios, what's really, really clear to me is that the near -term actions need to be very \nfocused on this improvement plan, and then that will set us up for the best actions thereaft er.  \n \n Operator :  Thank  you.  I would now like to turn the call back over to Mr.  Mike Kaufman n for any additional \nor closing remarks.   \n ", "original_text": "Mike Kaufman n for any additional \nor closing remarks.   \n ", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "588d2e4285aef70fd3f312687eeef4deb243c70ac83bd71a41ce9c378b2077fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a976e653-0963-48a7-ab7b-07059223f9da", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike. ", "original_text": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you . "}, "hash": "9efed9a5b83d116f7ec34994fe3475c37117b6c9ce0c06c68c59e3066f81472d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you . ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a976e653-0963-48a7-ab7b-07059223f9da": {"__data__": {"id_": "a976e653-0963-48a7-ab7b-07059223f9da", "embedding": null, "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike. ", "original_text": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5eef3d8b-b587-494c-9831-bd8e8f131fc2", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n", "original_text": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b72f4f247edb202eef2fd28a06c9bdc7573c9d6c4169e6e6a69b0795f94a370", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "876b317c-88b1-4053-a25c-803f27e59b31", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "original_text": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership . "}, "hash": "c462f7a75764bfbe6c20886068e1fa2f87ba8fc3ac9b1e094a3906222ff7933e", "class_name": "RelatedNodeInfo"}}, "text": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you . ", "start_char_idx": 48, "end_char_idx": 194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "876b317c-88b1-4053-a25c-803f27e59b31": {"__data__": {"id_": "876b317c-88b1-4053-a25c-803f27e59b31", "embedding": null, "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "original_text": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a976e653-0963-48a7-ab7b-07059223f9da", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike. ", "original_text": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "578bdff70f465e89357dcca71c0884acb6ad2de5e89dba1047d89a82e4df896d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad3e7099-f2a6-4050-b695-44bb4a60a259", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "original_text": "Jason, to you.   \n \n"}, "hash": "21143366c1f5342e9c52cc9d09814a9ee8160b45ff0d49934953a36ac82282f7", "class_name": "RelatedNodeInfo"}}, "text": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership . ", "start_char_idx": 194, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad3e7099-f2a6-4050-b695-44bb4a60a259": {"__data__": {"id_": "ad3e7099-f2a6-4050-b695-44bb4a60a259", "embedding": null, "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "original_text": "Jason, to you.   \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "876b317c-88b1-4053-a25c-803f27e59b31", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "original_text": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f14eb0747d9bfc3d92baba86603d82654a5296c16b58a7a868cc5e27b5e17853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d4b8c50-2b96-42b3-821a-3b26b071384e", "node_type": "1", "metadata": {"window": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "original_text": "Jason Hollar :  Yeah , thanks Mike. "}, "hash": "309ef2c9abea345630ff2b0f7dfa3af3d32d54212af4eee802f38449c97fd512", "class_name": "RelatedNodeInfo"}}, "text": "Jason, to you.   \n \n", "start_char_idx": 295, "end_char_idx": 315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d4b8c50-2b96-42b3-821a-3b26b071384e": {"__data__": {"id_": "5d4b8c50-2b96-42b3-821a-3b26b071384e", "embedding": null, "metadata": {"window": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "original_text": "Jason Hollar :  Yeah , thanks Mike. ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad3e7099-f2a6-4050-b695-44bb4a60a259", "node_type": "1", "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "original_text": "Jason, to you.   \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a8c409875353684e94ac96411038df755bb53fbb9c68c5b6f1a7a23c06038e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "925158bc-f37d-405e-a150-c5d887aebae6", "node_type": "1", "metadata": {"window": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  "}, "hash": "2d3669ea4382bdd6e7ac377897260b682c2483c214d8a26aed88157bf65ac77c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yeah , thanks Mike. ", "start_char_idx": 315, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "925158bc-f37d-405e-a150-c5d887aebae6": {"__data__": {"id_": "925158bc-f37d-405e-a150-c5d887aebae6", "embedding": null, "metadata": {"window": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d4b8c50-2b96-42b3-821a-3b26b071384e", "node_type": "1", "metadata": {"window": "Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "original_text": "Jason Hollar :  Yeah , thanks Mike. ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3b0d4f6c41785b7cce0396a757a122a144ecf1fe508a52b1d4bdc867a992023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebde7429-0ea7-43a9-8160-fca01a3f1288", "node_type": "1", "metadata": {"window": "Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "original_text": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . "}, "hash": "962490a4c10c86475aa0ce33c665330c610109907dbbbd4793c2de7c02e80cee", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "start_char_idx": 351, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebde7429-0ea7-43a9-8160-fca01a3f1288": {"__data__": {"id_": "ebde7429-0ea7-43a9-8160-fca01a3f1288", "embedding": null, "metadata": {"window": "Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "original_text": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "925158bc-f37d-405e-a150-c5d887aebae6", "node_type": "1", "metadata": {"window": "I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "original_text": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.  ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2b3198135c2b9dbb8075e5349090a81ff7336df7c47946363db7108d0bfc285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee350436-3886-4a58-b7b2-f032efc10393", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "original_text": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  "}, "hash": "d4c3999e58e78a50ca4f576dc2da9922f5bf896d9413cfb1591bfa590368b10e", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "start_char_idx": 454, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee350436-3886-4a58-b7b2-f032efc10393": {"__data__": {"id_": "ee350436-3886-4a58-b7b2-f032efc10393", "embedding": null, "metadata": {"window": "Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "original_text": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebde7429-0ea7-43a9-8160-fca01a3f1288", "node_type": "1", "metadata": {"window": "Jason, to you.   \n \n Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "original_text": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0c595c5d5c415520f70d5a1fed74850b84db27cc74a0c246aa54abab1102e84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c6af74-3560-478c-b190-ec7522d58468", "node_type": "1", "metadata": {"window": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n", "original_text": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n"}, "hash": "722a308a2afcad8b3d42b4f0d5900ee8894d4d1da56f5f4af70b2988880fd3ad", "class_name": "RelatedNodeInfo"}}, "text": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "start_char_idx": 654, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c6af74-3560-478c-b190-ec7522d58468": {"__data__": {"id_": "d1c6af74-3560-478c-b190-ec7522d58468", "embedding": null, "metadata": {"window": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n", "original_text": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee350436-3886-4a58-b7b2-f032efc10393", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah , thanks Mike.  I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "original_text": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.  ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff4b708b37465e1968614ab8db88a5dc8af3518a98cbb98e91d9fecee20fee19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "669518f9-5669-49a6-b522-75a16ac502f6", "node_type": "1", "metadata": {"window": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen . ", "original_text": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n"}, "hash": "c8cec2518266971a58bfa0af8db6c81048c2a3c5023df4cc55b1c5607371a2d9", "class_name": "RelatedNodeInfo"}}, "text": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "start_char_idx": 799, "end_char_idx": 986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "669518f9-5669-49a6-b522-75a16ac502f6": {"__data__": {"id_": "669518f9-5669-49a6-b522-75a16ac502f6", "embedding": null, "metadata": {"window": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen . ", "original_text": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c6af74-3560-478c-b190-ec7522d58468", "node_type": "1", "metadata": {"window": "I want to thank everybody for taking the time to be on the call today   \nand for all your  questions.   In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n", "original_text": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f5995bbd7c7ebace25ab02fa677aca9c3436ae4753e6f0b5ce386d6ff725152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b36bee87-32d8-45dc-9e02-f54e8eb46797", "node_type": "1", "metadata": {"window": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call . ", "original_text": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n"}, "hash": "e1a602311c83088e81410df210433a153d4f28bfcc0ffe50c77210d731b923fe", "class_name": "RelatedNodeInfo"}}, "text": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "start_char_idx": 986, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b36bee87-32d8-45dc-9e02-f54e8eb46797": {"__data__": {"id_": "b36bee87-32d8-45dc-9e02-f54e8eb46797", "embedding": null, "metadata": {"window": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call . ", "original_text": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "669518f9-5669-49a6-b522-75a16ac502f6", "node_type": "1", "metadata": {"window": "In addition to the leadership succession, I acknowledge we threw a lot out   \nat you today \u2013 including new  disclosures, various puts and takes, and examples of incremental action s  \nwe are taking .  We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen . ", "original_text": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "344d2a9c6b5aad7085d460c0b3bfad734eec58c198965ff75f33c8d0f461f909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c445a1df-ce6b-466f-a9b4-5bf6d321fecf", "node_type": "1", "metadata": {"window": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation . ", "original_text": "With that, t hank you  and have a great day.   \n \n"}, "hash": "0823725509d751fa987789b7940de543224fc2d13a34890fe188610865e3441a", "class_name": "RelatedNodeInfo"}}, "text": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "start_char_idx": 1137, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c445a1df-ce6b-466f-a9b4-5bf6d321fecf": {"__data__": {"id_": "c445a1df-ce6b-466f-a9b4-5bf6d321fecf", "embedding": null, "metadata": {"window": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation . ", "original_text": "With that, t hank you  and have a great day.   \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b36bee87-32d8-45dc-9e02-f54e8eb46797", "node_type": "1", "metadata": {"window": "We did all of  this in an effort to provide additional visibility as we are confident and  \nexcited about these opportunities  to drive growth.   But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call . ", "original_text": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "453eb6f99f7d45dc7544b1a18b418664b4d2d547eddb51c990cd0fdf0c96e934", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9aa52de-d29e-4d91-bed9-469a3c038463", "node_type": "1", "metadata": {"window": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Operator :  Thank you, ladies and gentlemen . "}, "hash": "6524d95980f086e5e1993e917492bed380561a02953e5226a375c710b7a61d55", "class_name": "RelatedNodeInfo"}}, "text": "With that, t hank you  and have a great day.   \n \n", "start_char_idx": 1232, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9aa52de-d29e-4d91-bed9-469a3c038463": {"__data__": {"id_": "d9aa52de-d29e-4d91-bed9-469a3c038463", "embedding": null, "metadata": {"window": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Operator :  Thank you, ladies and gentlemen . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c445a1df-ce6b-466f-a9b4-5bf6d321fecf", "node_type": "1", "metadata": {"window": "But there are three takeaways that I want you to  \nhave : \n \nFirst, we are committed to improving our results, as demonstrated by the introdu ction of our Medical  \nImprovement Plan.  \n \n Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation . ", "original_text": "With that, t hank you  and have a great day.   \n \n", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81d8d28145e3ff7e7d0240a8aaae4a976926596894b730179e15039e3ec185fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf06ec70-9817-4083-98e5-319378e6d3bf", "node_type": "1", "metadata": {"window": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "That will conclude today's conference call . "}, "hash": "999a10fc6fb60f71a7badbefe32a19daea4f884e4de0e1e17c2a2ac0f0da53a8", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you, ladies and gentlemen . ", "start_char_idx": 1282, "end_char_idx": 1328, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf06ec70-9817-4083-98e5-319378e6d3bf": {"__data__": {"id_": "cf06ec70-9817-4083-98e5-319378e6d3bf", "embedding": null, "metadata": {"window": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "That will conclude today's conference call . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9aa52de-d29e-4d91-bed9-469a3c038463", "node_type": "1", "metadata": {"window": "Second, we continue to be encouraged by the resiliency of our Pharma segment, which continues to  \nmeet both our sthort and long -term objectives.  \n \n And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Operator :  Thank you, ladies and gentlemen . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16f501be8f13b35bf02cba6cfdd6fb7c1e5e83a3a531cd58bdb5ac4f292efdf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59da77c7-0494-4a93-bd65-62961a0daf33", "node_type": "1", "metadata": {"window": "With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Thank you   \nfor your  participation . "}, "hash": "e4db5e424b373ca68c8f55eb1cd4ef8d7aecb77986b5ddf11529f80e1fd0215d", "class_name": "RelatedNodeInfo"}}, "text": "That will conclude today's conference call . ", "start_char_idx": 1328, "end_char_idx": 1373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59da77c7-0494-4a93-bd65-62961a0daf33": {"__data__": {"id_": "59da77c7-0494-4a93-bd65-62961a0daf33", "embedding": null, "metadata": {"window": "With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Thank you   \nfor your  participation . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf06ec70-9817-4083-98e5-319378e6d3bf", "node_type": "1", "metadata": {"window": "And third, that  we continue to take actions that are in our shareho lders\u2019 best interest.  \n \n With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "That will conclude today's conference call . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f1682ff3770c9b0e0dc56afa8e2d1d1bc4cb4d49ed547e9b45efba690421236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "775dbd78-a427-4afc-b0a1-c631e83bcc41", "node_type": "1", "metadata": {"window": "Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "You may now disconnect.  \n \n \n \n "}, "hash": "ac960fcaa102776c9448e03767ffdeb701cb21ede2e5ccdee6e535636670831d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you   \nfor your  participation . ", "start_char_idx": 1373, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "775dbd78-a427-4afc-b0a1-c631e83bcc41": {"__data__": {"id_": "775dbd78-a427-4afc-b0a1-c631e83bcc41", "embedding": null, "metadata": {"window": "Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "You may now disconnect.  \n \n \n \n ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54a1ec9b67e2980ad92a5477dbcb231a556c8e80103026c8b1debd9b76e6a2ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59da77c7-0494-4a93-bd65-62961a0daf33", "node_type": "1", "metadata": {"window": "With that, t hank you  and have a great day.   \n \n Operator :  Thank you, ladies and gentlemen .  That will conclude today's conference call .  Thank you   \nfor your  participation .  You may now disconnect.  \n \n \n \n ", "original_text": "Thank you   \nfor your  participation . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e24e309ad476658a8f3e4f4fa24e3e298118e04e33396ad806529ab10e9306aa", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect.  \n \n \n \n ", "start_char_idx": 1412, "end_char_idx": 1445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"77dd7ffe-e710-4159-aa23-a0118fc94b7d": {"doc_hash": "e5a16913bfb226d60cac9cca7d90582f4b8a661dc8904493cd8109410ba6a8ea", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0": {"doc_hash": "7a9bbd8a454ba433f9c73f50814c15f87d714c04fa0e6185896a538f2f6da777", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a": {"doc_hash": "91b1025363b179c974fb5944bfb92bfa9e2ce4a8d2662e2e3c04a42643b8a6a7", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "052c7f6f-962e-40a9-8360-f38a1efdd2b5": {"doc_hash": "848d4d9bb30d2f2fdf189842c6c3384cb75bbb560a7ed34c01d3506e16026220", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "2d5c2a2f-21af-4292-b98a-0c296fdd9082": {"doc_hash": "67b266a931b56ce9992650f7f33df7735a2c02fc201a06bb1f18c573245ae712", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1": {"doc_hash": "4c3de2842142296c96a035fb640e9f1da6e4578fc4e8644f586fd3fcac78acdd", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1": {"doc_hash": "31722959506963f1772bb890f9f516a1e701c02742ea7d811c6ccee8e5c9b785", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927": {"doc_hash": "63bcd29d06dece2fbd0e1db1f9fc44bc6e78c5cc75930bae2f46d9b8e0b43e50", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "158387f2-a8d1-49bf-a766-07dce22b9e0b": {"doc_hash": "2b4a63c37a58f28d6d5b2643c6512d2e0bce81c9a68e0c399b62c3cbe02a0e85", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "e83ad495-d5bf-46b4-9229-5021f0307c9c": {"doc_hash": "54a0fde13c6df70a19e2e6feca2e9ef61e8863d67c6ba3957c57297b3d2a31d1", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "f37a5b32-b125-4091-b78a-202a5da5e9fb": {"doc_hash": "57e6b22bab0e95186635f6dbebdef9d399a5a8f1dedbfd68cfb4a1f3361dcb7e", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "a6157d7b-ae61-43fa-b055-46c36b5856d0": {"doc_hash": "0939dac3803dc1887a0f21c2e05556688d8f97b8512acb2e19b69c2affe52efa", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "ed3836fb-b350-4ae3-9825-fc14652f9f16": {"doc_hash": "4ed603323797e3afdb410a201f0cf4788d091de61d921834c2cf0da7f547aa21", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "7f9939ee-c8ad-4287-802b-09465f156045": {"doc_hash": "9e8602d6639adbc7013aba12a4767b6971d9fc2c5e1927d1f4c34d4051591bc6", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "9bf4abde-cc2e-456a-ad3b-70f73844a35e": {"doc_hash": "1171882efaae2c7b348763117d20ebeb0058a8fececea5583baadc4cb263663e", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "61211d86-3dbe-46e5-99b6-1d2d37064550": {"doc_hash": "b10961091f5c44d80ec9f5f02dc0521921800c902f28844ad7db55f263303257", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "0a260bf9-e266-4737-964a-20747244334f": {"doc_hash": "eba3d3d944d53bdf433d764b0b524e1a3fc955d66f4fdd2fa023b59b89227b26", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "fcc0b2be-44bb-4b76-8e68-d8a9874799aa": {"doc_hash": "ddecfc68ad346ce331b7f58ff864682ea76d80b7a251a10d141bccf637502e6b", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "2f84b242-4d1a-4337-8a28-5c76b713cac5": {"doc_hash": "22539df09d55088387613a4f4a21f494a57aabf0effee7ae60a70ac614c9c535", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "0b49122b-2912-4bd8-bda9-53d0f76904b2": {"doc_hash": "087e87f2abe7623f30e658353066ac6951bd92070a74869317dffccb6d16d6ae", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "283a64d0-fbc8-4e45-b70d-e8e8746b991f": {"doc_hash": "548e678ff08ade78a25ca403550983b395fc4a0cd398c4a382e14d4ad07c0070", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "3f2e3e68-12d7-4ff8-ad8f-8efe92415870": {"doc_hash": "961ec7b0d34631c149861c0582fd8d420e409bcce24f6adaa8d90f29f8227825", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "f045787f-8e7c-4d01-9e18-d26d5ba880c5": {"doc_hash": "645d2d680bd0d4841d74e7cebe9b99017c8965a078b975b9d3cccf994cb4131d", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5": {"doc_hash": "fdcee9e702c2f521e87a4f3d67dcc19e0f25efa45c1af4a671223198514c9fe1", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "368d34fd-56cd-4a0b-894b-512fd781ac3b": {"doc_hash": "f86acdde991c2d5b00e025491e92f0ce5977cee2c52966282981c40392168451", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "d956a8c5-ac6a-41fb-87e2-8ee587aa2763": {"doc_hash": "0d53dec7f6b61af91e3bb8d912af855a4559e7dd531cbdf6cd05ebd499314a34", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "4ff6a62e-a128-47a1-9e48-7514b4d93fdc": {"doc_hash": "a2be9851a486b1608480b9629715ec367780293d40992f23596d27325953862d", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "56a23f46-ca55-47dd-8be9-622ad5778f3c": {"doc_hash": "3f57311387de060b674e657bcbd01fd3534ea372a0a16548df8cb3974f7b7262", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "306311a1-dd22-4b43-b868-19542c6ba4bb": {"doc_hash": "0ba7859be075ef6cc617f0e513c8a1d8efce358240feb0297c7e45e962c612d2", "ref_doc_id": "c898ba6e-3f15-4ba3-8f98-cf07232af897"}, "0ce5c954-3a2e-43e6-8639-c89f68f6012b": {"doc_hash": "1fa03347422b2eee09bb5509c8c3a7327e3238278dc97cfb980fae286833d798", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "d69db0a4-0afe-4673-84fd-b921048d5c9d": {"doc_hash": "7050a1d9ff11efffb3a4e189864360e9c3a29637fb1fd10d4a641da5fc23d2a6", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "133c809e-4a22-4e5b-8323-a39435cb596e": {"doc_hash": "9f5b7de6a61b2a9a311fbd142ea4d89a3f6d892d7dc7266131d29c8d5ff1a4fb", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9": {"doc_hash": "b454d94d34873e7c1ce6918edcf3f48286a68e931a3f8757c465ef08b6667cd7", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "3871e31d-2a32-4ac1-9144-77c8ee8687d2": {"doc_hash": "d9ba1d836662fd39daf1aaf56368e8e9c2debf944376045d5216387c8fdfbcd5", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "56cb784f-e811-455b-9b25-d7b39f80ff11": {"doc_hash": "15571c184f893a7b27d8d3d53419eece442ea78ee084189a2081260f1d9b2082", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "504c1846-d662-40dc-92df-dcb273bac41f": {"doc_hash": "93f380908aa61850fcd67d0ea40d7475046addd1002c4b6c4f607c286986a924", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "9b197624-55f4-4108-b6ca-84d83367b8b5": {"doc_hash": "f188e4eed0d5bc48df510bf508d42dbfcd67eca463b0fe8a611495daddc2a04f", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "2808e31f-422f-4cf1-9525-2c07393f3df3": {"doc_hash": "5beba99703e44032247e3136cb71b40b08ea16ecdba8de8bf82f7d0e86d41e0e", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5": {"doc_hash": "35c5e0740ee9b340f263a61696fa82f7fd0743dba6229efb3afc994bd32d4e25", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "4473baa4-20de-4865-bb60-a0bf9726ed90": {"doc_hash": "155e3a5ac6c0a870a185ee574bf5b1ffbf668809bc2f5b4b60fa3bcc06913059", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "c50f2c0f-5140-4246-b804-9196ead43812": {"doc_hash": "9fb9f2dd3e4b5f4a52a5ebe93e440573431ca3eb33d93f421208108806be8149", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "80ecd765-2ff4-47f8-837a-b481d6f785e6": {"doc_hash": "ce91cc8534a4244a8f79d5dd979b37bb7a8118e27834dd30849d9f4a90666449", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "e4a642d2-abb5-4f97-b485-f9ffe3da72ea": {"doc_hash": "2d5ba93f2d5bb1d1891fa0831ddba3dd36b720290651d57853da15118c5dad70", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "54d5f900-9034-49ac-a3eb-c1fc06095440": {"doc_hash": "ce30f85ebdbcae027bbc99c95af68b9435729a363f121d4d33cf19657b4a98e4", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "748442de-e8e7-4163-bbf2-8ed83c6e013f": {"doc_hash": "5a6a6a01e05157e33dc5b60c79c2b6679b43113644da2c1da94fc0a5ab6a7c26", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "9cf82343-3133-4347-a74e-ea57d31a4ca5": {"doc_hash": "91d8c88475dac710f8a61bc9fe3b1a393f97772262b9664065077effa99c0b7f", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "334f6fd8-2457-4bf9-ac23-330db8092f27": {"doc_hash": "803481398950c63c8ed4bb594e06d2db0b26bd62f10a3e4b5cdd024af090e5c7", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "225ce797-d8d6-49f5-ab4a-4f357314d7bb": {"doc_hash": "0bacda59fe69010b063538d122c25310d925daf3898b8408b0f8cbb4f7db9a3c", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "632230f6-599f-4ba9-bec8-c892a0dfad45": {"doc_hash": "9061834f77ca362c6a7b89488595043070d0c1ee0140d1099c2d599dac2e9d65", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "65c303c7-0ec0-4202-aeb1-696d44f9f23d": {"doc_hash": "1ed899f4eb42a79f6ea864e79c0987c0708155dd9640b5c9719f5bb47381a508", "ref_doc_id": "350f974d-a5e1-48dd-8d51-1965b8322899"}, "6817acf8-94d1-49f4-8471-a76f9959cb4c": {"doc_hash": "1121785da9bc2a422b86dc6be26ac6cb60e874d95133b261ef7c44ecb6bf1922", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "2484d589-145b-4fda-b552-fe014a52d46c": {"doc_hash": "86f0c5a6092e765715bf67770c375f0f8a481e2580a5ac5f76ef7e57c22ba9ac", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "a365971b-18e0-4426-9bb4-14f91ac1edb6": {"doc_hash": "58fe7acc0ed6f1a805c77bc2b80b756bc1ebf17da25a1c80999531f86d517bee", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "8416fd13-0eaa-4caa-9de4-3ae6059708f6": {"doc_hash": "e5827b55bb3e087781848caba51801fa3a469bf1c0d474b8e67fd452072f9149", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c": {"doc_hash": "833a6c3dfdd5d21c0851e0d52fb5b22231639f235c3d3a2ae4af8713f77955c6", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "f450187e-8c44-4441-ad8d-8ff123737b80": {"doc_hash": "e59f36605bb9f1243b52fc594b376f27affc636da361001d98d4175e0e34c0bd", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae": {"doc_hash": "5200ff254055cbd71fd74f00714242cf5ed922e26f2ab2cec348598028e795d9", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68": {"doc_hash": "1d19e49b1e67ff5b9b6e1384422948e79fb64397cb34fdae3ebd39aa10c0289d", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "3aade192-fc7e-4f42-8ddf-92db3eeb184b": {"doc_hash": "40daa27833ce3903554a94a930f60575b9c8d8065f4acd6ce1c1861eaee85705", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "dd431a45-c773-4719-b567-b185903679c3": {"doc_hash": "4fea45e1d95f1faf11ebffd6a1205e423765b258ff8a7e51146aa984d9fc9740", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "815a58ad-e5a0-464f-9b5c-84ff6712d337": {"doc_hash": "bb9ea0f1590aa968396b844c87dc1978f56f2544dc29d11403e471443d4a4d57", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "91a4e21e-30b0-457f-baa7-52a4f1a39624": {"doc_hash": "cb5c5df83ff60973d1a35d11e47fcf7975e9784f3ea198928e947963925cf092", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "2fdf851b-d343-4121-a7ef-f2b6abffa18f": {"doc_hash": "0c17eb3079f6864ae22a754b1be258c428cefb9d47f2a50705fdea57bfd239f7", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "545b5dd4-1ae8-4a76-907f-88c1a6778a35": {"doc_hash": "7811bfdc0125a3d31b953117a900dc0bccf31b5b7b18f3bc936003ee345105fb", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "b6851b8d-aaa9-4830-aa8f-8444a33c289a": {"doc_hash": "3a38cc747945b66c75347d4b58dec596e85e1b746e975841e89e229547ca82b7", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "69966aa9-ae8b-468d-b2e3-6ccd99ed797e": {"doc_hash": "4f3671876d9c4dc7bee74bc645ef4bc15d49f9e0b3efa725e924944e93359f5d", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d": {"doc_hash": "0e23d481230409fd61974f2caf6a98d6cf941f0f4ba1599ce797dc68010f96e2", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4": {"doc_hash": "f72d8ce5fdb191cf123292002ed36c9370290cf489bfba41ab8b87bc3bf5cbbe", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "0b578fa0-b25b-4fc2-8283-c59860cad4dc": {"doc_hash": "223373762427d5d7d620d6efef6ff18a01952a72747ddbfe1cf2bda347c0592a", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "f29ad4bb-a505-483a-b0ec-5566106d956c": {"doc_hash": "1a4b1e1a762ce451ccf9891fffc7591f45a208e8936e47188d7ada7e6a19ec3b", "ref_doc_id": "a0e928b1-0818-41a0-b648-c3b921e7ac7a"}, "656c20d0-76a2-4803-ade2-d6b8e2353c04": {"doc_hash": "85dacf796920db85cc99332c614a63f9907691e2511f8c7611646e9fc0a6dcf2", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "be4d0968-5965-446a-b9b3-fc2afa181077": {"doc_hash": "ac59697543a6b1777027942020a65bb0a7ff78a4bea0bfc7bca52eb97ccfe7d6", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "04ca7c48-b863-4535-9470-35d340fe0eab": {"doc_hash": "c2e3bc3cd47545e7225e6a310f54cb734eb4e4891891ab04ed0d4bba570ae3b4", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1": {"doc_hash": "6656fa4ccd3bdb915034ca9c7dfa534f2b75fa3de89bf63122f422e5e1f89c3c", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "73729b7d-58e9-4cf9-89a2-b4d77f54e9df": {"doc_hash": "55061d62262368a11f82fe470b518089467f71bc5f5ac4d7178347084b9ee814", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "906758ae-5ab3-40af-8927-3bf361f1cf28": {"doc_hash": "cb5e6ec3d53a9f70c54537462d7808e306880d7c87d5903ad2ced4f0a1b004b3", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "a1ca554b-732e-48ee-9774-5c58268801e4": {"doc_hash": "4133de7e4b22b2fb0e25fc58845c2a569c29478fefce02bc09241f39d44669d3", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "ca86e9ca-b782-4ee2-a0df-42e8e7740993": {"doc_hash": "14e2b0d72b5130bc67a81f360d3945926db7529dbc9b16fc3ab4d23f55fb0ae0", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "3b01d0b6-2642-4584-8fac-38a4db273f7d": {"doc_hash": "29de4ee761ae077203d8a5ee90b44a8c3f6fa59c1cf6aba32295f670d0b908f8", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "4918ad5b-c455-4e17-886c-0196723e771e": {"doc_hash": "40fadc3bae4af6178ed3cce0e065c727310340ffe9f50835bbc4ba018375c5d8", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "ae84a2ff-ac7a-447c-aef0-33f93fdaf039": {"doc_hash": "f8fc60cc9e5db2a1be27214cce8096f07b601beaa9efce7e2a658849c982e041", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "bd8bcbdb-0990-476c-a16d-fba6709a9bb2": {"doc_hash": "e162afbf2b3975655b3fd2524600b1af8b5a409196147c5f0c48c5b4f621ebff", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "695f3d85-2c5f-4a03-beb4-f04b6ecd265b": {"doc_hash": "8dcbbf090f3ab9cd12e607e92610895a9674cf2edb293f51ef88718fb29f78bf", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "f2c1839c-5568-4be4-be29-8763900a9359": {"doc_hash": "170bed372c28d0f0b2f155792b93922e3bf780537b8307ad20903a78d130ea62", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "f4115c47-d67d-4f52-81bc-28ce71d7ab57": {"doc_hash": "40939558bf897cd4e29d3423ca58eede5f7ac2a0e2b7aafff658f188f4831a67", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "a1a57cd0-1097-4bfb-9817-5aa2345bcd47": {"doc_hash": "90e89c61e6458278217653fe9884155ff17bdec81b4e448798a49f716204e495", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "807aef4b-3955-4fb2-b5b5-c51f7c3564ff": {"doc_hash": "72a029006e3a9e458162774e9c4221782e43dee4d02900712aed68b4614ba6f7", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "60983600-66d4-48e5-a06e-9cf1c0fb566b": {"doc_hash": "0d7e49ce59a7cf3abdfab4b7436ae7bde0d47a92d1ea7e1386cf28a095a40043", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "2a85e280-5561-44e0-a523-b98968f519ec": {"doc_hash": "7a01955d64609174dab86afba43cc4ee0107d629704e61aefdd642adb0f5ce31", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "15d0090d-5a12-4146-bfcd-31e6c9bb7609": {"doc_hash": "cc49f46506bffbf803c29057cb73aab45b140df65a87dec8c18c02f0a98de03d", "ref_doc_id": "65d1702b-a233-4b64-84ec-253e432e1c0e"}, "83b6851f-0537-46fd-9f7e-a4a07216ac7e": {"doc_hash": "dec0a6288d47fcb3bac5f45ed3628d4df9f9ceaf84baa5dccdcbe9333226f28b", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "561ba048-ad71-46e9-bf0f-736b660ca09c": {"doc_hash": "0a1ccbfaaaa5d09192f9af8eb85791497a579a261e77042c0d25bdc0543413ab", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "63418bdb-1d95-4752-8869-49cf44355fb0": {"doc_hash": "45372015851cd3f7d20e05c36606171bd09fed8675f063982e51dee5f7a384db", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "2435043d-b771-4200-b6b4-0a0d69d0208a": {"doc_hash": "62d737e9b388773c5adee9fdd6f661bbc8889d5665a42a8e0a844491dcdae6e3", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "cc04324b-3e92-474a-9565-e4c43cce8c76": {"doc_hash": "6063810713329a5588aa1ad8e416cfb0b7f8f90882154a5977a370666f580ea5", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "f96d3bff-7815-4bbf-8253-059d88ceeba3": {"doc_hash": "db01a57f31028d3660a66ba0b0e9ec541f342b57a8d208e03cea383435cd9041", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "87042e3b-5edb-4bf9-9e01-c564b3b224f2": {"doc_hash": "5745c38f8aa56254ba007832e417354443fccf537975b1c3d8685901bb0daa88", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "ce6f16a8-647d-4e36-a93f-64a732675583": {"doc_hash": "10c436c8956a931803d2ff4cddb8c48da276c0147613c9f75444e311edc7b825", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "fc6f00cd-9f2e-454b-96b3-a3912de2edcc": {"doc_hash": "ba83ef7a0e52da468bc53e0effa1aa0f35d86ff74302886435c3976ba8646413", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "073c1acf-48c0-4eac-8f5b-dca4c5ed0078": {"doc_hash": "30ccf4d4d6afa2b4d563c8e87137debbe02618d611af62a07cef0150bc07309f", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "cc073d7d-2989-46dc-b6a3-9fee7f6bee11": {"doc_hash": "9bf3c86180b05c23b17812b4c000149028af2c15dbfb3445334d67b5d2e4c52b", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "acf730fb-4c73-4640-aa1a-eb984bb07f93": {"doc_hash": "1469fb80cf44e36c8f05abcfbbef9b6e695e0402fc5b618c1f2750838230dd7a", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "2782d5b6-9cae-4265-8306-af494048da86": {"doc_hash": "37ac5b0cda6a389e42f63a3f2167b83f52924685213897c78ddf5d6b72770176", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "35a692b3-f848-419f-8dc3-a6fddecec6cc": {"doc_hash": "606a7720bb5848eb976919606ab610f60ebb73b026b870b79714c85ea28f9c22", "ref_doc_id": "c346995d-f3e6-4eee-b999-c708c41be3d0"}, "04286e88-d729-4d6c-a020-d14f126576aa": {"doc_hash": "2f2183d2d4b55cb08b018904239d128ccf5762de04709cad14aca3dfef218890", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "fd51e05a-7bb8-4944-85f3-24b0afd787e2": {"doc_hash": "9acf2c27ac3823ba7ca134f7dd6237cf265c05de2dd3bbc4a4a1a68ec3c676ad", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "8d7e281a-6666-4787-bae8-cb5f39523c23": {"doc_hash": "30648b0d34da87a060f95efdd3101a942dc493c1f6dbc5150dfdc606322fa064", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "3dfe5b51-69e0-4743-a563-b3b85452cb0a": {"doc_hash": "2ae3310de2cf471660a18e00ff7e55c01068602a50f02f3640b6c2afe6e59ca0", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "88ace672-1aee-44d1-ae83-7c9efeb502f0": {"doc_hash": "26204fe7a7e57d414a83baa7381472eddbbde78989c511802d3420e201c7a885", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "7c23439c-e2f5-4578-8488-60c51251f51c": {"doc_hash": "588fcbd16e42c966f47103dc944fa7d54e4272babc1da4a7e93ba3d00ea12c8e", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "5e955c05-9a36-4134-8875-98d608b498f9": {"doc_hash": "3a98c83d6cf5291384a820ac2815f1726e71e7b29c7542f066e72985bdc1be10", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67": {"doc_hash": "e62b89ec1328474b8f0f40ac97d2e1da26e9cdc38c580edb81dee3141431cffc", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "7db52f79-56f3-4b77-854b-7e2fffef850b": {"doc_hash": "c56fcd99f5bd54e4ea8dc952a497fc82f045f0db020367fe5997cfbf239b7453", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "98a5b75a-493f-4873-84a4-15fbdebdddc2": {"doc_hash": "0979b42f10d9b35f89eb173f32ac9ec5266c1823fb6edb66e91501f2ae988bf4", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "5aec7777-8729-47a4-916f-adb71b169c97": {"doc_hash": "1a3ab1069131815c819b01839ebaea82a3c9165ce41babb5b5e54cdc32145803", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "0bc50d30-2681-4f2f-95fc-ad4d90c15d54": {"doc_hash": "2f00164d3e7aae1e7d6ef723c430a516ead6fd95ae415d2ca58501473a3a4799", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "424b579b-a7c3-4d28-9eca-98f9231897f2": {"doc_hash": "ddef72ca42a3386ce75f78755aa6af14f4caaf25e6b8cc75694a5b3cb0614a6b", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2": {"doc_hash": "f0e8a543434aa0f3fbc80b3b9b32f3625813fb7d4276c3c9caa188b35724d494", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "b69a99f3-ae0e-4730-a4e4-0373c7f23d75": {"doc_hash": "772cd141601026f8baad7935225a2bc0325bfe88bf0c7a9d62618c22cb8658f8", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "ca28a5ea-196e-4cc7-b826-051c8bf8edcd": {"doc_hash": "9b50bfb7ec292b4ad1be6bf321478d7035493a00a89cbe47bcec184f5c47f12d", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7": {"doc_hash": "cb1aa69da15759972f7cce2b09add19afa0a59ddbf09b219f9f465d62ec29efb", "ref_doc_id": "b9f86132-8431-4532-8b36-81be49b4c509"}, "9f6d4d8e-9ca7-454e-9903-0e86d09baad4": {"doc_hash": "a5023bfdd5886cf19401dc304d4823b0c386f1f7a55cd810edbff8fb53ddbe01", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "95be8c6a-bae8-4318-b22c-439491b0c01e": {"doc_hash": "e37718951528860ff0a22817b93afe14fbd941cd810e8f1e5b09294dfbfa725f", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d": {"doc_hash": "22679d3f7222c76d1f2f15a0d716c02c5190fc6262a08c0633f9c2fd22e07c37", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "56ab7416-5392-4f44-8cd8-8b70aaeb435d": {"doc_hash": "7dda17bef8ea22f541176afcdc62d46ea8fea89dcdd57b6d3c7c6bb36dc7e049", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "ed234f12-ef85-4567-9f63-ee243911acf8": {"doc_hash": "0092af7f13854835ddbee27173ef6ba63fc3aec88976fc4d18371122e94d05ab", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "6ccd4ad5-1665-4b3d-85d2-0043a24f355c": {"doc_hash": "d8225e5555d439901ef3e49ba53a67cd88bb5d2937ab0c87d771a799ab0884c1", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba": {"doc_hash": "87e9059ee8c83dff9a9fe4a55f4e3ee0465753cb912b0ef49797aa58a2d9c4ed", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "19d9dc38-1ec9-4679-a560-6a993224224f": {"doc_hash": "8f38f36ae78844458573ad92eb87a5ba9dad7d5727371a86c8d556f0020b5f1d", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "5bf91eb6-c35d-49bf-8b8c-b860dd09285b": {"doc_hash": "4cf5a3d7d40a4f315e8697f86abae932334ed7d7985e9fee06f48b2a55015619", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "aea0568d-1d26-4d22-ae67-1275fc7ac7f4": {"doc_hash": "bc23352fce53921ccbcb2904bc11b242d57bee69d9310bf9f00dd42b844355d9", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "65620a6b-335d-4821-b673-d520f56f0d9e": {"doc_hash": "33ea5e814e45c66d781e8ad908f96d4c4fa98b4944f671aab036ad620aff94ab", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "10006d25-89c4-4489-92b5-db868d9de085": {"doc_hash": "1f62c527fc3880a12cf1147577032891c7420e2edb8d3946a30c11c14667180c", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "67060987-9cd9-40b6-9cb1-2bc70e819494": {"doc_hash": "a43d92739e6e332b1c6196b4a12607a963b040555b3382894a20565dcf904ccf", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "9c898dec-7ed9-44e2-95d5-864ed15bd192": {"doc_hash": "9609f07262fb3d5829d568eae3ad5ac98bdaf0ae2fef37d4a9e376a80ec4f068", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "3e350a6d-9987-4d65-923f-f5e827bf4fef": {"doc_hash": "f229bda0059bd01ff28b325558a2c47d93e7e953eae5fa26ab8d5f29fcbb1595", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "297de1b1-ec5f-495f-810e-648f4fc10c21": {"doc_hash": "f37f618ed8d187abaac6e642ad16fb78e60da93bb5a745491e41fca7540957f9", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "5bb13d19-de20-4971-bd3d-64374403dddc": {"doc_hash": "1f3e931d3b14d7fa26a86c50263bd58e7b981612021341a6c683518655ac876e", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b": {"doc_hash": "6dac337546835d00fd0761a74d86b41585d40035b9b1231d067f7e29b0ddaeb3", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "c1f0f083-3a59-462d-9231-289f59322250": {"doc_hash": "465a08bfe66f8188e3e41a06b5971b3bf4a1098679add63106d06d3947fd125e", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "75c5f6e7-727e-4e05-aab0-0f706e448a09": {"doc_hash": "aa6d1062d109c05d4a65316a153e26fa967130fc61e16abf980e194463f08445", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "15a9de53-f1d0-4a44-8ee0-5656c2ac151f": {"doc_hash": "f70a9c2aaa7f1fc0387af978eb46dde84efa97fe1c5a74749503fa922356e76a", "ref_doc_id": "28621069-0622-4966-b60c-1feb6586ae7c"}, "d034ea41-182d-4dcd-ac50-9141bab7bba5": {"doc_hash": "c2a75ee80a286a3c6e257b7a6dd9a7f8e0c3ad391c79cd03a4c5973989df3317", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "a8fae56e-f6a8-475b-affa-8c7fd79e1036": {"doc_hash": "8b5ef0e04f318fc6d7c4c5bae6ad096be05a244c8e4643a0feab441d81c6b89a", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47": {"doc_hash": "1c27bdd54f040f1fe38460348d0bf6cbdb88118ed2fa164d237bea504a276df2", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "71fce01f-fb21-4282-a2f3-d2ecf3705e39": {"doc_hash": "ad712479bea3993c42a1cd8534020acc30c36cd2ce78992adcb3ef59b3cc34c6", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "02ee8c60-5406-4cf1-9b45-90912b0f2268": {"doc_hash": "aa503495f12191ca36fa503c5cafee938cfb2c52df80794c9d45495b476b1bdb", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "25e33a3c-fba4-4676-9fee-3835fde92342": {"doc_hash": "b1f08c79e609b4a2d0c3c011abf31c30786431831d41014ad4c83d142fafb48b", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "24f9e384-819d-42c1-9c38-74f80c088a36": {"doc_hash": "e683f5ece1aecfd863c2f4b4ed40dc3ea7bc0559e913c794d62e352cc60465b8", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe": {"doc_hash": "367077e5ef2cfa89928f43998188e44daee0f86fa67e7b80a6b00d02b75abff3", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "620547c3-71ea-4d25-9781-2cdaf445d449": {"doc_hash": "8e9fc542f20fa10401a26a626637949f2db8016ef0420daf986f6600520a1fd6", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2": {"doc_hash": "040f0d8dacbd8f9368aad7fcb6a689cd2bcbf6dba47a8a6cb3d6ad7b3dccae46", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a": {"doc_hash": "7d7b7f315c847d0137060f54185fc23196a128aa9ca46f3308004d264f8d2529", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "24fa7907-9873-4474-847c-be24c355aa67": {"doc_hash": "a15be21363a5f9403e20ce7026a0e8dc54c6f0877eb80400fefd7d5c32072d68", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "1daa99fd-861f-47fa-b5d7-2e56888d79c4": {"doc_hash": "3380aa6da5d8e6b302d6acfb2d9748c99fe921a19338c45f770bc168d478e992", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "d763e999-61d1-4556-a712-891d9eb8533b": {"doc_hash": "49f8e5252bd4ad49bce91ed9dfefefd4d93710a6204c8bf552362bf3310903b4", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "a137233e-bd91-4104-98e2-ca117020b5f8": {"doc_hash": "1de5ca64b9540f913ca7c15d924e042d67a7d860a2c64250415bdbd07940dc2d", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "9219cb49-3fdf-4d24-a08f-b8ed645b844b": {"doc_hash": "813fcde9d4571dee506a7a2ea9afa68de55d1aa4936d900008f5552bd17ba55c", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "ac6c135b-3a96-42fb-833f-8d75fd1d1faa": {"doc_hash": "c809b72fb0e588b4e81d28335ee85b4be1759201ceb6c0db0345d28972dd3b3b", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "fcafdbc2-6981-43e6-8aff-b397d9884fdf": {"doc_hash": "dd1a9217bb25f3be6b79585371ae52dc1baa026d35aa89d68a5853a13ded918d", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee": {"doc_hash": "dfb5c6f491b49bbe7151d75bc31d02753908ec4e8145a2c50c92f53f43d55af0", "ref_doc_id": "6170c8c0-f838-4d2d-a1cd-4ce4c7284023"}, "e049061f-c8a1-48a3-8f24-ca2032d73656": {"doc_hash": "682dbdf1f62da4e8d8292114d5d2953bcfa43948407392841fcd8e1c40066b7d", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "fd2d866f-8e65-4926-937f-c8f13703115f": {"doc_hash": "f7d4fdc11fc861ff20f6b67ecbdf1667985043bc0d8a4f34fa6c52047f4fc8f2", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "2be9ce14-7a5a-46fa-924e-46b288780bc0": {"doc_hash": "8443e6102ac28b7ef5192f1e207b4243f557c51ee13a2c906762414024bf4f58", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "f189c81f-6b55-4c87-bce1-c08e3fc19ac0": {"doc_hash": "de08f1cbbe0c2982a0a8b1734f795025cd424409befe461b842dbbd06015e541", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "ca18d6c9-19c4-439c-b43a-1b85a99c8a27": {"doc_hash": "d22b9f5bdd49461b5ffe8280812211f51b8ad90a1d5fa99eb0e648af4898715f", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "d2db6b07-5549-4746-9164-5234e75df8ce": {"doc_hash": "e4e895cfa5a49f0ef2ccd9222f05f9c37b574696f439ab2090c68055b53a5849", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "dfa08349-7f4c-4e66-a003-1b5b9076e781": {"doc_hash": "582fea02f585a209e9e1cf9b45e7f1a15cc90d6d9193bae5434294e11c5b48d2", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "0a80b5ff-bfe8-486f-a800-e1e9747d9681": {"doc_hash": "7ebdc6fb39d526e32aa2a81e99979ea6ceb4b8d205d7b5d34624bac9001e6742", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "4146cc9d-c8b3-48c4-96a5-acf673b7b24c": {"doc_hash": "69e084d5c5157b9298f67e0531a2d49b55cbf53d978666b00ab91dad4779320a", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "84276a58-05c3-44ea-a242-73cc3805cce8": {"doc_hash": "6fffbc6c3bd1ddedb2204204b62f5c3ea5f32a397d87dfdde1b8eaaf00045063", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a": {"doc_hash": "fbe7641741fc266bbac1cea8fd3ba447c40ea60089edc428f248020e236d808c", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "8f3aacb0-9878-4302-97ca-c66dbfbf02dc": {"doc_hash": "8570a65215569fdc0b19a2f10f799073ee0f5208505b4cc0b48af353a16eb5a5", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "939780d6-e1ac-41ec-aab2-39e1cc7da9a7": {"doc_hash": "b424d622ef24fb429313821e2c8010634dc273c77fc08a082ede4ee449ff13f4", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "a5f602b3-843f-4c99-bfd4-5de2caced4e6": {"doc_hash": "999b9b58e046465c226ce8db57e2875ad529456e3b4014e30b38a05db3fa098a", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "b717dc42-181f-4b5a-af42-658567b1387b": {"doc_hash": "d9bbe9aa8b12701ef0fbd7c5bfbca7169b4930cc2c2954562fecb2b389906cd3", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "18ff74af-861c-4811-a923-5d4318a2337b": {"doc_hash": "d51e6627be7f688b1cbc94c56022e6fdf6878b07f4b4053c95f39b7e20428170", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "487de5a2-2fcb-4340-944b-8b50a704af56": {"doc_hash": "91a3ea386155bd31b6a68ae42748423cbc59574962b80c31edab6f155fdc6cf6", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1": {"doc_hash": "f490ca360049d76d80887226c903c4b3d54c3221785946656b1988d2b69bb06e", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "624d06ed-119d-47d4-82af-c1f4e77f0f0b": {"doc_hash": "773ec8bc5103694c62015770e2080430d171f33fbdee9b408d38fd7141c2acd0", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a": {"doc_hash": "cf2d7eb7a126073812d93b11c2a1573a205e4596c02924707e03f7e7a3cd7993", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "8c2ad050-a164-4a62-aae2-7a49060482d4": {"doc_hash": "d33a9f5712f7aea81bdcaf3ca032729864c90a57611decc0a38b583db1e85bb9", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "d84cbfc2-fe08-4a87-85e9-b3de45f962c3": {"doc_hash": "7605f7ea94374eb548ef466dfe517c9f01fda4906d1314878c333e81897bc154", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "92811701-c730-47a6-bd3b-cf4e4fa30d94": {"doc_hash": "aef6560925eb6a7fd015bca0c8753c9ac4de0be7ece174ee11fd7e3307e79c92", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "1c130caf-ea6e-4263-adef-8958ecd43a4a": {"doc_hash": "a541dcbb65a680f9489b2004d915df631fb3d332b1fae4ae64c9cfd9b98ff087", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "47c49868-079e-4cc8-ac23-d4d9999f0800": {"doc_hash": "27b4048d84e08d41c7101b13b540193f108256006a65a165d83ce2ed3d8ca050", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357": {"doc_hash": "b11bc33121a3e4daf19966e889c9a7e20e5b501d13cbf1cfd785b82739e1a16a", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21": {"doc_hash": "d31a73b3f70e367ac01499ee9db3a761f8c0edfeaeacc3e212ab178b8a23f280", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "d32947f6-1270-4553-bdee-b82d049b43e5": {"doc_hash": "5fe3e3e48db4b812a01dc1471fdce792882d73ebc0dea288452d42d93aae7e2b", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "3c1d49db-26f6-494f-aae2-53f754048748": {"doc_hash": "6da503b283417bab1588e6d87218f657ac54dccef1cf52776bb792082c0d2ca1", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "2b551a71-f483-4c51-be6b-af2b9b8fd9ca": {"doc_hash": "2d2024d83826d66798e8472fc1fbce2a24ea1c3c417fac34dbccdca37b30f2ce", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f": {"doc_hash": "6e18063d7cd551a0740f7c8ea9d00cc8cd71874f0f353331492417f5db5c0283", "ref_doc_id": "b7cf89a7-242e-48df-ae06-7376827a2fb8"}, "8b1a3978-18ed-4da0-a129-0ca6c1e24eb2": {"doc_hash": "ef9413e34b87278cbf1c07de71719b7c77facb7d3a853f332c08c7b358495433", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "d6383d63-eacf-41c2-b94e-293e059a9863": {"doc_hash": "a466a61e01217f437a325a1f8c19cc5f19d827372e14b37ccf1aebbe162ae537", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f": {"doc_hash": "e49a2287bcbfe780bb2e54778b060c1a30c76c88b8c85b3b5bf21b7d73db42a2", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "f0342688-f935-454c-bbc1-4c33a4f810df": {"doc_hash": "0388de18fe902cfc70ce49cbee1c76c7343207031c7a4649fa09b19cfde74ee0", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce": {"doc_hash": "a8f96bb639d70137facf18809f2f44ea930c1b964c2e3997c68b0ab930d1cd73", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "6f82226e-1dfb-45ef-8b51-04bc42270e1b": {"doc_hash": "57ecf15f5050b969a65247b00fc46dee19d73702d39112d2a84ef15926fd642d", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad": {"doc_hash": "c58d31de34bea9e02268b2cdcfd9c6863c4526d36a76592bd192a548b08eaa20", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "9d156036-227c-41d2-aa7e-5ad242174677": {"doc_hash": "90431c8e2507bed1381e333d2106dc157f2ad0f5cc60f93f9b605adbaa731b16", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "5f60abac-f775-4b8f-a7de-294c5b968148": {"doc_hash": "c0bc82b65502b847ffd9258f5b68c6ca9b030fa704cabe1954eef442d162ff54", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "e3adb4f7-cd34-46cf-902e-33ff93f788f1": {"doc_hash": "227bdffb58a012a9eb889f5fb8a05e6699a0947e6a5ac97daebd4899fcc60063", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "b5546a29-a3f6-4510-9eb6-85edafd06808": {"doc_hash": "31db4350116588225a733c8acfb575463b35a97a4933c81f740acc378e667cba", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "c4c545e5-44ea-49be-9bf2-aace5ea6bc72": {"doc_hash": "59894c46e005c042c8fbc1014fb907dc97b057b3dd16168fe3e30882ba993977", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "719f960f-663c-4275-973e-001e178d03ab": {"doc_hash": "d6ff1c5ad88d7d19a034afd506ced78b2e94a45a2d419c714eafde69573d0f90", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "37a4d36b-2c49-4d0d-9bdb-bac47ff21282": {"doc_hash": "463f597aefd2f00515b783ec8f2bb364cf2745bac15460bd9f832cda52d9a9b8", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "333c53b7-8b44-404d-8837-68ac20d43a15": {"doc_hash": "f79ace3ba2f8f50f938c8fb6ecd98b8f5e886aef0ce258b1f4dc538e1721f3a4", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "08793620-bb16-45d7-9ae7-27d30c21cb1b": {"doc_hash": "a4bb24d44f0011ecd0ba553e596efb349cd4a7199e060082389e668ba7b3a2f6", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "35c47bdc-4c26-407c-a8bf-3fdc63342e6e": {"doc_hash": "8330b23d57be75ff77dd3bdb5f0fd84c7ccee45f2fe6bdbc3da5081477b22b02", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "7628c771-536b-4e61-83cc-50b1a9cc0fdb": {"doc_hash": "ae0531ecce0da85d2c315b514989d6024aeb44560a5250764585e503a5a73d34", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "ac056211-4c01-490e-80dd-1d19b79c49ff": {"doc_hash": "ecf077293d5fc0dd8cfabb2039b242707887b6ae2402a3f13d745613ecbc2b43", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "9bbe3dd9-2462-4757-95ea-72989d6b8924": {"doc_hash": "6f064f40000bf814b53ce483f434b6d775d61a0be9d0980d289e20d9033c7c3e", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "d8e9b316-894c-4e1d-a07d-8b922da3f03e": {"doc_hash": "634d591c0387302382ab90da39e62df709532efb2a7211fda3680af10106a75a", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "9df61988-5e06-4893-ba62-b69d2015a3ab": {"doc_hash": "71b773d7eb4e85ed200bce1a8c83d423ff81a5e12f66ba9e3fc5b3aaf2dd2087", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5": {"doc_hash": "e6e1c05c5179466fc779a4a535d8ae07f9cbbd7fc3e3af08fd8ba2e4974c6053", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "ce830ded-4672-43f8-8dc1-1d6b77f0a28c": {"doc_hash": "c18b6886393892b5bd5a665553403023809de09e449b5e90d32765d708eb0d0a", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "3abd137b-25f1-45e6-b038-0f69eafe5b9e": {"doc_hash": "f5c655c3dd5d506a1d7949a915cd7a85532575f9ecdc944444ebf9a6b98adec6", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "0a2c1017-0a06-41ba-93fa-23d93dbe3411": {"doc_hash": "0f91f047c30e59c38393ceeb27ac9731e71b1b801ef68e996408a015da4f897a", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "9c49f6a9-6a76-46cb-aabb-e930acc067d0": {"doc_hash": "006ba1ea2eedf53e0e6c197c6111d916b180737e6fb0fc042e643a1a6e5eb445", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "8939bdda-3e87-4963-86e2-16d04e74160c": {"doc_hash": "56027b724bcb014699129e952cce886ffa1b45770ad47247d255a3290292adca", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "8e77de87-929e-4d67-bd93-7f856ea83dc9": {"doc_hash": "f66adc08e6fdaeb62e08c3b8502c0c816689b6a862732ea8de5eb51169374f85", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "2102d64e-86e7-4107-bf9c-4bf610a9726d": {"doc_hash": "32b8752dfa9379815e258b6042ea2e3d848ad041689d8dce6fbc7d6c9ac6d7b8", "ref_doc_id": "bf6aa88f-2553-453f-ae1f-6f3ad61d8879"}, "d982b89b-8b80-4f25-98ef-42d785f79e6b": {"doc_hash": "f8e63870fa2a1173355f5e2aed0630b7e11bcabe5a57da352313111c0a261163", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1374bc3c-4b28-4c12-aad0-471b746b97d3": {"doc_hash": "4b765279fbf03f411cfd81b7076ab58cb8a885294b8e1bb307516b59d7b7d569", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "3f6f5033-a6f0-4493-9112-d90dcf98b48f": {"doc_hash": "885603ea9de7f4e35b961f936544be5fe58aa36b271c86524a591d0c8364cff5", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a": {"doc_hash": "c0e5e055b5fe56c54facb1acfd3236e0648fcd62f06641d52b15ace42076c500", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "17eca2e7-efb9-453a-98e3-c856d22a84af": {"doc_hash": "3e6404d8b7dd8cb5968e644686a3fea8323e225e3a8ff8f1bf99a27dc405b0db", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "a378d6f4-9b27-42e3-812b-a47382f0363b": {"doc_hash": "5b2df326715f700a8b91d1e866a8557d0cbef049563eb671782d2709cd97a5ef", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "64fe58d2-0b9d-43c0-9fda-bf547028cec0": {"doc_hash": "9a3055016b4b9a53eb6015c2796efe0c185e472df10948d2327f56a50ddcbaf6", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "933af036-4ad4-427a-8ab6-6f843b647eca": {"doc_hash": "2b1d24dac1177e3c0a4d4b8924a09d6c1d415fa43d1a7900642611a83591e98b", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1eada1e2-a679-4702-873b-bf815f148baf": {"doc_hash": "99c94ab0493d40202297c31a4cebec3bde1876e0519014347d848512c0a66c30", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "fa4f16f2-c5f3-4523-889c-586b5ddebed2": {"doc_hash": "bb02504c8ec19599a82eb8d65a8b8a3a8a395744c3516b3ea021495a0ee1c175", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "58aedb05-e456-43ea-a01b-8176cf49a3a9": {"doc_hash": "86d740937cc74007a786206d4f689878a05b07993c9dba7cb3505c3e196fdfc0", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "0c31c71f-a130-4a9f-b117-0f628d12e522": {"doc_hash": "f1be0bcbe4aaa18e1b9937e2ccb583be271a7a0bc90869ecc69da8b3e2a04c90", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "60338c1b-2e27-4497-89ea-6f3ae945a8c0": {"doc_hash": "8c35cbcb4f6bd41b2aef673ff5baf858bcd088e45806bd19ea07b3d58f657d6a", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "8b881a63-425e-4815-96cf-c913a01d150c": {"doc_hash": "8d6f57e324a5f22f06ae0cd91e3868db283fb451f9b15a382d5a6a3bc0b85c3b", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "80bbd855-64bc-4ccd-a18c-8dea4c649eb3": {"doc_hash": "afaf13413f5d596ae570b17804721fce2f6984f59580f45c2610416daea5b8fd", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "78d5725d-37c2-43c6-9048-8c57fb5a8ee2": {"doc_hash": "d5770b836ec44128733033cdff9e29785342653f11c702e533702ab17a31cb4a", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "ea392b4d-8dd2-48d8-be52-73a86b8882a7": {"doc_hash": "06551cff0294475d20902567eb97f83488aa9db76eb6f79fa062cadf73404ae2", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "01073702-f57d-4126-8898-14541ddb3435": {"doc_hash": "3c9fd7afcd8431bb05139410cca732f427fcc623dbca1d44f4f61c76c839ac9b", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "467f234b-fe59-446a-8c16-0b49b0e7ee6f": {"doc_hash": "0b632bdf779e62c8aa7d2a7266081eca285bfa6064a0be126c070b97c12ca310", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1328339a-9fe4-4da3-a0e1-7ea5b565528b": {"doc_hash": "09816e0d7e6e25cc08538603231f563d574c9c010816840fac9aa01f372acaf2", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1f7dcbde-d06d-417f-8c04-5d71820fdff3": {"doc_hash": "27f78e25a35a5f358f189d4e5c2f65c5c9926bc14e87f2b73cd3bf1b1a831883", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce": {"doc_hash": "44252e20cc2d85812017a934961e9e848023afcb96a44f39ec35370a695031e3", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "69675c15-03c6-4890-9ca6-4499069ef558": {"doc_hash": "3f81640268ef82636343e94e47278120e9000b1950845040530439558bdb859f", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "0170d41a-778c-4f75-a556-e033b1335d14": {"doc_hash": "4b252b6020801f981ced0ac0f6e9cc0f88b4fdf52010056b5bde1938f07722e7", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "470d2ed0-ba69-48b5-9f45-55e61585f0d8": {"doc_hash": "ff7bc31111c08ed10e352d361f48885e7467e5316463a09f2d3550d19ae9a58d", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "f5177268-9f9d-428e-9820-0719e4f37732": {"doc_hash": "949379728322b9a28b27c4b449f795ebd3d9c85bf46a936778e48c8c68c60f1a", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1719eac8-bc5e-4944-8c49-6254d98e0102": {"doc_hash": "f198f251ea210637db2825e0763339eb1abe8fe36b24ce81411424d583884414", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1b6a6dab-a62e-4d86-9e76-29257e6c624a": {"doc_hash": "4e0c64768ae344aba485660b504be0e0970fdf9822ba3e8b51bfaa77484cc032", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "0487795a-fe00-40c0-9b89-988edd10f90b": {"doc_hash": "42fb398b383d655d8b9cc47368a5e19480206beac7384bbf0839621f2f9b9885", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "150505f3-cc8a-43f7-a7b1-67e44217e59d": {"doc_hash": "1e730cb141ca28ffdc57a731141d65172077680d24ea19fc1e1c0de5d3f60a55", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "ab945228-ca19-4b31-b766-8ff60081e80a": {"doc_hash": "8657eb53624dd28dc202abc7585d3390e5c844aa0a5d6a3a801d0be418e760f4", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf": {"doc_hash": "08dfaeb5d6c1026a63829c40997c30f5a4ffed1b0fb994eb5411079037ad5223", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "b11519a5-c811-4110-a295-e1ac1c1b609e": {"doc_hash": "73a53bf041479e65ae8e4ae001bc42ad1f1058d5d973d65c8b0ab4a41b7771dd", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "07c9530a-aba6-468c-9e51-35a795f85138": {"doc_hash": "5255fc64470946e18c15a9baebce08c64b9e76b49d349dcd9a6099c32799e3dd", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "2a480579-b271-4725-800e-c44182f263cd": {"doc_hash": "102562ccf9ecbbdcad7cee6561ab211fe333c85acc11a8ffbe9d7f3d354e589a", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "72f86a08-7dd3-489e-9e86-683540daba91": {"doc_hash": "23c68982a686ee435ca91acd70fa5ffdf69eb35ebc910714b8ba3ff3b64aae1c", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "dec2ff41-0113-4c77-9c03-0d60af25f621": {"doc_hash": "a37e70323c16237fdb3af0dd32450391a1bbf3b1fbc0751584f5b9a143042b61", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "751e2230-fed6-4028-940f-3b4c939b2f42": {"doc_hash": "25810c7c415107e4b8178cac0b22bf5b6ab453e8510124001f0943c7ead58376", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2": {"doc_hash": "41d80fafa2f4264ca5b3313cf680c13188dc892ba6cceb45cefeda39471b25eb", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "83900a24-e963-4b19-903b-44f532b35727": {"doc_hash": "22a98a58d0c18d1140d80bad4e1ce8d71177bea1b38a1e78bdffe5250f769735", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "665f6d76-5eca-45ac-aaef-e2c67b56b100": {"doc_hash": "b55f628d25918953a1cf92e374ccb37d0314b835a21c9225288f58b6a0ae0d26", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "1967b0fd-c351-4f14-bff6-8b824178084b": {"doc_hash": "1c269c37d1c4976ee4bd56d5849f3c330697a5059ce52c22ad1e2c7e713c8d3f", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0": {"doc_hash": "012a37dab1f965ccd7536a7b64cd2deeb8ed27ac6cd05fdd40e9a8ac07eb5a07", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "60b1d59a-2bc1-4436-8ee6-924601979425": {"doc_hash": "0e2c7d317fd713847004fb2562cfb3ca736e97162b0f6558c9df323772c0d9b8", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "47960c3d-65b4-413e-9fcd-5936c77a0263": {"doc_hash": "b27cc341577f56703ec4fa1d1f1e497724a9bbb91a05f518ef4c293fd15cfaea", "ref_doc_id": "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc"}, "d2738ebd-3eb8-457d-832e-c7f704aaf7bd": {"doc_hash": "feedc4a0cb8b82f22f16b859bd43a371d62a9e5fc09441f2b34f3e4d30991baf", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "cf51af5e-b8da-4952-b1bf-6725a67776dd": {"doc_hash": "3198ac7738dd4190cb3598ad869d0fecf5421b322ad6bc8cf2080848910f5efc", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "0cb64771-51c5-4e1b-a5f2-dabf86b049c5": {"doc_hash": "98c6c44540cb4bc5d006dfd707105cf5c9bdfaadf9ed5394a3888818335a22db", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117": {"doc_hash": "a62e9eac4f110fba9d48e0cb6ead52c3fd8961034e4a1987327f282bed300bf5", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "ddf13643-7081-4de8-b470-8f7c0236e1a1": {"doc_hash": "e1bf4ca0d01e91b6091677265fadefc80a0e63719b04aa1df93c52e5e3d7e233", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef": {"doc_hash": "297ef72432c44740fa5c02baaf48da10e70339f84abf3738823a5b51d5656cc6", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "66169882-127f-45c4-a776-caf19d0e1f61": {"doc_hash": "beb4d4c538cd51b0e4efd9c4b2799b2142783844a3b45b0578d6a4b1b7384746", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "d848ddcc-c9c3-43f1-8d69-689b8a63f888": {"doc_hash": "1cbb9f10b41cda09ba0a4299cf28ca5ed6cae72c9791ee975e81ebadf7bcb201", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "99a00ae6-2492-4440-96e3-775af60b6268": {"doc_hash": "40fbc9c374b20211515b3eba868e1ed2707176ea24ea10082f4d507204af0e37", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "5743eb27-c97f-4067-bda4-67a64e899acc": {"doc_hash": "2008418934d3f8b9dac09efd336a795ddc24df75b69e3d90d3c604c3fbaa8ee7", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "34e2acd3-ef61-41ba-b400-685cfaeacd85": {"doc_hash": "8c39f2b5c27cfa888dc07167294f47183bedeaea9546487b8c1a225e8abb6d88", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "87831237-90fa-4424-83b5-fb5dffcba2e7": {"doc_hash": "333b8f345e3b65cf9d9f7a8454d3c1b9d012556681e96fded6c848fd9834e874", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "17f79297-e729-404f-bea5-a2c508efcf15": {"doc_hash": "87880fa0c3cec5d102694f14e4c7ab5afd65a64be6faf091045a933e3aaf49dc", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "55ea9310-c28d-41e3-a1ee-c66a9e13e96b": {"doc_hash": "833ef3d25844f214fb834fb8fc40f2e63a18a113d560bbe4695a5ae947920123", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc": {"doc_hash": "06e40f00af2eaf46bb931b34ecc52f324d6dcf6b609844cb5054ddd6ffcaeeaa", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "179f2260-96af-4988-8783-df3e61c6ff58": {"doc_hash": "35f1c57217fcba708ca74a94a8b6f485292b998384d64abf0c91ce623bde5275", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "e49a92dd-7bc4-4dc1-847d-19cbdef4d113": {"doc_hash": "87c53b66fa6ffcbd34bcc184fbde86bb1459100e5daf5d21aa04487eda608378", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "e8d33700-97f5-4edd-95cf-a2e0c4700edf": {"doc_hash": "7b233685096e21f84f33455fcdb8ca45319ef974d94101ac6438caf2a4165551", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "7dad53a7-5623-474b-8da4-1c08bc05bc00": {"doc_hash": "a204f2fd58bdf60e33c47f3ccb897f567fe1846a4f80025ba790052d81e3cc6a", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "bd893f9b-ffc8-4375-bec6-6ee62fe7d312": {"doc_hash": "e11473494a4251ebc984a304377589da3c3b402fec2a4374e360fa383ca6eb91", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "7d1e90dc-a811-436f-839d-bdcf83cf08a2": {"doc_hash": "b6b22c33275cb6ece2a9d26ca09eba22619a447d7665a6cf2461cef9df75db99", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "2ab3a169-ccf2-4450-a4c3-987d1ae3570f": {"doc_hash": "188571bd5c8d6f1132037c6e0953badf889838a7295b0db2659b9bdb4222f710", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "66956909-3cd4-49e1-a23d-f9e9e5a0519b": {"doc_hash": "9f8853446600a987ef9dc24eade35dcbf247064e01f5540b91233c07ef31727d", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "cafc0e69-980f-4d2f-bd7e-8230c26893f7": {"doc_hash": "063c88dcc9e50ef7c82940473292654f8e479afb79c6854b6dcb60169839f8c2", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "1270ac96-9775-4b56-a287-20230defa564": {"doc_hash": "ac7dddc956fe100262b42d91968a34699e0d7882cd1faeef273a9c69bd7d9bf4", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "601fa7bb-abc2-486f-a521-eca1145b5ceb": {"doc_hash": "abfe2a65fdb20146cf441e33007fbb174f759a11a1b06521c611f58874ede8a4", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "4fafe797-bc26-4395-94bc-3cdd8b7967e1": {"doc_hash": "12f9ca5b246316f7b1a823f5e012fe80f9900c62c6ba7f8d4027df6be3243c48", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "5d8c9563-0699-4fb9-b1bc-1aa02a43deab": {"doc_hash": "09fd383d342f597aba1b3126ddbffd032850b9b761943656766f5e714ab26db6", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "c843a705-d066-44f1-b5e9-290bddce00fe": {"doc_hash": "8b338d04169e03afec15e50c84cdbbda4d0f99eacece8ab625292251ec5ff77c", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "cfb0a393-7e78-4739-ac51-85065fcdfc39": {"doc_hash": "7abefe9e19abc5b80201c560e7b6c59a2ba947dc04939ea7affd62f8ef1edb80", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "d99c1b11-1f1c-45c4-a242-d60647a82cf0": {"doc_hash": "a0a84b8b50ec10079377e0b4aaa360ba12a97398a4c392718b8ad439405ebe73", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "497a5e5d-ea00-4156-a0f1-0e76bf940582": {"doc_hash": "c7f9fd70f5f09c891a46913e0ae529ae4fc2c173371fd38ba96aee9df3c269f5", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "fc4c9b15-4bc1-4a09-8253-c63184ed18b6": {"doc_hash": "8d2641b3cb8d7583218e3ca3dfae86c05196d9ff160d07fb6cecb300ca9f25f3", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "526eeaf6-0850-4fe6-9f43-6440c42689a5": {"doc_hash": "a3f1610a202dd65c6ce4fa36f99973631b1c31e9634f783383a5eee5c183877a", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab": {"doc_hash": "45ae84cf2044d73ac9d1a43963c353ec33f9081ea32d9f088abbed7fb2061b7f", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "dfa29760-d276-4e3a-85a0-219dd8a3ff17": {"doc_hash": "a6560d40242e2e470d89916c2f58f58580f5c00a30e26ddf0a446889a78e3cdb", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "a02159d4-8490-42bf-9736-cceaba703747": {"doc_hash": "ca4473c35ba52cb02088e369af0d5b1a9cf9926f2f24cfb09e360beaa450b4c9", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "597f6b04-5676-42d1-b260-aae04b76d60f": {"doc_hash": "503b9fde4e1b607731af059df85549dfefa3cae8ae12dd189e1ab3d555c00350", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "ea84f927-bac8-4d87-a38c-43bc3df4cf2a": {"doc_hash": "89a5feb677291525d8222ed1b27233cff9cb23b3066e00a197f189816533bdd6", "ref_doc_id": "85c1c682-fee3-47d8-8099-7a22c82ceaa3"}, "bb1f3df9-daf0-4318-b8a3-15b67c6f1a28": {"doc_hash": "a5772f3f9de5c05e244099dce65b64d44e564226033545c2f8aae568e5121360", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "04e8843c-98c1-4f25-a718-b5c706d7aeb0": {"doc_hash": "be65f16f45c860eea30ee94da7f6f99622906e34b4709b39dd62bb23f6174713", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "c8712560-79d1-43e4-996f-5921d4575f19": {"doc_hash": "d48d547fd002e62d95bab202eb338bc408f99f36bd4987a4b85444ea1885ec22", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43": {"doc_hash": "6820dc6c3fe1665e59c8d3d51dc257c7aa2038c62ebfeb099c7273fcee1acbaa", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "62f4f7ba-e24f-49ec-b2b0-96680696375d": {"doc_hash": "02abff55d8928987b2269b9a568b58ea70cbc712e6e22de4cc61e1bb08fb7188", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "ff714d89-7fbc-4900-8ef5-cc90567e0450": {"doc_hash": "36da6ebe03f630d2f66b785f21011c2918b637530ddbd6e1a2b927df6274f1d2", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "184747cf-56d3-42be-af3a-b61391ff9751": {"doc_hash": "64097358b8f425d513c21461f07717ee9ee2e944e8b2e442ff7390af8fa470ba", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "5453fe51-e646-40b2-863c-5501a9fabe39": {"doc_hash": "8daa2807f6a8d1cb1c093f5fa1ddaad6057722aeb069cd87a0210502939ae8a9", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "dafc3286-829b-4796-8ab7-35dc23f04152": {"doc_hash": "6c92a9c88fc3617e08ee33e38df7fbb5a0802737135136831b97509e877c163f", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "bad40d9c-4172-4137-891e-e04b40cbcc28": {"doc_hash": "870a913b142f5e39293497d1cc23bebe3211cb65e2f228f5ed75d99cd2a4605d", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214": {"doc_hash": "a7c18b6d4d05ac8b3b823ceabf7b43b0aa0ae94ac95e97e432e21d50fa60e8ff", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "6b5c43f1-e90b-4df4-a442-c1ed780a04d5": {"doc_hash": "d1e4c4d2d42a9aa2bfe4376872ac5eac36302f064a691829082aa0a69b96dd48", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c": {"doc_hash": "691738418a5eb7794db720dffb561382b9aaea0d9ad1c9a66686d097de2a94da", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "795808fd-72ef-4cd2-bc93-edb3c974d759": {"doc_hash": "29fed8c82e05f41f17f58d272ca7f296877897c568daf3317e8c8380d21fe055", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "fb9850a5-52b2-4a5b-9eb1-334bea65d434": {"doc_hash": "cf50ab7f3ac5d3ec8f7d6eea9cda3dcb4ed291e05d6bb752996ad7019957c17e", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "046bd9ca-bb3d-400b-aee6-40d72019939c": {"doc_hash": "a972cbe85345a9ded31a8c7bb2ccb595292d1856049d285cbb5d38693adaa508", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "9724c6a3-ce12-4c10-8819-8e259c0fd53a": {"doc_hash": "e36bb6004413f21757b2a7883577953e1f216b342408f49a1bed540ddbf823c7", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "0969fa8b-6af0-4227-b59c-c77ee135a4eb": {"doc_hash": "9cb9237326fbbae8b094ac1e051ea8566340a766e22d35709c17d05857e62d7b", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de": {"doc_hash": "d2b382341368e88cce13b40ec6387232a3241d05f4b3624eac06c27f51d99f5d", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "80dec3cd-706d-4bf5-b8b4-a5395c452fdb": {"doc_hash": "a51360ca3d041741491613811d07bcc7116eb84ea2ee2ca9b129050ef6180d99", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2": {"doc_hash": "d288c13854b7bd20d9f1237dda7009d1a2f1987f9d393a6f80f21507594a19b1", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "4d1905d7-2d1c-4782-9c43-a179ba09a937": {"doc_hash": "fcef85a835ef535460f34cfe378ad4f32eda293b7ed0ae2399a45a98d39cfdcd", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "8c31712f-b362-4ed3-91d0-75a5a2a2673e": {"doc_hash": "7048d723dbddfc091d23a9f0b8ba0b2954fe93f28a6ea70fe702d525d280d547", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "af2bb731-21cc-40e1-a97b-b6f5868c07a7": {"doc_hash": "d491fbf44682bc1a87f6c1cda89b71f37fb9478633444062d182f6aae45ad0c2", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "60811646-47e3-43bc-b02e-81fdae97da6c": {"doc_hash": "c312319d9044d631fb4c637e06c595a65fb50db1dbf2985251e0597b99d08ef9", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "4d2b939c-dcb2-4902-9f6f-7383b144cb56": {"doc_hash": "5db7439219d357f7675f20338a7eee6d268e207a8776361b2ddddb524a197ada", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "59d8adda-f568-4030-9215-d41f6a2f5c06": {"doc_hash": "937ca8fc1d535c9231624460d38c546acdffc45ce3d9f2936c89c677f571e70d", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "ee60b070-0b6a-4248-8a46-2986248fd2e5": {"doc_hash": "8d1ec896fef5c97cf5a71eafab75fcfe955445b3f4852957a539c7813573afcf", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "b2104bab-0a8f-4fba-af9e-d15afce4c8b0": {"doc_hash": "8248454e35c08f7514e5248a9bf1c3888a9dbc6d5b3b92ec2a01639f5bbf9884", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "0835b4f3-bf55-46c1-a1f1-0e5443392c88": {"doc_hash": "edbabb1a8c94254e128ee427767d2a8b4713e2e8e6a7acaa9c8cfbd3be19de38", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "6dbaed9d-7410-4aed-88b3-a38c8d03f786": {"doc_hash": "3420c4ab77c13e6f9a7f11605ae17be000a2325a3aa92930acab5c60cc3e62f4", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e": {"doc_hash": "f61bffb5e738ac601187912122a1f11936d1e00dab20d23bf6cd9af686a17fa4", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "8ffde1fd-4af4-450e-9174-a524dce7b260": {"doc_hash": "99ca9013ba77f601401933e5dd7349371fcbde40bc57f9671465e7147c7011d9", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "8004bc41-723a-43b0-94bb-e9109e762a59": {"doc_hash": "21348acadb6e11f3adb90a0e585e72c445cf235f77b8284d43e902d2e143f5b4", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "fd27b1eb-1d34-4dc7-9300-a70554f1a28d": {"doc_hash": "8cd106aeb1c1e5c00fe0a6c23e779d5a805e2c24f12d67e1aa52dd8fbdcdc1be", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "89d4b50a-7153-43bb-9c4b-a12d4d1214b0": {"doc_hash": "9526f18149573cd15bcc9aae7072be0e683480c054bd909902bb65caef018ef6", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "2052f3b2-97db-49f9-8966-f088c1331719": {"doc_hash": "a27c33e64f0deba1815c8225e59327f7c47e06570a486cd1aa323ccecc51cd7d", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5": {"doc_hash": "c01d2c2c4ebe84767d3d45f1f091a155e911cbe5fcf4468fcb051bc2cf32d1ac", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "ddb55fbb-ef52-4117-bf6e-bf176df5fa08": {"doc_hash": "b545895f552f286f84a13736e2116f0bb1bbabf6eaec5a74e18ee3cdd9ced00a", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "b78b392f-67dc-479b-b1c2-33e2ae9f56f3": {"doc_hash": "18c5bb51ed45d7ea456374bd750217c1653f88784fe178157cbe0cea189357b4", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2": {"doc_hash": "29f0cce1d9a3f4abd9a30b8671ee9fe9742d61f43522bbb8fabdde93ac431999", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "c6f55b24-22c6-4b90-a70c-e1bb58277915": {"doc_hash": "f65aeeb2548aa9b7a8b99d974f53d81331c8d12aabfed140c4411f381a4281ff", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3": {"doc_hash": "6b5379e552d92a56af677da73259c2ffc58ca3ec01e23152f29f1fb42e6188c2", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "c4bbda4f-db47-4d20-bae4-878be10dfcbd": {"doc_hash": "9d2cd6e55c54b0ccd4a7e016d8da1a054dc08d92573f59eb73448a7a71bbd621", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "ff37c70e-cb7d-4660-9ba5-659cbba7c912": {"doc_hash": "808a95acb53943b552006cf486d88ef3e5392765bdec85f845b22b809b395545", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "c0e95903-e8b4-483f-866d-5f6975196e4e": {"doc_hash": "feb898d54e5ed28a8d5f60dbbaa500041af10d690da7b42bdb902326ded655b2", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "926461e9-5510-4475-bef1-91ec7b7c8e32": {"doc_hash": "22effca6e68187df2cf0e368846aeb633156653e6974a281773556d1c1022111", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "b6662cd1-3366-4ed5-9850-3f71e5c17b27": {"doc_hash": "dba88c588ea667a1259f1d20c03dc4a4819f4e39c0b92fb4f5ddd12213f8f7cd", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "b99e2c2e-6e6f-4124-a97d-de6181ff3676": {"doc_hash": "1598aaaa950559f3ca1ef77ad5ea74f3437a1acf9b9be45f3f26f37e7541d8bd", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "08d6ebac-a5df-4a9c-a3a0-eb07bc556366": {"doc_hash": "dcd409e7c296bcb7f9cfd0de1e9f3b1327f111a0d258e05d708dfe08eecdcfe1", "ref_doc_id": "659eb64f-95df-4d04-aef4-d5b54ea981e7"}, "4008a047-b46e-4d9c-8c1d-fa2df4908d00": {"doc_hash": "b7043adba349d1c354e2d3013f659f613ed860f6bc9e28a35b3e9e832bb7bddf", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "130e5868-8815-4f04-a588-f13b974c410b": {"doc_hash": "5d8b1c29263e91b5dad2aeb70d6f6d643bcd8985144b714ca4c00d39eb943109", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "db356b52-9965-4bff-aec6-d4d2b096b8a0": {"doc_hash": "34f2fc089d8aa5b3be8e775bf794a6b26103d1cf09a02efd289fb030f07f0a22", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "26af46d5-bebc-45f2-9520-c5eaa277daae": {"doc_hash": "da7e5b95be6806bd11d661fa6259c3a199e7b7659b03c3c197f5cb9fec9a9919", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "f83bf4fa-6a26-4287-a4a3-2a93c3495115": {"doc_hash": "e382f53fb2cf34cffd5e4b50be8992779716508f70e0b2bcaa9ef28156c08e14", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "ffc927bf-0fd0-4f78-9144-510ad3e0a498": {"doc_hash": "6830d7121491cb1d70c1308bb1cae36035504b3020d4bd3425d3e72172ab1702", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "bff9e035-9fda-486c-b57e-70c5bb41bd43": {"doc_hash": "303e507d92ca79278f3375943c18892f84100f30710d0735c910287ad8a439cd", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "df5d6e30-47c7-4b9e-8566-522ea7950864": {"doc_hash": "7d1303d78bbc7353eec56260f48701c34229daf7ce752cddc460d51a0219eb85", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "2fcac4af-db12-4b16-be5b-2dd4b5e3f106": {"doc_hash": "b45b6039305f252835c141fbf659909dee9e5a8a7cfbde0d661c7c4862523d2b", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "0258e207-4185-4aad-b97d-383ec1915b0d": {"doc_hash": "35e0b1eaac0443817befc8e7f5b6ca238f3b330ea438720487d4909c485c4442", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "407e0340-65c9-4fb2-9de6-43b244c935d9": {"doc_hash": "0c1db5e755e7a521a932b8b0c1ad3b4ca6c1abcb2dbb76610d0f3ff7d72c34af", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "8371396b-dee8-4436-bbf4-b3c5a8edee84": {"doc_hash": "8bac9a191653833740be1c6d653251edca9028bb3521385e1db1fc80647f2169", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f": {"doc_hash": "31abc507697b1ca01e05c47ca76a7623364df855774a964378d52d70c3ce8b73", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "b9b024aa-b88c-4764-888e-df27c6ab392d": {"doc_hash": "42302d9575a6b924680609f5e3266b22ffd2000e8f54c09edf7b0e4e60b193a3", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "e89030e1-0d78-4ce7-9696-a75cd73b997a": {"doc_hash": "d72ff8330f7d49590103a983bd32c38f653557d0ff98c5a378cfdfdc5c0e9959", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "05daebd8-ea1f-4473-abdb-3f2044aa35be": {"doc_hash": "dbbacfd041fe2be962b878c4485fe596cc972481cdbcad149f3aedad4455e888", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "94328f26-243e-412b-8e76-fba52cca218a": {"doc_hash": "0e7ab5bc08f30a460f365332792743abfe7125e30d2883df11c8ca20e3a1b450", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "c730cf0b-bfe1-4b19-81ee-29680b4c135e": {"doc_hash": "45b9d30b67eadf4a78df47888380c6dd6f006113824745c054ee36e7aa4a413d", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "f43da9f7-bf27-4392-be1e-5ac99a8d55cd": {"doc_hash": "f5da74e4b651a011201f725878e0bee29220e2a9b3e9ff66b465e5e0b5c9b9ef", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "16f591ea-dc5c-414c-8f3a-084d207ac9d7": {"doc_hash": "1690fd4db16faabcc9917054846c8e4883cc77f0f1d6c78116256c09b34e44cc", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "0122552c-276e-4d2e-b74b-e0e3b3071976": {"doc_hash": "bbb348984a439c8178c46d34b52d3411bf346d693f31517a546f842458450420", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "dbd0c1e8-cc84-4983-a348-7c05544b666e": {"doc_hash": "cbfedafdd08f72171269fe9687ea2a09c4a8d051280a6afbd98cafab9ac2416c", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "ad7785bc-edbc-4416-990a-caa14197da36": {"doc_hash": "cc2b1925f7d4a28acd1e42495733bdadd05351f63e99e81b7c951d131c3a1b01", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "bb7cf1aa-09da-4aaf-9188-7637629cd7f2": {"doc_hash": "c44830085411727d819bbc11391ad83748d2e17d30e3b057cad0c752a77fb3d9", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "403f3605-5340-4a16-b1cf-091eed4b7a08": {"doc_hash": "ee3a40a4259bc182229483ff080fa37d678865ccff427814490e9b9db1e81814", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "152feb8d-114f-41be-b28a-b7112c46a01d": {"doc_hash": "7749fb047f9fe9a0ce05248315e913415befc1bf9b288f63dc8404200aae625c", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "7b6da42b-7feb-4aa5-9132-cef750466183": {"doc_hash": "970a37ca18ab83bf9412c576f012c2a1e0dfbd99e319848606fb7b94de639646", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "a52d05e8-0b38-4970-8d48-158daee72380": {"doc_hash": "753e5bac36d096a086a247066bf8896ffee70b3754e23bc98f5517057747bd2d", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "846cf9ba-b4f9-42ae-b035-def750af0f0a": {"doc_hash": "d7ab3d4cef55632946321df2aa61dd626fb87478399663405d1a6ddcbc78868e", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "35add517-718c-485c-8857-548542f18750": {"doc_hash": "643473034a2065b4db30b06e4e4003ff97818ce0edf5de1554dd60fc23c537a8", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "832d2d96-d5bd-4b46-b3ea-c388b541b27c": {"doc_hash": "d50df6432edc9347d150434365d6b91b4f176a07e0528e23bc8401395f36fae2", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "aaa5dac5-9964-4c74-a71d-036e7eecdf1f": {"doc_hash": "ac255928f4a3e64cc07be44ca4d679c56e5690218024f01653d2feadb30f3b70", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "dfa944d6-786e-4831-a225-a5d2b423a383": {"doc_hash": "b61f1c8d13a92a4429ea44ccf577ef755100a2bb770649e2fca6d966c7c7505d", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "1bb0a9ac-f003-4248-8681-79fce599f3be": {"doc_hash": "5c72a0a06a1a4a210cbd499b56923e20fb55aff31c86e1a55c8ef7cfc3089bba", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "77d61f82-71d4-4404-80db-76c295d4a952": {"doc_hash": "8b3772af9eca62e60cdb250f4ebbcfb014df2c01ccdb36df2f86d70cf93f4acd", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "64194f12-4162-4967-b6de-10e7f273829b": {"doc_hash": "be56d4096a6f9b9d25769f0115e4ee483e65348a5e053f8532648d182287843b", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "75a04cfc-e435-4614-8b9e-d485d61a6432": {"doc_hash": "9ba7437b76eb16519c494bc439b96ce1b9ecba1927b5009f253c6675b5064be1", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "dccc76f9-0a68-4d37-be28-a893c80fa60c": {"doc_hash": "7f28ee78ca01ffe4f5f5cb8a2793b6d764524f539a866a22cc057d96932a19a3", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "eec74176-b1a8-49f8-a583-fd9a4415edc7": {"doc_hash": "3eb060a15663bd8ddc33f71824f779a904a0a2315ac5adc9b2bc6b22415a5acb", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "d041cf87-586a-4330-a205-058205b59256": {"doc_hash": "5fd79412dec2218d06f667ea26fc2f04d74ea713eb49aad2e9fe185ae1dd92db", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "80530559-fed8-40ab-b5c3-6f53a5e15e38": {"doc_hash": "91d45582d50fdf323a7b25bdb3e2942b259a5abd6f8dffd2dbcd09aefc206ace", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "b6adc80d-7788-49cc-b7af-89cc7b105ac9": {"doc_hash": "f990020975884c69174251f58492a93b222e800e66f81c5720dcc9a23dd45a66", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "6192e916-226b-45cb-8647-fe7c84c46f0e": {"doc_hash": "fd32573f2d94c65667ec41909df0d4ae2c09b9e7058ac7a84a20de5eaa7731fb", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "90ba958b-960a-470a-98d8-96d34068c2fb": {"doc_hash": "a07ed704667ef3fb9da68ef48d6e302c353cd643c38e2215d8f87665d5a20091", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "bd3fb0bc-ed66-4d02-8d34-9126e97284c7": {"doc_hash": "0adf8f9d4958bcbfa8ea00382e0f01b4d7e6e69ac158c44f6f27a1dcbaeee26c", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "0c2cdc5c-7450-44f9-8999-4f46e1177324": {"doc_hash": "d2c5ec13fb905db576098111525a97bb816f66e11f08288b4665bb7379677137", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "22a9d222-27c6-4347-8ff9-aff6d066817b": {"doc_hash": "7ce113336c5383ac0d14b673e066dd74558896fab48391717854b2a502ac108b", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "a563ed62-0705-45fd-8293-ec76e7cff961": {"doc_hash": "6c12eaa8e9f4c690f8f9991441ec92cbf424f5e752c5570e4ad0a9d360027b64", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "db1e4601-8f55-4cbb-9180-f42efb196379": {"doc_hash": "7a799ac26ab67ca5b47b7dca533494415c57340a1d218cd07bac678648960a0f", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "91062fcf-d4c4-456a-bc51-1c2ab063d494": {"doc_hash": "3a39666e82103df4437bf2fa3290c463e9d7ba44e074c4477af4558c0a71abaf", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0": {"doc_hash": "411c2442efceca92d56cf73084d323c49685fc02d137e18b02c85559b81faff7", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "3d770a0f-94d2-43cd-a18e-539002be3a47": {"doc_hash": "0ba7dade0bfcc6e17e0089914f8711a6e32ad8d5c10af97df051c755c40b3e4e", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "7dd5bee4-c86c-49de-a558-00f944835b7a": {"doc_hash": "2db9bfbb81ab5950fd60c51545d2d6dc406a71f348a97b784f06cb2420a4a381", "ref_doc_id": "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008"}, "27d4793f-2900-486d-86da-91c2ade01204": {"doc_hash": "5d83c554c0270ec88563419c97ec48628c9e99dd8e070b262f90d6a6446f4d36", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "183f8861-8164-4945-b18e-3bfd301eb00e": {"doc_hash": "7529acc05cc8b34c8abc70835a9660d9abb8e274677cfcc30483650b15418a57", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "25069839-7bd5-4554-88ee-3fc9e89e6f08": {"doc_hash": "fb6719b797074b7f5b482b1a0daeecf54bb6243aa27f21aa5ca9f03b362d7fd6", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca": {"doc_hash": "f19f3e23e1c54bfbde46f1dee0fc0532f43fa5bf2b69d9ae211103e8397bcb89", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "c7d55395-673e-4740-a4e5-37e6c22cd053": {"doc_hash": "ecb25b9b3fdec15d2647ffa16e3e6274858c0ab9c5a81a5d1b5b70e528131a94", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "9f1db7a3-fcff-490e-b173-8108a78ea571": {"doc_hash": "e7f0495d72834b5fcf2a51db633a6c952683eee8a30bdb5e58ba1d9931564e4c", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "eaf5966e-a969-4a7c-ae55-6293749029d2": {"doc_hash": "98b47256a5452744a46b826873a9a02ee517de9fa5d45e06bf9069666e6d2d6b", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "0fa2ef08-c47c-484d-bc26-a578607e4fc8": {"doc_hash": "4edb777535fdb91483a068d2bea4043d31efc2931a9929d951c54fa3b4c7d347", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "088dc78a-815c-4df5-8fd4-92a541b51548": {"doc_hash": "dab16f18aa2f8058a4e3191ea836c9efb2c860bcb420bb5eeb0b77ab67913731", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "9842b21b-6c13-4ff8-8e73-f9f5853d9aec": {"doc_hash": "daca914c01ec8f8b20244cf71adf0c36bfdcbec16978b59d5893139990b8668c", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8": {"doc_hash": "a22a9db52088ac19ec9d0d37dc5481a8a97492bad25900ad8a93765464954044", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "13fd4d8e-9560-4c43-809e-bdde10d02994": {"doc_hash": "6a69c2a0e5719728fe1251c22640a7ebbf066d716c4813bf0ea346010291b851", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "cc4ecd11-0086-4f52-b717-71ce15476155": {"doc_hash": "9ef2afc9432251cc237c4df8a5c21939ff178f062fb62349319603e24a16f9c3", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "2b499cc1-a8e9-4b0b-9161-5a4c2f798246": {"doc_hash": "bde8519103444f04713e3beec46892283a0633f673f8b2cd9c310c9e558e1897", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "1f07082c-63d1-48be-8d24-26e8086a704c": {"doc_hash": "d27a7df18525171fc9ddff4ca027f4c1b282a2feffc9eb10a7fd6e77448c6516", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "74c904c0-427e-45d8-ad5f-78d15d38f02a": {"doc_hash": "80003240fb99c7846476a825d844b487ae3b387b4bb179ae889fa26f962d575e", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "cddebe8c-8a51-48ab-a07a-9bf632fe55b2": {"doc_hash": "01de5cc796273e49156a7d432f34c54aafcdd49f2611534ed4c6f8ac2aab555d", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "4a06371b-eae7-420c-ab2f-2774b3541b76": {"doc_hash": "00b2b8df22cbdc43d3e82fac30ecadef3d86ec866d2c36ad13e7912df56994fe", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a": {"doc_hash": "3c8886adbff013cabb2ac7ef2d54f038cbbdfb33646dbc952a7c79564b12640e", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "427711d9-027b-468f-afc9-355f4289bec4": {"doc_hash": "c8b1964ee7667cdb629a5522d6b1fd8f49e6b93a9b1fd8efa2528f7d6973b139", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "606103d5-d433-492d-a6fd-fc01aff524f7": {"doc_hash": "9e29eaaca5c93c7c016261d186e68f10e660eeec9c7a5d6557496a6cf7cb6409", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "d00db7a9-73e5-4284-b78b-f111672056ee": {"doc_hash": "97ffa2d66cb1473c502e724238c8b2bce8c694157743599e4009251e3c8fac0c", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "da865a67-5fac-4dfe-90ce-fcbdacd21e25": {"doc_hash": "f3e90e37f1270cbd13a565b7ad5a0b4ca3deeebf50448b5594a140f478843dda", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "74da753c-7d50-4a7b-ac19-aca899883e76": {"doc_hash": "c7ac60eeb1553a1a1166f28d315d04f2f416bb53368ca7031910f85f2ef7f266", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "34adbcaf-c87e-4fca-89d3-36ce84a39052": {"doc_hash": "8996b83e7d7fd6af324b07351bd92519ccc8e7f02291e40e4ea43494a6ebe27b", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570": {"doc_hash": "50503131492a8a6f48507bff1d53f1d2dfd1cb8e1c7fd3fe10cef9f1ceb281c1", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "32f35bba-cb67-4778-b0e9-b439df6f98ee": {"doc_hash": "588ae148df423983839d8d849e38d9c7f6fabb51343ed85c198326bcf35418c9", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "2a7efbd1-ea64-48d7-9c4b-856fe3d19297": {"doc_hash": "aaf7789402dbac23e4f8ee91d28878d803397909880c82af0bcdc3a906878421", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "4720b41c-6f37-46fc-8ee9-68dd6d092a3b": {"doc_hash": "a2f540cbc0d853e6a7446cb98ab742a0b8caeecb466b8db3bfc519e8cb15ce97", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "5ec8e2a5-a37f-481e-8215-a41e1365ffff": {"doc_hash": "bb56c28eb6e5ab76bd234c8ed22961fa864f8d9b41387967904d4e510d6c5b1e", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "ef5225db-b017-4bd4-8faa-8ae84fe49a9f": {"doc_hash": "7c52c25cc7ba931c880be7c7ade7630d344aaea562516319027326da8863b5ff", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "813d549b-493d-49dd-a2b2-6146c65c149d": {"doc_hash": "713af25821c390308e4cdc524f3c5d5a573e38bf63490036bcc3d54b6975d427", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "f40a383f-761d-44ec-9120-b695011c574d": {"doc_hash": "c8eb4fc124c72799e0cf1d37614d3bf10b8bb503fb29a3b578e0c3b23b882be0", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "d248c887-bb0c-429e-8e89-edfad55057cb": {"doc_hash": "3a5d305906b1c5085ba36cce284b6b8937672a666f91eadc33e0c8536f49fb2e", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "a6e45e54-853a-4a8e-ab59-146f73435322": {"doc_hash": "2e1c8ab738ead7f2fd7bfb77da6538ddc14c729d0f1149723f9a23cedb008179", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "b2b8c820-8d8e-435b-9842-a3eac1ce9c32": {"doc_hash": "e1cb224b22fe86190cd06bc0b89f40c7c7c4cd333e32580113347daee4f82f57", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "fd8515fa-68e3-4729-94b1-f801c113cce5": {"doc_hash": "08deceb446b8e6053469be49c18eb5f444d05b56422b35ad52c73775d1d92ff4", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "6f1207c0-577e-4ea6-87b1-ab81005adf1e": {"doc_hash": "69bc26d14363da62fc9c3b78f3193dff5b3f46310ce5ea2007296a621cfe6250", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "5104056b-fc7d-4566-8e86-72997e6f1b38": {"doc_hash": "53b04c88601a6e1dc262e258f046b29cc929121f226039ebb668b958355c43d2", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "604d8a1b-d122-4272-8d5b-a93a459fe66f": {"doc_hash": "9558da1b4b0bfbdfa5e2738a32d2343814f855aff4ef223f31c28ee4a334908e", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71": {"doc_hash": "0728be2610ef97fbb638bc549c38369d103fc738ecff4ed1c804f2ba6b0bb95a", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "6140d053-f048-4368-be20-13a774ce1c77": {"doc_hash": "19ab44a602b00db541ce0f5b2feb64d1e31f2ebc0b99f863d494a97feb82f8e6", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "d99f0559-49f0-4571-b736-1ce5855943a7": {"doc_hash": "475ba4ee49a8af92b4cf26e08a43af43ddb7c3dd77eedc4accc266d2dfb7dbc5", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "ec1b63d9-b42f-4f39-a52c-671655f97cd2": {"doc_hash": "b2086c301ee1bb994a550252ffd011e4c7e479b23c0d03b99f671832e1d7be33", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "312efc53-9838-43a1-b0b0-63f2c2274b58": {"doc_hash": "2b614d8464cf6cad87ab3661df89548d047393a6661eb62d134d5de800f9addc", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "41e3db85-a3a0-457b-8bb4-80d43f3418b4": {"doc_hash": "cd1f876e77989c504b3dfe5398da2bbe6afccff2b197503ec9e4d6ec392c5441", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "44a00b16-3559-4b87-840a-0ed72d91bd89": {"doc_hash": "8984f00b7652102c44bbb9b1ddb9ae96e5bb14e4c705e628b8cf774d3ec67e33", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "99f2e669-b67f-4d8d-b622-cb94f4efeb79": {"doc_hash": "e9ab7d8392a7a0d7e0b2057307556c46ea7a5696d94afaefbdf8d6f44cfe1634", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "de8dc138-bbde-4f4a-b83b-51232aace9b5": {"doc_hash": "260ea00f0882cf6a16399b30f70113ef67fda464dad0696311e6a09a393237b4", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "4bb625e7-0895-4fb3-aaae-056341c16333": {"doc_hash": "085404c4d5774709504c7fb25ca310f69b287298d3fbf3c2b7a30f26f02ae1c8", "ref_doc_id": "83fd34ce-4c8d-4c31-84ac-b6d532db8725"}, "bc7b6607-5ae7-431f-9ac1-1a38d3902c83": {"doc_hash": "9d8ab920255f9e24c4a77ad53604713442bea75c0f27a6a11f265de18bb1245d", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "c2cf4332-52c3-4924-b176-36f67dd938e4": {"doc_hash": "91308e8ed79ba8482993e2e6361778826a6117c08714ad9aab58b9fb801adc73", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "f0a31827-e476-41ad-b7b3-d039a0331f52": {"doc_hash": "5aa8effede2039513999faf9916d8a5baf4f6b859aaf46fb11a42da04227bb76", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "0cc32c69-11d3-4eb0-b885-da244f0fa21f": {"doc_hash": "0aba99dd6d918ece3ca9c2babdf9105b0edcc376b44077d8174e71d212dfd5de", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "e0a16742-ca8f-417c-b181-26ad2776e396": {"doc_hash": "271de7f2e5b99775b1e774f0eec59016c66d52f58bccce938cd4bf2b03aa21c3", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06": {"doc_hash": "547bb73f6b6051f64cfab6782be67d43464e2465284a3a821e2320d35f095d71", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "72edadaa-1a15-473c-8139-3141caadf839": {"doc_hash": "f06fe10b6fa20cf8258c3ae3d7417a4841b0a1ac5eff6f2062128d4296243d36", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "468797f5-d305-4af8-9305-c9fc86226e2e": {"doc_hash": "2525e751bce6018eadaf453a04127132dd0406a24545d052e7d309889fea0bc9", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "fe20fcfb-faa7-4b90-af4e-a123218b4502": {"doc_hash": "b173afca97fb6e564152b7f3d99eff2f2b07ae2770eb65e6b1c6cbbe14fc8e3a", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "0732bebe-36b7-45aa-92e2-02f493386429": {"doc_hash": "270a023d9e434cba04b1eea9dc45d2bccddf01a419eb400b80c03d5fb12363f1", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba": {"doc_hash": "247ef181298ad67dbbc0e82280032e31b8723dc4413d4c51d9ce9705e376a5b3", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "6139342f-882e-4edf-9ea2-bfa4cd031c1a": {"doc_hash": "328e4cff4ee5e32cb11ac6cc3a2d8d61f2d4b1cce5da4b908843135912d47f20", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "4cc25d01-3b40-42a6-a812-aeb98bdfe566": {"doc_hash": "352abcaeae7b5156af85f38295dc6f1d4abc06c911d24ec477a5e5b573d19947", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "203f30cf-d2cb-4361-9f9f-93c92d2e5b32": {"doc_hash": "1885f7163237bcf50c510fea34ac8fa5cbfa41dc244706b91c4e62fa390f1124", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "5a0eb274-cb6c-48cc-8228-97432b631802": {"doc_hash": "8658d8747994c82862d355e3a904eec1c26036dd22e348de80c37a1cd89a8f2d", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "2b129e73-7814-4647-bbd5-9ac0c6540edf": {"doc_hash": "08feeee5af88daefaf0a79ff7c63ee719819873300f8ecdd1e97b5ce660f4ae3", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "34ee3e08-c2ee-4d1a-a898-af296f16de0d": {"doc_hash": "1f838476b748361e19c238ce50a12408c314178de74c481ad44dc8eff15ac6d3", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb": {"doc_hash": "d1bae31a9bb079832a6f54ce4d3cb4753a5cc374b5e3a7ffc07dffed68b4ef19", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "821c982a-1ba2-4d43-bc94-8eef85022a76": {"doc_hash": "23a1f0e3a90852c38e34b494e7008c5228a40dda0ca2456faeb077aa9a40d78d", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "71176fda-7be4-49a4-942a-6ca7ed5f1a89": {"doc_hash": "38ab1a1464f3911e94fcacd9ed3f7cd7eee0c0cde0bf5acda048e7c123e43131", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "e96c40cd-beed-4565-bad0-172eb949eac7": {"doc_hash": "7919df5a8a0c944b31bbda236b448f4a1768cda6ee6f0436fb7b44130418670e", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069": {"doc_hash": "746021d55750f3040860980c449ed14afa0437986ee719426ad41549ca1be04b", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "1cc2f625-c869-4d78-9a83-609da5a65aff": {"doc_hash": "58cfa0fb0e57a42ac7d676b4744200680a66a9b4ed6531973edb7d7cf3132119", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "35a2ca8c-101a-4302-bb33-cf95810e9e12": {"doc_hash": "3d8b85ac28e725ceb93d99b81568a2693e6adf8a93ac5a6e5ff91781220cd0c7", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "ddf0a2b1-8273-4889-8deb-e870c2a0be50": {"doc_hash": "00cbda25639e23ccfbf077cd0daad776c5c132c292e2dfe56d951f296f95a129", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "bbb740c9-01f2-4724-a762-f2a16be01bb5": {"doc_hash": "e2b5e74960b56f499c54660f6e0a420205533af45d46369a2d63a2abd525201a", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba": {"doc_hash": "121bcdfa4edf43001c3783a2f4524ee17beae048d052da7a33c85bd86dc652fb", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "a9084b08-8e80-433b-9f49-54009727b7a2": {"doc_hash": "559b55878e65479123b0aad30c9e671706792baf696ce26e2f0a123143a7b012", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "3ee3bdea-27e4-4398-9854-1a3582be4b2b": {"doc_hash": "9a8e378c76d47e9a3bb0c0bf8d066136c52ff5d46d83095f524a64599aa9c325", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e": {"doc_hash": "0b297243c1f85c77451caf57b90688979775a8389921ce17750033a5d806cf9f", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "f9fcb55f-22ea-4306-84b7-031188691673": {"doc_hash": "93b1d38394209957ba071aacc68e19cacc59864f14fc821d8346faef946f6922", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "46899054-50fa-4a53-ac83-3c65cdbd9736": {"doc_hash": "a84ad9a0c4380231fb7e8bfb8549075d43af9f263c76070e1d3b4d8dda87e33a", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "a64570de-ab77-40fd-9551-d7bb69a8297b": {"doc_hash": "c5d8b3355cd0a6be9be1dad83b64e88435c71dc1c87b8de6e081dc61d6c0100d", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "aee14e89-26e4-4fa1-8829-5e3b3896b8e9": {"doc_hash": "ccca31c5eebea2ced0634676dff49c42cac2aa1335921acc45feec4d516ba856", "ref_doc_id": "ebafefb4-f90a-427a-8f97-d2734c97672a"}, "d5fa6482-0203-46e3-861f-a38aa7a5fac1": {"doc_hash": "eb44a1ae2ed75950ce4178b625072675fca0f4c314eed9ec627b575f75e888ef", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "f3887cb9-3cb1-45c5-8609-587db162c5fa": {"doc_hash": "2761ecad59d674ba9c0bc06ef4e484d94ce4179dd97124068b57520d900cd30f", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "c20360fc-3cac-4e28-9fdb-ef605c1daac8": {"doc_hash": "10d0ca888bebfd8a495c7430ce00fa01a2be11a25054bf4c1b78a7023a357ed4", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "bd10b001-154a-440c-ae37-e518c58b760e": {"doc_hash": "bd6e49e8e0bda3cc8cf34f4f63655f40fbc5a513f8253f2eacb57943ad1f0de5", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "a107fe3d-987e-4c1a-ad27-cd45351bde62": {"doc_hash": "36100d318d7b1d455a49ff1332ee9f69496c747706c42c7d16507031e92593ab", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "8574857e-e51d-456d-8bf2-50897abb36a1": {"doc_hash": "8e00e5f80fa54e1d1860f8c650b4430b0d8df7bec8ed2dec93ba41e80527ead4", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "18775056-5c27-4a29-93e7-220ee34e35d6": {"doc_hash": "be6bc03753dd2e1b3d08541a3763766a6467994730706d45afc516d89f6cb3ef", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "1a913ae2-16cf-4118-a237-8a87195594e5": {"doc_hash": "8d844443570bbec711e18d6a5f47acd98f428c83bfc3da3eda8588661be2ad0e", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "0915b0a1-0901-469b-bef2-259a52d31978": {"doc_hash": "b319b121736f0637403d0492b5a11519ffba2a378b3fd0364b539e59c84a5695", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "4cc02cb9-1a69-4afb-ad6d-30c7beacb922": {"doc_hash": "c478673062bf382c4ced7436c8659c780ec01ea4abae6ca8c733307c903ee553", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "d4df449b-e980-4dc9-a19f-a6227ffe2379": {"doc_hash": "b51c71a25e38afc711434eb9065d9134f8cf01c6c7deacd157189a38e85362f7", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd": {"doc_hash": "c6b9c99516db9ae84852163c99cf14411f69a9e6e1c1260ddcecb989a962e7e6", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8": {"doc_hash": "e3dd622adfcc61997c0d6a758100eed423232d4af8a35f2ac1a1adfa96c7b38c", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "e3b74cc7-01fb-44a4-8623-df4c97307693": {"doc_hash": "90a9d4fe109781ad78c204791fed23c1946ad5b5c295eb39d51c7b2da913163f", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "04699087-0811-4897-9f93-198155bec3bb": {"doc_hash": "4a8601e61c28403c39d61fda06c3ff4c32a2a8cf3d8f6767c0e3125974373251", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee": {"doc_hash": "5a6107c3728f252d746326be39cb5c6913c35821156640a17f22e2f246f62344", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "11c5d621-de09-4ff5-907d-d500a2717a98": {"doc_hash": "84460f4bc36d5b267b783b6553976b6d1324b611793b1c032993270464f2d3b4", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "e8d3ca26-ecf8-402b-b9da-ae4197374d55": {"doc_hash": "34063b4a9f6492fb18717293b342beff53e7843b43c59a0f2d31e633738af28d", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "1aec910f-15c7-4dad-937a-10943d956d1b": {"doc_hash": "ef0b48e1112990131b2a2c5d2f3efa700197b2e46ff97c35a3ab6d25bef1be5f", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "8cd37a8f-3b37-43ea-8158-4eb2cac449c1": {"doc_hash": "3710e8684a734ae7498f9d9e2ea2c003e188cb6515fb91f3ca46e6ab686e0c2d", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "df35e488-514d-4812-91b2-0965059ee11e": {"doc_hash": "d42f46f4c19c8c0b0903f51abbbf7d5eea14f09e03dbc87b023bf4ac071841a5", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "64eb969a-3d7f-46df-8686-6efcb6dda70b": {"doc_hash": "ad24556df6b47c9b3af32a33ba0a4be634649e8fab78fdfc1dfe1f1afa2463d8", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "fe92c004-f4b8-432b-885d-13d66c68686d": {"doc_hash": "9a132e39683c61302eac6f722059e95d8e62cfdc9aa2491c89971c68164d4323", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "a48b98d6-9df7-458c-9540-7f807fbb3d15": {"doc_hash": "5b0ad3f13bcb2a6a8f1fb146e6a189251e967a0324f62e0c38c3bf5d4366bbb0", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "b1748cac-5a6e-4eec-b330-004dd4f6679d": {"doc_hash": "09b307320ba8028d6464831893ed317da95ef2438e7f6ad876b5106dc76cacb4", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792": {"doc_hash": "28c5235d773a5fe3a20290b46a9bb515ed0bcba2f507795dd88e0b64c7e6689b", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "c47ed845-5a87-4d6a-b8cb-a9661884227e": {"doc_hash": "5c31f0b55a8c10055584548335c875c27ffbd167f08d339ab80602b9db88c1c2", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e": {"doc_hash": "f7a7f9a4a6d85872a0c3edbc0ab8e72f4634b9d76b9c48e3d928380be6039813", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "f48272f2-a311-40e6-a9ef-81398d3a3d38": {"doc_hash": "3469b963b11e269c3d06a1f721571b19f492cadb5fa3e4a775df687cb44d58fa", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "1d031445-6d67-4917-8b9a-ea9641161bef": {"doc_hash": "c526be2f2ecdb42ff80e237eccec2c05ae6f28cfa3b2ecf82fdaa742a74029d0", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "71dde0e1-667f-42a7-b03c-65ffeac07438": {"doc_hash": "25ee9b8dc52d7ca53febbd6c10c069b4858e397f792e31177f1e2702ba108538", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "2c710396-95f0-4dd5-8085-c31b783c493d": {"doc_hash": "2b3728dbd7f06f5159487c7f2eecd6d740e98a4c2f3db0db56771d79fd7541d9", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "c3b29a7a-3b02-4e7e-99b1-75b74b45c706": {"doc_hash": "2a7e6266a27d03035861f00f1b9684dd454f4df8598816ba6dfa66d55fee6cd0", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "0e3e6446-7c21-45fb-a165-c36bbfb4b63f": {"doc_hash": "e693cd624e9a404f62d4f8ca6d8683efcc9e7214d87d48da9e1ecb969c148ef9", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "4279b290-a69c-4599-b6e6-96762234a187": {"doc_hash": "588d2e4285aef70fd3f312687eeef4deb243c70ac83bd71a41ce9c378b2077fc", "ref_doc_id": "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326"}, "5eef3d8b-b587-494c-9831-bd8e8f131fc2": {"doc_hash": "5b72f4f247edb202eef2fd28a06c9bdc7573c9d6c4169e6e6a69b0795f94a370", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "a976e653-0963-48a7-ab7b-07059223f9da": {"doc_hash": "578bdff70f465e89357dcca71c0884acb6ad2de5e89dba1047d89a82e4df896d", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "876b317c-88b1-4053-a25c-803f27e59b31": {"doc_hash": "f14eb0747d9bfc3d92baba86603d82654a5296c16b58a7a868cc5e27b5e17853", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "ad3e7099-f2a6-4050-b695-44bb4a60a259": {"doc_hash": "8a8c409875353684e94ac96411038df755bb53fbb9c68c5b6f1a7a23c06038e0", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "5d4b8c50-2b96-42b3-821a-3b26b071384e": {"doc_hash": "a3b0d4f6c41785b7cce0396a757a122a144ecf1fe508a52b1d4bdc867a992023", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "925158bc-f37d-405e-a150-c5d887aebae6": {"doc_hash": "a2b3198135c2b9dbb8075e5349090a81ff7336df7c47946363db7108d0bfc285", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "ebde7429-0ea7-43a9-8160-fca01a3f1288": {"doc_hash": "c0c595c5d5c415520f70d5a1fed74850b84db27cc74a0c246aa54abab1102e84", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "ee350436-3886-4a58-b7b2-f032efc10393": {"doc_hash": "ff4b708b37465e1968614ab8db88a5dc8af3518a98cbb98e91d9fecee20fee19", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "d1c6af74-3560-478c-b190-ec7522d58468": {"doc_hash": "2f5995bbd7c7ebace25ab02fa677aca9c3436ae4753e6f0b5ce386d6ff725152", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "669518f9-5669-49a6-b522-75a16ac502f6": {"doc_hash": "344d2a9c6b5aad7085d460c0b3bfad734eec58c198965ff75f33c8d0f461f909", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "b36bee87-32d8-45dc-9e02-f54e8eb46797": {"doc_hash": "453eb6f99f7d45dc7544b1a18b418664b4d2d547eddb51c990cd0fdf0c96e934", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "c445a1df-ce6b-466f-a9b4-5bf6d321fecf": {"doc_hash": "81d8d28145e3ff7e7d0240a8aaae4a976926596894b730179e15039e3ec185fc", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "d9aa52de-d29e-4d91-bed9-469a3c038463": {"doc_hash": "16f501be8f13b35bf02cba6cfdd6fb7c1e5e83a3a531cd58bdb5ac4f292efdf7", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "cf06ec70-9817-4083-98e5-319378e6d3bf": {"doc_hash": "9f1682ff3770c9b0e0dc56afa8e2d1d1bc4cb4d49ed547e9b45efba690421236", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "59da77c7-0494-4a93-bd65-62961a0daf33": {"doc_hash": "e24e309ad476658a8f3e4f4fa24e3e298118e04e33396ad806529ab10e9306aa", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}, "775dbd78-a427-4afc-b0a1-c631e83bcc41": {"doc_hash": "e46abb14cc30b1cedcc39645c6bc0a3c28b62a43da691de4977dc856b7c6f1a3", "ref_doc_id": "2a585e2c-3e2e-4cc7-b5f2-8224a8898566"}}, "docstore/ref_doc_info": {"c898ba6e-3f15-4ba3-8f98-cf07232af897": {"node_ids": ["77dd7ffe-e710-4159-aa23-a0118fc94b7d", "5ad1a99f-989b-4490-b3d4-c7b0882fd0a0", "1c6e6c1f-a88d-40f4-ba63-45e64379bb6a", "052c7f6f-962e-40a9-8360-f38a1efdd2b5", "2d5c2a2f-21af-4292-b98a-0c296fdd9082", "bbbf24b8-eb3a-48bd-a66e-3a33b47809c1", "8fa025e7-f8e1-4104-b3db-9ffa928f3ac1", "eaa4ee35-3fc7-49e3-8b2b-0c615b76d927", "158387f2-a8d1-49bf-a766-07dce22b9e0b", "e83ad495-d5bf-46b4-9229-5021f0307c9c", "f37a5b32-b125-4091-b78a-202a5da5e9fb", "a6157d7b-ae61-43fa-b055-46c36b5856d0", "ed3836fb-b350-4ae3-9825-fc14652f9f16", "7f9939ee-c8ad-4287-802b-09465f156045", "9bf4abde-cc2e-456a-ad3b-70f73844a35e", "61211d86-3dbe-46e5-99b6-1d2d37064550", "0a260bf9-e266-4737-964a-20747244334f", "fcc0b2be-44bb-4b76-8e68-d8a9874799aa", "2f84b242-4d1a-4337-8a28-5c76b713cac5", "0b49122b-2912-4bd8-bda9-53d0f76904b2", "283a64d0-fbc8-4e45-b70d-e8e8746b991f", "3f2e3e68-12d7-4ff8-ad8f-8efe92415870", "f045787f-8e7c-4d01-9e18-d26d5ba880c5", "0ed3f5e5-14cc-4ac2-ac10-9cffbc843ae5", "368d34fd-56cd-4a0b-894b-512fd781ac3b", "d956a8c5-ac6a-41fb-87e2-8ee587aa2763", "4ff6a62e-a128-47a1-9e48-7514b4d93fdc", "56a23f46-ca55-47dd-8be9-622ad5778f3c", "306311a1-dd22-4b43-b868-19542c6ba4bb"], "metadata": {"window": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nAugust 11 , 2022  8:30AM Eastern  \n \nOperator :  Good day and welcome to the fourth quarter and full year 2022 Cardinal Health, Inc, \nEarnings Conference Call .  Today's conference is being recorded .  At this time, I would like to turn the \nconference over to Mr. ", "original_text": " \nPage 1 of 18 \n \nQ4 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "350f974d-a5e1-48dd-8d51-1965b8322899": {"node_ids": ["0ce5c954-3a2e-43e6-8639-c89f68f6012b", "d69db0a4-0afe-4673-84fd-b921048d5c9d", "133c809e-4a22-4e5b-8323-a39435cb596e", "82186c0b-1bca-4f38-a586-ee9b6cf7e2d9", "3871e31d-2a32-4ac1-9144-77c8ee8687d2", "56cb784f-e811-455b-9b25-d7b39f80ff11", "504c1846-d662-40dc-92df-dcb273bac41f", "9b197624-55f4-4108-b6ca-84d83367b8b5", "2808e31f-422f-4cf1-9525-2c07393f3df3", "132c7290-1b04-4b4b-bdfb-3875a1ba7ac5", "4473baa4-20de-4865-bb60-a0bf9726ed90", "c50f2c0f-5140-4246-b804-9196ead43812", "80ecd765-2ff4-47f8-837a-b481d6f785e6", "e4a642d2-abb5-4f97-b485-f9ffe3da72ea", "54d5f900-9034-49ac-a3eb-c1fc06095440", "748442de-e8e7-4163-bbf2-8ed83c6e013f", "9cf82343-3133-4347-a74e-ea57d31a4ca5", "334f6fd8-2457-4bf9-ac23-330db8092f27", "225ce797-d8d6-49f5-ab4a-4f357314d7bb", "632230f6-599f-4ba9-bec8-c892a0dfad45", "65c303c7-0ec0-4202-aeb1-696d44f9f23d"], "metadata": {"window": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years .  Let me start by saying how excited I am to be taking on this new \nresponsibility.  I am grateful for the trust and the confidence the Board of Directors is placing in me.  \n \n I would also like to thank you, Mike, for the leadership and the many contributions to the company \nover the years. ", "original_text": " \nPage 2 of 18 \n \nJason Hollar :  Thanks Mike, I really appreciate the kind words and the opportunity to work closely with \nyou these past few years . ", "page_label": "2", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a0e928b1-0818-41a0-b648-c3b921e7ac7a": {"node_ids": ["6817acf8-94d1-49f4-8471-a76f9959cb4c", "2484d589-145b-4fda-b552-fe014a52d46c", "a365971b-18e0-4426-9bb4-14f91ac1edb6", "8416fd13-0eaa-4caa-9de4-3ae6059708f6", "9ddf2ede-a1ec-4d68-8ec9-47bbb34f6b3c", "f450187e-8c44-4441-ad8d-8ff123737b80", "ee9f1160-71b6-4ba4-9a0c-c299c8be46ae", "12e0dc9e-f6b4-42c2-a4dd-564fac9cdd68", "3aade192-fc7e-4f42-8ddf-92db3eeb184b", "dd431a45-c773-4719-b567-b185903679c3", "815a58ad-e5a0-464f-9b5c-84ff6712d337", "91a4e21e-30b0-457f-baa7-52a4f1a39624", "2fdf851b-d343-4121-a7ef-f2b6abffa18f", "545b5dd4-1ae8-4a76-907f-88c1a6778a35", "b6851b8d-aaa9-4830-aa8f-8444a33c289a", "69966aa9-ae8b-468d-b2e3-6ccd99ed797e", "ff2a9fe6-9ece-4d20-9768-2495e57b1b1d", "b812e6d1-33c6-4c37-8ce3-6fc6c87971b4", "0b578fa0-b25b-4fc2-8283-c59860cad4dc", "f29ad4bb-a505-483a-b0ec-5566106d956c"], "metadata": {"window": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n Turning to Medical on slide 7\u2026  \n \nFourth -quarter revenue decreased 11% to $3.8 billion, due to the divestiture of the Cordis business \nand lower products and di stribution volumes.  \n \n Medical segment loss of $16 million in the fourth quarter was due to net inflationary impacts and \nglobal supply chain constraints in products and distribution.  On a year -over-year basis, the favorable \ncomparison to the prior year $197  million PPE inventory reserve was mostly offset by the net \ninflationary and global supply chain constraint impacts, a lower contribution from PPE, and the Cordis \ndivestiture.  \n \n", "original_text": " \nPage 3 of 18 \n \nAnd, with ongoing progress in opioid litigation matters, we saw a decrease of approximately $15 \nmillion in opioid -related legal costs.  \n \n", "page_label": "3", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "65d1702b-a233-4b64-84ec-253e432e1c0e": {"node_ids": ["656c20d0-76a2-4803-ade2-d6b8e2353c04", "be4d0968-5965-446a-b9b3-fc2afa181077", "04ca7c48-b863-4535-9470-35d340fe0eab", "a8eec237-e1cc-47e9-8bd0-ab52e515a2d1", "73729b7d-58e9-4cf9-89a2-b4d77f54e9df", "906758ae-5ab3-40af-8927-3bf361f1cf28", "a1ca554b-732e-48ee-9774-5c58268801e4", "ca86e9ca-b782-4ee2-a0df-42e8e7740993", "3b01d0b6-2642-4584-8fac-38a4db273f7d", "4918ad5b-c455-4e17-886c-0196723e771e", "ae84a2ff-ac7a-447c-aef0-33f93fdaf039", "bd8bcbdb-0990-476c-a16d-fba6709a9bb2", "695f3d85-2c5f-4a03-beb4-f04b6ecd265b", "f2c1839c-5568-4be4-be29-8763900a9359", "f4115c47-d67d-4f52-81bc-28ce71d7ab57", "a1a57cd0-1097-4bfb-9817-5aa2345bcd47", "807aef4b-3955-4fb2-b5b5-c51f7c3564ff", "60983600-66d4-48e5-a06e-9cf1c0fb566b", "2a85e280-5561-44e0-a523-b98968f519ec", "15d0090d-5a12-4146-bfcd-31e6c9bb7609"], "metadata": {"window": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n Gross margin decreased 3% to $6.5 billion due to the Cordis divestiture .  \n \n Total company SG&A increased 1%, reflecting inflationary supply chain costs, our previously -\nmenti oned IT investments and higher costs to support sales growth, mostly offset by the Cordis \ndivestiture and benefits from cost savings initiatives.  \n \n Operating earnings decreased 12%, which primarily reflects a year -over-year headwind of \napproximately $300 million related to net inflationary impacts and global supply chain constraints in \nMedical, partially offset by Pharma segment profit growth.  \n \n", "original_text": " \nPage 4 of 18 \n \nNow, transitioning to our consolidated results for the year\u2026  \n \nFiscal \u201822 revenues increased 12% to $181 billion, driven by the Pharma segment.  \n \n", "page_label": "4", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c346995d-f3e6-4eee-b999-c708c41be3d0": {"node_ids": ["83b6851f-0537-46fd-9f7e-a4a07216ac7e", "561ba048-ad71-46e9-bf0f-736b660ca09c", "63418bdb-1d95-4752-8869-49cf44355fb0", "2435043d-b771-4200-b6b4-0a0d69d0208a", "cc04324b-3e92-474a-9565-e4c43cce8c76", "f96d3bff-7815-4bbf-8253-059d88ceeba3", "87042e3b-5edb-4bf9-9e01-c564b3b224f2", "ce6f16a8-647d-4e36-a93f-64a732675583", "fc6f00cd-9f2e-454b-96b3-a3912de2edcc", "073c1acf-48c0-4eac-8f5b-dca4c5ed0078", "cc073d7d-2989-46dc-b6a3-9fee7f6bee11", "acf730fb-4c73-4640-aa1a-eb984bb07f93", "2782d5b6-9cae-4265-8306-af494048da86", "35a692b3-f848-419f-8dc3-a6fddecec6cc"], "metadata": {"window": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n Moving to  Medical on slide 11...  \n \nFiscal \u201822 Medical revenue decreased 5% to $15.9 billion, primarily due to the divestiture of the \nCordis business.  To a lesser extent, lower products and distribution volumes were partially offset by \ngrowth in at -Home Solutions.  \n \n Segment profit decreased 63 % to $216 million, primarily due to the net inflationary impacts and global \nsupply chain constraints in Products and Distribution. ", "original_text": " \nPage 5 of 18 \n \nwe saw an approximate $50 million headwind from inflationary supply chain costs, primarily in the \nsecond  half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b9f86132-8431-4532-8b36-81be49b4c509": {"node_ids": ["04286e88-d729-4d6c-a020-d14f126576aa", "fd51e05a-7bb8-4944-85f3-24b0afd787e2", "8d7e281a-6666-4787-bae8-cb5f39523c23", "3dfe5b51-69e0-4743-a563-b3b85452cb0a", "88ace672-1aee-44d1-ae83-7c9efeb502f0", "7c23439c-e2f5-4578-8488-60c51251f51c", "5e955c05-9a36-4134-8875-98d608b498f9", "5f4a99f9-df0c-4cd0-9cdb-96339bf9fb67", "7db52f79-56f3-4b77-854b-7e2fffef850b", "98a5b75a-493f-4873-84a4-15fbdebdddc2", "5aec7777-8729-47a4-916f-adb71b169c97", "0bc50d30-2681-4f2f-95fc-ad4d90c15d54", "424b579b-a7c3-4d28-9eca-98f9231897f2", "0d3dcaf6-9c23-4874-a6ff-d3066f0482c2", "b69a99f3-ae0e-4730-a4e4-0373c7f23d75", "ca28a5ea-196e-4cc7-b826-051c8bf8edcd", "ac1cf7bc-fdea-4ecf-9a61-7d3c729f4ff7"], "metadata": {"window": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.   And, we see \nincreased contributions from our growth areas, primarily Specialty, including biosimilars.  \n \n Before moving to Medical, a couple points on the Pharma fiscal \u201823 cadence\u2026  \n \nSimilar to last year, we expect the year-over-year segment profit growth to be significantly back -half \nweighted, which primarily reflects the year -over-year impact of inflationary supply chain costs in the \nfirst half.  Specifically, in the first quarter of next year, we expect segment profit between $400 and \n$420 million. ", "original_text": " \nPage 6 of 18 \n \nWe expect opioid -related legal costs, including initial costs for implementation of the settlement\u2019s \ninjunctive relief terms, of approximately $80 million in fiscal \u201823, a $20 mil lion tailwind.  ", "page_label": "6", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "28621069-0622-4966-b60c-1feb6586ae7c": {"node_ids": ["9f6d4d8e-9ca7-454e-9903-0e86d09baad4", "95be8c6a-bae8-4318-b22c-439491b0c01e", "fc6ed40d-86c4-44c6-a16c-62396e3d2c7d", "56ab7416-5392-4f44-8cd8-8b70aaeb435d", "ed234f12-ef85-4567-9f63-ee243911acf8", "6ccd4ad5-1665-4b3d-85d2-0043a24f355c", "c9a722f6-09a2-43ba-a57e-f7c928e0a3ba", "19d9dc38-1ec9-4679-a560-6a993224224f", "5bf91eb6-c35d-49bf-8b8c-b860dd09285b", "aea0568d-1d26-4d22-ae67-1275fc7ac7f4", "65620a6b-335d-4821-b673-d520f56f0d9e", "10006d25-89c4-4489-92b5-db868d9de085", "67060987-9cd9-40b6-9cb1-2bc70e819494", "9c898dec-7ed9-44e2-95d5-864ed15bd192", "3e350a6d-9987-4d65-923f-f5e827bf4fef", "297de1b1-ec5f-495f-810e-648f4fc10c21", "5bb13d19-de20-4971-bd3d-64374403dddc", "889ea7d0-e5eb-48a9-8eb4-87cfe878f35b", "c1f0f083-3a59-462d-9231-289f59322250", "75c5f6e7-727e-4e05-aab0-0f706e448a09", "15a9de53-f1d0-4a44-8ee0-5656c2ac151f"], "metadata": {"window": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n On Medical\u2019s quarterly cadence\u2026  \n \nWhile we are assuming a similar segment profit total in fiscal \u201823 versus fiscal \u201822, we do expect the \ncadence to be the reverse of the prior year.  Specifically, in the first quarter, we expect  segment profit \nranging from a loss of $20 million to profit of $20 million.  We expect the gross impact of inflation and \nglobal supply chain constraints in the first quarter to be approximately $150 million, with \napproximately 25% of this offset through ou r mitigation actions .  \n \n", "original_text": " \nPage 7 of 18 \n \nAnd finally, we expect increased contributions from our strategic growth areas, primarily at -Home \nSolutions.  \n \n", "page_label": "7", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6170c8c0-f838-4d2d-a1cd-4ce4c7284023": {"node_ids": ["d034ea41-182d-4dcd-ac50-9141bab7bba5", "a8fae56e-f6a8-475b-affa-8c7fd79e1036", "c8f62df5-cbfe-441d-a8f9-0ea3b82eca47", "71fce01f-fb21-4282-a2f3-d2ecf3705e39", "02ee8c60-5406-4cf1-9b45-90912b0f2268", "25e33a3c-fba4-4676-9fee-3835fde92342", "24f9e384-819d-42c1-9c38-74f80c088a36", "64229ce7-c859-4f2f-ae7f-8ba4a3f634fe", "620547c3-71ea-4d25-9781-2cdaf445d449", "7e66f376-f3b3-4f14-8a49-b8ead9b2bda2", "bb4c9c2c-ac36-49a8-8ed0-b833b400dc2a", "24fa7907-9873-4474-847c-be24c355aa67", "1daa99fd-861f-47fa-b5d7-2e56888d79c4", "d763e999-61d1-4556-a712-891d9eb8533b", "a137233e-bd91-4104-98e2-ca117020b5f8", "9219cb49-3fdf-4d24-a08f-b8ed645b844b", "ac6c135b-3a96-42fb-833f-8d75fd1d1faa", "fcafdbc2-6981-43e6-8aff-b397d9884fdf", "cdfba4f7-ebb1-494f-80a8-ff6c57e035ee"], "metadata": {"window": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes.  For example, \nin our surgical glove portfolio, we are investing $125 million for construction of a new manufacturing \nfacility dedicated to increase supply of our leading Protexis brand gloves.  \n \n The third area of focus is to accelerate our growth businesses, primarily at-Home Solutions.   These \nbusinesses have growth rates in excess of our core, along with a higher margin opportunity, and \nwe\u2019ve been making investments to drive at least $60M of total segment profit growth by fiscal \u201825. ", "original_text": " \nPage 8 of 18 \n \nresult of investments within targeted categories such as surgical gloves and electrodes. ", "page_label": "8", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b7cf89a7-242e-48df-ae06-7376827a2fb8": {"node_ids": ["e049061f-c8a1-48a3-8f24-ca2032d73656", "fd2d866f-8e65-4926-937f-c8f13703115f", "2be9ce14-7a5a-46fa-924e-46b288780bc0", "f189c81f-6b55-4c87-bce1-c08e3fc19ac0", "ca18d6c9-19c4-439c-b43a-1b85a99c8a27", "d2db6b07-5549-4746-9164-5234e75df8ce", "dfa08349-7f4c-4e66-a003-1b5b9076e781", "0a80b5ff-bfe8-486f-a800-e1e9747d9681", "4146cc9d-c8b3-48c4-96a5-acf673b7b24c", "84276a58-05c3-44ea-a242-73cc3805cce8", "daf30fdc-5fd0-43a6-b6ba-c7e2d4abcc5a", "8f3aacb0-9878-4302-97ca-c66dbfbf02dc", "939780d6-e1ac-41ec-aab2-39e1cc7da9a7", "a5f602b3-843f-4c99-bfd4-5de2caced4e6", "b717dc42-181f-4b5a-af42-658567b1387b", "18ff74af-861c-4811-a923-5d4318a2337b", "487de5a2-2fcb-4340-944b-8b50a704af56", "663520c4-a0c4-4368-8e9e-ce0bfa06b9e1", "624d06ed-119d-47d4-82af-c1f4e77f0f0b", "bb2989f5-3db7-4b5f-b6c3-adbb3780b44a", "8c2ad050-a164-4a62-aae2-7a49060482d4", "d84cbfc2-fe08-4a87-85e9-b3de45f962c3", "92811701-c730-47a6-bd3b-cf4e4fa30d94", "1c130caf-ea6e-4263-adef-8958ecd43a4a", "47c49868-079e-4cc8-ac23-d4d9999f0800", "a1f0dc96-b8e2-41a1-9a5c-0d09c13f1357", "68a4e19f-c308-4ec2-bd3f-83dcf94d9d21", "d32947f6-1270-4553-bdee-b82d049b43e5", "3c1d49db-26f6-494f-aae2-53f754048748", "2b551a71-f483-4c51-be6b-af2b9b8fd9ca", "c2dbc7cb-ff16-4e4a-a849-c6ace04a857f"], "metadata": {"window": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n We recently announced a tuck -in acquisition of the Bendcare GPO and an investment in their \nmanaged services organization.  These will further strengthen Specialty Solutions\u2019 Cornerstone \nRheumatology GPO, which offers innovative office management solutions and  robust specialty drug \naccess to over 1,300 rheumatology providers nationwide.  \n \n Upstream with biopharma manufacturers, we are investing for future growth in our 3PL business, as \nevidenced through our cold chain storage expansion, which increases our curre nt capacity by 200% . \n", "original_text": " \nPage 9 of 18 \n \nIn Specialty, we  are continuing  to see downstream momentum in oncology and emerging therapeutic \nareas driven by our offerings, including Navista TS.  \n \n", "page_label": "9", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "bf6aa88f-2553-453f-ae1f-6f3ad61d8879": {"node_ids": ["8b1a3978-18ed-4da0-a129-0ca6c1e24eb2", "d6383d63-eacf-41c2-b94e-293e059a9863", "5da83df1-89c4-40b8-a9a0-32dfe8ba7b3f", "f0342688-f935-454c-bbc1-4c33a4f810df", "e667b0c7-c2ca-4260-8db6-01f05ff9c1ce", "6f82226e-1dfb-45ef-8b51-04bc42270e1b", "aada70ef-1f26-4a90-bd4e-bcb6e721e3ad", "9d156036-227c-41d2-aa7e-5ad242174677", "5f60abac-f775-4b8f-a7de-294c5b968148", "e3adb4f7-cd34-46cf-902e-33ff93f788f1", "b5546a29-a3f6-4510-9eb6-85edafd06808", "c4c545e5-44ea-49be-9bf2-aace5ea6bc72", "719f960f-663c-4275-973e-001e178d03ab", "37a4d36b-2c49-4d0d-9bdb-bac47ff21282", "333c53b7-8b44-404d-8837-68ac20d43a15", "08793620-bb16-45d7-9ae7-27d30c21cb1b", "35c47bdc-4c26-407c-a8bf-3fdc63342e6e", "7628c771-536b-4e61-83cc-50b1a9cc0fdb", "ac056211-4c01-490e-80dd-1d19b79c49ff", "9bbe3dd9-2462-4757-95ea-72989d6b8924", "d8e9b316-894c-4e1d-a07d-8b922da3f03e", "9df61988-5e06-4893-ba62-b69d2015a3ab", "e0b1b2c8-7d10-44b9-bc9e-44c1aca02da5", "ce830ded-4672-43f8-8dc1-1d6b77f0a28c", "3abd137b-25f1-45e6-b038-0f69eafe5b9e", "0a2c1017-0a06-41ba-93fa-23d93dbe3411", "9c49f6a9-6a76-46cb-aabb-e930acc067d0", "8939bdda-3e87-4963-86e2-16d04e74160c", "8e77de87-929e-4d67-bd93-7f856ea83dc9", "2102d64e-86e7-4107-bf9c-4bf610a9726d"], "metadata": {"window": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion .  Thanks, Lisa .  So first of all, let's start with your \nfirst one there about why now .  So, ebbs and flows, I understand what you mean, and of course, I think \nwhat you're referring to is we espe cially talked about the sales force right before the pandemic, we \nmade a significant restructuring to have that team very much focused on driving our Cardinal brand \nmix. ", "original_text": " \nPage 10 of 18 \n \nJason Hollar :  Yeah, great list to start off the discussion . ", "page_label": "10", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b26e492b-e48b-4bd1-9fd5-69ce5081fbcc": {"node_ids": ["d982b89b-8b80-4f25-98ef-42d785f79e6b", "1374bc3c-4b28-4c12-aad0-471b746b97d3", "3f6f5033-a6f0-4493-9112-d90dcf98b48f", "60dfd17e-eb5d-40ec-b3d3-59b4e0f8176a", "17eca2e7-efb9-453a-98e3-c856d22a84af", "a378d6f4-9b27-42e3-812b-a47382f0363b", "64fe58d2-0b9d-43c0-9fda-bf547028cec0", "933af036-4ad4-427a-8ab6-6f843b647eca", "1eada1e2-a679-4702-873b-bf815f148baf", "fa4f16f2-c5f3-4523-889c-586b5ddebed2", "58aedb05-e456-43ea-a01b-8176cf49a3a9", "0c31c71f-a130-4a9f-b117-0f628d12e522", "60338c1b-2e27-4497-89ea-6f3ae945a8c0", "8b881a63-425e-4815-96cf-c913a01d150c", "80bbd855-64bc-4ccd-a18c-8dea4c649eb3", "78d5725d-37c2-43c6-9048-8c57fb5a8ee2", "ea392b4d-8dd2-48d8-be52-73a86b8882a7", "01073702-f57d-4126-8898-14541ddb3435", "467f234b-fe59-446a-8c16-0b49b0e7ee6f", "1328339a-9fe4-4da3-a0e1-7ea5b565528b", "1f7dcbde-d06d-417f-8c04-5d71820fdff3", "f71a87c7-4a26-455e-8ea2-9cc9c15ea9ce", "69675c15-03c6-4890-9ca6-4499069ef558", "0170d41a-778c-4f75-a556-e033b1335d14", "470d2ed0-ba69-48b5-9f45-55e61585f0d8", "f5177268-9f9d-428e-9820-0719e4f37732", "1719eac8-bc5e-4944-8c49-6254d98e0102", "1b6a6dab-a62e-4d86-9e76-29257e6c624a", "0487795a-fe00-40c0-9b89-988edd10f90b", "150505f3-cc8a-43f7-a7b1-67e44217e59d", "ab945228-ca19-4b31-b766-8ff60081e80a", "16e0ec51-a23e-4ffd-9f65-ba3cd8ff9daf", "b11519a5-c811-4110-a295-e1ac1c1b609e", "07c9530a-aba6-468c-9e51-35a795f85138", "2a480579-b271-4725-800e-c44182f263cd", "72f86a08-7dd3-489e-9e86-683540daba91", "dec2ff41-0113-4c77-9c03-0d60af25f621", "751e2230-fed6-4028-940f-3b4c939b2f42", "7ca0c3b7-0bcf-418b-afc6-17b0e7048fb2", "83900a24-e963-4b19-903b-44f532b35727", "665f6d76-5eca-45ac-aaef-e2c67b56b100", "1967b0fd-c351-4f14-bff6-8b824178084b", "16ce8c2c-36b3-4daa-ac4a-be7f797e8fd0", "60b1d59a-2bc1-4436-8ee6-924601979425", "47960c3d-65b4-413e-9fcd-5936c77a0263"], "metadata": {"window": " \nPage 11 of 18 \n \nperformance within the business .  I have made a mark within this or ganization .  I've been very focused \non capital deployment, driving cash in the company and have made that impact .  When I think about \nwhat , why I feel like I'm the right person going forward here, we have a lot of great aspects within the \norganization . ", "original_text": " \nPage 11 of 18 \n \nperformance within the business . ", "page_label": "11", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "85c1c682-fee3-47d8-8099-7a22c82ceaa3": {"node_ids": ["d2738ebd-3eb8-457d-832e-c7f704aaf7bd", "cf51af5e-b8da-4952-b1bf-6725a67776dd", "0cb64771-51c5-4e1b-a5f2-dabf86b049c5", "f4035d1f-2d5e-4bb8-8ca9-6dfacae19117", "ddf13643-7081-4de8-b470-8f7c0236e1a1", "14c68d3e-ec65-4d5b-a941-86ae4b4a2cef", "66169882-127f-45c4-a776-caf19d0e1f61", "d848ddcc-c9c3-43f1-8d69-689b8a63f888", "99a00ae6-2492-4440-96e3-775af60b6268", "5743eb27-c97f-4067-bda4-67a64e899acc", "34e2acd3-ef61-41ba-b400-685cfaeacd85", "87831237-90fa-4424-83b5-fb5dffcba2e7", "17f79297-e729-404f-bea5-a2c508efcf15", "55ea9310-c28d-41e3-a1ee-c66a9e13e96b", "9bbba4d9-a959-49b7-8a1f-9b14b2af09dc", "179f2260-96af-4988-8783-df3e61c6ff58", "e49a92dd-7bc4-4dc1-847d-19cbdef4d113", "e8d33700-97f5-4edd-95cf-a2e0c4700edf", "7dad53a7-5623-474b-8da4-1c08bc05bc00", "bd893f9b-ffc8-4375-bec6-6ee62fe7d312", "7d1e90dc-a811-436f-839d-bdcf83cf08a2", "2ab3a169-ccf2-4450-a4c3-987d1ae3570f", "66956909-3cd4-49e1-a23d-f9e9e5a0519b", "cafc0e69-980f-4d2f-bd7e-8230c26893f7", "1270ac96-9775-4b56-a287-20230defa564", "601fa7bb-abc2-486f-a521-eca1145b5ceb", "4fafe797-bc26-4395-94bc-3cdd8b7967e1", "5d8c9563-0699-4fb9-b1bc-1aa02a43deab", "c843a705-d066-44f1-b5e9-290bddce00fe", "cfb0a393-7e78-4739-ac51-85065fcdfc39", "d99c1b11-1f1c-45c4-a242-d60647a82cf0", "497a5e5d-ea00-4156-a0f1-0e76bf940582", "fc4c9b15-4bc1-4a09-8253-c63184ed18b6", "526eeaf6-0850-4fe6-9f43-6440c42689a5", "0b2127bf-ddc3-4a22-a5a1-3c82385c85ab", "dfa29760-d276-4e3a-85a0-219dd8a3ff17", "a02159d4-8490-42bf-9736-cceaba703747", "597f6b04-5676-42d1-b260-aae04b76d60f", "ea84f927-bac8-4d87-a38c-43bc3df4cf2a"], "metadata": {"window": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n Operator :  Thank you .  Moving to Michael Cherny of Bank of America .  Please go ahead.   \n \n", "original_text": " \nPage 12 of 18 \n \nKevin Moran :  Next question.   \n \n", "page_label": "12", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "659eb64f-95df-4d04-aef4-d5b54ea981e7": {"node_ids": ["bb1f3df9-daf0-4318-b8a3-15b67c6f1a28", "04e8843c-98c1-4f25-a718-b5c706d7aeb0", "c8712560-79d1-43e4-996f-5921d4575f19", "e14ecb78-ce5d-4a06-bdd9-6d9fd0994b43", "62f4f7ba-e24f-49ec-b2b0-96680696375d", "ff714d89-7fbc-4900-8ef5-cc90567e0450", "184747cf-56d3-42be-af3a-b61391ff9751", "5453fe51-e646-40b2-863c-5501a9fabe39", "dafc3286-829b-4796-8ab7-35dc23f04152", "bad40d9c-4172-4137-891e-e04b40cbcc28", "5f3bfb3c-b85e-4a46-bf84-a0e8964c8214", "6b5c43f1-e90b-4df4-a442-c1ed780a04d5", "03dd2d9a-3cc2-4c0e-a62c-5709eefee14c", "795808fd-72ef-4cd2-bc93-edb3c974d759", "fb9850a5-52b2-4a5b-9eb1-334bea65d434", "046bd9ca-bb3d-400b-aee6-40d72019939c", "9724c6a3-ce12-4c10-8819-8e259c0fd53a", "0969fa8b-6af0-4227-b59c-c77ee135a4eb", "41d5fa7a-f7d9-4ae5-b6fb-5c9fd45192de", "80dec3cd-706d-4bf5-b8b4-a5395c452fdb", "d9bdcc62-11cc-4a37-83e9-abd0402ad4a2", "4d1905d7-2d1c-4782-9c43-a179ba09a937", "8c31712f-b362-4ed3-91d0-75a5a2a2673e", "af2bb731-21cc-40e1-a97b-b6f5868c07a7", "60811646-47e3-43bc-b02e-81fdae97da6c", "4d2b939c-dcb2-4902-9f6f-7383b144cb56", "59d8adda-f568-4030-9215-d41f6a2f5c06", "ee60b070-0b6a-4248-8a46-2986248fd2e5", "b2104bab-0a8f-4fba-af9e-d15afce4c8b0", "0835b4f3-bf55-46c1-a1f1-0e5443392c88", "6dbaed9d-7410-4aed-88b3-a38c8d03f786", "95a7f3fd-af6a-4911-a9a2-594d4a80dd1e", "8ffde1fd-4af4-450e-9174-a524dce7b260", "8004bc41-723a-43b0-94bb-e9109e762a59", "fd27b1eb-1d34-4dc7-9300-a70554f1a28d", "89d4b50a-7153-43bb-9c4b-a12d4d1214b0", "2052f3b2-97db-49f9-8966-f088c1331719", "8cf757a7-2e76-4b58-9fb9-7f23f023b0d5", "ddb55fbb-ef52-4117-bf6e-bf176df5fa08", "b78b392f-67dc-479b-b1c2-33e2ae9f56f3", "b8a498b2-89b1-42eb-a46a-e16a43d8e0f2", "c6f55b24-22c6-4b90-a70c-e1bb58277915", "4b48d411-2c0d-460a-8f8b-7841aaf5d0b3", "c4bbda4f-db47-4d20-bae4-878be10dfcbd", "ff37c70e-cb7d-4660-9ba5-659cbba7c912", "c0e95903-e8b4-483f-866d-5f6975196e4e", "926461e9-5510-4475-bef1-91ec7b7c8e32", "b6662cd1-3366-4ed5-9850-3f71e5c17b27", "b99e2c2e-6e6f-4124-a97d-de6181ff3676", "08d6ebac-a5df-4a9c-a3a0-eb07bc556366"], "metadata": {"window": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823.  Now, we would expect that to continue to increase each and every quarter \nover the course of the year as we roll through various other increases .  I mean, these are the big waves, \nbut there's always going to be other increases along the way .  And our supplier fees that go along with \nthis too . ", "original_text": " \nPage 13 of 18 \n \nfor the first qu arter of  \u201823. ", "page_label": "13", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d1cdd7ce-6a26-47fb-93fe-dcf8eeaf2008": {"node_ids": ["4008a047-b46e-4d9c-8c1d-fa2df4908d00", "130e5868-8815-4f04-a588-f13b974c410b", "db356b52-9965-4bff-aec6-d4d2b096b8a0", "26af46d5-bebc-45f2-9520-c5eaa277daae", "f83bf4fa-6a26-4287-a4a3-2a93c3495115", "ffc927bf-0fd0-4f78-9144-510ad3e0a498", "bff9e035-9fda-486c-b57e-70c5bb41bd43", "df5d6e30-47c7-4b9e-8566-522ea7950864", "2fcac4af-db12-4b16-be5b-2dd4b5e3f106", "0258e207-4185-4aad-b97d-383ec1915b0d", "407e0340-65c9-4fb2-9de6-43b244c935d9", "8371396b-dee8-4436-bbf4-b3c5a8edee84", "8e9f22ce-61dc-46a6-b6e6-3052c4e0296f", "b9b024aa-b88c-4764-888e-df27c6ab392d", "e89030e1-0d78-4ce7-9696-a75cd73b997a", "05daebd8-ea1f-4473-abdb-3f2044aa35be", "94328f26-243e-412b-8e76-fba52cca218a", "c730cf0b-bfe1-4b19-81ee-29680b4c135e", "f43da9f7-bf27-4392-be1e-5ac99a8d55cd", "16f591ea-dc5c-414c-8f3a-084d207ac9d7", "0122552c-276e-4d2e-b74b-e0e3b3071976", "dbd0c1e8-cc84-4983-a348-7c05544b666e", "ad7785bc-edbc-4416-990a-caa14197da36", "bb7cf1aa-09da-4aaf-9188-7637629cd7f2", "403f3605-5340-4a16-b1cf-091eed4b7a08", "152feb8d-114f-41be-b28a-b7112c46a01d", "7b6da42b-7feb-4aa5-9132-cef750466183", "a52d05e8-0b38-4970-8d48-158daee72380", "846cf9ba-b4f9-42ae-b035-def750af0f0a", "35add517-718c-485c-8857-548542f18750", "832d2d96-d5bd-4b46-b3ea-c388b541b27c", "aaa5dac5-9964-4c74-a71d-036e7eecdf1f", "dfa944d6-786e-4831-a225-a5d2b423a383", "1bb0a9ac-f003-4248-8681-79fce599f3be", "77d61f82-71d4-4404-80db-76c295d4a952", "64194f12-4162-4967-b6de-10e7f273829b", "75a04cfc-e435-4614-8b9e-d485d61a6432", "dccc76f9-0a68-4d37-be28-a893c80fa60c", "eec74176-b1a8-49f8-a583-fd9a4415edc7", "d041cf87-586a-4330-a205-058205b59256", "80530559-fed8-40ab-b5c3-6f53a5e15e38", "b6adc80d-7788-49cc-b7af-89cc7b105ac9", "6192e916-226b-45cb-8647-fe7c84c46f0e", "90ba958b-960a-470a-98d8-96d34068c2fb", "bd3fb0bc-ed66-4d02-8d34-9126e97284c7", "0c2cdc5c-7450-44f9-8999-4f46e1177324", "22a9d222-27c6-4347-8ff9-aff6d066817b", "a563ed62-0705-45fd-8293-ec76e7cff961", "db1e4601-8f55-4cbb-9180-f42efb196379", "91062fcf-d4c4-456a-bc51-1c2ab063d494", "a3ee71b4-2f72-4162-9411-dfe48bcf7bb0", "3d770a0f-94d2-43cd-a18e-539002be3a47", "7dd5bee4-c86c-49de-a558-00f944835b7a"], "metadata": {"window": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand .  So \none, how do you envision t his revenue mix, what it will be by 2025?   And then how should we think \nabout sort of the the EBIT mix?   It's 29% of revenue . ", "original_text": " \nPage 14 of 18 \n \nIt seems that it's about 29% of revenue for the segment that comes from Cardinal Health brand . ", "page_label": "14", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "83fd34ce-4c8d-4c31-84ac-b6d532db8725": {"node_ids": ["27d4793f-2900-486d-86da-91c2ade01204", "183f8861-8164-4945-b18e-3bfd301eb00e", "25069839-7bd5-4554-88ee-3fc9e89e6f08", "4118f57c-07d1-4ac6-adb5-75e1f2a0e5ca", "c7d55395-673e-4740-a4e5-37e6c22cd053", "9f1db7a3-fcff-490e-b173-8108a78ea571", "eaf5966e-a969-4a7c-ae55-6293749029d2", "0fa2ef08-c47c-484d-bc26-a578607e4fc8", "088dc78a-815c-4df5-8fd4-92a541b51548", "9842b21b-6c13-4ff8-8e73-f9f5853d9aec", "67a8ec0b-11f0-41b0-aa13-fb56b7e982d8", "13fd4d8e-9560-4c43-809e-bdde10d02994", "cc4ecd11-0086-4f52-b717-71ce15476155", "2b499cc1-a8e9-4b0b-9161-5a4c2f798246", "1f07082c-63d1-48be-8d24-26e8086a704c", "74c904c0-427e-45d8-ad5f-78d15d38f02a", "cddebe8c-8a51-48ab-a07a-9bf632fe55b2", "4a06371b-eae7-420c-ab2f-2774b3541b76", "a601f84b-cd7e-4a81-9c5b-3f5e5d64753a", "427711d9-027b-468f-afc9-355f4289bec4", "606103d5-d433-492d-a6fd-fc01aff524f7", "d00db7a9-73e5-4284-b78b-f111672056ee", "da865a67-5fac-4dfe-90ce-fcbdacd21e25", "74da753c-7d50-4a7b-ac19-aca899883e76", "34adbcaf-c87e-4fca-89d3-36ce84a39052", "d75b1a7b-b19b-4e58-8c93-fa4ef95fd570", "32f35bba-cb67-4778-b0e9-b439df6f98ee", "2a7efbd1-ea64-48d7-9c4b-856fe3d19297", "4720b41c-6f37-46fc-8ee9-68dd6d092a3b", "5ec8e2a5-a37f-481e-8215-a41e1365ffff", "ef5225db-b017-4bd4-8faa-8ae84fe49a9f", "813d549b-493d-49dd-a2b2-6146c65c149d", "f40a383f-761d-44ec-9120-b695011c574d", "d248c887-bb0c-429e-8e89-edfad55057cb", "a6e45e54-853a-4a8e-ab59-146f73435322", "b2b8c820-8d8e-435b-9842-a3eac1ce9c32", "fd8515fa-68e3-4729-94b1-f801c113cce5", "6f1207c0-577e-4ea6-87b1-ab81005adf1e", "5104056b-fc7d-4566-8e86-72997e6f1b38", "604d8a1b-d122-4272-8d5b-a93a459fe66f", "0ff95c51-fd9c-4925-91d9-cfa0ff1c2e71", "6140d053-f048-4368-be20-13a774ce1c77", "d99f0559-49f0-4571-b736-1ce5855943a7", "ec1b63d9-b42f-4f39-a52c-671655f97cd2", "312efc53-9838-43a1-b0b0-63f2c2274b58", "41e3db85-a3a0-457b-8bb4-80d43f3418b4", "44a00b16-3559-4b87-840a-0ed72d91bd89", "99f2e669-b67f-4d8d-b622-cb94f4efeb79", "de8dc138-bbde-4f4a-b83b-51232aace9b5", "4bb625e7-0895-4fb3-aaae-056341c16333"], "metadata": {"window": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no .  M&A is not a \ncornerstone of that plan .  We will be looking to always augment, especially our growth businesses .  So, \nwhen we talk about that second point, the accelerating our growth business is primarily at -Home \nSolutions , that is very much an organic investment story . ", "original_text": " \nPage 15 of 18 \n \nJason Hollar :  So as \u2013 the short answer for the medical improvement plan is no . ", "page_label": "15", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ebafefb4-f90a-427a-8f97-d2734c97672a": {"node_ids": ["bc7b6607-5ae7-431f-9ac1-1a38d3902c83", "c2cf4332-52c3-4924-b176-36f67dd938e4", "f0a31827-e476-41ad-b7b3-d039a0331f52", "0cc32c69-11d3-4eb0-b885-da244f0fa21f", "e0a16742-ca8f-417c-b181-26ad2776e396", "a0fbcc03-2943-4ac3-8d85-24acdc5c0e06", "72edadaa-1a15-473c-8139-3141caadf839", "468797f5-d305-4af8-9305-c9fc86226e2e", "fe20fcfb-faa7-4b90-af4e-a123218b4502", "0732bebe-36b7-45aa-92e2-02f493386429", "da839dfa-d4b4-4ccf-aadc-67f40b43c9ba", "6139342f-882e-4edf-9ea2-bfa4cd031c1a", "4cc25d01-3b40-42a6-a812-aeb98bdfe566", "203f30cf-d2cb-4361-9f9f-93c92d2e5b32", "5a0eb274-cb6c-48cc-8228-97432b631802", "2b129e73-7814-4647-bbd5-9ac0c6540edf", "34ee3e08-c2ee-4d1a-a898-af296f16de0d", "46cb54fb-4f6d-4620-bb0f-979ba6deb2cb", "821c982a-1ba2-4d43-bc94-8eef85022a76", "71176fda-7be4-49a4-942a-6ca7ed5f1a89", "e96c40cd-beed-4565-bad0-172eb949eac7", "5b1d758d-f1a1-4f84-8d2a-36ce4fda5069", "1cc2f625-c869-4d78-9a83-609da5a65aff", "35a2ca8c-101a-4302-bb33-cf95810e9e12", "ddf0a2b1-8273-4889-8deb-e870c2a0be50", "bbb740c9-01f2-4724-a762-f2a16be01bb5", "3e2f3268-f38e-47b9-b1c1-9d89e9ea05ba", "a9084b08-8e80-433b-9f49-54009727b7a2", "3ee3bdea-27e4-4398-9854-1a3582be4b2b", "d04cb37d-a9e0-4d7b-8e96-dfe9ee7b758e", "f9fcb55f-22ea-4306-84b7-031188691673", "46899054-50fa-4a53-ac83-3c65cdbd9736", "a64570de-ab77-40fd-9551-d7bb69a8297b", "aee14e89-26e4-4fa1-8829-5e3b3896b8e9"], "metadata": {"window": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making .  We are leaning into some of the investments I mentioned before, especially on the \nCapEx .  I do think that we need to continue to augment some of the capabilities .  We have several very \nkey n ew team members in that team that, when you think about a lot of the supply chain challenges \nthat we're talking about over , especially this past year and even the last quarter, we have augmented \nthat team significantly with terrific talent, industry relevan t talent, but most importantly, products talent, \ntalent that knows the supply chain, knows manufacturing, that was able to make an immediate impact \nin finalizing this plan and allowing us to take it over the line . ", "original_text": " \nPage 16 of 18 \n \nWhat this is doing is putting a finer point on this pla n and making it more visible, the commitments that \nwe're making . ", "page_label": "16", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cff0d2f2-7bc2-45f4-ad4a-cd5bcf346326": {"node_ids": ["d5fa6482-0203-46e3-861f-a38aa7a5fac1", "f3887cb9-3cb1-45c5-8609-587db162c5fa", "c20360fc-3cac-4e28-9fdb-ef605c1daac8", "bd10b001-154a-440c-ae37-e518c58b760e", "a107fe3d-987e-4c1a-ad27-cd45351bde62", "8574857e-e51d-456d-8bf2-50897abb36a1", "18775056-5c27-4a29-93e7-220ee34e35d6", "1a913ae2-16cf-4118-a237-8a87195594e5", "0915b0a1-0901-469b-bef2-259a52d31978", "4cc02cb9-1a69-4afb-ad6d-30c7beacb922", "d4df449b-e980-4dc9-a19f-a6227ffe2379", "af8cf046-6fe2-49e6-a64b-2f607e4aa9bd", "366a5a95-e7c8-44b3-bd9d-8cfd5a2d33b8", "e3b74cc7-01fb-44a4-8623-df4c97307693", "04699087-0811-4897-9f93-198155bec3bb", "24f390f7-9ebe-4d46-bf1e-20a2f08ed4ee", "11c5d621-de09-4ff5-907d-d500a2717a98", "e8d3ca26-ecf8-402b-b9da-ae4197374d55", "1aec910f-15c7-4dad-937a-10943d956d1b", "8cd37a8f-3b37-43ea-8158-4eb2cac449c1", "df35e488-514d-4812-91b2-0965059ee11e", "64eb969a-3d7f-46df-8686-6efcb6dda70b", "fe92c004-f4b8-432b-885d-13d66c68686d", "a48b98d6-9df7-458c-9540-7f807fbb3d15", "b1748cac-5a6e-4eec-b330-004dd4f6679d", "58ac0b0c-c5e1-46a2-ba61-1461bdd6a792", "c47ed845-5a87-4d6a-b8cb-a9661884227e", "b6e4e8e9-beeb-47c3-a6a4-332ee07a323e", "f48272f2-a311-40e6-a9ef-81398d3a3d38", "1d031445-6d67-4917-8b9a-ea9641161bef", "71dde0e1-667f-42a7-b03c-65ffeac07438", "2c710396-95f0-4dd5-8085-c31b783c493d", "c3b29a7a-3b02-4e7e-99b1-75b74b45c706", "0e3e6446-7c21-45fb-a165-c36bbfb4b63f", "4279b290-a69c-4599-b6e6-96762234a187"], "metadata": {"window": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n Jason Hollar:  Yeah .  So let me let me start  \u2013 whenever I step into any project, let alone a role, it is always \nabout defining where's the best opportunity t o create value .  Where is the opportunities?  ", "original_text": " \nPage 17 of 18 \n \nyou reassess t he portfolio and consider whether Medical and Pharmacy \u2013 Pharma \u2013 need to be together \nlong term?  \n \n", "page_label": "17", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2a585e2c-3e2e-4cc7-b5f2-8224a8898566": {"node_ids": ["5eef3d8b-b587-494c-9831-bd8e8f131fc2", "a976e653-0963-48a7-ab7b-07059223f9da", "876b317c-88b1-4053-a25c-803f27e59b31", "ad3e7099-f2a6-4050-b695-44bb4a60a259", "5d4b8c50-2b96-42b3-821a-3b26b071384e", "925158bc-f37d-405e-a150-c5d887aebae6", "ebde7429-0ea7-43a9-8160-fca01a3f1288", "ee350436-3886-4a58-b7b2-f032efc10393", "d1c6af74-3560-478c-b190-ec7522d58468", "669518f9-5669-49a6-b522-75a16ac502f6", "b36bee87-32d8-45dc-9e02-f54e8eb46797", "c445a1df-ce6b-466f-a9b4-5bf6d321fecf", "d9aa52de-d29e-4d91-bed9-469a3c038463", "cf06ec70-9817-4083-98e5-319378e6d3bf", "59da77c7-0494-4a93-bd65-62961a0daf33", "775dbd78-a427-4afc-b0a1-c631e83bcc41"], "metadata": {"window": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you .  Before Jason ends the call, I would like to say that I appreciate all of your \ncongratulations and comments and enjoyed working with all of you .  I look forward to a smooth transition \nwith Jason and I have complete confidence in his leadership .  Jason, to you.   \n \n", "original_text": " \nPage 18 of 18 \n \nMike Kaufmann :  Thank you . ", "page_label": "18", "file_name": "CAH-Q4-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q4-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 214241, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}